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Chapter 1: Introduction 
Chapter 1.1: Protein kinases as targets for inhibitor design 
Protein kinases constitute one of the largest protein families in human1,2 and play an 
important role in the regulation of a diverse range of cellular functions. Protein kinases 
are defined by their ability to catalyze the transfer of the terminal phosphate of ATP to 
substrates that usually contain serine, threonine or tyr sine residues, and mediate many 
of signal transduction pathways in eukaryotic cells.3 Protein kinases are very important 
in cell growth, metabolism, cell cycle progression, apoptosis, and differentiation. The 
majority of these targets are being investigated for the treatment of cancer. However, 
deregulation of protein kinases function has been implicated in other disorders, 
including immunological, neurological, metabolic, and infectious diseases.4-6 Therefore, 
the discovery and development of selective and potent protein kinase inhibitors to treat 
diseases caused by the deregulation of signaling pathways has become an extremely 
promising and widespread approach for drug discovery.7,8 
Chapter 1.1.1 Kinase inhibitor binding sites 
So far approximately 518 protein kinases are identifi d in the human genome that 
share a catalytic domain highly conserved in sequence and structure but which are 
significantly different in how their catalysis is regulated.1 They normally share a 
conserved arrangement of secondary structure elements which are arranged into twelve 
subdomains that fold into a bi-lobed catalytic core structure.5 Between N-terminal lobe 
and C-terminal lobe of the kinase fold is the ATP-binding pocket (Figure 1.1). ATP 
binds in the cleft with the adenine ring forming hydrogen bonds with the hinge region, 
which connects the N-terminus and C-terminus. The ribose and triphosphate groups of 
ATP bind in a hydrophilic channel extending to the substrate binding site. This active 




Figure 1.1. Structure of the catalytic domain of cAbl according to ref. 10. The N-terminal lobe 
consists of a β sheet and one conserved α helix (helix C). The C-terminal lobe is largely helical and 
contains the activation segment which includes residues that are phosphorylated for activity in many 
kinases. The hinge region connects these two lobes. The residues close to N-terminus are purple, and 
those close to C-terminus are blue (PDB: 1IEP). The picture was adopted from ref. 5. 
All kinases have a conserved activation loop that is marked by DFG (Asp-Phe-Gly) 
and APE (Ala-Pro-Glu) motifs at the start and end of the loop, respectively. Most kinase 
inhibitors discovered are ATP competitive and present hydrogen bonds to the hinge 
region in the target kinase active site, mimicking the hydrogen bonds formed by the 
adenine ring of ATP. Four different types of kinase inhibitors can be classified: type I 
inhibitors, type II inhibitors, allosteric inhibitors, and covalent inhibitors.33  
Most of the ATP-competitive inhibitors belong to type I inhibitors targeting the active 
conformation of kinases (Figure 1.2a), a conformation conductive to phosphotransfer. 
Type I inhibitors normally hold a heterocyclic ring occupying the purine binding site 
and side chains on this scaffold occupy the adjacent hydrophobic pockets. 
Correspondingly, type II inhibitors target the inactive conformation of kinases, which is 









pocket is exposed due to the arrangement of the activation loop (Figure 1.2b). The 
active site of type II kinase is highly flexible and can rearrange to accommodate a 
variety of inhibitors.34 
 
Figure 1.2. Kinase inhibitor binding modes. a) ABL1 in complex with the type I ATP-competitive 
inhibitor PD166326 (PDB: 1OPK). Shown here is the DFG-in conformation of the activation loop 
(dark blue). b) The DFG-out conformation of the activation loop of ABL1 (dark blue) with the type 
II inhibitor imatinib (PDB: 1IEP). The picture was dopted from ref. 33. 
The inhibitor binding at an allosteric site which is adjacent to the ATP-binding site is 
the third class of kinase inhibitors. The allosteric inhibitors are prone to exhibit high 
selectivity due to the unique binding site and regulatory mechanisms. The well 
characterized example is PD318088 and its derivatives, the inhibitors for protein kinase 
MEK1 and MEK2 (Figure 1.3).35  
 
Figure 1.3. MEK1 protein kinase structure and the active site are occupied by MgATP and inhibitor 
PD318088, and the structure of other derivatives according to ref. 35. ATP is dark blue, and 





















































The forth class of kinase inhibitors is capable of forming irreversible, covalent bonds 
to the kinase active site, most by reacting with a nucleophilic cysteine residue.36 The 
analysis of human kinome shows that there are 46 kinases which have the particular 
cysteine residue and about 200 kinases that have a cysteine located adjacent to ATP 
pocket. This means a large number of protein kinases might be probably targeted with 
this approach. 
Chapter 1.1.2 Kinase inhibitors as potential drugs 
The first protein kinase inhibitors were developed by Hiroyoshi Hidaka in the early 
1980s.4,9 Naphthalene sulphonamides, such as N-(6-amino-hexyl)-5-chloro-1- 
naphthalenesulphonamide had already been developed as antagonists of the 
calcium-binding protein calmodulin, which also acted upon several protein kinases at 
higher concentration. 
The discovery of staurosporine which is produced by bacteria of the genus 
streptomyces and was found to be a nanomolar inhibitor of PKC12 led several 
companies to make and test many derivatives of this bisindolyl maleimide. However, 
staurosporine and several derivatives were later proven to lack selectivity and inhibited 
some other protein kinases in vitro.13,14 
  By the end of the 1980s, no protein kinase inhibitors had entered human clinical 
trials.4 It is a challenge to develop ATP-competitive inhibitors with sufficient potency 
and selectivity to compete with ATP in the intracellular environment due to its relative 
high concentration of 2-10 mM. In addition to the 518 kinases encoded in the human 
genome, there are over 2000 other nucleotide-dependnt enzymes, including 
polymerases, chaperones, motor proteins, reductases, nd methyltransferases, which 
possess potential binding sites.33  
  The identification of cyclosporine as cellular taget in 1991 was a turning point for 
the development of kinase inhibitors.4 Cyclosporin A (Figure 1.4) was approved for 
clinical use in 1983 and has revolutionized organ tr splantation by its ability to prevent 
graft rejection. Schreiber and his colleagues showed that the complex that was formed 
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between cyclosporine and cyclophilin was a potent inhibitor of calcineurin, which is a 
Ca2+-calmodulin-dependent protein phosphatase. Modulation of the phosphorylation of 
one or more intracellular proteins plays an important role in the effects of cyclosporin. 
                                      
Figure 1.4. Structure of cyclosporin. 
  At present, some of the most promising drugs as anticancer agents in development 
are inhibitors of protein kinases. Until 2009, 11 kinase inhibitors have received US Food 
and Drug Administration approval as cancer treaments and a further more kinase 
inhibitors are known to be undergoing human clinical tri ls.33 The structures of some of 
these inhibitors are shown in Figure 1.5. The first important drug to be developed by 
targeting a protein kinase is Gleevec which is developed as an inhibitor of Abelson 
tyrosine kinase (Abl) and approved for clinical use in 2001. Gleevec is marketed by 
Novartis15 for the treatment of chronic myelogenous leukaemia (CML). The structure of 
Abl with Gleevec displayed that the drug extends much further into the catalytic site.16 
Later, some other protein kinases inhibitors were approved for clinical use such as 
Iressa17 (in 2003), Tarceva18 (in 2005), and Tykerb19 (in 2007). 
Protein kinases are already the second largest group f drug targets after 
G-protein-coupled receptors and they account for 30-35% of the drug discovery 
programs of many companies.4,7 Protein kinase inhibitors are important not only for the 
treatment of diseases, but also as reagents to help us to understand more about the 
































































































VEGFR, PDGFR, c-Kit, c-Fms inhibitor 
Figure 1.5. Structures of some kinase inhibitors marketed in the U.S. as of 2009 according to ref. 33. 
Chapter 1.2: Organometallic scaffolds for enzyme inhibition 
  The pharmaceutical industry and chemical biology are dominated by organic 
chemistry, with inorganic compounds playing only a minor role.20 Metals have potential 
advantageous properties over the common organic-based drugs, such as the wide range 
of coordination numbers and geometries, accessible redox states, thermodynamic and 
kinetic characteristics, and a wide structural diversity. Although metals have long been 
used for medicinal purpose more or less, the potential of metal-based anticancer agents 
has been realized and explored since the discovery of the biological activity of cisplatin 
in the late 1970s. Cisplatin is classified as classical chemotherapeutics which refers to 
the drugs that target DNA in the field of metal-based anticancer drug design.31 The 
cytotoxicity of cisplatin has been studied extensively and is known to originate mainly 
from the formation of covalent cross-links that result from the binding of cisplatin to 
two purines of DNA. Such a substitution product is able to inhibit DNA and RNA 
synthesis and thereby induce cell death. However, cisplatin shows insufficient efficiency 
against some of the most frequent human cancers, moreover, patients treated with 
 7 
cisplatin often undergo acquired resistance and heavy side effects.37 Both the 
advantages and drawbacks of cisplatin have motivated scientists to search for other 
metal-based drugs with better therapeutic properties.  
Nonclassical chemotherapeutics which refers to the drugs that target cellular 
signaling pathways overexpressed in cancer cells has emerged recently, such as with 
proteins and enzymes as targets for anticancer drug desi n.31 
Chapter 1.2.1 Metal complexes as enzyme inhibitors through 
ligand-substitution 
  Metal complexes with labile ligands have long been known to undergo ligands 
substitution reactions with biomolecular targets. Metal ions can bind to nitrogen, sulfur 
or selenium of the histidine, cysteine or seleno cysteine residues in proteins. 
     
Figure 1.6. Structures of inhibitor 1.1 and 1.2. The crystal structure shows the binding sites of gold 
according to ref. 39 (gold atoms as pink stick, PDB: 2AAQ). 
  Human thioredoxin reductase (hTrxR) is an interesting target for anticancer drugs due 
to its association with many cellular processes and tumour proliferation.38 Gold(I) is 
highly electrophilic and shows high affinity to the s lenocysteine residue of hTrxR. As a 
result, gold(I) complexes constitute one of the most potent inhibitors of hTrxR. Becker 
et al. presented the gold(I) complex 1.1 (Figure 1.6) as an inhibitor of hTrxR and the 





















gold unit bound to an exposed cysteine and an additional gold atom which lost both 
chloride and phosphole ligand formed a linear S-Au-S adduct in the active site by the 
cocrystal structure of 1.1 with hGR. 
Dyson et al. developed a new series of glutathione transferase inhibitors in 2009.40 To 
study the nature of the interactions of inhibitor 1.2 (Figure 1.6) with the enzyme, 
crystallographic analysis and mass spectrometry were used. These data suggested that 
ruthenium complex 1.2 originally binds to glutathione transferase by loss of the two 
chloride ligands and is then further cleaved, releasing the ruthenium fragment. The 
potential drawback of this kind of inhibition with metal complexes is the lack of 
selectivity.41 The metals may bind to other proteins having metal binding sites which 
makes the delivery of inhibitors to specific targets difficult. 
Chapter 1.2.2 Substitutionally inert metal complexes as enzyme 
inhibitors 
  Metals have been attractive and included in anticcer agents because of the wide 
range of reactivities. On the other hand, metals can also be used as scaffold with well 
defined, three dimensional structures. Substitutionally inert metal complexes serve as 
enzyme inhibitors providing a promising scaffold due to the stability of the complexes 
in cells and the possibility to design the scaffold for specific biomolecular target by 
mimicking known inhibitors.41 
  In contrast to the complexes which easily undergo li ands exchange in solution, the 
Che group explored the anticancer activity of gold(III) inhibitors containing 
multi-anionic chelating ligands.41 In 2003, gold-1a (Figure 1.7) was discovered and had 
a series of advantages compared to Cisplatin. For example, it is substitutionally inert 
under physiological conditions and 240-fold more potent than Cisplatin. Further in vitro 
and in vivo studies revealed that gold-1a is a promising anticancer agent for the 
treatment of colon and liver cancer. A derivative with a hydroxyl group on porphyrin of 
gold-2a was developed with improved lipophilicity and aqueo s stability with IC50 
values in the nanomolar range in a panel of human breast cancer cell lines. Gold-2a was 
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found to regulate the association of class I histone deacetylase (HDAC) and histone 
acetylation at the promoter of Wnt/β-catenin signaling molecules and may represent a 











Figure 1.7. Structure of gold(III) porphyrin complexes. 
Professor Meggers’ group recently demonstrated a str tegy of exploring the 
versatility of organometallic complexes as structural scaffold for the design of selective 
protein kinase inhibitors. The natural product staurosporine (Figure 1.8) was used as 
lead structure to design bioactive organometallic complexes. 
 
Figure 1.8. a) ATP in the ATP-binding site of CDK-2. b) Staurosporine in the ATP binding site of 
CDK-2. Adopted from ref. 21. 
Staurosporine is a member of the class of indolocarbazole alkaloids and adopts a 
defined globular structure with the carbohydrate moiety being oriented perpendicular to 
the plane of the indolocarbazole heterocycle. The indolocarbazole moiety occupies the 


























bonding pattern of the adenine base, and the carbohydrate moiety forming hydrophobic 
contacts and hydrogen bonds within the globular ribose binding site. Thus, 
staurosporine closely matches the shape of the ATP-binding site which makes it a highly 
potent inhibitor for many protein kinases.21-23 
In order to match the overall shape of the ATP-binding site of protein kinases similar 
to staurosporine, the metal-chelating pyridocarbazole was designed as scaffold in which 
the main features of the indolocarbazole heterocycle are retained and the 
pyridocarbazole serves as bidentate ligand for metal complexes (Figure 1.9) targeting to 
the ATP binding site. This gives the opportunity to build defined globular shapes by the 

























Figure 1.9. Design of ruthenium complexes as protein kinase inhib tors by using staurosporine as 
lead structure. A, B, C and D represent the organic ligands coordinated to the metal center. 
  Based on this scaffold, several organometallic inhibitors for the protein kinases of 
GSK324-29, Pim126,28,30, MSK126 and TrkA32 were reported over the last 6 years. Some 
of the published inhibitors belong to the most potent and selective compounds known 



































Figure 1.10. Structures of some organoruthenium inhibitors for their respective protein kinases. 
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  Some published organoruthenium kinase inhibitors are shown in Figure 1.10. With 
different pyridocarbazoles and modifications on the coordinated moiety, these 
organoruthenium complexes can target different protein kinases potently and selectively, 
respectively. In the kinase active site, the metal center only exerts a purely structural 
role, without any interaction with the residues. Besid s, such complexes are air-stable, 
stable in water, and in buffer solutions containing millimolar concentrations of thiols. 
The stability of the complexes is due to the inert character of typical coordinative bonds 
to ruthenium. This, together with its relative low price of the starting material RuCl3, its 
low toxicity, and predictable and established synthetic chemistry,31 makes ruthenium a 
very attractive transition metal for establishing the scaffold of protein kinase inhibitors. 
Overall, these results demonstrate the generality of the design strategy. 
Chapter 1.3: Aim of the work 
Most of the published organoruthenium inhibitors over the last few years were 
half-sandwich complexes. Based on previous work in our group, the focus of this thesis 
is the development of potent and selective protein kinase inhibitors with well defined 
three-dimensional octahedral ruthenium scaffolds (Figure 1.11). It was envisioned that 
the octahedral scaffolds can further improve the sel ctivity of inhibitors based on the 
bulky and rigid configuration. 
 









With well defined three-dimensional structures, octahedral scaffolds can possiblely 
explore all areas of the biologically relevant chemical space in the protein kinase active 
site, and another advantage is that octahedral scaffolds are usually more chemically 
inert than half-sandwich scaffold which is attractive for the investigation of their 
biological functions. However, with 6 different substituents, an octahedral center is 
capable of forming 30 different stereoisomers compared to just 2 for a half-sandwich 
scaffold, which provides more opportunities to achieve inhibitors for protein kinases 
with high affinity and selectivity. On the other hand, it is also a challenge to find a way 
to control the stereochemistry of the metal complexes. One possible solution is using 
symmetrical multidentate ligand instead of monodentate ligand. 
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Chapter 2: Targeting Large Kinase Active Site with Rigid, 
Bulky Octahedral Ruthenium Complexes 
  This chapter discusses a new strategy for the design of selective protein kinase 
inhibitors that uses rigid, bulky octahedral ruthenium complexes to discriminate 
between kinase active sites based on the size of the ATP binding pocket. It was 
envisioned that octahedral complexes would be uniquely suited to selectively target 
large active sites by establishing rigid shapes which are easily modified by assembling a 
structure from a single center and changing the chara ter of the coordinating ligands. 
The p21-activated kinase 1 (PAK1) which is known to contain a relatively open ATP 
binding site3 was selected as a model system.  
Chapter 2.1: Initial screening of an organometallic library for 
PAK1 inhibition 
  An initial screening of a library of 48 organoruthenium complexes (done by former 
lab colleague Jasna Maksimoska and see appendix for details) led to the identification 
of the GSK3 and Pim1 half-sandwich inhibitors NP309 and DW12 (Figure 2.1) as the 
most potent complexes for PAK1. These inhibitors, screened as racemic mixtures, have 












NP309 (R=F), DW12 (R=H)
GSK3 & Pim1 inhibitors                                                 
Figure 2.1. The structures of racemic NP309 and DW12. 
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A subsequent cocrystal structure obtained by Jasna Maksimoska of (R)-DW12 with 
the kinase domain of PAK1 (amino acids 249-545, inact v ting mutation Lys299Arg) at 
2.35 Å resolution (Figure 2.2) revealed the important determinants for this affinity: the 
maleimide moiety and the indole -OH group account for four hydrogen bonds to the 
backbone of the hinge region. In addition, the monodentate carbonyl ligand interacts 
with the residues of the glycine-rich loop. Most inerestingly, the η5-cyclopentadienyl 
moiety is not in close contact with any amino acid side chains of the protein. Thus, this 
cocrystal structure highlights the large amount of vacant space accessible in the PAK1 
active site which is not available in many other kinases such as Pim1 and GSK3.4 
                                               
Figure 2.2. Cocrystal structure at 2.35 Å of (R)-DW12 with PAK1 (249-545, mutation Lys299Arg). 
a) Important H-bonding interactions between (R)-DW12 and PAK1. b) Surface view through the 
active site to demonstrate the open ATP-binding site of PAK1. Adopted from ref. 4. 
Chapter 2.2: Designing a precursor for combinatorial 
coordination chemistry 
To quickly scan for the most suitable ligand combination to fill up the coordination 
sphere around the ruthenium center, it would be desirable to have a compound which 
can serve as a common precursor for a large and diverse set of metal containing 
complexes. The synthesis of such a ruthenium complex 2.3, shown in Scheme 2.1, has 
four leaving groups in addition to the pyridocarbazole ligand, thus allowing for rapid 
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access to a diversity of novel structures by simple ligands replacement chemistry. To 
elaborate compounds to fill the vacant chemical space in the ATP binding site of PAK1, 
octahedral ruthenium complexes 2.4 that contained the pyridocarbazole moiety and CO 















































       
Scheme 2.1. Synthesis of racemic octahedral ruthenium complexes 2.4. 
  Accordingly, pyridocarbazole 2.1 was cyclometallated with 0.75 equiv of 
[(η6-benzene)RuCl2]2 in the presence of 1.1 equiv of potassium carbonate i  acetonitrile 
at 50 °C affording the racemic η6-half-sandwich complex 2.2 in 88% yield. The benzene 
ring was next replaced by three acetonitrile molecules upon UV-photolysis in 
acetonitrile at room temperature, followed by TBS-deprotection using TBAF 
(tetrabutylammonium fluoride, 1 M in THF) at 0 °C, which afforded the ruthenium 
precursor 2.3 in 41% yield over two steps. The complex 2.3 shown in Scheme 2.1 was 
the major diastereoisomer obtained in which chloride was trans to the indole nitrogen.5 
Another diastereomer was also obtained in 25% yield in which chloride was cis to the 
indole nitrogen. Although difficult, these two diastereomers were separated by silica gel 
chromatography. The use of these individual diastereomers to synthesize octahedral 
ruthenium complexes demonstrated that both diastereomers had the same reactivity and 
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provided the same product. Thus, the mixture of these two isomers was subsequently 
used as a general precursor for the synthesis of a variety of octahedral complexes 2.4. 
Chapter 2.3: Evaluation of the diastereoselectivity of 
coordination chemistry with precursor 2.3 
  In order to evaluate the diastereoselectivity of c ordination chemistry with a 
ruthenium precursor containing four replaceable ligands, the imide of precursor 2.3 was 
protected with a benzyl group to yield precursor 2.5 used for this model system. 












































2.8:2.7 = 7.1:1 (DMF), 65%
2.8:2.7 = 7.2:1 (DMF), 68%
2.8
 
Scheme 2.2. Synthesis of complexes 2.7 and 2.8 starting from precursor 2.5 and 2.6 as a model 
system to evaluate the diastereoselectivity of coordination chemistry with precursor 2.3. All the 
complexes are racemic. 
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Accordingly, a solution of 2.5 in DMF was first purged with CO gas for 5 min and 
stirred at 75 °C for 1 hour. Subsequently, the addition of 1 equiv of bpy and increasing 
the temperature to 95 °C for 1.5 hours afforded the diastereomer 2.8 as the main product 
along with the diastereomer 2.7 as the single side product (2.8:2.7 = 7.2:1). The 
diastereoselectivity was solvent dependent. In an aprotic solvent mixture of 
toluene:CHCl3 (4:1) the selectivity decreased to 2.4:1, whereas in a mixture of 
EtOH:CHCl3 (4:1) the diastereoselectivity was higher with 2.8:2.7 = 20:1. Interestingly, 
the other three possible diastereomers were not observed in this reaction. Also, curiously, 
the reaction of the diastereomeric precursor 2.6 with CO and bpy under the same 
conditions afforded the same main product 2.8 with almost an identical 
diastereoselectivity (2.8:2.7 = 7.1:1) (Scheme 2.2). The relative configuration of the 
predominant diastereomer 2.8 was determined via X-ray crystallography. As shown in 
Figure 2.3, the CO is placed in a position perpendicular to the pyridocarbazole and the 
chloride ligand trans to the pyridine moiety of the pyridocarbazole. 
 
Figure 2.3. Crystal structure of complex 2.8. ORTEP drawing with 50% probability thermal 
ellipsoids. All the single crystal structures in this thesis were obtained by Dr. Klaus Harms. 
Quantum chemical calculations were carried out by Deepa Devarajan from the group 
of Prof. Dr. G. Frenking using density functional theory (DFT) employing the BP86 and 
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B3LYP functionals in conjunction with various basis sets, as well as ab initio 
calculations at the MP2 level in order to elucidate th  mechanism of the reaction of 2.5 
and 2.6 with CO and bpy yielding selectively 2.8 with formation of 2.7 as a minor 
diastereoisomer. The calculations were carried out f r he model complexes where the 
benzyl groups in 2.5 and 2.6 were replaced by hydrogen. All five possible diastereomers 
of the product molecules 2.9 - 2.13 were calculated and the calculated relatived energies 























































Scheme 2.3. Calculated relative energies in kcal/mol of five possible diastereoisomers 2.9 - 2.13. 
The results showed that the diastereomers 2.9 and 2.10 were the two most stable 
isomers, explaining why only the former two species were experimentally observed. 
Structure 2.9 was slightly lower in energy than 2.10 at all levels of theory which were 
employed when solvent effects were not considered. 
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Chapter 2.4: Synthesis and screening of octahedral ruthenium 
complexes with different bidentate ligands 
  To identify the most interesting scaffold for the d velopment of PAK1 inhibitors, 
different bidentate ligands were investigated and a library of octahedral ruthenium 




































Scheme 2.4. Synthesis of library complexes containing different bidentate ligands. 
  Reactions were performed starting from the ruthenium precursor 2.3. Accordingly, a 
solution of precursor 2.3 in DMF was purged with CO gas for 5 minutes, followed by 
stirring at 75 °C under the atmosphere of CO for 1 hour. To the resulting solution was 
added the respective bidentate ligand and the mixture stirred at 95 °C under an 
atmosphere of nitrogen for 1-3 hours, which depended on the characteristic of the 
bidentate ligands, affording the crude products. The final products were obtained by the 
purification through silica gel chromatography. The structures of the complexes 
synthesized using this method are displayed in Figure 2.4. All the complexes were 





































































































































































































































































Figure 2.4. Racemic complexes synthesized for screening against PAK1 with different bidentate 
ligands. The relative configurations of FL182 and FL306 were tentatively assigned by 1H NMR. 
 23 
  The two diastereoisomers that were formed for the complexes in Figure 2.4 were able 
to be separated in most of the cases. The relative configurations were assigned by 1H
NMR spectroscopy based on the presence or absence of an upfield shifted indole H-7 
proton caused by the ring-current of the adjacent co jugated aromatic π-systems. As 
shown in Figure 2.5, an upfield shift of the H-7 proton correlates to a cis configuration 


























1,10-phenanthroline cis to the indole
upfield-shifted H-7 due to ring-current effect
1,10-phenanthroline trans to the indole
no ring-current effect  
 
Figure 2.5. Example of the assignment of the relative stereoch mistry of racemic octahedral 
complexes in Figure 2.4 by 1H NMR spectroscopy. 
  In addition, the relative configuration was further proven by the crystal structure of 
complex FL151-1. X-ray quality crystals of the complex FL151-1 suitable for single 
crystal diffraction were obtained from acetone by slow evaporation. The molecular 
structure of FL151-1 shown in Figure 2.6 confirms the earlier assignment by 1H NMR 
H7 
H7 
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spectroscopy in which the 1,10-phenanthroline bidentat  ligand is positioned cis to the 
indole moiety. 
 





































































































Figure 2.7. Remaining activities of PAK1 with 20 ruthenium complexes (see Figure 2.4 for the 
structures). Measured at a single inhibitor concentration of 1 µM and in the presence of 1 µM ATP. 
All the complexes measured above are racemic. 
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  Initial inhibitory activities of this library wer measured against PAK1 at a single 
concentration of the ruthenium complexes of 1 µM in the presence of 1 µM ATP, and the 
data are shown in Figure 2.7. These data demonstrate th  overall the potency of these 
ruthenium complexes is improved by switching from half-sandwich scaffold to 
octahedral scaffold. Out of the 20 complexes, FL172 was the most promising scaffold 
for PAK1, with only 18% activity remaining at 1 µM of FL172 with 1 µM ATP (IC50 
value was around 300 nM). Interestingly, it was found that the reaction of 2.3 with CO 
gas, and then with 2-(N-phenylaminomethyl)pyridine without any prior workup yielded 
the racemic complex FL172 under complete diastereoselectivity and oxidation of the 
amine to imine. The mechanism of the diastereoselectivity in the reaction is still not 
well understood. However, the bidentate ligand 2-(N-phenyliminomethyl)pyridine was 
tried as a reference in the coordination chemistry to validate the importance of this 
bidentate ligand in the diastereoselectivity. Surprisingly, totally four diastereoisomers 
were formed and proven by 1H NMR spectroscopy. Therefore, it can be concluded that 
one crucial step for the diastereoselectivity is the oxidation of the amine to imine of the 
bidentate ligand. 
Chapter 2.5: Inhibitory property and selectivity of FL172 as 
PAK1 inhibitor 
  To investigate the selectivity profile of this scaffold, the racemic complex FL172 was 
tested against a panel of 264 protein kinases (Millipore UK Ltd). PAK1, which was not 
available in the Kinase Profiler panel, was measured with a separate assay. The results 
revealed that FL172 showed impressive selectivity over other protein kinases, whereas, 
at a concentration of 3 µM of FL172 in the presence of 10 µM ATP, only 15 kinases 
(5.7% of total) displayed an activity of less than 20%, including PAK1, GSK3, and 
Pim1 (see appendix for details). 
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Figure 2.8. Circular dichroism spectra of the two enantiomers of FL172, measured at 1 µM of the 
two enantiomers in DMSO. 
  To further investigate the inhibitory properties of FL172, the complex was resolved 
into individual enantiomers (Figure 2.8) using a chiral HPLC column (see Experimental 
Section for details). The structures of ∆- and Λ- enantiomers are shown in Figure 2.9. 
The absolute configurations of both enantiomers were established from the cocrystal 
structure with PAK1 (Jasna Maksimoska, Department of Chemistry at the University of 



























Figure 2.9. Individual enantiomers of FL172. The absolute configurations were established from the 
cocrystal structure with PAK1 (Jasna Maksimoska). 
Subsequently, the individual enantiomers of FL172 were tested against PAK1, 
GSK3β, and Pim1 with an ATP concentration of 1 µM, and the IC50 values are 
summarized in Table 2.1 combined with the results of DW12 and NP309. 
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Table 2.1. IC50 values in nM of DW12, NP309 and FL172 against GSK3β, Pim1 and PAK1 in the 
presence of 1 µM ATP. 
 GSK3β Pim1 PAK1 
rac-DW12 0.32 0.14 1090 
rac-NP309 0.28 0.17 770 
∆-FL172 440 140 3480 
Λ-FL172 1480 440 130 
  The IC50 values revealed a strong modulation in selectivity with the Λ-enantiomer of 
FL172 (130 nM) being 27-fold more potent for PAK1 compared to ∆-FL172. Λ-FL172 
showed relatively low binding affinity to GSK3β and Pim1, and the IC50 values were 
1.48 µM and 440 nM, respectively. Comparing with NP309, by just replacing the 
cyclopentadienyl moiety for a chloride and a bulky bidentate phenyliminopyridine 
ligand in Λ-FL172 (Figure 2.10), the initial picomolar affinities for Pim1 and GSK3β 
dropped by factors of 2588 and 5285, respectively, whereas the affinity for PAK1 was 
improved by a factor of 6 at the same time. 
 
Figure 2.10. Kinase selectivity switched by the transformation of a small half-sandwich scaffold into 

























Chapter 2.6: Cocrystal structure of Λ-FL172 with PAK1 
  A 1.65 Å resolution cocrystal structure of Λ-FL172 bound to PAK1 was obtained by 
Jasna Maksimoska (University of Pennsylvania and The Wistar Institute, Philadelphia, 
USA) revealed the molecular details of the binding of this octahedral scaffold in PAK1 
active site.4 Whereas the pyridocarbazole moiety and CO ligand bi analogously to 
(R)-DW12. The maleimide moiety and the indole -OH group account for four canonical 
hydrogen bonds to the backbone of the hinge region. In addition, the monodentate 
carbonyl ligand establishes interactions to the residues of the glycine-rich loop and the 
bulky bidentate phenyliminopyridine ligand now stretches the entire distance from the 
N-terminal glycine-rich loop to the C-terminal domain (Figure 2.11). In this bulky 
octahedral complex the distance between the oxygen atom of the CO ligand and the 
para-carbon of the pyridine in trans serves as a rigid yardstick of about 8 Å which can
only be well accommodated in the active site of PAK1, but not in most other protein 
kinases. 
 
Figure 2.11. Cocrystal structure of Λ-FL172 with PAK1 (amino acids 249-545, mutation Lys299Arg) 
at 1.65 Å (by Jasna Maksimoska, University of Pennsylvania and The Wistar Institute, Philadelphia, 
USA). a) Some important interactions. b) Surface view to visualize the shape complementarity of 
PAK1 and Λ-FL172. 
a b 
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Chapter 2.7: Derivatives of FL172 as improved selective PAK1 
inhibitors 
  Although the binding affinity of Λ-FL172 for kinase Pim1 was dramatically reduced 
by a factor of 2588 compared to NP309, the selectivity of Λ-FL172 for PAK1 over 
Pim1 was only 3-fold. Thus, improving the selectivity over Pim1 is a crucial issue for 
the development of PAK1 inhibitors. 
  The cocrystal structure of Λ-FL172 with PAK1 (Figure 2.8) showed that the phenyl 
ring and the pyridine in the 2-(N-phenyliminomethyl)pyridine bidentate ligand were 
close to the backbone in the active site. It is possible that modifications of the bidentate 
ligand may allow the inhibitor to form an increased number of positive interactions with 
the backbone of the kinase. The 2-(N-phenylaminomethyl)pyridine ligand of FL172 
was synthesized by reductive amination from 2-pyridinecarboxaldehyde and aniline to 
form Schiff base, then reduced by sodium borohydride (Scheme 2.5). Interestingly, a 
large number of aniline and 2-pyridinecarboxaldehyde derivatives are commercially 










Scheme 2.5. The synthesis of 2-(N-phenylaminomethyl)pyridine. 
  The derivatives of 2-(N-phenylaminomethyl)pyridine used as the bidentate ligands in 
the synthesis of derivatives of FL172 are shown in Figure 2.12. A methyl group was 
first used to modify the ortho-, meta-, and para- position of aniline, respectively, to 
identify whether there is enough space to accommodate these functional groups in the 
active site of PAK1. These three complexes were test d against PAK1 at a concentration 
of 100 nM in the presence of 1 µM ATP. It was found that PAK1 showed 97% 
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remaining activity with complex FL224 (Figure 2.13). Thus, it turned out that the para- 
position of aniline might be already too close to the backbone of PAK1 to accommodate 
any modifications. 
Figure 2.12. The derivatives of FL172 with series of phenylaminopyridine ligands. The secondary 
amine in the ligands was oxidized to imine during the synthesis of theruthenium complex. All the 
derivatives were synthesized as racemic mixtures. 
  The derivatives of FL172 were synthesized in analogy to FL172 first by reacting 
precursor 2.3 with CO gas, and then the corresponding bidentate ligands. Most of these 
complexes were purified by silica gel chromatography (see Experimental Section for 
details). The racemic derivatives were tested against PAK1 at a concentration of 100 nM 
in the presence of 1 µM ATP and the results are shown in Figure 2.13. The data 
displayed that FL256 and FL411 could be promising complexes out of 23 derivatives, 
which have a hydroxyl group on the meta-position of phenyl ring and an amino group 
on the para-position of pyridine, respectively. PAK1 showed 58% remaining activity 
















































































































































































































































Figure 2.13. Inhibition of PAK1 by racemic derivatives of FL172 at a single inhibitor concentration 
of 100 nM and in the presence of 1 µM ATP. 
 
















































Figure 2.14. Circular dichroism spectra of the two enantiomers of FL411, measured at 1 µM of the 
two enantiomers in DMSO. The absolute configurations were assigned by correlation with the CD 
spectra of FL172. 
Complexes FL256 and FL411 were later resolved into their individual enantiomers 
(∆-FL256, Λ-FL256, ∆-FL411, and Λ-FL411, respectively) using a chiral HPLC 
column (see Experimental Section for details). The CD spectra of the two enantiomers 
of FL411 with their corresponding structures are shown in Figure 2.14. The absolute 
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configurations were assigned by correlation with the CD spectra of FL172.15 
Next, these complexes were measured against PAK1 and Pim1 at a concentration of 
100 nM of each enantiomer in the presence of 1 µM ATP. The results are shown in Table 
2.2 along with the result of FL172. 
Table 2.2. Activities in % of PAK1 and Pim1 with individual enantiomers of FL256, FL411 and 
FL172 at a concentration of 100 nM and in the presence of 1 µM ATP. 
 ∆-FL256 Λ-FL256 ∆-FL411 Λ-FL411 ∆-FL172 Λ-FL172 
PAK1 95 41 102 52 76 50 
Pim1 40 57 78 87 68 76 
  The data demonstrate that the Λ-enantiomers of FL256 and FL411 were more potent 
for PAK1 compared to ∆-enantiomers as FL172. The introduction of a hydroxyl group 
on the meta-position of the phenyl ring improved the binding affinity of Λ-FL256 for 
PAK1 as well as Pim1 without influence on the selectivity. Λ-FL411 displayed the same 
potency with Λ-FL172 for PAK1. However, the remaining activity of Pim1 with 
Λ-FL411 was slightly higher compared to Λ-FL172 under the same conditions. Thus, 
Λ-FL411 might be the potential PAK1 inhibitor as potent as Λ-FL172, but more 
selective over Pim1. 
  To further investigate the selectivity of FL411, individual enantiomers were 
measured against PAK1, GSK3β, and Pim1 with an ATP concentration of 1 µM, and the 
IC50 values are summarized in Table 2.3. 
Table 2.3. IC50 values in nM of individual enantiomers of FL411 against GSK3β, Pim1 and PAK1 in 
the presence of 1 µM ATP. 
 GSK3β Pim1 PAK1 
∆-FL411 1930 470 5200 
Λ-FL411 14400 2840 110 
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  The data demonstrate that the additional amino group on the para-position of 
pyridine in phenyliminomethylpyridine improved the potency of Λ-FL411 for PAK1 
slightly with an IC50 value of 110 nM, but the affinity of Λ-FL411 for Pim1 (2.84 µM) 
and GSK3β (14.4 µM) was decreased significantly. The selectivity of Λ-FL411 over 
Pim1 and GSK3β was 25-fold and 130-fold, respectively, which was further improved 
compared to Λ-FL172 by the introduction of an amino group. 
Chapter 2.8: Crystallographic data of FL327 and FL389 for the 
determination of the relative configurations of FL172 and FL411 
Crystal structures of FL327 and FL389 shown in Figure 2.15 verified the relative 
configurations of the related complexes FL172 and FL411 indirectly.  
 
Figure 2.15. a) Crystal structure of complex FL327. b) Crystal structure of complex FL389. ORTEP 
drawing with 50% probability thermal ellipsoids. 
FL327 and FL389 were synthesized in analogy to FL172 and FL411 by reacting 
ruthenium precursor 2.3 first with CO gas, and then with the bidentate ligands 
2-(phenylaminomethyl)-5-methylpyridine or 2-(phenylaminomethyl)-5-aminopyridine, 
respectively. X-ray quality crystals of the complexes FL327 and FL389 suitable for 
single crystal diffraction were obtained in acetone by slow evaporation. In the molecular 
structures, pyridine was on the axial position trans to the carbonyl ligand as in the 
cocrystal structure with PAK1 of Λ-FL172. The imino nitrogen in the bidentate ligand 
a b
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was within the pyridocarbazole plane and trans to the indole nitrogen. 
Chapter 2.9: The importance of the carbon monoxide ligand in 
PAK1 inhibitors FL172 
The CO ligand on the axial position was beneficial for the potency against Pim1.5 To 
investigate the possibility of using other monodentate ligands in the PAK1 inhibitor 
scaffold FL172 to improve the selectivity over Pim1, complex FL637 was synthesized 
in which the CO ligand was changed to PMe3. The synthesis of FL637 was performed 
in analogy to FL172 through the reaction of ruthenium precursor 2.3 with PMe3 instead 
of CO at 45 °C in DMF, then the addition of 2-(N-phenylaminomethyl)pyridine at 95 °C 
for 2 hours, affording the product in 26% yield (Scheme 2.6). Accordingly, the isomer 
shown was obtained as the major product in the reaction, along with small amounts of 
uncharacterizable other diastereomers. On the other hand, it proved the importance of 
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Scheme 2.6. Synthesis of racemic FL637. 
  FL637 was tested against PAK1 at concentrations of 3 µM, 1 µM, and 0.3 µM in the 
presence of 1µM ATP. The results combining FL172 are shown in Table 2.4. The data 
demonstrate that by changing the CO ligand to PMe3, th  binding affinity for PAK1 was 
significantly decreased. In comparison to the CO ligand establishing interactions to the 
residues of the glycine-rich loop (Figure 2.10), the PMe3 ligand might have a steric 
clash with the N-terminal domain in the PAK1 active site. With the PMe3 ligand, the 
active site needs to open even more to accommodate all the changes. 
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Table 2.4. Activities in % of PAK1 with racemic FL637 and FL172. Measured at concentrations of 
3 µM, 1 µM and 0.3 µM of the inhibitors and in the pr sence of 1 µM ATP. 
 FL637 FL172 
3 µM 66 24 
1 µM 86 28 
0.3 µM 95 51 
Chapter 2.10: Replacing chloride of FL172 by other 
monodentate ligands 
  In the cocrystal structure of FL172 with PAK1 (Figure 2.10), the chloride ligand 
points towards the solvent without any interactions with the backbone of the kinase 
active site. Thus, it was envisioned that using a bigger monodentate ligand to replace the 
chloride might be suitable to occupy the extended vacant chemical space. This might 
further improve the potency of the inhibitors for PAK1, as well as the selectivity over 
Pim1. 
  It turned out that the chloride in this octahedral scaffold was very unreactive after 
trying to replace the chloride under a series of different conditions without forming any 
new species except recovering the starting material FL172. The suitable reaction 
condition is shown in Scheme 2.7. Accordingly, the reaction was performed in DMSO at 
a concentration of 30 mM of racemic FL172 in the presence of 12 equiv of AgOTf 
(silver trifluoromethanesulfonate), heating at 95 °C under an atmosphere of nitrogen for 
7 hours. The mono cationic racemic product FL866 was obtained by silica gel 
































Scheme 2.7. Replacing chloride in racemic FL172 with DMSO. 
  The acetonitrile derivative FL862 was produced under the reaction conditions 
described in Scheme 2.7 by using acetonitrile instead of DMSO as solvent, but longer 
reaction time (overnight) was needed. FL862 and FL866 were further used as reaction 



































































































Scheme 2.8. Synthesis of derivatives of FL172 with other monodentate ligands instead of chloride. 
All the derivatives were racemic. 
  FL862 and FL866 could be further used as reaction intermediates to produce new 
complexes with other monodentate ligands (Scheme 2.8). Interestingly, the reaction of 
FL862 with sodium azide in DMF at 85 °C for 1 hour did not furnish the azido complex, 
but rather yielded the cyclized tetrazole product FL864 in a quantitive yield. The azido 
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complex FL922 was obtained in 66% yield from the reaction of FL866 with 5 equiv of 
sodium azide in DMF at 85 °C for 1 hour. FL922 could be further used in ‘Click’ 
chemistry with alkynes. For example, stirring FL922 with an excess of dimethyl 
acetylenedicarboxylate in a solvent mixture of DCM and DMF at room temperature for 
1 hour afforded the cyclized triazole product FL931 in a quantitive yield. Heating 
FL862 in pyridine at 95 °C overnight afforded FL889 in 9% yield, in which a pyridine 
replaced the acetonitrile ligand. These racemic derivatives were measured against PAK1 
with an ATP concentration of 1 µM, and the IC50 values are listed in Table 2.5. 
Table 2.5. IC50 values of the racmic derivatives of FL172 with 1 µM ATP. 
 FL864 FL866 FL889 FL922 FL931 
PAK1 1.2 µM 1 µM 150 nM 300 nM > 3 µM 
  The data demonstrate that with different monodentat  ligands, the derivatives showed 
remarkable differences in affinity for PAK1. The potency of FL889 was improved by a 
factor of 2 compared to FL172 with an IC50 value of 150 nM. In contrast, replacing the 
chloride with a tetrazole, DMSO, or triazole in complexes FL864, FL866, and FL931, 
respectively, significantly decreased the potency. The IC50 values of these derivatives 
were 1.2 µM, 1 µM, and more than 3 µM, respectively. The azido complex FL889 
showed the same potency as FL172, probably because the azide doesn’t form any 
contacts in the PAK1 active site. The affinity of tetrazole complex (FL864) compared to 
pyridine complex (FL889) was 8-fold difference, probably due to the electronic effects 
of the monodentate ligand. However, since the synthesis of FL889 is very sluggish and 
only results in a 9% yield starting from FL172, it is not practical to use this scaffold to 
develop PAK1 inhibitors. 
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Chapter 2.11: An improved PAK1 inhibitor generated by 
modification of the pyridocarbazole 
  The pharmacophore pyridocarbazole ligand in the scaffold of FL172 playes an 
important role in the inhibition of PAK1. The maleimide moiety and the indole hydroxyl 
group together account for four hydrogen bonds to the backbone of the hinge region, 
therefore these two moieties must be kept in this scaffold. Looking into the cocrystal 
structure of FL172 with PAK1, the fluorine is close to the residue of Arg299, but does 
not have any interactions with the backbone. Furthermore, the pyridocarbazole can be 
easily modified by using differently substituted 2-bromopyridines in the cross coupling 


























Scheme 2.9. Retrosynthetic analysis of pyridocarbazoles. 
A total retrosynthetic analysis of pyridocarbazoles is shown in Scheme 2.9. As 
described in the literature,6 pyridocarbazoles were synthesized from the reaction of 
pyridylindoles with TBS-protected dibromomaleimide by a sequence of substitution and 
photocyclization. Pyridylindoles were accessible by Suzuki cross-coupling of indole 
boronic acids with bromopyridines. Thus, it was envisioned that introducing certain 
functional groups on the pyridocarbazole might provide an opportunity to improve the 
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Scheme 2.10. Synthesis of complex FL735. All the ruthenium complexes are racemic. 2.21 is shown 
as the major diastereomer. 
The synthesis of one such inhibitor, FL735, is shown in Scheme 2.10. Accordingly, 
boronic acid 2.15 was prepared from Boc-protected indole 2.14 in 95% yield and used 
without further purification in the subsequent Suzuki cross-coupling reaction with 
bromopyridine 2.16. A mixture of boronic acid 2.15 and bromopyridine 2.16 was 
refluxed in DME/H2O (8:1) in the presence of 2.75 equiv of Na2CO3 and 0.075 equiv of 
Pd(PPh3)4 under nitrogen overnight affording pyridylindoles with the Boc-protection 
group partially removed. Unable to easily separate these two compounds, the purified 
mixture was adsorbed onto silica gel and heated under high vacuum to provide 
pyridylindole 2.17 in 71% yield over two steps. Pyridylindole 2.17 was treated with 3 
equiv of LiHMDS at -15 °C in anhydrous THF for 1 hour, quenched with 1.05 equiv of 
TBS-protected dibromomaleimide, and the mixture was stirred at 10 °C overnight to 
furnish the relatively unstable monobromide intermediate 2.18 in 72% yield. This was 
carried forward after purification via flush chromatography through a short bed of silica 
gel. Cyclization of the monobromide intermediate by an anaerobic photocyclization 
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using a medium pressure Hg lamp with a pyrex filter afforded the pyridocarbazole 2.19 
in 84% yield. FL735 was produced in analogy to FL172 first by reacting 
pyridocarbazole 2.19 with [(η6-benzene)RuCl2]2 in the presence of potassium carbonate 
in acetonitrile, affording the racemic η6-half-sandwich complex 2.20 in 72% yield. 
Ruthenium precursor 2.21 was produced by UV-photolysis of 2.20 in MeCN to replace 
the benzene ring, followed by TBS-deprotection using TBAF at 0 °C to yield a mixture 
of two diastereomers in 84% over two steps. Precursor 2.21 was used to synthesize 
complex FL735 by stirring it with CO in DMF, followed by the addition of 
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Scheme 2.11. Synthesis of complex FL1088. All the ruthenium complexes are racemic. Complex 
2.27 is shown as the major diastereomer. 
The synthesis of complex FL1088 is shown in Scheme 2.11. Accordingly, 
pyridylindole 2.23 was produced in 81% yield by Suzuki cross-coupling of boronic acid 
2.15 and bromopyridine 2.22 prepared according to the literature using toluene as 
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solvent instead of benzene.11 Pyridocarbazole 2.25 was constructed in 39% yield over 
two steps by condensation of pyridylindole 2.23 with TBS-protected dibromomaleimide, 
and then photocyclization with a UV-lamp. The half-sandwich complex 2.26 was 
produced in good yield (76%), which could then be converted to the precursor 2.27 in 
69% yield by photolysis and deprotection of TBS groups, yielding a mixture of two 
diastereomers. Precursor 2.27 was first reacted with CO, and then 
2-(phenylaminomethyl)pyridine to afford complex 2.28 in moderate yield (45%). The 
deprotection was performed in THF with 10% HCl to pr vide the aldehyde-complex 
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Scheme 2.12. Synthesis of complex FL1118. All the ruthenium complexes are racemic. Complex 
2.31 is shown as the major diastereomer. 
The synthesis of complex FL1118 is shown in Scheme 2.12. Accordingly, 
pyridocarbazole 2.2912 was cyclometallated with [(η6-benzene)RuCl2]2 in the presence 
of potassium carbonate affording the racemic η6-half-sandwich complex 2.30 in 81% 
yield. Precursor 2.31 was furnished in 85% yield by replacing the benzene ri g with 
three acetonitrile groups through photolysis as a mixture of two diastereomers. This was 
then first reacted with CO, followed by the addition f 2-(phenylaminomethyl)pyridine 
to afford complex 2.32 in 36% yield in which TBS group on the imide was removed 
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during the reaction. Finally, deprotection of 2.32 was performed in THF with TBAF to 






































Scheme 2.13. Synthesis of racemic complexes FL1103 and FL1109. 
With complex FL1088 in hand, the reactivity of the aldehyde group could be utilized 
to produce more derivatives. Reductive amination with aniline and sodium 
cyanoborohydride in MeOH/THF at 50 °C produced FL1103 in 18% yield. Using 
sodium cyanoborohydride to reduce the aldehyde group afforded complex FL1109 in 
25% yield. These derivatives described above were test d against PAK1 in the presence 
of 1 µM ATP and the IC50 values are listed in Table 2.6. 
Table 2.6. IC50 values of the racemic derivatives of FL172 with modified pyridocarbazole in the 
presence of 1 µM ATP. 
 FL735 FL1088 FL1103 FL1109 FL1118 
PAK1 145 nM 93 nM > 3 µM 2 µM 560 nM 
  The data demonstrate that the affinity of FL1103, FL1109, and FL1118 for PAK1 
was decreased when compared to FL172. Additionally, the potency of FL735 (145 nM) 
and FL1088 (93 nM) for PAK1 was improved by factors of 2 and 3 compared to FL172, 
respectively. FL1088 was 3-fold more potent than FL172, perhaps due to the reactivity 
of the aldehyde group which could react with certain residue in the PAK1 active site. 
Overall, the pyridocarbazole in FL735 with a hydroxyl group on the 5-position of 
indole and a methoxy group on the 3-position of pyridine could be the most promising 
































Scheme 2.14. Synthesis of racemic complex FL1422. 
 
Figure 2.16. Circular dichroism spectra of the two enantiomers of FL1422, measured at 1 µM of 
two enantiomers in DMSO. The absolute configurations were assigned by correlation with the CD 
spectra of FL172. 
The synthesis of complex FL1422 is shown in Scheme 2.14. Complex FL1422 was 
synthesized in analogy to FL735 by reacting the ruthenium precursor 2.21 first with CO, 
and then with the bidentate ligand 2-(phenylaminomethyl)-4-aminopyridine to give the 
product in 35% yield. For the resolution of the racemic mixture of FL1422, the amino 
group at the 4-position of the pyridine was Boc-protected and removed after the 
separation of individual enantiomers ∆-FL1422 and Λ-FL1422 (see Experimental 
Section for details) using a chiral HPLC column. The CD spectra together with the 
structures of ∆- and Λ- enantiomers are shown in Figure 2.16 and the absolute 

















































Table 2.7. IC50 values of Λ-FL1422 against GSK3β, Pim1 and PAK1 in the presence of 1 µM ATP. 
 GSK3β Pim1 PAK1 
Λ-FL1422 7 µM 2 µM 23 nM 
The Λ-enantiomer of FL1422 was measured against PAK1, Pim1, and GSK3β with 
an ATP concentration of 1 µM and the IC50 values are listed in Table 2.7. The data 
demonstrate that the potency of inhibitor Λ-FL1422 (23 nM) for PAK1 was improved 
almost 5-fold compared to Λ-FL411 (110 nM) by replacing the fluorine on the 
pyridocarbazole for a methoxy group. The selectivity over GSK3β (300-fold) and Pim1 
(87-fold) was also improved by factors of 2.3 and 3.3, respectively. A possible 
explanation for this improved selectivity could be that the methoxy group in Λ-FL1422 
forms interactions with the residue Arg299 as hydrogen bond acceptor in the PAK1 
active site. In contrast, in the Pim1 active site, th  methoxy group might be too close to 
the isopropyl group of Val126.10 As a result, the selectivity of Λ-FL1422 over Pim1 was 
significantly improved. Thus, it can be concluded that the bulky organoruthenium 
complex Λ-FL1422 constitutes a promising scaffold for the generation of improved 
PAK1 inhibitors by functionalizing the associated ligands in a combinatorial and 
structural-based fashion. 
 45 
Chapter 2.12: Discussion and conclusion 
PAK1 is implicated in tumorigenesis and metastasis, thus pharmacological inhibitors 
of PAK1 are promising candidates for cancer therapy.7,8 However, to the best of our 
knowledge, there are no selective organic inhibitors with IC50 values in the nanomolar 
range known for PAK1 or other group-I PAK kinases.4,7,9 In this chapter a strategy for 
the design of selective organometallic inhibitors for the open and thus difficult to target 
ATP-binding site of the protein kinase PAK1 using ri id and bulky octahedral 
ruthenium complexes as structural scaffolds was applied successfully. The octahedral 
ruthenium complex Λ-FL1422 was developed as a potent inhibitor for PAK1 with an 
IC50 value of 23 nM in the presence of 1 µM ATP. This inhibitor is very selective over 
GSK3β (300-fold), Pim1 (87-fold), and other kinases. Octahedral ruthenium complexes 
with the ability to construct globular, rigid struct res with defined shapes in a 
straightforward fashion provide opportunities for the generation of inhibitors with 
unprecedented target selectivities. 
  2-(N-phenylaminomethyl)pyridine was discovered as the most promising bidentate 
ligand in the scaffold of PAK1 inhibitors based on a screening of different bidentate 
ligands. This scaffold displayed high affinity for PAK1. Interestingly, the synthesis of 
this scaffold was quite diastereoselective, which made the screening relatively simple 
using this ligand. However, the mechanism of the diastereoselectivity needs to be 
further investigated. 
A cocrystal structure of Λ-FL172 bound to PAK1 revealed the molecular details of 
the binding of this octahedral scaffold to PAK1. The maleimide moiety and the indole 
-OH group together mediate four canonical hydrogen bo ds to the backbone of the 
hinge region. In addition, the monodentate carbonyl ligand establishes interactions with 
the residues of the glycine-rich loop. The bulky bidentate iminopyridine ligand stretches 
the entire distance from the N-terminal glycine-rich loop to C-terminal domain which 
can be well accommodated by the active site of PAK1. 
  Λ-FL172 showed an IC50 value of 130 nM for PAK1 in the presence of 1 µM ATP 
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but only 3-fold selectivity over Pim1. Comparatively, by the modification with an amino 
group on the para-position of pyridine in the phenylaminomethylpyridine bidentate 
ligand (Λ-FL411), the selectivity over Pim1 was improved by a factor of 7 compared to 
Λ-FL172. Furthermore, by the introduction of a methoxy group on the pyridocarbazole 
ligand instead of the fluorine, the affinity of Λ-FL1422 for PAK1 was improved by a 
factor of 5.6 with an IC50 value of 23 nM in the presence of 1 µM ATP compared to 
Λ-FL172. At the same time, the selectivity over Pim1 was improved by a factor of 25 to 
87-fold overall compared to Λ-FL172. 
  Compared to the published ATP-competitive PAK1 inhibitors with small organic 
molecules such as CEP-13479 and OSU-0301213 which have been developed with IC50 
values in the single digit micromolar range, Λ-FL1422 displays better affinity for PAK1 
and impressive selectivity over the other protein ki ases. Recently, the organic 
compound 2,2’-dihydroxy-1,10-dinaphthyldisulfide was discovered as a PAK1 inhibitor 
binding at an allosteric site.14 This allosteric inhibitor displays poor potency, albeit with 
a favorable selectivity profile. However, the lability of the disulfide bond under 
physiological conditions significantly limits its eff ctiveness in cellular systems. 
Overall, the bulky organoruthenium complex Λ-FL1422 constitutes a promising 
scaffold for the generation of improved PAK1 inhibitors by functionalizing the 
associated ligands in a combinatorial and structural-based fashion. 
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Chapter 3: Ruthenium Scaffold with Cyclic Tridentate 
Ligands as Potential Protein Kinase Inhibitors 
  Transition metal complexes with thioether ligands are of much interest due to their 
similarities to biological systems and their kinetic and thermodynamic properties. 
Crown thioether ligands are effective π-acid ligands for metal ions and also tend to 
stabilize first-, second-, and third-row metals in low oxidation states.11  
One essential feature of the crown thioether is the exodentate position of the sulfur 
donor atoms in most compounds (the sulfur atoms are directed out of the cavity). One 
exception is the 1,4,7-trithiacyclononane in which the sulfur atoms are preorganized in 
an endodentate fashion (the sulfur atoms are directed toward the center of the ring) 
prone to metal complexation due to the sterical constrain in the 9-member ring.12 
Therefore, this preorganization makes the complexation of 1,4,7-trithiacyclononane 
more stable in contrast to other flexible crown thioethers.11,13  
  In this chapter, the development of potent and selective inhibitors for MLCK, 
DAPK1 and Pim1 kinases is discussed, respectively. All the developed octahedral 
ruthenium inhibitors contain the cyclic tridentate ligand: 1,4,7-trithiacyclononane, and 
the selectivity of these inhibitors is achieved by using different pyridocarbazoles and 
monodentate ligands in the complex. 
Chapter 3.1: Development of MLCK inhibitors 
Chapter 3.1.1: Scaffold synthesis of MLCK inhibitors 
  The scaffold of MLCK inhibitors was initially identified by screening racemic 
ruthenium complex FL475 (Figure 3.1) against a panel of 232 human wild-type protein 
kinases (Millipore KinaseProfiler and see appendix for details). The screening result 
demonstrated that there was only 2% remaining activity for MLCK at a concentration of 
100 nM of FL475 in the presence of 10 µM ATP. The IC50 value against MLCK was 
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further determined which was only 13 nM in the presence of 100 µM ATP. Thus, 
complex FL475 could be the potential lead structure for the development of MLCK 
inhibitors, which includes the pharmacophore ligand pyridocarbazole, tridentate ligand 













FL475                                                           
Figure 3.1. Structure of racemic ruthenium complex FL475. 
The scaffold can be constructed as shown in Scheme 3.1. The synthsis of 
pyridocarbazoles was already described in chapter 2. The ruthenium fragment was 
introduced by reacting TBS-protected pyridocarbazoles 3 with ruthenium precursor 25 
in the presence of potassium carbonate in DMF under mic owave irradiation without 
need to exclude water and air, followed by using an anionic monodentate ligand to 
replace the one remaining acetonitrile group in the same pot. The TBS protection group 






































Scheme 3.1. Synthesis of racemic ruthenium complexes using microwave irradiation. R1, R2: 
different substituents on pyridocarbazole, X: different monodentate ligands. 
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Chapter 3.1.2: Identification of suitable monodentate ligands in 
the scaffold 
Three different moieties can be investigated in this scaffold: pyridocarbazole, 
1,4,7-trithiacyclononane ring, and monodentate ligand. To identify the most suitable 
monodentate ligand in the scaffold, a library of ruthenium complexes with different 






























Scheme 3.2. Synthesis of a library of ruthenium complexes with different monodentate ligands. 3.81: 
X=N3 yield: 48%, 3.82: X=NO2 yield: 65%, 3.83: X=NCSe yield: 33%, 3.84: X=NCO yield: 46%, 
3.85: X=CN yield: 42%, 3.86: X=NCS yield: 52%, 3.87: X=CO yield: 52%. All the complexes were 
synthesized as racemic mixtures. 3.87 was monocationic complex with PF6
- as counterion. 
Here the plain pyridocarbazole and 1,4,7-trithiacyclononane scaffold was used as 
starting point. Anionic ligands such as -N3, -NO2, -NCSe, -NCO, -CN, -NCS, and -CO 
were tried in this library. All the complexes were synthesized under microwave 
irradiation and purified by silica gel chromatography. -NCS and -NCSe usually behave 
as ambidentate ligand.20,23 In 3.86 the Ru-N bonding linkage isomer was observed (see 
subchapter 3.2). Complex 3.83 was assigned as Ru-N bonding isomer according to the 
IR bands of the -NCSe group. In the IR spectrum of 3.83, the absorption frequency of 
the -NCSe group is at 2101 cm-1 as two bands which is consistent with the literature33 
and the Lange’s handbook of chemistry (15th Edition, Spectroscopy, Table 7.22) in 
which the absorption frequency of -NCSe is in the range of 2000-2200 cm-1 as two 
bands. The racemic complexes were tested against protein kinases MLCK, Pim1, and 
GSK3α with 100 µM ATP and the IC50 values are shown in Table 3.1. 
 51 
Table 3.1. IC50 values of the racemic ruthenium complexes for MLCK, Pim1 and GSK3α in the 
presence of 100 µM ATP. 
IC 50 3.81 3.82 3.83 3.84 3.85 3.86 3.87 
MLCK  57 nM 120 nM 15 nM 101 nM 330 nM 74 nM 3 nM 
Pim1 58 nM 33 nM 6.4 nM 93 nM 90 nM 50 nM 450 pM 
GSK3α 7.4 µM > 30 µM 1.8 µM 3.8 µM > 30 µM 3.2 µM 14 nM 
The data demonstrate that the monodentate ligand causes notable influence on the 
binding affinity of the inhibitors in the kinase active site. The most potent inhibitor for 
MLCK was complex 3.87 with an IC50 value of 3 nM, but it also displayed high affinity 
for Pim1 and GSK3α,7 which meant 3.87 was not ideal to be used as the lead structure 
to develop selective MLCK inhibitors. The binding affinity for MLCK was decreased 
by a factor of 22 when -NCSe (3.83) was changed to -CN (3.85) in the complex. 
Complex 3.83 showed high binding affinity against MLCK of which t e IC50 value was 
15 nM. However, it also had strong effect on Pim1 and the IC50 value was only 6 nM. 
3.81 and 3.86 also showed relatively high potency for MLCK and the IC50 values were 
57 nM and 74 nM, respectively. Especially, the IC50 value of 3.81 for Pim1 was 58 nM 
which showed better selectivity than 3.86. The selectivity for MLCK over Pim1 was 
improved slightly by switching -NCSe to -N3, which could be further improved by the 
modification of the pyridocarbazole moiety. Overall, this scaffold showed very low 
affinity with kinase GSK3α except 3.87. With the ambidentate ligand -NCS or -NCSe in 
the complex, the linkage isomerizes under certain conditions which makes the synthesis 
and purification of the complexes more complicated. Correspondingly, -N3 has only one 
mode of binding to the ruthenium center. Thus, considering the potency, selectivity, and 
stability of the complex, azide can be the potential anionic monodentate ligand in the 
development of selective inhibitors for MLCK. 
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Chapter 3.1.3: Modification of the pyridocarbazole moiety 
  Since our lab colleague Nicholas Pagano developed a very successful synthetic route 
to pyridocarbazoles,6 functionalized pyridocarbazoles can be easily constructed by using 
substituted indoles and pyridines. Thus it could be a very powerful tool to modify the 
MLCK inhibitors to improve the potency and selectivity by using pyridocarbazoles with 
different substituents. The synthesis of a series of pyridocarbazoles with different 
substituents and ruthenium complexes with respectiv pyridocarbazole is summarized 
below. 












    DME/H2O/reflux
2. Silica gel, 80°C
    high vacuum  
Indole (R1) Pyridine (R2) Pyridylindole Yield (%)  
3.34  OCH3 H 3.54 87 
3.14  SCH3 F 3.15 87 
3.14  SCH3 H 3.19 76 
3.14  SCH3 N(Allyl) 2 3.24 73 
3.34  OCH3 F 3.35 84 
3.34  OCH3 OCH3 3.39 80 
3.3  OiPr F 3.8 97 
3.3  OiPr H 3.4 87 
  The synthesis of pyridylindoles by Suzuki cross-coupling is shown above (Table 3.2). 
Derivatives of the indole boronic acids were prepard in two synthetic steps from the 
appropriate commercially available or published indoles by Boc-protection, followed by 
introducing boronic acid.34 These boronic acids were yielded quantitively and used in 
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the subsequent Suzuki cross-coupling reaction with bromopyridines as crude. The 
mixture of boronic acids and bromopyridines was refluxed in DME/H2O (8:1) in the 
presence of 2.75 equiv of Na2CO3 and 0.075 equiv of Pd(PPh3)4 under nitrogen 
overnight affording pyridylindoles with the Boc-protection group partially removed. 
Unable to easily separate the two compounds in these ca es, the purified mixture in each 
case was adsorbed onto silica gel and heated at 80 °C under high vacuum to provide 
pyridylindoles in the range of 76-97% yield over two steps which were used to produce 
corresponding pyridocarbazoles. 






























Pyridylindole (R1, R2) Intermediate Pyridocarbazole Yield (%)  
3.54 OCH3, H 3.55 3.56 56 
3.15 SCH3, F 3.16 3.17 18 
3.19 SCH3, H 3.20 3.21 42 
3.24 SCH3, N(Allyl) 2 3.25 3.26 39
a 
3.35 OCH3, F 3.36 3.37 45 
3.39 OCH3, OCH3 3.40 3.41 51 
3.8 OiPr, F 3.9 3.10 57 
3.4 OiPr, H 3.5 3.6 58 
a) monoallyl-protected product obtained in 11% yield during photocyclization. 
  The synthesis of pyridocarbazoles from pyridylindoles is shown above (Table 3.3). 
Accordingly, pyridylindoles were treated carefully with 3 equiv of LiHMDS at -15 °C 
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in anhydrous THF for 1 hour and quenched with 1.05 equiv of TBS-protected 
dibromomaleimide, after stirring the mixture at 10 °C overnight, furnishing the 
relatively unstable monobromide intermediates which were carried forward after 
purified through a short flash silica gel chromatography. Cyclization of the 
monobromide intermediates by an anaerobic photocyclization with a medium pressure 
Hg lamp with a pyrex filter afforded the corresponding pyridocarbazoles in the range of 
18-58% yield over two steps. The allyl-deprotection of 3.26 was performed in DCM in 
the presence of 6 equiv of 1,3-dimethylbarbituric acid and 0.2 equiv of Pd(PPh3)4 under 
reflux for 7 hours to provide deprotected pyridocarbazole. The key step for the synthesis 
of pyridocarbazoles is the condensation of pyridylindoles with dibromomaleimide 
which significantly influences the synthetic yield. Electron-withdrawing groups on the 
pyridylindole decreases the yield of the reaction probably as a result of the decreased 
nucleophilicity of the joined heterocycles and the quality of LiHMDS also influences 
this reaction. 

































 R1 R2 Yield (%) 
FL123 OH F 42 
FL1381 OCH3 H 62 
FL1288 SCH3 F 45 
FL1343 SCH3 H 48 
FL1358 SCH3 NH2 49 
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FL1055 OCH3 F 68 
FL1229 OCH3 OCH3 57 
FL1335 OiPr F 48 
FL1359 OiPr H 53 
With pyridocarbazoles and ruthenium precursor 2 in hand, the synthesis of metal 
complexes was quite convenient which was conducted as escribed in chapter 3.1.1. 
The reactions were mostly clean and the products were easy to be purified by silica gel 
chromatography. The yield of these reactions in this library was in the range of 42-68% 
(Table 3.4). 
 
Figure 3.2. Crystal structure of complex FL1359. ORTEP drawing with 50% probability thermal 
ellipsoids. 
  X-ray quality crystals of the complex FL1359 suitable for single crystal diffraction 
were obtained from acetone by slow evaporation. The molecular structure of FL1359 is 
shown in Figure 3.2 which confirmed the relative configuration of the ruthenium 
scaffold. Because of the cyclic nature of the tridentate ligand and the sp3 hybridization 
at the coordinating sulfur atoms, 1,4,7-trithiacyclononane has to occupy both 





perpendicular to the pyridocarbazole plane for the coordination of the azide ligand. The 
bond angle of Ru1-N5-N6 is 119.4˚ due to the sp2 hybridization of the N5 and the bond 
of N5-N6-N7 is almost linear (176.7˚). 
Next, the library of these ruthenium complexes was measured against protein kinases 
MLCK and Pim1 in the presence of 100 µM ATP and the IC50 values are displayed in 
Table 3.5. The first derivative inhibitor made for MLCK was complex FL123. 
Introduction of a hydroxyl group on the 5-position f the indole and a fluorine on the 
3-position of the pyridine improved the binding affinity for MLCK by a factor of 3 
compared to 3.81 with an IC50 value of 19 nM. As expected, FL123 also showed high 
potency against Pim1 and the IC50 value was 18 nM. Same with 3.81, there was no 
selectivity for MLCK over Pim1. The hydroxyl group on the indole moiety can possibly 
form hydrogen bonds in the Pim1 active site.21,22 
Table 3.5. IC50 values in nM of racemic complexes against MLCK andPim1 in the presence of 100 
µM ATP. 
 FL123 FL1381 FL1055 FL1288 FL1343 FL1358 FL1229 FL1359 FL1335 
MLCK  19 15 10 84 18 22 40 27 21 
Pim1 18 52 44 982 154 609 161 847 520 
To improve the selectivity of the inhibitors for MLCK over Pim1, hydrophobic group 
was introduced instead of the hydroxyl group on the5-position of indole and 
modifications on the 3-position of pyridine were tested. The data demonstrate that a 
profound influence on the potency and selectivity of the ruthenium complexes is 
achieved by the modification on the 5-position of indole and/or 3-position of pyridine. 
The introduction of a big hydrophobic group on the 5-position of indole decreases the 
binding affinity for Pim1 dramatically. Replacing the hydroxyl group of FL123 by a 
methoxy group (FL1055) reduced the binding affinity for Pim1 by a factor f 2.4 
compared to FL123. Modification with a methoxy group both on the 5-position of 
indole and 3-position of pyridine (FL1229) decreased the potency of the inhibitor for 
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Pim1, but the selectivity for MLCK (40 nM) over Pim1 (161 nM) was only 4-fold. 
However, using a methylthio group (FL1288) or an isopropyloxy group (FL1335) 
instead of the hydroxyl group, the binding affinity for Pim1 was reduced by factors of 
54 and 29 compared to FL123, respectively. But the binding affinity of FL1288 for 
MLCK (84 nM) was decreased by a factor of 4.4 when compared to FL123. The data 
showed the modification of a fluorine on the 3-positi n of pyridine also influenced the 
potency and selectivity of the inhibitors, but there was no consistent effect found in this 
screening data, which probably depends on the binding mode of the inhibitors in the 
kinase active site. Although complex FL1358 displayed high affinity for MLCK (22 nM) 
and selectivity over Pim1 (27-fold), the synthesis of the pyridocarbazole pharmacophore 
ligand was more complicated than other inhibitors. Considering the factors of potency, 
selectivity and simplicity of the inhibitors, complex FL1359 was supposed to be the 
most promising lead structure for the development of MLCK inhibitors. With an IC50 
value of 27 nM for MLCK, FL1359 displayed a significant selectivity over Pim1 
(31-fold). 
Chapter 3.1.4: Modification of the tridentate ligand moiety 
In order to verify the obtained ruthenium complexes were indeed promising lead 
structures for the design of organometallic complexes as inhibitors for the protein 
kinases different from Pim1, complex FL1359 was used as a starting point for the 
proof-of-principle design of the more potent and selective inhibitors for MLCK. It was 
envisioned that the modification on the 1,4,7-trithiacyclononane ring should influence 
the binding affinity for MLCK and Pim1. But due to the low reactivity of the 
1,4,7-trithiacyclononane, there are not too many options for functionalizing this 
9-member ring directly. Once the ligand turns unsymmetric, more diastereoisomers will 
be formed in the coordination reactions, which makes the reaction more complicated 
and the separation of these diastereoisomers more difficult. On the other hand, it will 
give more opportunities to design the potent and selective inhibitors for protein kinases, 
as long as the chemistry is under control. 
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The different tridentate ligands shown in Figure 3.3 were used to modify the MLCK 
inhibitors. Three diastereoisomers can be formed when using these tridentate ligands in 












                                 
Figure 3.3. Tridentate ligands for modification of MLCK inhibitors. 
As using ruthenium precursor 2 as the starting point to synthesize the metal 
complexes, ruthenium precursors were first made containi g respective tridentate 
ligands. The synthesis of complex FL1392 is shown in Scheme 3.3. Compound 
1,4,7-trithiacyclodecan-9-one was used as starting point. After reductive amination with 
1.2 equiv of methyl amine in the presence of 2 equiv of sodium borohydride as 
reductive reagent, the secondary amine in compound 3.62 was protected with Alloc 
group using 1.5 equiv of allyl chloroformate as reag nt in the presence of 1 equiv of 
pyridine and catalytic amount of DMAP in dichloromethane in 76% yield. Ruthenium 
species 3.64 was provided from the reaction of compound 3.63 with RuCl2(dmso)4 by 
refluxing in chloroform for 5 hours. Followed by refluxing 3.64 in acetonitrile with 2 
equiv of silver trifluoromethanesulfonate for 6 hours to furnish the ruthenium precursor 
3.65 in 72% yield over two steps, which was reacted with pyridocarbazole 3.6 in DMF 
in the presence of 1.1 equiv of potassium carbonate under microwave irradiation, 
followed by using sodium azide to replace the one remaining acetonitrile group to 
afford the Alloc protected complex FL1392. Three diastereomers were formed in this 
reaction, but only the first isomer can be obtained purely by silica gel chromatography 
as the major product. The Alloc-deprotection of the complex was performed in 
dichloromethane with 8 equiv of N,N-dimethylbarbitur c acid and Pd(PPh3)4 as catalyst 







































































Scheme 3.3. Synthesis of racemic complexes FL1392. 
 
Figure 3.4. Crystal structure of complex FL626-1. ORTEP drawing with 50% probability thermal 
ellipsoids. 
The relative configuration of FL1392 was proven indirectly by the crystal structure 
of FL626-1 (Figure 3.4). FL626-1 was synthesized in analogy to FL1392 by reacting 
3.37 with precursor 3.74 in which Boc group was on the secondary amine under 
microwave irradiation, and then sodium cyanate was used to replace the remaining 
acetonitrile (Scheme 3.4). The crystals of FL626-1 were obtained from chloroform by 
slow evaporation. In the molecular structure, C22 was within the plane of 
pyridocarbazole and far away from it, probably due to the steric hindrance effect of the 
































































Scheme 3.4. Synthesis of racemic complex FL626-1. 
Complex FL1473 was synthesized (Scheme 3.5) starting with the tridentate ligand 
3.66, and the ruthenium precursor 3.68 was produced in the similar route using 
[RuCl2(η
6-C6H6)]2 instead of RuCl2(dmso)4 and acetonitrile/ethanol mixture (1:2) as 
solvent. Three diastereomers were formed during the synthesis of FL1473, which can 
not be separated by silica gel chromatography. Fortunately, the major product can be 
purified by crystallization of the mixture in acetone, but the yield of the reaction was 
















































Scheme 3.5. Synthesis of racemic complex FL1473. 
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The crystal structure of FL1473 shown in Figure 3.5 displays that N28 is on the axial 
position trans to the azide, due to the steric hindrance of the methyl group on the N28. 
In complex FL1473, the bond length of Ru-S1, Ru-S2, and Ru-N28 is 2.28 Å, 2.28 Å, 
and 2.18 Å, respectively. Ru-N28 is slightly shorter han Ru-S bond. The nitrogen 
makes the 9-member ring more strained, which probably results in the low yield of this 
reaction. 
 
Figure 3.5. Crystal structure of the complex FL1473. ORTEP drawing with 50% probability thermal 
ellipsoids. 
To verify whether the modifications improved the potency of the resulting inhibitors 
or not, racemic complexes FL1392 and FL1473 were measured against MLCK and the 
IC50 values were 110 nM and 230 nM in the presence of 100 µM ATP, respectively. The 
binding affinity was decreased by factors of 4 and 8.5 for MLCK compared to FL1359, 
respectively, probably due to the hydrophobic effect of the methyl group on the nitrogen 
in the tridentate ligand in both complexes. Thus, introduction of a hydrophilic group on 
the 9-member ring might be a promising opportunity. 
The synthesis of racemic complex FL1528-1 is summarized in Scheme 3.6. Starting 
with 1,4,7-trithiocyclononane, oxidization with 0.9 equiv of mCPBA in chloroform 
afforded mono-sulfoxide compound 3.60 in 64% yield, which was subsequently 
coordinated with the ruthenium precursor RuCl2(dmso)4 to yield the intermediate of 
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ruthenium species. Ruthenium precursor 3.61 was produced in the same way with 3.65 
in 80% yield over two steps, which was used to furnish FL1528-1 with the 
pyridocarbazole 3.6 under microwave irradiation. Similarly, three diastereomers were 
formed in the reaction and FL1528-1 was obtained purely by silica gel chromatography 
as the first fraction in 12% yield and the other two isomers were obtained as a mixture 
























































Scheme 3.6. Synthesis of racemic MLCK inhibitor FL1528-1. 
 
Figure 3.6. Crystal structure of complex FL1528-1. ORTEP drawing with 50% probability thermal 
ellipsoids. 
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X-ray quality crystals of complex FL1528-1 suitable for single crystal diffraction 
were obtained from DMF/diethyl ether by slow diffusion. The molecular structure 
shown in Figure 3.6 confirms the relative configuration of FL1528-1, in which the 
sulfoxide group is within the plane of pyridocarbazole ligand and positioned trans to the 
indole moiety. 
IC50 values of FL1528-1 against MLCK, PAK1, DAPK1, GSK3α, Flt4, and Pim1 in 
the presence of 100 µM ATP are shown in Table 3.6. Excitingly, FL1528-1 displayes an 
improved potency and selectivity significantly compared to the lead structure FL1359. 
With an IC50 value of 4.4 nM for MLCK, FL1528-1 showed at least 10-fold selectivity 
over the other five protein kinases on which our group is working (Pim1: 98-fold). 
Table 3.6. IC50 values of racemic FL1528-1 against MLCK, PAK1, DAPK1, GSK3α, Flt4 and Pim1 
in the presence of 100 µM ATP. 
IC 50 MLCK  PAK1 DAPK1 GSK3α Flt4 Pim1 
FL1528-1 4.4 nM > 100 µM 113 nM 31 µM 48 nM 435 nM 
Furthermore, a screening result shown in Figure 3.7 of complex FL1528-1 against a 
panel of 230 human wild-type protein kinases (Millipore UK Ltd) demonstrates the 
excellent selectivity profile of FL1528-1. In 230 tested human protein kinases, with a 
concentration of 30 nM of FL1528-1 (10 µM ATP) there were 205 kinases remained 
more than 50% activity. Impressively, only 7 kinases (MLCK: 2%, ZIPK: 5%, DAPK2: 
12%, Ret: 13%, DAPK1: 15%, Rsk2: 19% and Rsk1: 20%) displayed activity below 
20% under these conditions (see appendix for details). It was verified that the IC50 
values of FL1528-1 for ZIPK and Ret were 18 nM and 70 nM in the presence of 100 
µM ATP, respectively. FL1528-1 showed 4-fold selectivity for MLCK over ZIPK. 
Therefore, it can be concluded that organoruthenium co plex FL1528-1 constitutes a 
highly selective molecular probe for the protein kiase MLCK. 
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Figure 3.7. Selectivity profile of racemic FL1528-1 tested against a panel of 230 human wild-type 
protein kinases at a single concentration of 30 nM and an ATP concentration of 10 µM. The most 
inhibited kinases in this panel were MLCK (2%), ZIPK (5%), DAPK2 (12%), Ret (13%), DAPK1 
(15%), Rsk2 (19%) and Rsk1 (20%). Duplicate measurements were performed and the average was 
taken. See appendix for more details. 
Chapter 3.2: Development of DAPK1 inhibitors 
Chapter 3.2.1 Scaffold synthesis of DAPK1 inhibitors 
  The scaffold of DAPK1 inhibitors was initially identified from a screening of 
organoruthenium complexes including half-sandwich complexes and octahedral 
complexes against different kinases performed by former lab members. It was found 
that the potency for DAPK1 was improved almost 500-fold by changing half-sandwich 
complex to octahedral complex (Figure 3.8). Complex 3.86 was the only scaffold 
preferred by DAPK1 in this screening. Thus, scaffold 3.86 was used as the starting point 





















Figure 3.8. Racemic complex 3.86 was identified as initial DAPK1 inhibitor. 
  The scaffold of DAPK1 inhibitors was constructed in analogy to the MLCK inhibitors 
just using thiocyanate as monodentate ligand. In the same way, synthesis of the 
ruthenium scaffold was performed under microwave irradiation (Scheme 3.7). 
Thiocyanate is known to be an ambidentate ligand in the coordination chemistry,20,23 
and it can form Ru-N bond and Ru-S bond with the ruthenium center in this reaction 
which can be separated by silica gel chromatography. It was identified that the first 
fraction was always the Ru-N bonding linkage isomer, which will be proven in chapter 











































Scheme 3.7. Synthesis of racemic ruthenium complexes with microwave irradiation. R1, R2: 
different substituents on pyridocarbazole 
Chapter 3.2.2: Preliminary structure-affinity relationship study 
  To verify complex 3.86 suitable as the lead structure of DAPK1 inhibitors, the 
racemic derivative complex FL823-1 was synthesized as starting point (Figure 3.9), in 
which a hydroxyl group was on the 5-position of indole and a fluorine on the 3-position 






















IC50 = 200 nM IC50 = 20 nM  
Figure 3.9. IC50 values of racemic 3.86 and FL823-1 for DAPK1 with 100 µM ATP. 
  FL823-1 was tested against DAPK1 in the presence of 100 µM ATP and the IC50 
value was 20 nM which was improved by a factor of 10 compared to 3.86 (200 nM) by 
introducing a hydroxyl group and a fluorine on the pyridocarbazole. To investigate the 
selectivity profile of this scaffold, FL823-1 was measured against protein kinases 
GSK3α, GSK3β, and Pim1, and the IC50 values were 500 nM, 600 nM, and 3 nM, 
respectively, in the presence of 100 µM ATP (measured by G. Ekin Atilla-Gokcumen). 
The scaffold displayed high selectivity over both isoforms of GSK3, but very high 
affinity for Pim1. Thus, developing potent DAPK1 inh bitors but selective over Pim1 is 
of great interest.  
Chapter 3.2.3: Affinity effect of different monodentate ligand on 
the axial position 
  To investigate the influence on the binding affinity to DAPK1 of the monodentate 
ligand in the scaffold, a series of ruthenium complexes with different monodentate 
ligands were synthesized by reacting ruthenium precursor 2.3 first with 1 equiv of 
1,4,7-trithiacyclononane in DMF, and then different monodentate ligands (Figure 3.10). 



























Figure 3.10. Synthesis of ruthenium complexes with different monodentate ligands. FL253: X=CN 
yield: 17%, FL475: X=NCO yield: 27%, FL528: X=NCSe yield: 45%, FL576: X=CO yield: 50%, 
FL823-2: X=SCN yield: 34%. All the complexes were racemic. FL528 was assigned as Ru-N 
bonding isomer according to complex 3.83 by IR spectra. FL576 was monocationic complex with 
PF6
- as counterion. 
  Next, these complexes were tested against DAPK1 as racemic mixture in the presence 
of 100 µM ATP and the IC50 values are listed in Table 3.7. 
Table 3.7. IC50 values of racemic ruthenium complexes with different monodentate ligands on the 
axial position in the presence of 100 µM ATP. (measured by G. Ekin Atilla-Gokcumen) 
 FL823-1 FL253 FL475 FL528 FL576 FL823-2 
DAPK1 20 nM > 10 µM 500 nM 3 nM 250 nM 30 nM 
The data demonstrate that there is significant influence on the affinity of the scaffold 
for DAPK1 with different monodentate ligands on the axial position. Complex FL253 
was completely inactive when using a cyanide instead of the isothiocyanate and the IC50 
value was more than 10 µM. The binding affinity was also decreased by factors f 25 
and 12.5 compared to FL823-1, respectively, when using -NCO (FL475) or -CO 
(FL576) on the axial position. The big difference of the affinity for DAPK1 between 
-CN and -CO is due to the difference of hydrophobicity of these two ligands. Although 
they are isoelectronic, the coordinated carbonyl group is more hydrophobic compared to 
cyanide which tends to form hydrogen bonds with the lone pair of nitrogen. Therefore, 
cyanide is more disfavored in the hydrophobic pocket in DAPK1 active site.24,25 The 
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affinity of the -SCN complex (FL823-2) was slightly higher than the -NCS complex 
(FL823-1), probablely due to the different angle of the coordinated monodentate ligands. 
However, when using a more hydrophobic ligand -NCSe instead of -NCS, the potency 
of FL528 for DAPK1 was increased significantly by a factor of 7 compared to FL823-1. 
Therefore, the data demonstrated that a hydrophobic group on the axial position is more 
favorable in the active site of DAPK1. 
Chapter 3.2.4: Improved DAPK1 inhibitor by modification on the 
pyridocarbazole moiety 
  Although FL528 showed high affinity for DAPK1 with an IC50 value of 3 nM in the 
presence of 100 µM ATP, it was much more potent for Pim1 with an IC50 value of lower 
than 0.3 nM. Thus, it was still promising to use th isothiocyanate as monodentate 
ligand to develop the more potent and selective DAPK1 inhibitors. It was envisioned 
that the same strategy of the development of MLCK inhibitors might be suitable for 
DAPK1 project. Especially, both catalytic domains of DAPK1 and MLCK have very 
high sequence similarity. With a series of pyridocarbazoles in hand, it can be very 
convenient to identify the promising pharmacophore ligand for the scaffold of DAPK1 
inhibitors.  
All the derivatives of inhibitors for DAPK1 are shown in Table 3.8. These racemic 
derivatives were synthesized in analogy to MLCK inhibitors by first reacting 
corresponding pyridocarbazoles with the ruthenium precursor 2 under microwave 
irradiation, followed by the addition of sodium thiocyanate to replace the remaining 
acetonitrile group. The isothiocyanato complexes were abtained by silica gel 
chromatography except FL1334, which was a mixture of isothiocyanato and 
thiocyanato complexes with the ratio of around 1 : 1. 
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Table 3.8. Ruthenium complexes with different substituents on the pyridocarbazole. All the 












































 R1 R2 Yield (%) 
FL812-1 OCH3 F 33 
FL1289-1 SCH3 F 17 
FL1334 SCH3 NH2 43 
FL1352-1 SCH3 H 23 
FL1353-1 OiPr F 37 
FL1370-1 OiPr H 40 
Derivative FL812-1 was first synthesized and tested against DAPK1 and Pim1. The 
IC50 values against DAPK1 and Pim1 in the presence of 100 µM ATP were 6 nM and 7 
nM, respectively. The potency of FL812-1 for DAPK1 was improved by a factor of 3, 
and for Pim1 was decreased by a factor of 2 compared to FL823-1 by changing the 
hydroxyl group on the indole to a methoxy group. But FL812-1 still had no selectivity 
over Pim1. Interestingly, the modification with a hydrophobic group on the 5-position of 
indole improved the potency of inhibitors for DAPK1. As discussed in the MLCK 
inhibitors subchapter, introduction of a big hydroph bic group on the 5-position of 
indole disfavores Pim1 kinase significantly. Thus, to further improve the potency and 
selectivity of DAPK1 inhibitors, the modification of pyridocarbazole with hydrophobic 
substituents was tried in this scaffold. These derivatives were tested against DAPK1 and 
Pim1 in the presence of 100 µM ATP and the results are shown in Table 3.9. 
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Table3.9. IC50 values in nM of racemic derivatives with different pyridocarbazoles for DAPK1 and 
Pim1 in the presence of 100 µM ATP. 
 FL812-1 FL1289-1 FL1334 FL1352-1 FL1353-1 FL1370-1 
DAPK1 6 12.5 3.7 4.2 2 3.9 
Pim1 7 172 72 100 169 434 
The data demonstrate that a profound influence on the potency and selectivity of the 
ruthenium complexes is achieved by the modification on the 5-position of indole with a 
hydrophobic group and/or 3-position of pyridine. A big hydrophobic group on the 
5-position of indole significantly improved the selectivity of inhibitors over Pim1. 
Using a methylthio group (FL1289-1) instead of the methoxy group, the potency for 
DAPK1 (12.5 nM) was decreased by a factor of 2 compared to FL812-1. At the same 
time, the affinity for Pim1 (172 nM) was decreased by a factor of 24. Using an amino 
group instead of the fluorine (FL1334) or just removing the fluorine (FL1352-1) on the 
pyridine moiety, both increased the affinity for DAPK1 and Pim1, and the IC50 values 
were 3.7 nM and 4.2 nM for DAPK1, and 72 nM and 100 nM for Pim1, respectively. 
However, the selectivity over Pim1 was further improved. FL1334 and FL1352-1 
showed 19-fold and 24-fold selectivity over Pim1, respectively. In addition, the potency 
and selectivity of FL1353-1 was further improved with an isopropyloxy group on the 
5-position of indole and a fluorine on the 3-position of pyridine in the scaffold. The IC50 
value for DAPK1 was 2 nM and for Pim1 was 169 nM which was improved by factors 
of 3 and 24 compared to FL812-1, respectively, and the selectivity over Pim1 of 
FL1353-1 was around 85-fold. After removing the fluorine on the pyridine in complex 
FL1370-1, the selectivity over Pim1 was further improved (111-fold), but the potency 
for DAPK1 was decreased to 3.9 nM. Thus, overall, complex FL1353-1 was the most 
promising inhibitor for DAPK1 in the library. By the modification of the 
pyridocarbazole, the potency of FL1353-1 for DAPK1 was improved by a factor of 100 
compared to complex 3.86. 
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Complex FL1353-1 was further tested against PAK1, MLCK, GSK3α, and Flt4 to 
investigate the selectivity profile of this scaffold. The IC50 values are listed in Table 3.10. 
With an IC50 value of 2 nM for DAPK1, FL1353-1 showed at least 12-fold selectivity 
over the other five kinases (MLCK: 12-fold, Pim1: 84-fold). 
Table 3.10. IC50 values of racemic FL1353-1 against DAPK1, Pim1, PAK1, MLCK, GSK3α and 
Flt4 in the presence of 100 µM ATP. 
 DAPK1 Pim1 PAK1 MLCK GSK3 α Flt4 
FL1353-1 2 nM 169 nM > 100 µM 25.3 nM > 100 µM 163 nM 
  Furthermore, a screening result shown in Figure 3.11 of complex FL1353-1 against a 
panel of 102 human wild-type protein kinases (Millipore UK Ltd) demonstrates the 
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Figure 3.11. Selectivity profile of racemic FL1353-1 tested against a panel of 102 human wild-type 
protein kinases at a single concentration of 10 nM a d an ATP concentration of 10 µM, with DAPK1 
displaying a remaining activity of 12% under these conditions and the remaining kinases below 50% 
activity being ZIPK (22%), Rsk2 (27%), Rsk1 (31%), MELK (37%) and Pim1 (38%). Duplicate 
measurements were performed and the average was taken. See appendix for more details. 
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In 102 tested human protein kinases, with a concentration of 10 nM of racemic 
FL1353-1 (10 µM ATP) there were 96 kinases remained more than 50% activity. 
Impressively, only DAPK1 (12% activity) displayed activity below 20% under these 
conditions (see appendix for details), and the other kinases showed lower than 50% 
activity were ZIPK (22%), Rsk2 (27%), Rsk1 (31%), MELK (37%), and Pim1 (38%). It 
was verified that the IC50 value of FL1353-1 for ZIPK was 8.8 nM in the presence of 
100 µM ATP. FL1353-1 showed 4-fold selectivity over ZIPK. Therefore, it can be 
concluded that organoruthenium complex FL1353-1 was developed as a highly potent 
and selective inhibitor for protein kinase DAPK1. 
Chapter 3.2.5: Determination of the relative configuration of 
FL1353-1 
 
Figure 3.12. Crystal structure of complex FL1370-1. ORTEP drawing with 50% probability thermal 
ellipsoids. 
  The crystal structure of FL1370-1 shown in Figure 3.12 verified the relative 
configuration of the related complex FL1353-1 indirectly. Crystallization of FL1353-1 
didn’t succeed. X-ray quality crystals of the complex FL1370-1 suitable for single 
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crystal diffraction were obtained in acetone and methanol mixture solvent by slow 
evaporation. In the molecular structure, the isothiocyanate ligand is on the axial position 
perpendicular to the pyridocarbazole and the angle of Ru01-N100-C101 bond is almost 
linear (171.8˚) which is consistent with the literature.26,27 
In complex FL1353-1, the ruthenium center binding with the isothiocyanate binding 
mode (Ru-N bond) was also proven by 15N NMR measurements, which was performed 
with complexes FL534-1 and FL534-2 (Figure 3.13). It was synthesized in analogy to 
FL823 just using potassium thiocyanate-15N instead of sodium thiocyanate as the 
























Figure 3.13. Structure of racemic complexes FL534-1 and FL534-2. 
  The 15N NMR spectra of FL534-1 and FL534-2 shown in Figure 3.14 were recorded 
in anhydrous DMSO-d6. FL534-2 was measured as a mixture of both linkage isomers 
and NH3 liquid was used as standard in the measurement. The chemical shift of 
isothiocyanate in FL534-1 was 125.5 ppm, more up-field shifted than thiocyanate in 
FL534-2 which was 236.5 ppm. The result was consistent with the data in Lange’s 
Handbook of Chemistry (15th Edition, Spectroscopy, Table 7.63), in which the cmical 
shift of isothiocyanates is in the range of 95-120 ppm and the chemical shift of 
thiocyanates is in the range of 265-280 ppm with liquid NH3 as standard, more 
downfield-shifted than isothiocyanates. Thus, it fur her proved the relative configuration 
of FL1353-1 which is the Ru-N linkage isomer. 
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Figure 3.14. 15N NMR spectra of FL534-1 and FL534-2. NH3 liquid was used as standard, and 
FL534-2 was measured as a mixture of both linkage isomers. 
Chapter 3.2.6: Isomerization of Ru-N and Ru-S of Complex 
FL1353 monitored by 1H NMR spectra 
  Thiocyanate is well known as ambidentate ligand and linkage isomers of cobalt28 and 
platinum29 complexes for example containing thiocyanate have been studied. However, 
very little work has been reported on ruthenium thiocyanate linkage isomers.30 The 
linkage isomerization was performed in DMSO-d6/D2O (9:1) at room temperature and 
monitored by 1H NMR spectra starting from these two pure racemic isomers FL1353-1 
(Ru-N bonding) and FL1353-2 (Ru-S bonding). The ratios of these two linkage isomers 
(Ru-N bonding and Ru-S bonding) are listed in Table 3.11 as a function of time. 





1 hour 1 : 0 0.05 :1 
2 hours 1 : 0 0.11 : 1 
4 hours 1 : 0.05 0.2 : 1 
  560.0    520.0    480.0    440.0    400.0    360.0    320.0    280.0    240.0    200.0    160.0    120.0    80.0     40.0    0.0    -40.0    -80.0   







21 hours 1 : 0.15 0.8 : 1 
45 hours 1 : 0.25 2 : 1 
70 hours 1 : 0.28 2.9 : 1 
4 days 1 : 0.28 3.3 : 1 
5 days 1 : 0.29 1 : 0.29 
7 days 1 : 0.29 1 : 0.29 
10 days 1 : 0.29 1 : 0.29 
  The data demonstrate that FL1353-1 isomerized more slowly compared to FL1353-2 
and Ru-N bonding was more favorable in this equilibrium. After 3 days, they both 
reached equilibrium with the ratio of 1:0.29 of two linkage isomers (Ru-N:Ru-S), in 
which the Ru-N bonding isomer was the major one. The 1H NMR spectra only showed 
the isomerization of these two linkage isomers withou  any decomposition of the 
complexes which meant that the linkage isomerized without dissociation from 
ruthenium center. 
Chapter 3.2.7: Cocrystal structure of (R)-FL1353-1 with DAPK1 
  To understand the molecular details of the binding of the octahedral scaffold to 
DAPK1, cocrystallization of racemic FL1353-1 (Ru-N) and FL1353-2 (Ru-S) with 
DAPK1 was carried out, respectively, by lab colleague Katja Kräling. A cocrystal 
structure was obtained by Yann Geisselbrecht from the group of Prof. Dr. Lars-Oliver 
Essen and is shown in Figure 3.15. The cocrystal was initially executed with Ru-S 
isomer, but it isomerized to Ru-N isomer during thecocrystallization. The angle of 
Ru-N-C (linkage) is 142.9˚ in the cocrystal structure, slightly bendier than in the single 




Figure 3.15. Cocrystal structure of (R)-FL1353-1 with DAPK1 at the resolution of 2.2 Å. a) 
Hydrogen bonding interactions between the hinge region and (R)-FL1353-1. b) Hydrophobic 
interactions of (R)-FL1353-1 in the active site. The absolute configuration at the ruthenium was 
assigned according to the Cahn-Ingold-Prelog rules treating the complex as being pseudo-tetrahedral 
with the 1,4,7-trithiacyclononane being formally regarded as a single substituent, with the priority 
order of the substituents being 1,4,7-trithiacyclononane > pyridine [N(C,C,C)] > NCS > indole 
[N(C,C,lone pair)]. 
The structure reveals that the (R)-enantiomer of FL1353-1 occupies the ATP-binding 
site. Whereas the maleimide moiety forms two canonical hydrogen bonds with the hinge 
region of DAPK1 (Val96 and Glu94) (Figure 3.15a). Furthermore, the isopropyl ether 
oxygen at the indole moiety forms a water-mediated contact to the amino acids Lys42 
(2.7 Å), Glu64 (2.8 Å), and Asp161 (2.5 Å), and theisopropyl substituent reaches into a 
small hydrophobic pocket composed out of Lys42, Ile77, Leu93, Leu91, and Leu68 
(Figure 3.15b). The pyridocarbazole heterocycle is sandwiched by key hydrophobic 
contacts from amino acids of the N-terminal (Leu19, Val27, and Leu93) and C-terminal 
(Ile77, Val96, Met146, and Ile160) domains. The 1,4,7-trithiacyclononane ligand points 
towards the more hydrophilic entrance of the ATP-binding site and occupies the 
extended chemical space in the domain. The isothiocyanate ligand on the axial position 
points towards the hydrophobic pocket of glycin-rich loop forming close contact with 
the side chain residues of Val27, Ala25, and Lys42, as well as the backbone residues of 






















Chapter 3.3: Improved inhibitor for Pim1 kinase 
  Our group published 3.87 (Scheme 3.2) as Pim1 kinase inhibitor in 2006 with an IC50 
value of 450 pM in the presence of 100 µM ATP.7 Based on the structure-affinity 
relationship study of half-sandwich ruthenium inhibitors,17,21 it was envisioned that the 
potency of this inhibitor might be improved by introducing the hydrophilic hydroxyl 






















































Scheme 3.8. Synthesis of racemic FL1360 starting from pyridocarbazole 3.69. 
  The synthesis of racemic FL1360 starting from pyridocarbazole 3.6935 is shown in 
Scheme 3.8. Accordingly, pyridocarbazole 3.69 was cyclometallated with 0.75 equiv of 
[(η6-benzene)RuCl2]2 in the presence of 1.1 equiv of potassium carbonate i  acetonitrile 
at 50 °C affording the η6-half-sandwich complex 3.70 in 95% yield. The benzene ring 
was replaced by three acetonitrile molecules upon UV-photolysis in acetonitrile at room 
temperature, followed by TBS-deprotection using TBAF (1 M in THF) at 0 °C, which 
 78 
afforded the ruthenium precursor 3.71. The complex 3.71 shown in Scheme 3.7 is the 
major diastereoisomer obtained in 33% yield over two steps, which was subsequently 
used as a precursor for the synthesis of octahedral complex FL1360. The solution of 
3.71 in DMF was first reacted with CO gas at 75 °C, and then with 1 equiv of 
1,4,7-trithiacyclononane at 95 °C to provide the racemic cationic complex FL1360 in 






























Figure 3.16. Potency for Pim1 was improved by the transformation of half-sandwich scaffold into 
octahedral scaffold. 
  Complex FL1360 was measured as racemic mixture against Pim1 and GSK3α in the 
presence of 100 µM ATP and the IC50 values were 75 pM and 20 nM, respectively. 
Correspondingly, lab colleague Howard Bregman synthesized the half-sandwich 
complex HB2 (Figure 3.16) with the bis-hydroxyl pyridocarbazole and the IC50 value of 
HB2 for Pim1 was 250 pM and for GSK3α was 500 pM in the presence of 100 µM ATP. 
The potency of this scaffold for Pim1 was improved by a factor of 3.3 by switching the 
cyclopentadienyl ligand into 1,4,7-trithiacyclononane ligand. At the same time, the 
potency for GSK3α was decreased by a factor of 16 compared to HB2. 
  According to the previous study of MLCK and DAPK1 inhibitors discussed above, 
1,4,7-trithiacyclononane scaffold disfavors GSK3α kinase. Here, the selectivity over 
GSK3α of FL1360 was also significantly improved. Compared to 3.87 (450 pM for 
Pim1), the potency of FL1360 for Pim1 was improved by a factor of 6, probably 
because both hydroxyl groups form hydrogen bonding interactions with the backbone in 
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the Pim1 active site. 
Table 3.12. IC50 values of racemic FL1360 against protein kinases of Pim1, DAPK1, PAK1, MLCK, 
GSK3α, and Flt4 in the presence of 100 µM ATP. 
 Pim1 DAPK1 PAK1 MLCK GSK3 α Flt4 
FL1360 75 pM 315 nM 82 nM 2.2 nM 8 nM 29 nM 
Complex FL1360 was also tested against protein kinases of PAK1, MLCK, DAPK1, 
GSK3α, and Flt4 in the presence of 100 µM ATP and the results are listed in Table 3.12. 
The data demonstrat that FL1360 showed high affinity to the other five different protein 
kinases and the IC50 values were all in nanomolar range. But the Pim1 inhibitor of 
FL1360 still displays at least 29-fold selectivity over the other five kinases. 
Charpter 3.4: Discussion and conclusion 
Potent and selective organoruthenium inhibitors for MLCK, DAPK1, and Pim1 were 
developed with the trithiacyclononane scaffold containing different pyridocarbazoles 
and monodentate ligands. 
MLCK is a serine/threonine specific protein kinase and one of the key regulatory 
enzymes in Ca2+-dependent responses.8,9 Recent research demonstrated that increased 
MLCK activity might be involved in the bronchoconstric ion in asthma attacks.14,15 A 
nanomolar inhibitor FL1528-1 for MLCK was developed. The MLCK inhibitor scaffold 
was identified by screening several potential organoruthenium inhibitors against a panel 
of human protein kinases, which turned out to be a v ry useful method for the discovery 
of new inhibitors for certain kinases.  
The potency and selectivity over the other kinases especially for Pim1 of the MLCK 
inhibitors can be improved by modifying the three moieties in the scaffold. First, using 
azide as the monodentate ligand gave the inhibitor relatively high potency for MLCK 
and stability compared to other monodentate ligands such as: -NCO, -NCS, -NO2, and 
-CN. Second, the selectivity of the inhibitors for MLCK over Pim1 was improved easily 
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by the modification of pyridocarbazole. It was found that the introduction of a big 
hydrophobic group on the 5-position of indole disfavored Pim1 dramatically. For 
example, using an isopropyloxyl group (FL1359) instead of the methoxyl group 
(FL1381) on the pyridocarbazole, the binding affinity for Pim1 was reduced from 52 
nM to 847 nM in the presence of 100 µM ATP by a factor of 16. Lastly, the potency of 
the lead structure of MLCK inhibitors (FL1359) was further improved by the 
modification of the tridentate ligand trithiacyclononane. The results demonstrated that a 
hydrophobic group modified on the tridentate ligand decreased the potency of the 
MLCK inhibitors. Contrarily, the introduction of a small sulfoxide group increased the 
binding affinity for MLCK from 27 nM (FL1359) to 4.4 nM (FL1528-1) in the 
presence of 100 µM ATP by a factor of 6. FL1528-1 displayed high potency for MLCK 
and impressive selectivity over the other kinases. FL1528-1 was measured against a 
panel of human protein kinases. In 230 tested protein kinases, with a concentration of 
30 nM of FL1528-1 (10 µM ATP) there were 205 kinases remained more than 50%
activity. Impressively, only 2 kinases displayed activity below 10% under these 
conditions including MLCK. 
DAPK is a novel cytoskeletal-associated cell death serine/threonine kinase whose 
activation by Ca2+/calmodulin may be linked to the biochemical mechanism underlying 
the cytoskeletal alterations that occur during celld ath.31 The role of the kinase activity 
of DAPK in eukaryotic cell apoptosis has made it a drug discovery target for 
neurodegenerative disorders.32 Octahedral ruthenium complex FL1353-1 was developed 
as a very potent and selective inhibitor for protein kinase DAPK1. With an IC50 value of 
2 nM for DAPK1 in the presence of 100 µM ATP, FL1353-1 showed 84-fold selectivity 
over Pim1 and completely inactive for GSK3α. 
  The DAPK1 inhibitor scaffold was identified from a screen of organoruthenium 
complexes against a panel of protein kinases. Complex FL823-1 showed improved 
binding affinity to DAPK1 by the introduction of a hydroxyl group on the 5-position of 
indole and a fluorine on the 3-position of pyridine with an IC50 value of 20 nM in the 
presence of 100 µM ATP, but more potent for Pim1. The affinity influence of different 
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monodentate ligands in the scaffold was investigated. It was identified that a 
hydrophobic monodentate ligand was more favorable in the DAPK1 active site and the 
isothiocyanate was used as the monodentate ligand in the scaffold to develop more 
potent and selective DAPK1 inhibitors. 
  The potency and selectivity of DAPK1 inhibitors was improved by the modification 
of the pyridocarbazole. It was found that a profound i fluence on the potency and 
selectivity of the ruthenium complexes was achieved by the modification on the 
5-position of indole with a hydrophobic group and/or 3-position of pyridine. With a big 
hydrophobic group such as isopropyloxy group (FL1353-1) on the 5-position of indole, 
the IC50 value for DAPK1 was improved from 20 nM to 2 nM in the presence of 100 
µM ATP by a factor of 10 compared to FL823-1. At the same time, the IC50 value for 
Pim1 was decreased from 3 nM to 169 nM by a factor of 53. It turned out that 
FL1353-1 displayed high kinase selectivity after testing it against a panel of 102 human 
protein kinases. With a concentration of 10 nM of FL1353-1, only DAPK1 displayed 
activity below 20% in the presence of 10 µM ATP. The relative configuration of 
FL1353-1 was verified by the X-ray single crystal diffraction and 15N NMR spectra.  
A cocrystal structure of (R)-FL1353-1 with DAPK1 revealed the details of 
interactions of the inhibitor in DAPK1 active site. Whereas the maleimide moiety forms 
two canonical hydrogen bonds with the hinge region of DAPK1 (Val96 and Glu94). 
Furthermore, the isopropyl ether oxygn at the indole moiety forms a water-mediated 
contact to the amino acids Lys42, Glu64, and Asp161, and the isopropyl substituent 
reaches into a small hydrophobic pocket composed out of Lys42, Ile77, Leu93, Leu91, 
and Leu68. The 1,4,7-trithiacyclononane ligand points towards the more hydrophilic 
entrance of the ATP-binding site and occupies the ext nded chemical space in the 
domain. The isothiocyanate ligand on the axial position points towards the hydrophobic 
pocket of glycin-rich loop forming close contact with the side chain residues of Val27, 
Ala25, and Lys42, as well as the backbone residues of Gly20, Val26, and Ser21 in the 
active site. 
A picomolar range organoruthenium inhibitor FL1360 for Pim1 was obtained. The 
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potency for Pim1 was improved by a factor of 6 by the introduction of a hydroxyl group 
on the 5-position of indole and a hydroxylmethy group on the 3-position of pyridine 
compared to complex 3.87. The selectivity of FL1360 over GSK3α was 106-fold, 
improved significantly by switching the cyclopentadienyl group to a trithiacyclononane 
compared to the half-sandwich complex HB2 (2-fold). FL1360 also showed high 
selectivity over PAK1, MLCK, DAPK1, and Flt4. 
In addition, the microwave irradiation methodology was used in the synthesis of the 
organoruthenium inhibitors. Starting from the ruthenium complex 2 which is proven to 
be a novel precursor to synthesize kinase inhibitors, it is very convenient to construct 
metal complexes with different pyridocarbazoles with relatively short reaction time and 
high yield under microwave irradiation. The microwave irradiation is proven to be very 
efficient in this kind of reactions. 
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Chapter 4: Ruthenium Scaffold with Acyclic Tridentate 
Ligands as Potential Protein Kinase Inhibitors 
Chapter 4.1: Design of TrkA inhibitors with octahedral 
ruthenium scaffold 
  Lab colleague Nicholas Pagano published a low nanomolar half-sandwich lactam 
metallo-pyridocarbazole inhibitor (Figure 4.1) for protein kinase TrkA, which displayed 
high potency (IC50: 6 nM with 100 µM ATP) and impressive selectivity out of 229 
tested human protein kinases.1 
 
Figure 4.1. Structure of TrkA inhibitor NP. 
  In this scaffold the lactam pharmacophore was developed instead of maleimide to 
achieve the selectivity of the inhibitor over the other kinases, especially for Pim1.1 But 
synthesis of the lactam pharmacophore was a little more complicated than 
pyridocarbazole synthesis. The strategy of exploring potent, selective protein kinase 
inhibitors with octahedral ruthenium scaffold has been applied successfully in the 
previous chapters either containing bidentate ligands or cyclic tridentate ligands. Here a 
new organoruthenium scaffold containing pyridocarbazole as the hinge-binder plus 
acyclic tridentate ligands is designed. 
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Chapter 4.2: Discovery of octahedral lead structure for protein 
kinase TrkA 
  2,6-Bis(methyliminomethyl)pyridine was used as starting point. Synthesis of the 
scaffold is shown in Scheme 4.1. Accordingly, the scaffold was constructed by reacting 
ruthenium precursor 4.17 with tridentate ligand 4.28 in DMF at 70 °C for 1 hour. Two 
diastereomers were formed in the reaction in which pyridine of 4.2 was at the position 
cis (FL792-1) or trans (FL792-2) to the indole moiety of pyridocarbazole in 26% and 
24% yield, respectively. These two diastereomers can be assigned by 1H NMR 
spectroscopy as discussed in chapter 2.4. The scaffold is simple and the synthesis is 

































Scheme 4.1. Synthesis of FL792-1 and FL792-2. 
Next, FL792-1 and FL792-2 were screened against a panel of 227 human protein 
kinases at the concentration of 1 µM in the presence of 10 µM ATP. The result (see 
appendix for details) demonstrate that out of 227 tested human protein kinases, this 
scaffold displayed impressive selectivity profile, with only four kinases (CHK2: 3% 
with FL792-2, GSK3α: 9% with FL792-1, Pim1: 6% with FL792-1 and 8% with 
FL792-2, and TrkA: 4% with FL792-1) displaying less than 10% activity under these 
conditions. It was verified that the IC50 value of complex FL792-1 for TrkA was 480 
nM in the presence of 100 µM ATP. Thus, in principle, it might be the lead structure to 
develop potent and selective TrkA inhibitors with less synthetic effort. 
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Chapter 4.3: Modification on the pyridocarbazole moiety to 
improve the potency of TrkA inhibitors 
  To improve the potency of the TrkA inhibitors, different pyridocarbazoles were used 













































































































































Scheme 4.2. Synthesis of derivatives of TrkA inhibitors. All precursors 4.3-4.6 were used as a 
mixture of two diastereomers and only one isomer is shown. 
  Accordingly, ruthenium precursors 4.3-4.6 were synthesized in analogy to precursor 
2.3 (chapter 2.2) by first reacting corresponding pyridocarbazole ligand with 
[(η6-benzene)RuCl2]2 in the presence of potassium carbonate in acetonitrile affording 
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the η6-half-sandwich complex, and then the benzene ring was replaced by three 
acetonitrile molecules upon UV-photolysis in acetonitrile, followed by 
TBS-deprotection using TBAF, which afforded the ruthenium precursor complex as a 
mixture of two diastereomers in each case which was used in the subsequent reaction 
without separation. Following, the precursors 4.3-4.6 were reacted with 1 equiv of 
tridentate ligand 4.2 in DMF at 70 °C to afford the corresponding ruthenium complexes 
as a mixture of two diastereomers with the ratio of ar und 1:1 in each case, which were 
separated by silica gel chromatography. Complexes FL1138-1, FL1124-1, FL609-1, 
and FL1190-1 were tested against TrkA in the presence of 100 µM ATP and the IC50 
values are listed in Table 4.1. 
Table 4.1. IC50 values of the derivatives for TrkA in the presence of 100 µM ATP. 
 FL1138-1 FL1124-1 FL609-1 FL1190-1 
TrkA >3 µM 360 nM 110 nM 41 nM 
  The data demonstrate that substitution with a hydrophobic group on the 5-position of 
indole disfavored TrkA. The IC50 value of FL1138-1 was more than 3 µM, completely 
inactive for TrkA by modifying pyridocarbazole with a methoxy group on the 5-position 
of indole and a fluorine on the 3-position of pyridine. The potency of FL1124-1 (360 
nM) was improved slightly by changing the pyridine moiety into an isoquinoline 
compared to FL792-1. Introduction of a hydroxyl group on the 5-position f indole 
significantly improved the potency. The affinity ofFL609-1 (110 nM) and FL1190-1 
(41 nM) was improved by factors of 4 and 12 compared to FL792-1, respectively. 
To investigate the selectivity of this scaffold over Pim1, FL1190-1 was measured 
against Pim1 and it turned out that this scaffold displayed very high potency for Pim1 as 
well, with an IC50 value of 10 nM in the presence of 100 µM ATP. The key to achieve 
the selectivity for TrkA inhibitor NP over Pim1 is using lactam as pharmacophore 
ligand instead of pyridocarbazole.1 Thus, it was envisioned that introducing the lactam 













                                                  
Figure 4.2. Structure of complex FL1220. 
  To synthesize complex FL1220, a new synthetic route needs to be developed 
different from the synthesis of FL792, as the synthesis of analogous tris-acetonitrile 
precursor with lactam ligand never succeeded so far due to its lability of the lactam. 
Ruthenium precursor 4.72,3 similar to 1,4,7-trithiacyclononane precursor (chapter 3) was 
prepared by refluxing the tridentate ligand 4.2 and [(η6-benzene)RuCl2]2 in 














Scheme 4.3. Synthesis of ruthenium precursor 4.7. 
  To discover the ideal reaction condition for the synthesis of FL1220, pyridocarbazole 
3.37 was used as model system. The best condition ever tried is shown in Scheme 4.4. 
Correspondingly, ligand 3.37 and 1.1 equiv of precursor 4.7 with 1.1 equiv of potassium 
carbonate as base in ethanol were refluxed for 1.5 hours yielding a mixture of two 
diastereoisomers which had TBS group on the imide. Interestingly, TBS protected 
FL1138-1 was the major isomer and the ratio of these two diastereomers was 1:0.15. 
Deprection of TBS group was following performed with TBAF in MeCN, after which 



































Scheme 4.4. Model system to discovery the reaction condition of pyridocarbazole with ruthenium 
precursor 4.7. 
  Next, synthesis of complex FL1220 was performed in a similar way (Scheme 4.5) by 
reacting lactam ligand 4.81 with 1.1 equiv of precursor 4.7 in the presence of 1.1 equiv 
of potassium carbonate in ethanol, refluxing for 6 hours, followed by TIPS-deprotection 
with TBAF in MeCN to yield FL1220 in 18% over two steps. Complex FL1220 was 
measured against TrkA. Unfortunately, the IC50 value was only 83 nM in the presence of 
100 µM ATP, which was decreased by a factor of 14 compared to the published inhibitor 
NP, by replacing the Cp and CO moiety for the tridentate ligand scaffold. Thus, it was 






























Scheme 4.5. Synthesis of complex FL1220. 
Chapter 4.4: Applying different tridentate ligands to improve the 
potency for TrkA inhibitors 
  Complex FL1190-1 is a promising scaffold to develop potent TrkA inhibitors but one 
needs to overcome the lack of selectivity over the Pim1 kinase. It was envisioned that it 
was possible to improve the potency and selectivity of inhibitors by modifying the 


























































































Scheme 4.6. Synthesis of ruthenium complexes with different tridentate ligands from precursor 4.6. 
4.6 was used as a mixture of two diastereomers and only one isomer is shown. FL1356 was racemic 
mixture. 
The tridentate ligands used to modify the TrkA inhibitors are shown in Figure 4.3 and 
the synthesis of ruthenium complexes with these ligands from precursor 4.6 is 
summarized in Scheme 4.6. The coordination reactions were performed in analogy to 
FL1190 by stirring equivalent precursor 4.6 and corresponding tridentate ligand in 
DMF at 70 °C. Two diastereoisomers were obtained in each reaction and all the 
complexes were tested against TrkA in the presence of 100 µM ATP. The IC50 values are 
listed in Table 4.2. 
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Table 4.2. IC50 values of ruthenium complexes with different tridentate ligands for TrkA in the 
presence of 100 µM ATP. 
 FL1219-1 FL1219-2 FL1260-1 FL1260-2 FL1356-1 FL1356-2 
TrkA  240 nM 300 nM 60 nM 20 nM 102 nM 56 nM 
  The data demonstrate that the potency of complex FL1219 for TrkA was decreased 
significantly compared to FL1190, due to the steric clash of the isopropyl group in the 
ATP binding site and the active site needs to open even more to accommodate the 
change. The best ligand in the library was 4.10 which improved the affinity of 
FL1260-2 for TrkA by a factor of 2 compared to FL1190-1 with an IC50 value of 20 nM. 
It was in the following measured against Pim1. Unfortunately, it still displayd high 
affinity for Pim1 with an IC50 value of 8 nM in the presence of 100 µM ATP. 
Chapter 4.5: Conclusion and Outlook 
  Scaffold FL792 was discovered to be very selective by screening it a ainst a panel of 
227 human protein kinases. With tridentate ligand 2,6-bis(methyliminomethyl)pyridine, 
only two diastereoisomers formed in the synthesis. It was a good starting point to 
develop inhibitors for certain protein kinases due to the simplicity and selectivity of this 
scaffold. 
  TrkA was used as the target of complex FL792-1. With the modification of the 
pyridocarbazole, FL1190-1 was verified to be the most promising scaffold for TrkA 
with an IC50 value of 41 nM in the presence of 100 µM ATP, with a hydroxyl group on 
the 5-position of indole, and isoquinoline instead of the pyridine. Unfortunately, it also 
showed high affinity for Pim1 kinase. Following, a series of tridentate ligands were 
tried to modify the scaffold. It turned out that the potency for TrkA of FL1260-2 was 
improved by a factor of 2 compared to FL1190-1 by using the tridentate ligand of 
2,6-bis(methylthiomethyl)pyridine, but still no improvement on the selectivity over 
Pim1. 
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  Overall, this octahedral scaffold doesn’t behave well for TrkA as initially designed so 
far, and the affinity for TrkA and selectivity over Pim1 of this scaffold need to be 
improved further. First, a right pharmacophore ligand needs to be developed which 
disfavors Pim1 but not TrkA. For example, amino group on the 5-position of indole 
might be an option, and a methoxy group on the 3-position of pyridine instead of 
isoquinoline moiety. Second, modification of the tridentate ligand moiety might be still 
interesting. Such as introduction of an ester group n the 4-position of pyridine in the 
tridentate ligand might form interactions with the backbone of TrkA in the active site, 
without influence on the symmetry of the tridentate ligand. Last, the chloride ligand in 
this scaffold can possibly be replaced by other monode tate ligands such as -NO2, 
triazole or tetrazole as modifications in PAK1 inhibitors to utilize the extended space to 
develop more potent and selective TrkA inhibitors. Our group is also trying to use 
tetradentate ligands to develop octahedral ruthenium inhibitors for TrkA. 
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Chapter 5: Summary and Outlook 
  A new strategy for the design of selective protein kinase inhibitors has been initiated 
with chemically inert metallo-pyridocarbazoles scaffold by the group of Prof. Meggers 
since 2004. The natural product staurosporine was used as lead structure, in which the 
indolocarbazole alkaloid structure was replaced with simple metal complex to match the 
shape of the ATP-binding site of protein kinases (Figure 5.1). Whereas previous work 
was focused mainly on half-sandwich complexes, this t esis had the goal to develop 

























Figure 5.1. Design of ruthenium complexes as protein kinase inhib tors by using staurosporine as 
lead structure. A, B, C and D represent the organic ligands coordinated to the metal center. 
  In chapter 2, a new strategy for the design of selective protein kinase inhibitors that 
makes use of a discrimination between the sizes of ATP-binding sites through the use of 
rigid, bulky octahedral ruthenium complexes was developed. Protein kinase PAK1 
which contains an open ATP-binding site was chosen as a model system and the 
organoruthenium complex Λ-FL1422 (Figure 5.2) was developed as an inhibitor for 
PAK1 with an IC50 value of 23 nM in the presence of 1 µM ATP which is the only 
selective inhibitor with IC50 value in the low nanomolar range for PAK1 or other 






























Figure 5.2. Structures of Λ-FL172 and Λ-FL1422. 
In addition, a cocrystal structure of Λ-FL172 bound to PAK1 revealed the molecular 
details of the binding of this octahedral scaffold to PAK1 (Figure 5.3).4 Whereas, the 
maleimide moiety and the indole -OH group together m diate four canonical hydrogen 
bonds to the backbone of the hinge region. In addition, he monodentate carbonyl ligand 
establishes interactions to the residues of the glycine-rich loop and the bulky bidentate 
phenyliminopyridine ligand stretches the entire distance from the N-terminal glycine 
rich loop to the C-terminal domain. In this bulky octahedral scaffold, the distance 
between the oxygen atom of the CO ligand and the para-carbon of the pyridine in trans 
serves as a rigid yardstick of about 8 Å which can only be well accommodated in the 
active site of PAK1, but not in most other protein ki ases. 
 
Figure 5.3. Cocrystal structure of Λ-FL172 with PAK1 (amino acids 249-545, mutation Lys299Arg) 
at 1.65 Å (by Jasna Maksimoska, Universit of Pennsylvania and The Wistar Institute, Philadelphia, 
USA). a) Some important interactions. b) Surface view to visualize the shape complementarity of 
PAK1 and Λ-FL172. 
a b 
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  In chapter 3, a novel scaffold containing 1,4,7-trithiacyclononane, pyridocarbazole, 
and monodentate ligand was used to develop protein kinase inhibitors. With the 
modifications of the ligands coordinated to the ruthenium center, potent and selective 
octahedral organoruthenium inhibitors for MLCK, DAPK1, and Pim1 were developed, 
respectively. The inhibitor FL1528-1 (Figure 5.4) for protein kinase MLCK with an 
IC50 value of 4.4 nM in the presence of 100 µM ATP was discovered based on the 
screening of the 1,4,7-trithiacyclononane scaffold with different pyridocarbazoles 
modified with a series of substituents on the indole and/or pyridine. The selectivity 
profile of FL1528-1 was verified by screening it against a panel of 230 human protein 














Figure 5.4. Structure of racemic complex FL1528-1. 
Using a similar scaffold, the ruthenium complex FL1353-1 (Figure 5.5) was 
developed and verified to be a very potent and selective inhibitor for DAPK1 with an 
IC50 value of 2 nM in the presence of 100 µM ATP. It showed 84-fold selectivity over 













Figure 5.5. Structure of racemic complex FL1353-1. 
 97 
Furthermore, a cocrystal structure of (R)-FL1353-1 bound to DAPK1 obtained by 
Katja Kräling in collaboration with Yann Geisselbrecht and Prof. Dr. L.-O. Essen 
revealed the details of interactions of the inhibitor n the DAPK1 active site (Figure 5.6). 
The structure reveals that the maleimide moiety forms two canonical hydrogen bonds 
with the hinge region of DAPK1 (Val96 and Glu94) (Figure 5.6a). In addition, the 
isopropyl ether oxygen at the indole moiety forms a w ter-mediated contact to the 
amino acids Lys42, Glu64, and Asp161, and the isopropyl substituent reaches into a 
small hydrophobic pocket composed out of Lys42, Ile77, Leu93, Leu91, and Leu68 
(Figure 5.6b). The 1,4,7-trithiacyclononane ligand points towards the more hydrophilic 
entrance of the ATP-binding site and occupies the ext nded chemical space in the 
domain. The isothiocyanate ligand on the axial position points towards the hydrophobic 
pocket of the glycin-rich loop forming close contact with the side chain residues of 
Val27, Ala25, and Lys42, as well as the backbone residues of Gly20, Val26, and Ser21 
in the active site. 
 
Figure 5.6. Cocrystal structure of (R)-FL1353-1 with DAPK1 at the resolution of 2.2 Å. a) 
Hydrogen bonding interactions between the hinge region and (R)-FL1353-1. b) Hydrophobic 
interactions of (R)-FL1353-1 in the active site. (cocrystallized by Katja Kräling and the cocrystal 
structure was obtained by Yann Geisselbrecht from the group of Prof. Dr. Lars-Oliver Essen) 
The potency and selectivity of metal-containing Pim1 inhibitors was further 
improved by using an octahedral ruthenium scaffold (Figure 5.7). FL1360 was 
discovered to be a very potent inhibitor for Pim1 with an IC50 value of 75 pM in the 






















significantly improved by switching the cyclopentadienyl group to a 





























Figure 5.7. Potency for Pim1 was improved by the transformation of half-sandwich scaffold into 
octahedral scaffold. 
In chapter 4, a ruthenium scaffold containing an acycli  tridentate ligand was 
explored. Complex FL792 was discovered to be a very selective scaffold by screening it 
against a panel of 227 human kinases, which was used as a lead structure to develop the 
TrkA inhibitors. Based on the modifications of pyridocarbazole and tridentate ligand, 
FL1260-2 (Figure 5.8) showed high potency for TrkA with an IC50 value of 20 nM in 
the presence of 100 µM ATP, but lacking selectivity over Pim1. The potency and 











Figure 5.8. Structure of complex FL1260-2. 
Organoruthenium inhibitors for MLCK, DAPK1, and Pim1 were developed with a 
same scaffold. The potency and selectivity of the inhibitors were achieved by modifying 
the surrounding ligands of ruthenium center, which further proved that the metal center 
only exerts a purely structural role in the kinase ctive site and controls the orientation 
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of the organic ligands. The success of the development of potent and selective 
octahedral organoruthenium inhibitors verified the versatility of the approach initiated 
by our group to the design of protein kinase inhibitors with metal complexes as 
structural scaffolds. 
Recently, notable progress has been made in the field of medicinal bioinorganic 
chemistry and many new approaches to the design of ovel metal-based anticancer 
drugs are emerging as some examples mentioned previously.5 Therefore, it will be very 
interesting to evaluate whether these organoruthenium inhibitors can be utilized as 
potential therapeutic agents. 
  Although ruthenium has low toxicity,6,7 it is of great interest to explore protein kinase 
inhibitors with stable iron complexes. Iron is a necessary trace element found in nearly 
all living organisms and participates in many biological oxidations and transportations. 
The potential drawback of iron complexes is that they are usually not as stable as 
ruthenium complexes. However, multidentate ligands (tridentate or tetradentate ligands) 
can be used to stabilize the iron complexes, such as 2,6-bis(methyliminomethyl)- 
pyridine or its derivatives.8,9 It might be also possible to extend the strategy to other 
transition metals, as long as the metal complexes formed are stable under physiological 
conditions. Our group already published metal complexes containing osmium or iridium 
as protein kinase inhibitors.10,11 
  The here developed methodology might be also applicable to other classes of targets. 
Large target sites are beneficial because our approch has an advantage to design 
three-dimensional structures from a metal center in a very convenient fashion. 
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Chapter 6: Experimental Section 
Chapter 6.1: Synthesis 
General Procedures. NMR spectra were recorded on a Bruker AM-400 (400 MHz) 
AM-500 (500 MHz), or AV-300 (300 MHz) spectrometer. Low-resolution mass spectra 
were obtained on an LC platform from Micromass using the ESI technique. 
High-resolution mass spectra were obtained on a Micromass Autospec instrument using 
either CI or ES ionization or a Thermo Finnigan LTQ FT instrument using ES ionization. 
Infrared spectra were recorded on a Bruker IFS 88 or Perkin Elmer 1600 series FTIR 
spectrometer. Photolysis was performed with a medium pressure Hg lamp (150 W or 
700 W). Microwave reactions were conducted using a CEM Discover reactor. CD 
spectra were recorded on a JASCO J-810 spectropolarimeter. Solvents and reagents 
were supplied from Aldrich, Acros, or Strem. Reactions were performed under an 
atmosphere of nitrogen unless otherwise specified. Compound 2.1,6 
5-isopropyloxyindole 3.11, 1,4,7-trithiacyclodecan-9-one4, 5-methylthioindole 3.122, 
bis-allyl-2-bromo-5-aminopyridine 3.233, TBS-protected pyridocarbazole 3.696, 3.81, 
3.85, 3.875, 4.17, 4.48, and 4.59 were synthesized as published. NMR standards used are 
as follows: (1H NMR) CDCl3: 7.26 ppm, CD3CN: 1.94 ppm, DMSO-d6: 2.50 ppm, 
(CD3)2CO: 2.05 ppm, DMF-d7: 8.03, 2.92, 2.75 ppm. (
13C NMR) CDCl3: 77.23 ppm, 
DMSO-d6: 39.51 ppm, DMF-d7: 163.15, 34.89, 29.76 ppm. 











Complex 2.2. A suspension of the ligand 2.1 (180 mg, 0.33 mmol), K2CO3 (50 mg, 0.36 
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mmol), and [RuCl2(η
6-C6H6)]2 (123 mg, 0.25 mmol) in CH3CN (50 mL) was purged 
with nitrogen and stirred at 50 °C for 3 h. The resulting dark red suspension was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 50:1, then 35:1) as the eluting 
solvent. The half-sandwich complex 2.2 was isolated as a dark red solid (220 mg, 88%). 
1H NMR (300 MHz, CD3CN): δ (ppm) 9.46 (t, J = 2.6 Hz, 1H), 8.86 (dd, J = 9.4, 2.3 
Hz, 1H), 8.25 (d, J = 2.5 Hz, 1H), 7.88 (d, J = 9.1 Hz, 1H), 7.23 (dd, J = 8.8, 2.6 Hz, 
1H), 6.08 (s, 6H), 1.07 (s, 9H), 1.01 (s, 9H), 0.55 (s, 6H), 0.30 (s, 6H). 13C NMR (75.5 
MHz, CDCl3): δ (ppm) 175.1, 173.9, 157.1 (d, JC-F = 251.4 Hz), 153.0, 150.2, 146.5, 
140.9, 140.4, 140.2, 133.9, 125.0, 121.5 (d, JC-F = 8.4 Hz), 120.7, 119.9 (d, JC-F = 19.9 
Hz), 115.0, 114.6, 113.9 (d, JC-F = 4.9 Hz), 83.4, 26.5, 26.0, 19.1, 18.4, -4.0, -4.2. IR 
(film): ν (cm-1) 2955, 2930, 2857, 1746, 1688, 1562, 1462, 1335, 110, 1296, 1258, 
1238, 829. HRMS calculated for C35H41FN3O3Si2Ru (M - Cl)













Complex 2.3. A red solution of 2.2 (180 mg, 0.24 mmol) in CH3CN (220 mL) was 
purged with nitrogen for 10 min and then irradiated with a mercury medium pressure 
lamp (150W, pyrex filter) for 3 hours while nitrogen was bubbled through the solution. 
The resulting dark green solution was dried in vacuo and the crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (first 75:1, then 35:1). The combined product eluents were 
isolated as a mixture of two diastereoisomers (175 mg, 91%). To the stirred green 
solution of the mixture (175 mg, 0.22 mmol) in CH3CN was added tetrabutylammonium 
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fluoride (660 µL, 1 M in THF, 0.66 mmol) at 0 °C, and the solution was stirred at 0 °C 
for 5 min. To the resulting green solution was added glacial acetic acid (38 µL, 0.66 
mmol) and it was stirred for 2 min at 0 °C. The solution was dried in vacuo and the 
crude material was adsorbed onto silica gel and subjected to silica gel chromatography 
with dichloromethane : methanol (first 50:1, then 20:1) to yield the precursor complex 
2.3 (57 mg, 45%) and a second diastereoisomer in lower amounts (31 mg, 25%). 
Analytical data for the main diastereomer 2.3: 1H NMR (400 MHz, DMF-d7): δ (ppm) 
10.88 (s, 1H), 9.53 (t, J = 2.9 Hz, 1H), 9.27 (s, 1H), 8.65 (dd, J = 9.5, 2.5 Hz, 1H), 8.28 
(d, J = 2.4 Hz, 1H), 7.81 (d, J = 8.7 Hz, 1H), 7.17 (dd, J = 8.7, 2.5 Hz, 1H), 3.04 (s, 3H), 
2.27(s, 6H). 13C NMR (100.6 MHz, DMF-d7): δ (ppm) 171.4, 171.1, 157.1 (d, JC-F = 
246.0 Hz), 156.3, 152.2, 148.0, 144.1, 141.2, 140.9, 131.6, 127.4, 125.1, 122.8, 121.1 (d, 
JC-F = 8.5 Hz), 116.3 (d, JC-F = 13.6 Hz), 115.5 (d, JC-F = 20.6 Hz), 115.1, 110.1 (d, JC-F 
= 4.6 Hz), 109.0 (the methyl group peaks were hidden by the solvent peak). IR (film): ν 
(cm-1) 2277, 1721, 1649, 1529, 1497, 1469, 1437, 1384, 1083, 1028, 774. HRMS 
calculated for C23H16FN6O3Ru (M - Cl)












Complex FL172. A solution of precursor complex 2.3 (7 mg, 0.012 mmol) in DMF (2 
mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere of 
CO for 1 hour. To the resulting solution was added 2-(phenylaminomethyl)pyridine (120 
µL, 100 mM in DMF), then the solution was stirred at 95 °C under an atmosphere of 
nitrogen for 1.5 hours, after which the purple soluti n was dried under high vacuum. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
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chromatography with dichloromethane : methanol (50:1) to yield compound FL172 as a 
single diastereomer (3.5 mg, 44%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 (s, 
1H), 9.22 (s, 1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.38 (dt, J = 
7.7, 0.9 Hz, 1H), 8.36 (t, J = 2.6 Hz, 1H), 8.31 (dd, J = 2.5, 0.4 Hz, 1H), 8.21 (s, 1H), 
8.16 (td, J = 7.6, 1.9 Hz, 1H), 8.13 (m, 2H), 7.69 (m, 2H), 7.59 (m, 1H), 7.48 (m, 1H), 
7.44 (td, J = 5.4, 1.3 Hz, 1H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H). 13C NMR (100.6 MHz, 
DMSO-d6): δ (ppm) 200.7, 170.4 (d, JC-F = 16.9 Hz), 169.7, 157.6, 155.1, 154.4, 153.1, 
151.8, 147.5 (d, JC-F = 217.4 Hz), 141.3 (d, JC-F = 33.8 Hz), 140.5, 139.7, 131.7, 129.5, 
129.1 (d, JC-F = 23.9 Hz), 128.3, 124.3, 122.4, 120.3 (d, JC-F = 8.3 Hz), 117.9, 117.6 (d, 
JC-F = 19.6 Hz), 116.5, 114.4, 111.0, 108.1. IR (film): ν (cm
-1) 3199, 2919, 1962, 1687, 
1650, 1499, 1469, 1428, 1405, 1384, 1335, 1028. HRMS calculated for 
C30H17ClFN5O4RuNa (M + Na)














Complex FL411. A solution of precursor complex 2.3 (7 mg, 0.012 mmol) in DMF (2 
mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere of 
CO for 1 hour. To the resulting solution was added 2-(phenylaminomethyl)- 
4-aminopyridine (120 µL, 100 mM in DMF), then the solution was stirred at 95 °C 
under an atmosphere of nitrogen for 3 hours, after which the purple solution was dried 
under high vacuum. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (35:1) to obtain complex 
FL411 (2.5 mg, 30%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.86 (s, 1H), 8.90(s, 
1H), 8.70 (dd, J = 9.4, 2.4 Hz, 1H), 8.60 (d, J = 8.9 Hz, 1H), 8.32 (t, J = 2.6 Hz, 1H), 
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8.29 (d, J = 2.3 Hz, 1H), 8.18 (s, 1H), 8.09 (m, 2H), 7.65 (m, 2H), 7.54 (m, 1H), 7.45 (d, 
J = 2.5 Hz, 1H), 7.14 (dd, J = 8.9, 2.6 Hz, 1H), 6.78 (d, J = 6.3 Hz, 1H), 6.53 (s, 2H), 
6.43 (dd, J = 6.3, 2.5 Hz, 1H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 200.6, 170.6, 
170.4 (d, JC-F = 13.4 Hz), 157.6, 155.3 (d, JC-F = 211.5 Hz), 155.1, 153.2 (d, JC-F = 5.3 
Hz), 151.7, 147.3, 146.5, 140.6, 140.5 (d, JC-F = 33.4 Hz), 131.7, 129.3, 128.6, 124.1, 
122.4, 120.2 (d, JC-F = 8.5 Hz), 118.0, 117.3 (d, JC-F = 20.1 Hz), 116.3, 114.3, 114.2, 
110.6 (d, JC-F = 4.9 Hz), 110.4, 108.0. IR (film): ν (cm
-1) 3312, 3204, 1960, 1715, 1470, 
1454, 1385, 1335, 1099, 1024, 403. HRMS calculated for C30H18ClFN6O4RuNa (M + 
Na)+ 704.9998, found (M + Na)+ 704.9991. 
Complexes 2.7 and 2.8. A solution of precursor complex 2.5 or 2.6 (10 mg, 0.016 
mmol) in 2.5 ml solvent was purged with CO gas for 5 min, then stirred at 75 °C under 
an atmosphere of CO for 1 hour. To the resulting solution was added bipyridine (160 µL, 
100 mM in toluene), then the solution was stirred at 95 °C under an atmosphere of 
nitrogen for 1.5 hours, after which the solution was dried under high vacuum. The crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
toluene : acetone (3:1) to yield complexes 2.7 and 2.8. Yields and diastereoselectivities 
depend on the used solvent. Toluene/CHCl3 (4:1): 67% overall yield, 2.8:2.7 = 2.4:1; 












Complex 2.7: 1H NMR (300 MHz, CDCl3): δ (ppm) 9.78 (d, J = 8.9 Hz, 1H), 9.52 (dd, 
J = 5.1, 1.1 Hz, 1H), 9.39 (dd, J = 8.4, 1.1 Hz, 1H), 8.75 (d, J = 7.2 Hz, 1H), 8.25 (d, J
= 8.1 Hz, 1H), 8.15-8.09 (m, 2H), 7.86-7.77 (m, 2H), 7.69 (m, 1H), 7.53-7.50 (m, 2H), 
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7.46 (d, J = 4.4 Hz, 1H), 7.35-7.30 (m, 2H), 7.25-7.06 (m, 4H), 5.88 (d, J = 8.1 Hz, 1H), 
4.96 (s, 2H). 13C NMR (100.6 MHz, CDCl3): δ (ppm) 200.8, 169.9, 169.5, 157.5, 157.2, 
154.9, 151.2, 148.3, 143.9, 138.7, 137.4, 137.3, 134.8, 128.8, 128.6, 127.7, 126.8, 126.7, 
126.2, 125.2, 124.2, 123.2, 122.8, 122.2, 121.9, 11.5, 116.2, 115.5, 113.4, 113.1, 112.5, 
41.6. IR (film): ν (cm-1) 2924, 2853, 1957, 1749, 1696, 1495, 1471, 1420, 1387, 1341, 
1229, 739. HRMS calculated for C35H22ClN5O3RuNa (M + Na)
+ 720.0347, found (M + 












Complex 2.8: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 9.49 (d, J = 4.7 Hz, 1H), 8.97 
(dd, J = 8.4, 1.0 Hz, 1H), 8.82 (d, J = 8.1 Hz, 1H), 8.77 (d, J = 5.0 Hz, 1H), 8.74 (d, J = 
5.4 Hz, 1H), 8.51 (d, J = 5.4 Hz, 1H), 8.31 (td, J = 8.0, 1.3 Hz, 1H), 8.11 (m, 1H), 7.85 
(m, 1H), 7.73 (dd, J = 5.2, 1.0 Hz, 1H), 7.56-7.47 (m, 2H), 7.42-7.24 (m, 8H), 4.87 (s, 
2H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 201.9, 169.01, 168.96, 156.4, 156.0, 
154.6, 153.6, 152.4, 150.1, 148.1, 142.9, 139.7, 138.3, 137.3, 133.3, 129.8, 128.6, 127.7, 
127.4, 127.3, 127.1, 126.2, 124.3, 123.7, 123.6, 123.5, 123.4, 120.7, 119.7, 117.5, 115.1, 
111.6, 40.7. IR (film): ν (cm-1) 2923, 2853, 1955, 1749, 1696, 1495, 1468, 1419, 1387, 
1351, 1231, 760. HRMS calculated for C35H22ClN5O3RuNa (M + Na)
+ 720.0347, found 













Complex FL637. To a solution of precursor complex 2.3 (7 mg, 0.012 mmol) in DMF 
(2 mL) was added PMe3 (12 µL, 1 M in THF), then stirred at 45 °C under nitrogen for 1 
hour. To the resulting solution was added 2-(phenylaminomethyl)pyridine (120 µL, 100 
mM in DMF), then the solution was stirred at 95 °C under an atmosphere of nitrogen for 
2 hours, after which the solution was dried under high vacuum. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (50:1) to obtain complex FL637 (2.2 mg, 26%). 1H NMR 
(300 MHz, acetone-d6): δ (ppm) 9.75 (s, 1H), 9.18(s, 1H), 8.69 (d, J = 8.8 Hz, 1H), 
8.50-8.47 (m, 2H), 8.31 (d, J = 2.5 Hz, 1H), 8.24 (d, J = 7.8 Hz, 1H), 8.15 (s, 1H), 
7.91-7.83 (m, 3H), 7.64-7.59 (m, 2H), 7.52 (m, 1H), 7.37 (m, 1H), 7.21 (m, 1H), 7.13 

















Complex FL866. To a solution of complex FL172 (7 mg, 0.01 mmol) in DMSO (0.35 
mL) was added silver trifluoromethanesulfonate (32.3 mg, 0.126 mmol), then stirred at 
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95 °C under nitrogen for 7 hours, after which the soluti n was dried under high vacuum. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
chromatography with dichloromethane : methanol (10:1) to obtain complex FL866 (4.9 
mg, 54%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 10.07 (s, 1H), 9.62(s, 1H), 8.90 
(dd, J = 9.1, 2.4 Hz, 1H), 8.69 (t, J = 2.5 Hz, 1H), 8.58 (d, J = 7.3 Hz, 1H), 8.47 (d, J = 
2.5 Hz, 1H), 8.41-8.37 (m, 2H), 8.33 (td, J = 7.8, 1.5 Hz, 1H), 8.29-8.26 (m, 2H), 
7.81-7.72 (m, 4H), 7.63 (m, 1H), 7.22 (dd, J = 9.0, 2.7 Hz, 1H), 3.59 (s, 3H), 3.26 (s, 
3H). HRMS calculated for C32H23FN5O5SRu (M)












Complex FL922. To a solution of complex FL172 (7 mg, 0.01 mmol) in DMSO (0.35 
mL) was added silver trifluoromethanesulfonate (32.3 mg, 0.126 mmol), then stirred at 
95 °C under nitrogen for 7 hours, after which the soluti n was dried under high vacuum. 
The residue was dissolved in DMF (1.5 mL), then sodium azide (11.6 mg, 0.178 mmol) 
was added. The mixture was stirred at 85 °C under nitrogen for 1 hour, after which the 
solution was dried under high vacuum. The crude material was adsorbed onto silica gel 
and subjected to silica gel chromatography with dichloromethane : methanol (first 20:1, 
then 15:1) to obtain complex FL922 (4.7 mg, 66%). 1H NMR (300 MHz, acetone-d6): δ 
(ppm) 9.92 (s, 1H), 9.35(s, 1H), 8.70 (dd, J = 9.4, 2.4 Hz, 1H), 8.45 (t, J = 2.5 Hz, 1H), 
8.41 (m, 1H), 8.32 (d, J = 2.3 Hz, 1H), 8.19 (td, J = 7.7, 1.6 Hz, 1H), 8.12-8.05 (m, 4H), 



















Complex FL931. To a solution of complex FL922 (4.2 mg, 0.006 mmol) in DCM/DMF 
(2.5 mL/0.5 mL) was added dimethyl acetylenedicarboxylate (13.3 mg, 0.094 mmol), 
then stirred at room temperature under nitrogen for 2 hours, after which the solution was 
dried under high vacuum. The crude material was adsorbed onto silica gel and subjected 
to silica gel chromatography with dichloromethane : methanol (first 20:1, then 10:1) to 
obtain complex FL931 in quantitive yield. 1H NMR (300 MHz, acetone-d6): δ (ppm) 
9.94 (s, 1H), 9.26 (s, 1H), 8.76 (dd, J = 9.4, 2.4 Hz, 1H), 8.46 (t, J = 2.5 Hz, 1H), 8.37 
(m, 1H), 8.30 (m, 1H), 8.22-8.16 (m, 2H), 8.02-7.99 (m, 2H), 7.68-7.63 (m, 2H), 7.57 
(m, 1H), 7.46-7.44 (m, 2H), 6.92 (dd, J = 8.9, 2.5 Hz, 1H), 6.39 (d, J = 8.9 Hz, 1H), 
3.77 (s, 6H). HRMS calculated for C36H23FN8O8RuNa (M + Na)

















Complex FL864. To a solution of complex FL172 (8.5 mg, 0.013 mmol) in acetonitrile 
(1 mL) was added silver trifluoromethanesulfonate (90 mg, 0.35 mmol), then refluxed 
 110 
under nitrogen overnight, after which the solution was dried under high vacuum. The 
residue was dissolved in DMF (1.5 mL), then sodium azide (23.2 mg, 0.357 mmol) was 
added. The mixture was stirred at 85 °C under nitrogen for 0.5 hour, after which the 
solution was dried under high vacuum. The crude material was adsorbed onto silica gel 
and subjected to silica gel chromatography with dichloromethane : methanol (10:1) to 
obtain complex FL864 (3 mg, 32%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.90 (s, 
1H), 9.21 (s, 1H), 8.76 (dd, J = 9.4, 2.4 Hz, 1H), 8.44 (t, J = 2.5 Hz, 1H), 8.37 (dt, J = 
7.7, 1.0 Hz, 1H), 8.29 (dd, J = 2.6, 0.3 Hz, 1H), 8.22-8.16 (m, 2H), 8.02-7.99 (m, 2H), 
7.68-7.63 (m, 2H), 7.56 (m, 1H), 7.47-7.45 (m, 2H), 6.89 (dd, J = 8.9, 2.5 Hz, 1H), 6.16 
(d, J = 8.9 Hz, 1H), 2.35 (s, 3H). HRMS calculated for C32H21FN9O4Ru (M + H)
+ 

















Complex FL889. To a solution of complex FL172 (8.5 mg, 0.013 mmol) in acetonitrile 
(1 mL) was added silver trifluoromethanesulfonate (90 mg, 0.35 mmol), then refluxed 
under nitrogen overnight, after which the solution was dried under high vacuum. The 
residue was dissolved in pyridine (0.9 mL), then stirred at 95 °C under nitrogen 
overnight, after which the solution was dried under high vacuum. The crude material 
was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (10:1) to obtain complex FL889 (1.2 mg, 9%). 1H NMR 
(300 MHz, acetone-d6): δ (ppm) 10.07 (s, 1H), 9.44 (s, 1H), 8.84 (dd, J = 9.2, 2.3 Hz, 
1H), 8.77 (t, J = 2.5 Hz, 1H), 8.68-8.66 (m, 2H), 8.53 (m, 1H), 8.39-8.31 (m, 3H), 8.21 
(m, 1H), 7.97-7.93 (m, 2H), 7.79-7.63 (m, 6H), 6.91 (dd, J = 8.9, 2.5 Hz, 1H), 6.38 (d, J 
 111 
= 8.8 Hz, 1H). HRMS calculated for C35H22FN6O4Ru (M)








Compound 2.23. A biphasic suspension of 2.15 (1.2 g, 3.06 mmol), 2.22 (644 mg, 2.80 
mmol), tetrakis(triphenylphosphine)palladium(0) (226 mg, 0.19 mmol) and Na2CO3 
(816 mg, 7.70 mmol) in 1,2-dimethoxyethane (12.3 mL) and water (3.2 mL) was purged 
with nitrogen and refluxed overnight. The resulting reaction mixture was cooled to 
room temperature, diluted with water and extracted with EtOAc for three times. The 
combined organic layers were washed with brine, dried using Na2SO4, filtered and 
concentrated to dryness in vacuo. The crude material was adsorbed onto silica gel and 
subjected to silica gel chromatography with hexane : EtOAc (first 6:1, then 3:1) as the 
eluting solvent. The combined product eluents were isolated as a mixture of 
Boc-protected pyridylindole and 2.23. The resulting solid was dissolved into DCM and 
adsorbed onto silica gel (10 g) using rotary evaporti n. The white powder was heated 
to 80 °C overnight under high vacuum. The silica gel was cooled to room temperature, 
filtered through celite with EtOAc and the filtrate was dried in vacuo to provide 2.23 
(898 mg, 81% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.39 (s, 
1H), 8.63 (s, 1H), 7.83-7.75 (m, 2H), 7.26 (d, J = 8.5 Hz, 1H), 7.06 (d, J = 2.1 Hz, 1H), 
6.92 (d, J = 1.9 Hz, 1H), 6.80 (dd, J = 8.7, 2.2 Hz, 1H), 5.87 (s, 1H), 4.19-4.05 (m, 4H), 












Compound 2.24. A solution of 2.23 (750 mg, 1.89 mmol) in anhydrous THF (5 mL) 
was prepared after drying 2.23 under high vacuum overnight. After cooling the soluti n 
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to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (5.7 mL, 5.70 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (734 
mg, 1.99 mmol) in THF (5 mL) cooled to 0 °C was added and the reaction mixture was 
stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple reaction 
mixture was carefully poured into stirring ice cold 10% HCl (35 mL) and extracted with 
EtOAc twice. The combined organic layers were washed with saturated NaHCO3 
followed by brine, dried using Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1 to 1:1) as the eluting solvent. 
The combined product eluents were dried in vacuo to provide 2.24 (650 mg, 50%) as a 











Compound 2.25. A solution of 2.24 (650 mg, 0.95 mmol) in toluene (220 mL) was 
irradiated with a medium pressure Hg lamp (150 W) with pyrex filter for 3 hours with 
constant nitrogen flow through the solution. The resulting red solution was concentrated 
to dryness in vacuo. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with hexane : EtOAc (1:1) as the eluting solvent. The 
combined product eluents were dried in vacuo to provide 2.25 (500 mg, 84%) as a 
yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.94 (s, 1H), 9.48 (d, J = 2.0 Hz, 
1H), 9.09 (d, J = 2.1 Hz, 1H), 8.62 (d, J = 2.5 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.15 
(dd, J = 8.7, 2.5 Hz, 1H), 6.08 (s, 1H), 4.28-4.11 (m, 4H), 1.06 (s, 18H), 0.62 (s, 6H), 














Complex 2.27. A suspension of the ligand 2.25 (200 mg, 0.33 mmol), K2CO3 (50 mg, 
0.36 mmol), and [RuCl2(η
6-C6H6)]2 (124 mg, 0.25 mmol) in CH3CN (30 mL) was 
purged with nitrogen for 5 minutes and stirred at 55 °C under nitrogen for 1.5 h. The 
resulting dark red soulution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
methanol (20:1) as the eluting solvent. The half-sandwich complex 2.26 was isolated as 
a dark red solid (206 mg, 76%). A red solution of 2.26 (200 mg, 0.24 mmol) in CH3CN 
(900 mL) was purged with nitrogen for 5 min and then irradiated with a mercury 
medium pressure lamp (700W) for 1.5 hours while nitrogen was bubbled through the 
solution. The resulting dark green solution was drie  in vacuo and the crude material 
was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1). The combined product eluents were isolated as a 
mixture of two diastereoisomers. To the stirred green solution of the mixture (170 mg, 
0.20 mmol) in CH3CN (5 mL) was added tetrabutylammonium fluoride (600 µL, 1 M in 
THF, 0.60 mmol) at 0 °C, and the solution was stirred at 0 °C for 3 min. To the resulting 
green solution was added glacial acetic acid (34.7 µL, 0.60 mmol), and it was stirred for 
1 min at 0 °C. The solution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
















Complex 2.28. A solution of precursor complex 2.27 (10 mg, 0.016 mmol) in DMF (1.8 
mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere of 
CO for 1 hour. To the resulting solution was added 2-(phenylaminomethyl)pyridine (160 
µL, 100 mM in DMF), then the solution was stirred at 95 °C under an atmosphere of 
nitrogen for 4 hours, after which the solution was dried under high vacuum. The crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (50:1) to obtain complex 2.28 (5.1 mg, 45%). 1H NMR 
(300 MHz, acetone-d6): δ (ppm) 9.86 (s, 1H), 9.21 (s, 1H), 9.09 (d, J = 1.4 Hz, 1H), 
8.59 (d, J = 8.9 Hz, 1H), 8.43 (d, J = 1.5 Hz, 1H), 8.35 (d, J = 7.8 Hz, 1H), 8.32 (d, J = 
2.6 Hz, 1H), 8.21 (s, 1H), 8.14 (td, J = 7.5, 2.0 Hz, 1H), 8.09-8.06 (m, 2H), 7.73-7.68 













Complex FL1088. To a solution of 2.28 (6.4 mg, 0.009 mmol) in THF (1 mL) was 
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added 10% HCl solution (1 mL) under nitrogen at room temperature carefully. The 
resulting solution was stirred for additional 1 hour, followed by quenching with 
saturated NaHCO3 solution (2.5 mL). The mixture was extracted with DCM twice, and 
the combined organic layers were concentrated. The crude material was adsorbed onto 
silica gel and subjected to silica gel chromatography with dichloromethane : methanol 
(15:1) to yield complex FL1088 (5 mg, 83%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 
10.20 (s, 1H), 9.99 (s, 1H), 9.24 (s, 1H), 8.82 (d, J = 1.5 Hz, 1H), 8.65 (dd, J = 9.0 Hz, 
1H), 8.38-8.34 (m, 3H), 8.18-8.10 (m, 3H), 7.74-7.69 (m, 2H), 7.60 (m, 1H), 7.46-7.41 












Complex FL1103. To a solution of complex FL1088 (5.4 mg, 0.008 mmol) in 
MeOH/THF (0.7 mL/0.2 mL) was added aniline (0.8 µL, 0.009 mmol) and 
p-toluenesulfonic acid (0.15 mg, 0.001 mmol), then stirred under nitrogen at 50 °C for 3 
hours, followed by quenching with saturated NaHCO3 solution, after which the solution 
was dried under high vacuum. The crude material wasadsorbed onto silica gel and 
subjected to silica gel chromatography with dichloromethane : methanol (35:1) to obtain 
complex FL1103 (1.3 mg, 18%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.80 (s, 1H), 
8.97 (m, 1H), 8.77 (s, 1H), 8.56 (d, J = 8.9 Hz, 1H), 8.30 (d, J = 2.2 Hz, 1H), 8.27-8.23 
(m, 2H), 8.17 (s, 1H), 8.14 (td, J = 7.7, 2.0 Hz, 1H), 7.77-7.74 (m, 2H), 7.63-7.53 (m,
3H), 7.43-7.37 (m, 2H), 7.15-7.10 (m, 3H), 6.72 (m,1H), 6.64-6.61 (m, 2H), 5.96 (t, J = 













Complex FL1109. To a solution of complex FL1088 (4.7 mg, 0.007 mmol) in 
MeOH/THF (1 mL/0.5 mL) was added sodium cyanoborohydride (0.9 mg, 0.014 mmol), 
then stirred under nitrogen at 50 °C for 3 hours, followed by quenching with saturated 
NaHCO3 solution, after which the solution was dried under high vacuum. The crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (first 15:1, then 10:1) to obtain complex FL1109 (1.2 mg, 
25%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.80 (s, 1H), 9.19 (s, 1H), 8.98 (m, 1H), 
8.58 (d, J = 8.9 Hz, 1H), 8.42 (d, J = 1.6 Hz, 1H), 8.36 (m, 1H), 8.31 (m, 1H), 8.18-8.08 
(m, 3H), 8.71-7.65 (m, 2H), 7.58 (m, 1H), 7.49-7.42 (m, 2H), 7.13 (dd, J = 8.9, 2.6 Hz, 
1H), 4.82-4.72 (m, 3H). HRMS calculated for C31H21ClN5O5Ru (M + H)
+ 680.0269, 














Complex 2.31. A suspension of the ligand 2.29 (71 mg, 0.11 mmol), K2CO3 (16 mg, 
0.12 mmol), and [RuCl2(η
6-C6H6)]2 (40 mg, 0.08 mmol) in CH3CN (10 mL) was purged 
with nitrogen for 5 minutes and stirred at 50 °C under nitrogen for 6 h. The resulting 
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dark red soulution was dried in vacuo and the crude material was adsorbed onto silica 
gel and subjected to silica gel chromatography with d c loromethane : methanol (20:1) 
as the eluting solvent. The half-sandwich complex 2.30 was isolated as a dark red solid 
(76 mg, 81%). A red solution of 2.30 (80 mg, 0.09 mmol) in CH3CN (220 mL) was 
purged with nitrogen for 5 min, then irradiated with a mercury medium pressure lamp 
(150W, pyrex filter) for 3 hours while nitrogen was bubbled through the solution. The 
resulting dark green solution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
methanol (10:1). The combined product eluents were isolated as a mixture of two 












Complex FL1118. A solution of precursor complex 2.31 (15.3 mg, 0.016 mmol) in 
DMF (1.8 mL) was purged with CO gas for 5 min, then stirred at 75 °C under an 
atmosphere of CO for 1 hour. To the resulting soluti n was added 
2-(phenylaminomethyl)pyridine (160 µL, 100 mM in DMF), then the solution was 
stirred at 95 °C under an atmosphere of nitrogen for 5 hours, after which the solution 
was dried under high vacuum. The crude material wasadsorbed onto silica gel and 
subjected to silica gel chromatography with dichloromethane : methanol (100:1) to 
obtain complex 2.32 (5.4 mg, 36%). To the stirred solution of 2.32 (5.4 mg, 0.006 mmol) 
in THF (1 mL) was added tetrabutylammonium fluoride (24 µL, 1 M in THF, 0.024 
mmol) at 0 °C and the solution was stirred at 0 °C for 2 min, then 10 min at room 
temperature. To the resulting suspension was added glacial acetic acid (1.4 µL, 0.60 
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mmol), then the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 10:1, then 5:1) to yield complex 
FL1118 (2.3 mg, 57%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.0 (s, 1H), 9.32 (s, 
1H), 9.30 (d, J = 1.2 Hz, 1H), 9.20 (s, 1H), 8.72 (d, J = 1.3 Hz, 1H), 8.35-8.30 (m, 2H), 
8.17-8.11 (m, 2H), 7.93-7.91 (m, 2H), 7.73-7.68 (m,3H), 7.59 (m, 1H), 7.45 (m, 1H), 
7.26 (m, 1H), 7.03 (dd, J = 8.9, 2.5 Hz, 1H). HRMS calculated for C31H17ClN5O6Ru (M 






Compound 2.15. To a solution of 5-[(tert-butyldimethylsilyl)oxy]-1-(tert-butoxy- 
carbonyl)-indole (600 mg, 1.73 mmol) in anhydrous THF (4 mL) was added triisopropyl 
borate (0.60 mL, 2.60 mmol). The reaction mixture was cooled to 0 °C and lithium 
diisopropylamide (2.0 M solution in heptane-tetrahydrofuran-ethylbenzene) (1.3 mL, 
2.60 mmol) was added dropwise over 15 minutes. After s irring for an additional 45 
minutes at 0 °C, 2 M HCl (4.3 mL) was carefully added and stirred at 0 °C for 5 minutes. 
The resulting organic layer was separated and the aqu ous layer was extracted using 
EtOAc twice. The combined organic layers were dried using Na2SO4, filtered and 
concentrated to dryness in vacuo to provide 2.15 (642 mg, 95%) which was carried 







Compound 2.17. A biphasic suspension of 5-(tert-butyldimethylsilyl)indole-2-boronic 
acid (755 mg, 1.93 mmol), 2-bromo-5-methoxypyridine (330 mg, 1.75 mmol), 
tetrakis(triphenylphosphine)palladium(0) (142 mg, 0.12 mmol) and Na2CO3 (512 mg, 
4.83 mmol) in 1,2-dimethoxyethane (17.5 mL) and water (2.0 mL) was purged with 
nitrogen and refluxed overnight. The resulting reaction mixture was cooled to room 
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temperature, diluted with water and extracted with EtOAc for three times. The 
combined organic layers were washed with brine, dried using Na2SO4, filtered and 
concentrated to dryness in vacuo. The crude material was adsorbed onto silica gel and 
subjected to silica gel chromatography with hexane : EtOAc (8:1) as the eluting solvent. 
The combined product eluents were isolated as a mixture of Boc-protected 
pyridylindole and 2.17. The resulting solid was dissolved into DCM and adsorbed onto 
silica gel (7 g) using rotary evaporation. The white powder was heated to 80 °C 
overnight under high vacuum. The silica gel was cooled to room temperature, filtered 
through celite with EtOAc and the filtrate was drie n vacuo to provide 2.17 (440 mg, 
71% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.43 (s, 1H), 8.28 
(d, J = 2.8 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.28 (m, 1H), 7.23 (d, J = 8.4 Hz, 1H), 
7.07 (d, J = 2.0 Hz, 1H), 6.80-6.76 (m, 2H), 3.91 (s, 3H), 1.04 (s, 9H), 0.23 (s, 6H). 13C 
NMR (75.5 MHz, CDCl3): δ (ppm) 154.9, 149.7, 143.6, 137.6, 136.4, 132.3, 130.1, 
121.8, 120.4, 117.2, 111.6, 110.2, 98.7, 55.9, 26.0, 18.4, -4.2. IR (film): ν (cm-1) 3054, 
2956, 1592, 1563, 1464, 1263, 1150, 1028, 965, 888,34, 781, 731. HRMS calculated 
for C20H27N2O2Si (M + H)












Compound 2.18. A solution of 2.17 (520 mg, 1.47 mmol) in anhydrous THF (4.4 mL) 
was prepared after drying 2.17 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (4.4 mL, 4.40 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (569 
mg, 1.54 mmol) in THF (4.4 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
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reaction mixture was carefully poured into stirring ice cold 10% HCl (30 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 solution followed by brine, dried using Na2SO4, filtered and concentrated to 
dryness in vacuo. The crude material was adsorbed onto silica gel and subjected to silica 
gel chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried n vacuo to provide 2.18 (680 mg, 72%) as a solid 










Compound 2.19. A solution of 2.18 (680 mg, 1.06 mmol) in toluene (220 mL) was 
irradiated with a medium pressure Hg lamp (150 W) with pyrex filter for 3 hours with 
constant nitrogen flow through the solution. The resulting red solution was concentrated 
to dryness in vacuo. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting 
solvent. The combined product eluents were dried in vacuo to provide 2.19 (500 mg, 
84%) as a yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 10.14 (s, 1H), 8.68 (d, J = 
2.9 Hz, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.57 (d, J = 2.5 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 
7.08 (dd, J = 8.7, 2.5 Hz, 1H), 4.02 (s, 3H), 1.08 (s, 9H), 1.06 (s, 9H), 0.64 (s, 6H), 0.33 
(s, 6H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 175.9, 174.1, 155.1, 150.9, 144.5, 141.4, 
134.8, 133.1, 131.0, 123.3, 123.1, 120.9, 119.2, 114.8, 114.0, 111.7, 110.9, 56.0, 26.7, 
26.1, 19.3, 18.6, -3.8, -4.2. IR (film): ν (cm-1) 2934, 2858, 1746, 1691, 1628, 1603, 1568, 
1468, 1408, 1371, 1341, 1310, 1261, 1220, 1043, 964, 887, 830, 775. HRMS calculated 
for C30H39N3O4Si2Na (M + Na)












Complex 2.20. A suspension of the ligand 2.19 (100 mg, 0.18 mmol), K2CO3 (27 mg, 
0.19 mmol), and [RuCl2(η
6-C6H6)]2 (89 mg, 0.18 mmol) in CH3CN/MeOH/DCM (3.5 
mL/3.5 mL/2 mL) was purged with nitrogen for 5 minutes and stirred at 55 °C under 
nitrogen for 3 h. The resulting dark red suspension was dried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (20:1) as the eluting solvent. The half-sandwich complex 
2.20 was isolated as a dark red solid (100 mg, 72%). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 8.96 (d, J = 2.2 Hz, 1H), 8.61 (d, J = 2.2 Hz, 1H), 8.34 (d, J = 2.4 Hz, 1H), 7.60 
(d, J = 8.7 Hz, 1H), 7.12 (dd, J = 8.7, 2.4 Hz, 1H), 5.87 (s, 6H), 4.07 (s, 3H), 1.06 (s, 
9H), 1.02 (s, 9H), 0.59 (s, 6H), 0.30 (s, 3H), 0.28 (s, 3H). 13C NMR (75.5 MHz, CDCl3): 
δ (ppm) 175.8, 174.4, 155.2, 154.0, 150.0, 146.6, 144.1, 137.9, 133.4, 125.2, 122.3, 
120.2, 115.1, 114.4, 114.0, 113.6, 83.4, 56.6, 26.7, 26.1, 19.3, 18.6, -3.7, -4.1. IR (film): 
ν (cm-1) 2930, 2892, 2857, 1741, 1685, 1564, 1460, 1421, 1342, 1306, 1256, 1213, 1045, 
905, 831, 778, 694, 666. HRMS calculated for C36H44N3O4Si2Ru (M - Cl)
+ 740.1908, 













Complex 2.21. A red solution of 2.20 (60 mg, 0.08 mmol) in CH3CN (220 mL) was 
purged with nitrogen for 10 min, then irradiated with a mercury medium pressure lamp 
(150W, pyrex filter) for 2 hours while nitrogen was bubbled through the solution. The 
resulting dark green solution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
methanol (15:1). The combined product eluents were isolated as a mixture of two 
diastereoisomers (53 mg, 84%). To the stirred green solution of the mixture (121 mg, 
0.15 mmol) in CH3CN (6 mL) was added tetrabutylammonium fluoride (445 µL, 1 M in 
THF, 0.45 mmol) at 0 °C, and the solution was stirred at 0 °C for 3 min. To the resulting 
green solution was added glacial acetic acid (26 µL, 0.45 mmol), and it was stirred for 2 
min at 0 °C. The solution was dried in vacuo and the crude material was adsorbed onto 
silica gel and subjected to silica gel chromatography with dichloromethane : methanol 
(first 35:1, then 15:1) to yield the precursor complex 2.21 (43 mg, 49%) and a second 
diastereoisomer in lower amounts (31 mg, 35%). Analytical data for the main 
diastereomer 2.21: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.82 (s, 1H), 9.18 (br, 
1H), 9.03 (s, 1H), 8.34 (br, 1H), 8.04 (br, 1H), 7.59 (d, J = 8.7 Hz, 1H), 7.00 (d, J = 8.7 
Hz, 1H), 4.04 (s, 3H), 2.94 (s, 3H), 2.22 (s, 6H). IR (film): ν (cm-1) 3245, 2925, 2278, 
1741, 1702, 1565, 1465, 1424, 1398, 1348, 1325, 1215, 1061, 1014, 863, 700, 640, 487. 















Complex FL1422. A solution of precursor complex 2.21 (6 mg, 0.010 mmol) in DMF 
(1.8 mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere 
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of CO for 1 hour. To the resulting solution was adde  2-(phenylaminomethyl)-4- 
aminopyridine (100 µL, 100 mM in DMF), then the solution was stirred at 95 °C under 
an atmosphere of nitrogen for 4 hours, after which the solution was dried under high 
vacuum. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 50:1, then 35:1) to obtain 
complex FL1422 (2.5 mg, 35%). 1H NMR (500 MHz, DMSO-d6): δ (ppm) 10.95 (s, 
1H), 9.09 (s, 1H), 8.89 (s, 1H), 8.34 (d, J = 2.3 Hz, 1H), 8.27 (d, J = 8.7 Hz, 1H), 8.11 
(d, J = 2.4 Hz, 1H), 7.94 (d, J = 7.7 Hz, 2H), 7.89 (d, J = 2.3 Hz, 1H), 7.64 (t, J = 7.9 
Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.29 (d, J = 2.3 Hz, 1H), 7.03 (br, 2H), 6.98 (dd, J = 
8.8, 2.5 Hz, 1H), 6.63 (d, J = 6.3 Hz, 1H), 6.32 (dd, J = 6.3, 2.5 Hz, 1H). 13C NMR 
(100.6 MHz, DMSO-d6): δ (ppm) 201.1, 170.9, 170.6, 170.3, 156.3, 154.3, 154.2, 153.9, 
153.1, 151.3, 147.3, 146.5, 142.3, 138.0, 131.2, 129.4, 128.6, 124.2, 122.4, 121.1, 117.6, 
115.7, 114.3, 113.4, 111.6, 110.4, 110.1, 108.0, 69.8. IR (film): ν (cm-1) 3351, 3216, 
1960, 1747, 1711, 1631, 1567, 1493, 1468, 1341, 1218, 1023, 766, 702. HRMS 
calculated for C31H22ClN6O5Ru (M + H)
+ 695.0379, found (M + H)+ 695.0385. 
Synthesis of an initial library of octahedral ruthenium complexes from precursor 
complex 2.3. 
Reactions were performed starting from the ruthenium precursor 2.3. A solution of 2.3 
in DMF (9 mM, 2.5 mL) was purged with CO gas for 5 minutes, followed by stirring at 
75 °C under an atmosphere of CO for 1 hour. To the resulting solution was added 1 
equiv of different bidentate ligands, then the mixture was stirred at 95 °C under an 
atmosphere of nitrogen for 1-3 hours, which depended on the characteristic of the 
bidentate ligands, affording the products, which were purified by the silica gel 
chromatography with dichloromethane and methanol. The constitutions each were 















Complex FL115-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL115-1 (3 mg, 29%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.86 
(s, 1H), 9.36 (d, J = 8.9 Hz, 1H), 9.20 (t, J = 2.6 Hz, 1H), 8.81 (dd, J = 9.4, 2.6 Hz, 1H), 
8.20 (d, J = 2.2 Hz, 1H), 8.12 (s, 1H), 8.08 (td, J = 7.8, 1.5 Hz, 1H), 7.67 (m, 2H), 6.78 
(dd, J = 8.8, 2.6 Hz, 1H), 5.96 (d, J = 8.9 Hz, 1H), 4.82 (m, 3H), 4.22 (m, 1H). HRMS 
calculated for C24H16ClFN5O4Ru (M + H)














Complex FL115-2. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL115-2 (2.5 mg, 25%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.82 
(s, 1H), 9.25 (d, J = 5.2 Hz, 1H), 8.74 (dd, J = 9.5, 2.4 Hz, 1H), 8.45 (d, J = 8.9 Hz, 1H), 
8.21 (d, J = 2.4 Hz, 1H), 8.10 (s, 1H), 8.02 (td, J = 7.7, 1.5 Hz, 1H), 7.90 (m, 1H), 7.69 
(d, J = 7.8 Hz, 1H), 7.60 (m, 1H), 7.09 (dd, J = 8.9, 2.6 Hz, 1H), 4.92 (m, 3H), 4.51 (m, 
1H). HRMS calculated for C24H16ClFN5O4Ru (M + H)

















Complex FL114-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 40:1) to 
obtain complex FL114-1 (3.5 mg, 33%). Including two diastereoisomers with the ratio 
of around 1:1. 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.86 (s, 2H), 9.48 (m, 1H), 
9.37 (m, 1H), 9.23 (t, J = 2.7 Hz, 1H), 9.17 (t, J = 2.6 Hz, 1H), 8.82 (dd, J = 9.4, 2.5 Hz, 
2H), 8.20-8.08 (m, 6H), 7.69-7.65 (m, 4H), 6.78 (m,2H), 6.07 (d, J = 8.8 Hz, 1H), 5.89 
(d, J = 8.7 Hz, 1H), 5.31 (m, 2H), 5.16 (m, 1H), 4.55 (m, 1H), 4.30 (m, 2H), 1.71 (d, J = 
6.3 Hz, 3H), 1.42 (d, J = 7.0 Hz, 3H). HRMS calculated for C25H18ClFN5O4Ru (M + 
















Complex FL114-2. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL114-2 (3 mg, 29%). Including two diastereoisomers with the ratio of 
around 1:1. 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.81 (s, 2H), 9.36 (m, 1H), 9.24 
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(m, 1H), 8.76-8.69 (m, 2H), 8.49 (d, J = 8.8 Hz, 1H), 8.41 (d, J = 8.9 Hz, 1H), 8.21 (d, J
= 2.5 Hz, 2H), 8.11-8.04 (m, 4H), 7.91 (t, J = 2.5 Hz, 1H), 7.85 (t, J = 2.5 Hz, 1H), 
7.69-7.57 (m, 4H), 7.10 (dd, J = 2.5, 1.5 Hz, 1H), 7.07 (dd, J = 2.5, 1.5 Hz, 1H), 5.29 
(m, 3H), 4.60 (m, 2H), 4.45 (m, 1H), 1.78 (d, J = 6.6 Hz, 3H), 1.64 (d, J = 6.7 Hz, 3H). 
HRMS calculated for C25H18ClFN5O4Ru (M + H)














Complex FL111-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL111-1 (1 mg, 9%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 
1H), 9.79 (d, J = 5.8 Hz, 1H), 9.40 (t, J = 2.8 Hz, 1H), 8.96 (dd, J = 9.3, 2.5 Hz, 1H), 
8.77 (d, J = 8.1 Hz, 1H), 8.63 (d, J = 8.4 Hz, 1H), 8.38 (td, J = 8.0, 1.5 Hz, 1H), 
8.11-8.01 (m, 3H), 7.93 (m, 1H), 7.76 (d, J = 5.5 Hz, 1H), 7.35 (m, 1H), 6.69 (dd, J = 
8.8, 2.6 Hz, 1H), 5.84 (d, J = 8.8 Hz, 1H). HRMS calculated for C28H15Cl2FN5O4Ru (M 















Complex FL111-2. The crude material was adsorbed onto silica gel and subjected to 
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silica gel chromatography with dichloromethane : methanol (35:1) to obtain complex 
FL111-2 (5.5 mg, 50%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 (s, 1H), 9.61 (d, 
J = 5.6 Hz, 1H), 8.74 (d, J = 7.9 Hz, 1H), 8.68-8.64 (m, 2H), 8.55 (d, J = 8.9 Hz, 1H), 
8.32-8.27 (m, 2H), 8.19 (s, 1H), 8.11 (td, J = 8.1, 1.6 Hz, 1H), 7.87 (m, 1H), 7.80 (t, J = 
2.6 Hz, 1H), 7.52 (d, J = 5.4 Hz, 1H), 7.35 (m, 1H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H). 
HRMS calculated for C28H16ClFN5O4Ru (M + H)















Complex FL161-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL161-1 (1.1 mg, 10%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 
(s, 1H), 9.38 (t, J = 2.6 Hz, 1H), 8.96 (dd, J = 9.3, 2.5 Hz, 1H), 8.56 (t, J = 8.3 Hz, 2H), 
8.23 (t, J = 7.9 Hz, 1H), 8.10-7.94 (m, 4H), 7.71 (d, J = 5.5 Hz, 1H), 7.31 (m, 1H), 6.70 
(dd, J = 8.8, 2.6 Hz, 1H), 5.78 (d, J = 8.9 Hz, 1H), 3.46 (s, 3H). HRMS calculated for 
C29H18ClFN5O4Ru (M + H)
















Complex FL161-2. The crude material was adsorbed onto silica gel and subjected to 
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silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL161-2 (2.6 mg, 24%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 
(s, 1H), 8.66-8.53 (m, 4H), 8.31 (d, J = 2.6 Hz, 1H), 8.21 (s, 1H), 8.16 (t, J = 7.9 Hz, 
1H), 8.07 (td, J = 8.2, 1.7 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.71 (t, J = 2.2 Hz, 1H), 
7.49 (d, J = 5.5 Hz, 1H), 7.30 (m, 1H), 7.16 (dd, J = 8.9, 2.6 Hz, 1H), 3.41 (s, 3H). 
HRMS calculated for C29H18Cl2FN5O4Ru (M + Cl)
















Complex FL174-1. HRMS calculated for C34H19ClFN5O4Ru (M)

















Complex FL174-2. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL174-2 (3 mg, 37%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.83 
(s, 1H), 8.77 (dd, J = 8.2, 1.3 Hz, 1H), 8.67 (d, J = 8.2 Hz, 1H), 8.62-8.56 (m, 2H), 8.33 
(t, J = 7.9 Hz, 1H), 8.26 (d, J = 2.6 Hz, 1H), 8.17 (s, 1H), 8.15-7.81 (m, 4H), 7.61-7.48 
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(m, 5H), 7.35 (m, 1H), 7.12 (dd, J = 8.8, 2.6 Hz, 1H). HRMS calculated for 
C34H20ClFN5O4Ru (M + H)

















Complex FL178. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL178 (1.2 mg, 15%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.85 
(s, 1H), 8.64-8.60 (m, 2H), 8.55 (d, J = 8.2 Hz, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.28 (d, J
= 2.6 Hz, 1H), 8.19-8.14 (m, 2H), 7.87 (t, J = 7.9 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 
7.29 (m, 1H), 7.20 (dd, J = 8.9, 2.6 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 3.45 (s, 3H), 1.93 
(s, 3H). HRMS calculated for C30H20ClFN5O4Ru (M + H)


















Complex FL134. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL134 (4 mg, 43%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 (s, 
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1H), 9.41 (s, 1H), 8.65 (dd, J = 9.5, 2.4 Hz, 1H), 8.55 (d, J = 8.7 Hz, 2H), 8.48 (d, J = 
8.3 Hz, 1H), 8.32 (d, J = 2.6 Hz, 1H), 8.18 (s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.89 (d, J = 
8.4 Hz, 1H), 7.77 (t, J = 2.5 Hz, 1H), 7.36 (m, 1H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H), 2.64 
(s, 3H), 1.92 (s, 3H). HRMS calculated for C30H20ClFN5O4Ru (M + H)
+ 670.0226, 













Complex FL151-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL151-1 (2.5 mg, 22%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 
11.13 (s, 1H), 10.05 (dd, J = 5.3, 1.1 Hz, 1H), 9.27 (t, J = 2.6 Hz, 1H), 9.04 (s, 1H), 9.00 
(dd, J = 8.3, 1.1 Hz, 1H), 8.95 (dd, J = 9.2, 2.5 Hz, 1H), 8.74 (dd, J = 8.3, 1.2 Hz, 1H), 
8.40-8.22 (m, 3H), 8.01 (dd, J = 5.1, 1.2 Hz, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.71 (dd, J = 
8.2, 5.1 Hz, 1H), 6.40 (dd, J = 8.8, 2.5 Hz, 1H), 5.31 (d, J = 8.8 Hz, 1H). HRMS 
calculated for C30H16ClFN5O4Ru (M + H)















Complex FL151-2. The crude material was adsorbed onto silica gel and subjected to 
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silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL151-2 (3 mg, 26%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.97 
(dd, J = 5.2, 1.3 Hz, 1H), 9.89 (s, 1H), 8.91 (dd, J = 8.3, 1.3 Hz, 1H), 8.73 (dd, J = 8.2, 
1.4 Hz, 1H), 8.63-8.59 (m, 2H), 8.38-8.21 (m, 5H), 7.83 (dd, J = 5.1, 1.5 Hz, 1H), 
7.77-7.70 (m, 2H), 7.17 (dd, J = 8.8, 2.6 Hz, 1H). HRMS calculated for 
C30H16ClFN5O4Ru (M + H)















Complex FL182-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 40:1) to 
obtain complex FL182-1 (3.1 mg, 40%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 
(s, 1H), 9.74 (m, 1H), 9.31 (t, J = 2.6 Hz, 1H), 8.90 (dd, J = 9.3, 2.6 Hz, 1H), 8.39 (td, J 
= 7.8, 1.4 Hz, 1H), 8.21-8.17 (m, 2H), 8.11 (s, 1H), 8.06 (m, 1H), 6.74 (dd, J = 8.8, 2.6 
Hz, 1H), 5.92 (d, J = 8.8 Hz, 1H), 4.92 (m, 1H), 4.68 (m, 1H), 3.89 (m, 1H), 3.17 (m, 
1H). HRMS calculated for C26H16ClFN5O5Ru (M + H)


















Complex FL182-2. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 35:1) to 
obtain complex FL182-2 (3.6 mg, 47%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.85 
(s, 1H), 9.53 (m, 1H), 8.71 (dd, J = 9.5, 2.4 Hz, 1H), 8.51 (d, J = 8.9 Hz, 1H), 8.31 (td, J
= 7.8, 1.4 Hz, 1H), 8.25 (d, J = 2.6 Hz, 1H), 8.16 (m, 1H), 8.12 (s, 1H), 7.97 (m, 1H), 
7.93 (t, J = 2.5 Hz, 1H), 7.11 (dd, J = 8.9, 2.6 Hz, 1H), 4.91 (m, 1H), 4.64 (m, 1H), 3.66 
(m, 1H), 3.12 (m, 1H). HRMS calculated for C26H16ClFN5O5Ru (M + H)
+ 633.9862, 
















Complex FL162-1. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL162-1 (3 mg, 40%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 (s, 1H), 9.26 (m, 
1H), 8.88 (dd, J = 9.3, 2.5 Hz, 1H), 8.21 (dd, J = 2.3, 0.8 Hz, 1H), 8.17 (s, 1H), 
7.10-7.02 (m, 2H), 5.44 (m, 2H), 4.95 (m, 2H), 4.71 (m, 1H), 4.49 (m, 1H), 3.84 (m, 
1H), 3.16 (m, 1H). HRMS calculated for C24H16ClFN5O6Ru (M + H)
+ 625.9811, found 


















Complex FL162-2. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL162-2 (3.6 mg, 47%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.84 (s, 1H), 8.74 
(dd, J = 9.6, 2.4 Hz, 1H), 8.56 (t, J = 2.5 Hz, 1H), 8.46 (d, J = 8.9 Hz, 1H), 8.23 (d, J = 
2.6 Hz, 1H), 8.09 (s, 1H), 7.09 (dd, J = 8.9, 2.6 Hz, 1H), 5.27 (m, 2H), 4.91 (m, 2H), 
4.65 (m, 1H), 4.33 (m, 1H), 3.60 (m, 1H), 3.11 (m, 1H). HRMS calculated for 
C24H16ClFN5O6Ru (M + H)















Complex FL306. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 30:1) to 
obtain complex FL306 (4.7 mg, 57%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.85 
(s, 1H), 9.59 (dd, J = 5.6, 1.1 Hz, 1H), 8.65-8.58 (m, 2H), 8.50 (d, J = 7.9 Hz, 1H), 
8.41-8.33 (m, 2H), 8.22 (t, J = 7.7 Hz, 1H), 7.86-7.82 (m, 2H), 7.63 (m, 1H), 7.42 (d, J 
= 8.2 Hz, 1H), 7.17 (dd, J = 8.9, 2.6 Hz, 1H), 7.07 (m, 1H), 6.61 (m, 1H), 5.50 (d, J = 
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8.4 Hz, 1H). HRMS calculated for C30H16ClFN6O4RuNa (M + Na)
+ 702.9841, found (M 
+ Na)+ 702.9857. 
Synthesis of the modified FL172 with derivatized 2-(phenylaminomethyl)pyridines. 
The synthesis was performed in analogy to FL172 by reacting ruthenium precursor 2.3 
in DMF (9 mM, 2.5 mL) first with CO gas stirring at75 °C for 1 hour, then by addition 
of 1 equiv of derivatized 2-(phenylaminomethyl)pyridine stirring at 95 °C under 













Complex FL227. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL227 (4.2 mg, 51%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 (s, 1H), 9.18 (s, 
1H), 8.73 (dd, J = 9.3, 2.4 Hz, 1H), 8.63 (m, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.42 (m, 1H), 
8.31 (d, J = 2.5 Hz, 1H), 8.184 (s, 1H), 8.180 (td, J = 7.8, 1.6 Hz, 1H), 8.05 (d, J = 7.7 
Hz, 1H), 7.57-7.35 (m, 5H), 7.12 (dd, J = 8.9, 2.6 Hz, 1H), 2.64 (s, 3H). HRMS 
calculated for C31H19ClFN5O4RuNa (M + Na)













Complex FL226. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL226 (3.2 mg, 39%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.21 (s, 
1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.37 (m, 1H), 8.34 (t, J = 
2.5 Hz, 1H), 8.31 (d, J = 2.6 Hz, 1H), 8.19 (s, 1H), 8.16 (td, J = 7.7, 1.8 Hz, 1H), 
7.95-7.92 (m, 2H), 7.56 (t, J = 7.7 Hz, 1H), 7.49-7.39 (m, 3H), 7.15 (dd, J = 8.9, 2.6 Hz, 
1H), 2.52 (s, 3H). HRMS calculated for C31H19ClFN5O4RuNa (M + Na)
+ 704.0045, 












Complex FL224. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL224 (5.1 mg, 61%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.18 (s, 
1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.36 (m, 1H), 8.33-8.31 (m, 
2H), 8.20 (s, 1H), 8.15 (td, J = 7.7, 1.8 Hz, 1H), 8.03-8.00 (m, 2H), 7.50-7.40 (m, 4H), 
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7.15 (dd, J = 8.9, 2.6 Hz, 1H), 2.47 (s, 3H). HRMS calculated for C31H20ClFN5O4Ru (M 












Complex FL237. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL237 (4.2 mg, 53%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.15 (s, 
1H), 8.68 (dd, J = 9.4, 2.3 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.35-8.30 (m, 3H), 8.19 (s, 
1H), 8.16-8.07 (m, 3H), 7.48-7.39 (m, 2H), 7.24-7.19 (m, 2H), 7.15 (dd, J = 8.9, 2.6 Hz, 
1H), 3.94 (s, 3H). HRMS calculated for C31H19ClFN5O6RuNa (M + Na)
+ 719.9994, 














Complex FL262-1. Used as crude. HRMS calculated for C35H27ClFN6O4Ru (M + H)
+ 













Complex FL262-2. Used as crude. HRMS calculated for C36H22FN6O4Ru (M - Cl + 
CH3CN)













Complex FL252. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 45:1) to 
obtain complex FL252 (3.5 mg, 49%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 
(s, 1H), 9.23 (s, 1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.57 (d, J = 8.9 Hz, 1H), 8.38 (m, 
1H), 8.36 (t, J = 2.5 Hz, 1H), 8.31 (d, J = 2.3 Hz, 1H), 8.23-8.14 (m, 4H), 7.51-7.43 (m, 
4H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H). HRMS calculated for C30H17ClF2N5O4Ru (M + H)
+ 















Complex FL254. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL254 (3.8 mg, 46%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 (s, 1H), 9.23 (s, 
1H), 8.68 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.38-8.34 (m, 2H), 8.31 (d, 
J = 2.6 Hz, 1H), 8.21 (s, 1H), 8.16 (td, J = 7.6, 1.8 Hz, 1H), 7.50-7.42 (m, 2H), 7.39 (d, 
J = 2.3 Hz, 2H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H), 6.67 (t, J = 2.2 Hz, 1H), 3.94 (s, 6H). 
HRMS calculated for C32H22ClFN5O6Ru (M + H)














Complex FL256. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 45:1) to 
obtain complex FL256 (3.3 mg, 42%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.89 
(s, 1H), 9.18 (s, 1H), 9.10 (br, 1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 9.2 Hz, 
1H), 8.37 (m, 1H), 8.34 (t, J = 2.5 Hz, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.21 (s, 1H), 8.15 
(td, J = 7.7, 1.8 Hz, 1H), 7.62 (t, J = 2.1 Hz, 1H), 7.57-7.41 (m, 4H), 7.15 (dd, J = 8.9, 
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2.6 Hz, 1H), 7.04 (m, 1H). HRMS calculated for C30H17ClFN5O5RuNa (M + Na)
+ 














Complex FL258. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL258 (2.7 mg, 33%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.21 (s, 
1H), 8.69 (dd, J = 9.4, 2.3 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.37 (m, 1H), 8.34 (t, J = 
2.5 Hz, 1H), 8.31 (d, J = 2.6 Hz, 1H), 8.21 (s, 1H), 8.16 (td, J = 7.7, 1.8 Hz, 1H), 7.78 (t, 
J = 2.2 Hz, 1H), 7.66 (m, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.50-7.42 (m, 2H), 7.15 (dd, J = 
8.9, 2.6 Hz, 1H), 7.11 (m, 1H), 4.81 (m, 1H), 1.41 (m, 6H). HRMS calculated for 
C33H24ClFN5O5Ru (M + H)














Complex FL262-3. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 45:1) to 
obtain complex FL262-3 (1.3 mg, 15%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 
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(s, 1H), 9.19 (s, 1H), 8.82 (dd, J = 3.4, 2.4 Hz, 1H), 8.70 (dd, J = 9.2, 2.4 Hz, 1H), 8.58 
(d, J = 8.9 Hz, 1H), 8.38 (m, 1H), 8.31 (d, J = 2.6 Hz, 1H), 8.17 (s, 1H), 8.16 (td, J = 
7.7, 1.7 Hz, 1H), 8.03 (dd, J = 7.9, 1.6 Hz, 1H), 7.53-7.39 (m, 4H), 7.21 (m, 1H), 7.13 
(dd, J = 8.9, 2.6 Hz, 1H), 4.14 (s, 3H). HRMS calculated for C31H19ClFN5O6RuNa (M + 
Na)+ 719.9994, found (M + Na)+ 720.0002. The amino-complex is also isolated in the 
reaction: 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 (s, 1H), 9.24 (dd, J = 3.9, 2.4 
Hz, 1H), 8.81 (dd, J = 9.2, 2.4 Hz, 1H), 8.58 (d, J = 8.9 Hz, 1H), 8.27 (d, J = 2.5 Hz, 
1H), 8.16 (m, 1H), 8.11 (s, 1H), 7.89 (td, J = 7.3, 2.0 Hz, 1H), 7.79-7.72 (m, 2H), 
7.32-7.23 (m, 2H), 7.14-7.03 (m, 4H), 5.81 (dd, J = 14.1, 10.9 Hz, 1H), 4.54 (dd, J = 














Complex FL262-4. Used as crude. HRMS calculated for C31H19ClFN5O6Ru (M + Na)
+ 














Complex FL262-6. Used as crude. HRMS calculated for C31H16Cl2F4N5O4Ru (M + Cl)
- 
 141 












Complex FL262-7. Used as crude. HRMS calculated for C34H24FN6O4Ru (M - Cl + 
CH3CN)















Complex FL262-8. Used as crude. HRMS calculated for C32H22ClFN5O6Ru (M + H)
+ 













Complex FL355. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL355 (2.7 mg, 32%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.86 (s, 1H), 8.69 (dd, 
J = 9.4, 2.3 Hz, 1H), 8.58-8.55 (m, 2H), 8.29 (d, d, J = 2.6 Hz, 1H), 8.17 (s, 1H), 
7.97-7.34 (m, 8H), 7.12 (dd, J = 8.9, 2.6 Hz, 1H), 3.39-2.99 (m, 4H), 2.18 (m, 1H), 1.90 
(m, 1H). HRMS calculated for C33H22ClFN5O4Ru (M + H)















Complex FL262-9. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 50:1, then 40:1) to 
obtain complex FL262-9 (2.3 mg, 27%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.90 
(s, 1H), 9.42 (s, 1H), 9.00 (t, J = 2.1 Hz, 1H), 8.71-8.65 (m, 2H), 8.58 (d, J = 8.9 Hz, 
1H), 8.48-8.45 (m, 3H), 8.31 (d, J = 2.6 Hz, 1H), 8.21 (s, 1H), 8.21 (td, J = 6.9, 2.5 Hz, 
1H), 8.03 (t, J = 8.2 Hz, 1H), 7.54-7.48 (m, 2H), 7.16 (dd, J = 8.9, 2.6 Hz, 1H). HRMS 
calculated for C30H17ClFN6O6Ru (M + H)















Complex FL309-2. Used as crude. HRMS calculated for C32H22ClFN5O6Ru (M + H)
+ 












Complex FL343. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (50:1) to obtain complex 
FL343 (2.9 mg, 35%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.13 (s, 
1H), 8.69 (dd, J = 9.4, 2.4 Hz, 1H), 8.58 (d, J = 8.9 Hz, 1H), 8.34 (t, J = 2.5 Hz, 1H), 
8.31 (d, J = 2.5 Hz, 1H), 8.20 (s, 1H), 8.18 (m, 1H), 8.13-8.09 (m, 2H), 7.72-7.65 (m, 
2H), 7.58 (m, 1H), 7.31-7.24 (m, 2H), 7.15 (dd, J = 8.9, 2.6 Hz, 1H), 2.47 (s, 3H). 
HRMS calculated for C31H19ClFN5O4RuNa (M + Na)
















Complex FL389. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (35:1) to obtain complex 
FL389 (2.5 mg, 30%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 (s, 1H), 8.83 (s, 
1H), 8.70 (dd, J = 9.4, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.31 (t, J = 2.5 Hz, 1H), 
8.27 (d, J = 2.5 Hz, 1H), 8.19 (s, 1H), 8.07-8.02 (m, 2H), 7.98 (d, J = 8.6 Hz, 1H), 
7.64-7.58 (m, 2H), 7.49 (m, 1H), 7.19-7.11 (m, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.06 (s, 
2H). HRMS calculated for C30H18ClFN6O4RuNa (M + Na)













Complex FL327. The crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (45:1) to obtain complex 
FL327 (3.1 mg, 37%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.88 (s, 1H), 9.12 (s, 
1H), 9.06 (s, 1H), 8.69 (dd, J = 9.5, 2.4 Hz, 1H), 8.59 (d, J = 8.9 Hz, 1H), 8.33 (t, J = 
2.5 Hz, 1H), 8.31 (d, J = 2.6 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.20 (s, 1H), 7.96 (m, 
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1H), 7.59 (m, 1H), 7.53 (m, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.39 (m, 1H), 7.15 (dd, J = 
8.9, 2.6 Hz, 1H), 7.02 (m, 1H), 2.01 (s, 3H). HRMS calculated for C31H20ClFN5O5Ru 
(M + H)+ 698.0175, found (M + H)+ 698.0178. 
Chapter 6.1.2: Synthesis of MLCK inhibitors 
General procedure for the synthesis of 3.81-3.86: 
A suspension of the plain pyridocarbazole (10 mM), K2CO3 (1.1 equiv), and 
[Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (1.1 equiv) in DMF (1.2 mL) was stirred at 85 °C 
under microwave irradiation for 30 minutes, followed by adding the monodentate ligand 
salt (2 equiv), then the mixture was stirred at 85 °C for an additional 30 minutes. The 
resulting suspension was dried in vacuo and the crude material was adsorbed onto silica 
gel and subjected to silica gel chromatography with d c loromethane : methanol (15:1) 










Complex 3.82. Yield: 65%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.04 (s, 1H), 
9.13 (dd, J = 8.4, 1.1 Hz, 1H), 9.05 (dd, J = 5.0, 1.1 Hz, 1H), 8.73 (d, J = 7.5 Hz, 1H), 
7.80-7.75 (m, 2H), 7.51 (m, 1H), 7.30 (m, 1H), 3.13-2.20 (m, 12H). 13C NMR (125.8 
MHz, DMSO-d6): δ (ppm) 170.9, 170.8, 154.3, 151.9, 150.8, 143.7, 132.3, 130.3, 125.7, 
124.1, 123.8, 123.3, 121.1, 118.7, 114.8, 114.7, 111.9, 34.8, 33.4, 33.3, 32.1, 31.1, 29.7. 
IR (film): ν (cm-1) 3012, 2930, 2154, 1747, 1702, 1582, 1481, 1412, 1345, 1288, 1230, 











Complex 3.83. Yield: 33%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.05 (s, 1H), 
9.09 (dd, J = 8.4, 1.1 Hz, 1H), 9.05 (dd, J = 5.1, 1.1 Hz, 1H), 8.73 (d, J = 7.5 Hz, 1H), 
7.79 (dd, J = 8.4, 5.1 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.51 (m, 1H), 7.31 (m, 1H), 
3.05-2.27 (m, 12H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 170.9, 170.8, 153.5, 
151.9, 150.8, 143.2, 132.0, 130.2, 125.8, 124.1, 123.9, 123.5, 121.1, 118.8, 114.9, 114.7, 
112.1, 106.7, 35.3, 34.7, 33.3, 33.1, 32.4, 30.3. IR (film): ν (cm-1) 3143, 3150, 2101, 










Complex 3.84. Yield: 46%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.03 (s, 1H), 
9.13-9.08 (m, 2H), 8.75 (d, J = 7.4 Hz, 1H), 7.80-7.74 (m, 2H), 7.53 (m, 1H), 7.31 (m, 
1H), 3.08-2.22 (m, 12H). 13C NMR (125.8 MHz, DMSO-d6): δ (ppm) 171.0, 170.9, 
153.8, 151.9, 150.5, 143.4, 132.1, 130.3, 125.7, 124.1, 123.8, 123.3, 121.1, 118.7, 114.9, 
114.6, 111.7, 34.8, 34.1, 33.5, 32.9, 32.0, 29.4. IR (film): ν (cm-1) 3052, 2978, 2226, 











Complex 3.86. Yield: 52%. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.07 (s, 1H), 
9.15 (dd, J = 8.4, 1.0 Hz, 1H), 9.05 (dd, J = 5.1, 1.0 Hz, 1H), 8.76 (d, J = 7.8 Hz, 1H), 
7.81 (dd, J = 8.4, 5.1 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.54 (m, 1H), 7.33 (m, 1H), 
3.31-2.24 (m, 12H). 13C NMR (125.8 MHz, DMSO-d6): δ (ppm) 170.9, 170.7, 153.7, 
151.8, 150.9, 143.2, 132.64, 132.58, 130.4, 125.9, 124.2, 123.8, 123.5, 121.0, 118.8, 
114.75, 114.70, 112.1, 34.35, 34.28, 33.7, 32.6, 32.1, 9.7. IR (film): ν (cm-1) 2952, 
2913, 2101, 1746, 1708, 1481, 1441, 1413, 1345, 1290, 1265, 1229, 1018, 820, 794, 





Compound 3.2. A solution of 3.1 (750 mg, 4.29 mmol) in THF (5 mL) was purged with 
nitrogen while cooling to 0 °C. To the solution was added di-tert-butyl dicarbonate (981 
mg, 4.50 mmol), followed by the careful addition of solid 4-dimethylaminopyridine 
(621 mg, 4.50 mmol). The resulting suspension was wrmed to room temperature 
naturally and stirred overnight. The reaction mixture was cooled to 0 °C and 1 M HCl (3 
mL) was added carefully. After stirring at 0 °C for 5 minutes, the organic layer was 
separated and the aqueous layer was extracted with EtOAc twice. The combined organic 
layers were washed with brine, dried using Na2SO4, filtered and concentrated to dryness 
in vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (10:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.2 (1.16 g, 98%) as a solid. 1H NMR 
 148 
(300 MHz, CDCl3): δ (ppm) 7.99 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 3.4 Hz, 1H), 7.04 (d, 
J = 2.3 Hz, 1H), 6.91 (dd, J = 8.9, 2.3 Hz, 1H), 6.47 (d, J = 3.6 Hz, 1H), 4.55 (septet, J 
= 6.1 Hz, 1H), 1.66 (s, 9H), 1.34 (d, J = 6.1 Hz, 6H). 13C NMR (100.6 MHz, CDCl3): δ 
(ppm) 154.1, 126.6, 115.9, 115.2, 107.2, 107.1, 77.4, 71.0, 28.4, 22.3. IR (film): ν (cm-1) 
2977, 1730, 1614, 1583, 1466, 1373, 1263, 1163, 1116, 023, 974, 849, 763, 722. 
HRMS calculated for C16H22NO3 (M + H)






Compound 3.3. A solution of 3.2 (600 mg, 2.18 mmol) in anhydrous THF (4 mL) was 
prepared after drying 3.2 overnight under high vacuum. Following the addition f 
triisopropyl borate (0.76 mL, 3.28 mmol), the reaction mixture was cooled to 0 °C and 
lithium diisopropylamide (2.0 M solution in heptane-tetrahydrofuran-ethylbenzene) 
(1.64 mL, 3.28 mmol) was added dropwise over 15 minutes. After stirring for an 
additional 45 minutes at 0 °C, 2 M HCl (5.4 mL) was carefully added and stirred at 0 °C 
for 5 minutes. The resulting organic layer was separated and the aqueous layer was 
extracted using EtOAc twice. The combined organic layers were dried using Na2SO4, 
filtered and concentrated to dryness in vacuo to provide 3.3 (668 mg, 96%) which was 






Compound 3.4. A biphasic suspension of 3.3 (624 mg, 1.96 mmol), 2-bromopyridine 
(281 mg, 1.78 mmol), tetrakis(triphenylphosphine)palladium(0) (144 mg, 0.12 mmol) 
and Na2CO3 (518 mg, 4.89 mmol) in 1,2-dimethoxyethane (18 mL) and water (2.1 mL) 
was purged with nitrogen and refluxed overnight. The resulting reaction mixture was 
cooled to room temperature, diluted with water and extracted with EtOAc for three 
times. The combined organic layers were washed withbrine, dried using Na2SO4, 
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filtered and concentrated to dryness in vacuo. The crude material was adsorbed onto 
silica gel and subjected to silica gel chromatography with hexane : EtOAc (first 6:1, 
then 3:1) as the eluting solvent. The combined product eluents were isolated as a 
mixture of Boc-protected pyridylindole and 3.4. The resulting solid was dissolved into 
DCM and adsorbed onto silica gel (8 g) using rotary evaporation. The white powder 
was heated to 80 °C overnight under high vacuum. The silica gel was cooled to room 
temperature, filtered through celite with EtOAc and the filtrate was dried in vacuo to 
provide 3.4 (390 mg, 87% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ 
(ppm) 9.55 (s, 1H), 8.56 (d, J = 4.5 Hz, 1H), 7.78-7.68 (m, 2H), 7.28 (d, J = 8.8 Hz, 1H), 
7.17-7.12 (m, 2H), 6.93 (s, 1H), 6.88 (dd, J = 8.8, 2.0 Hz, 1H), 4.53 (septet, J = 6.1 Hz, 
1H), 1.36 (d, J = 6.1 Hz, 6H). 13C NMR (100.6 MHz, CDCl3): δ (ppm) 152.5, 150.5, 
149.3, 137.4, 136.7, 132.2, 129.7, 122.0, 119.9, 116.0, 112.1, 106.5, 100.3, 71.3, 22.4. 
IR (film): ν (cm-1) 3189, 2973, 1592, 1543, 1443, 1381, 1369, 1211, 134, 1113, 1070, 
969, 774, 742. HRMS calculated for C16H17N2O (M + H)












Compound 3.5. A solution of 3.4 (380 mg, 1.51 mmol) in anhydrous THF (4.5 mL) was 
prepared after drying 3.4 under high vacuum overnight. After cooling the soluti n to -15 
°C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (4.5 mL, 4.50 mmol) was 
added dropwise over 15 minutes and the resulting suspension was stirred at -15 °C for 
an additional 1 hour. A solution of TBS-protected dibromomaleimide (584 mg, 1.58 
mmol) in THF (4.5 mL) cooled to 0 °C was added and the reaction mixture was stirred 
at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple reaction 
mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and extracted with 
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EtOAc twice. The combined organic layers were washed with saturated NaHCO3 
followed by brine, dried using Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried in vacuo to provide 3.5 as a solid which was 









Compound 3.6. A solution of 3.5 in toluene (950 mL) was irradiated with a medium 
pressure Hg lamp (700 W) for 1 hour with constant nitrogen flow through the solution. 
The resulting red solution was concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with hexane : 
EtOAc (3:1) as the eluting solvent. The combined product eluents were dried in vacuo 
to provide 3.6 (400 mg, 58% over two steps) as a yellow solid. 1H NMR (300 MHz, 
CDCl3): δ (ppm) 10.25 (br, 1H), 9.42 (dd, J = 8.5, 1.7 Hz, 1H), 8.99 (dd, J = 4.3, 1.7 Hz, 
1H), 8.64 (d, J = 2.4 Hz, 1H), 7.63 (dd, J = 8.5, 4.3 Hz, 1H), 7.50 (d, J = 8.8, 1H), 7.20 
(dd, J = 8.8, 2.4 Hz, 1H), 4.79 (septet, J = 6.1 Hz, 1H), 1.44 (d, J = 6.1 Hz, 6H), 1.07 (s, 
9H), 0.63 (s, 6H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 175.7, 174.2, 153.5, 150.5, 
140.7, 138.6, 134.6, 134.4, 130.9, 123.2, 122.9, 121.9, 120.3, 119.1, 115.2, 112.1, 110.8, 
71.3, 26.7, 22.3, 19.3, -3.8. IR (film): ν (cm-1) 2956, 2930, 1748, 1690, 1469, 1333, 
1313, 1282, 1216, 1114, 1066, 1041, 847, 826, 799. HRMS calculated for C26H30N3O3Si 













Complex FL1359. A suspension of the ligand 3.6 (6 mg, 0.013 mmol), K2CO3 (2 mg, 
0.014 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (10.1 mg, 0.014 mmol) in DMF 
(0.5 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (1.7 mg, 0.026 mmol), the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as the eluting solvent. The metal complex FL1359 
was isolated as a green solid (4.6 mg, 53%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 
10.99 (s, 1H), 9.06-9.03 (m, 2H), 8.28 (d, J = 2.5 Hz, 1H), 7.74 (dd, J = 8.3, 5.1 Hz, 1H), 
7.64 (d, J = 8.9 Hz, 1H), 7.17 (dd, J = 8.9, 2.5 Hz, 1H), 4.66 (septet, J = 6.0 Hz, 1H), 
3.05-2.18 (m, 12H), 1.36 (d, J = 6.0 Hz, 6H). 13C NMR (125.8 MHz, DMSO-d6): δ 
(ppm) 171.0, 153.9, 151.0, 150.2, 147.1, 143.7, 132.0, 130.4, 124.1, 123.1, 121.1, 117.2, 
115.5, 114.5, 110.9, 109.6, 70.5, 34.5, 33.9, 33.3, 2.7, 31.7, 29.4, 22.11, 22.08. IR 
(film): ν (cm-1) 3198, 2967, 2929, 2033, 1746, 1703, 1600, 1461, 14 9, 1339, 1211, 







Compound 3.8. A biphasic suspension of 3.3 (668 mg, 2.09 mmol), 2-bromo-5- 
fluoropyridine (333 mg, 1.90 mmol), tetrakis(triphenylphosphine)palladium(0) (154 mg, 
0.13 mmol) and Na2CO3 (555 mg, 5.23 mmol) in 1,2-dimethoxyethane (19 mL) and 
water (2.3 mL) was purged with nitrogen and refluxed overnight. The resulting reaction 
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mixture was cooled to room temperature, diluted with water and extracted with EtOAc 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (8:1) as 
the eluting solvent. The combined product eluents were isolated as a mixture of 
Boc-protected pyridylindole and 3.8. The resulting solid was dissolved into DCM and 
adsorbed onto silica gel (10 g) using rotary evaporti n. The white powder was heated 
to 80 °C overnight under high vacuum. The silica gel was cooled to room temperature, 
filtered through celite with EtOAc and the filtrate was dried in vacuo to provide 3.8 
(500 mg, 97% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.27 (s, 
1H), 8.41 (d, J = 2.8 Hz, 1H), 7.75 (dd, J = 8.8, 4.3 Hz, 1H), 7.44 (td, J = 8.6, 2.9 Hz, 
1H), 7.29 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 2.2 Hz, 1H), 6.88 (dd, J = 8.8, 2.3 Hz, 1H), 
6.85 (d, J = 1.8 Hz, 1H), 4.53 (septet, J = 6.1 Hz, 1H), 1.36 (d, J = 6.1 Hz, 6H). 13C 
NMR (75.5 MHz, CDCl3): δ (ppm) 160.3, 156.9, 152.6, 147.0, 137.5, 137.1, 136.6, 
132.2, 129.7, 124.0, 123.8, 120.7, 120.6, 116.0, 112.1, 106.5, 100.10, 100.09, 71.3, 22.4. 
IR (film): ν (cm-1) 3428, 3411, 2977, 1548, 1454, 1427, 1381, 1228, 105, 1150, 1114, 
968, 918, 835, 792, 532. HRMS calculated for C16H16FN2O (M + H)
+ 271.1241, found 












Compound 3.9. A solution of 3.8 (500 mg, 1.85 mmol) in anhydrous THF (5.6 mL) was 
prepared after drying 3.8 under high vacuum overnight. After cooling the soluti n to -15 
°C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (5.6 mL, 5.60 mmol) was 
added dropwise over 15 minutes and the resulting suspension was stirred at -15 °C for 
an additional 1 hour. A solution of TBS-protected dibromomaleimide (718 mg, 1.94 
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mmol) in THF (5.6 mL) cooled to 0 °C was added and the reaction mixture was stirred 
at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple reaction 
mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and extracted with 
EtOAc twice. The combined organic layers were washed with saturated NaHCO3 
followed by brine, dried using Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried n vacuo to provide 3.9 (710 mg, 68%) as a solid 










Compound 3.10. A solution of 3.9 (300 mg, 0.54 mmol) in toluene (950 mL) was 
irradiated with a medium pressure Hg lamp (700 W) for 20 minutes with constant 
nitrogen flow through the solution. The resulting red solution was concentrated to 
dryness in vacuo. The crude material was adsorbed onto silica gel and subjected to silica 
gel chromatography with hexane : EtOAc (8:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.10 (215 mg, 84%) as a yellow solid. 1H
NMR (300 MHz, CDCl3): δ (ppm) 10.05 (s, 1H), 8.96 (dd, J = 9.4, 2.8 Hz, 1H), 8.78 (d, 
J = 2.8 Hz, 1H), 8.53 (d, J = 2.4 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.17 (dd, J = 8.8, 2.5 
Hz, 1H), 4.75 (septet, J = 6.1 Hz, 1H), 1.44 (d, J = 6.1 Hz, 6H), 1.07 (s, 9H), 0.65 (s, 
6H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 175.3, 173.8, 159.6, 156.2, 153.6, 141.4, 
141.1, 140.5, 135.24, 135.22, 134.3, 131.7, 122.9, 122.2, 122.1, 119.6, 119.5, 119.1, 
117.9, 117.6, 114.7, 112.1, 110.7, 71.2, 26.6, 22.3, 19.3, -3.8. IR (film): ν (cm-1) 3464, 
2930, 1748, 1692, 1468, 1310, 1288, 1252, 1215, 1058, 1039, 827, 763, 478, 451. 
HRMS calculated for C26H29FN3O3Si (M + H)














Complex FL1335. A suspension of the ligand 3.10 (7 mg, 0.015 mmol), K2CO3 (2 mg, 
0.016 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (11.3 mg, 0.016 mmol) in DMF 
(0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (1.9 mg, 0.029 mmol), then the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as the eluting solvent. The metal complex FL1335 
was isolated as a solid (4.8 mg, 48%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.1 (s, 
1H), 9.06 (t, J = 2.3 Hz, 1H), 8.74 (dd, J = 9.4, 2.1 Hz, 1H), 8.28 (d, J = 2.5 Hz, 1H), 
7.63 (d, J = 8.9 Hz, 1H), 7.19 (dd, J = 8.9, 2.5 Hz, 1H), 4.67 (septet, J = 6.0 Hz, 1H), 
3.02-2.27 (m, 12H), 1.36 (d, J = 6.0 Hz, 6H). 13C NMR (125.8 MHz, DMSO-d6): δ 
(ppm) 170.7, 170.6, 158.2, 155.7, 153.9, 151.3, 147.1, 140.9, 140.1, 139.8, 131.1, 124.1, 
120.8, 120.7, 117.3, 116.1, 115.9, 115.5, 114.5, 110.22, 110.17, 109.7, 70.4, 33.9, 33.4, 
33.3, 32.9, 32.5, 30.0, 22.09, 22.06. IR (film): ν (cm-1) 2030, 1744, 1711, 1559, 1458, 
1411, 1336, 1261, 1224, 1197, 1111, 966, 818, 756. HRMS calculated for 
C26H25FN6O3S3RuNa (M + Na)





Compound 3.13. A solution of 3.12 (830 mg, 5.09 mmol) in THF (5 mL) was purged 
with nitrogen while cooling to 0 °C. To the solution was added di-tert-butyl dicarbonate 
(1.17 g, 5.37 mmol), followed by the careful addition of solid 4-dimethylaminopyridine 
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(738 mg, 5.37 mmol). The resulting suspension was wrmed to room temperature 
naturally and stirred overnight. The reaction mixture was cooled to 0 °C and 1 M HCl 
(3.6 mL) was added carefully. After stirring at 0 °C for 5 minutes, the organic layer was 
separated and the aqueous layer was extracted with EtOAc twice. The combined organic 
layers were washed with brine, dried using Na2SO4, filtered and concentrated to dryness 
in vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (15:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.13 (1.09 g, 81%) as a solid. 1H NMR 
(300 MHz, CDCl3): δ (ppm) 8.05 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 3.6 Hz, 1H), 7.49 (d, 
J = 1.8 Hz, 1H), 7.27 (dd, J = 8.5, 1.9 Hz, 1H), 6.51 (d, J = 3.7 Hz, 1H), 2.52 (s, 3H), 
1.67 (s, 9H). 13C NMR (100.6 MHz, CDCl3): δ (ppm) 131.9, 131.5, 126.7, 124.9, 120.3, 
115.7, 106.9, 84.1, 28.3, 17.7. IR (film): ν (cm-1) 2978, 1734, 1451, 1369, 1340, 1280, 
1248, 1202, 1161, 1136, 1085, 1023, 764, 723. HRMS calculated for C14H17NO2SNa (M 






Compound 3.14. A solution of 3.13 (500 mg, 1.90 mmol) in anhydrous THF (3 mL) 
was prepared after drying 3.13 overnight under high vacuum. Following the addition of 
triisopropyl borate (0.66 mL, 2.85 mmol), the reaction mixture was cooled to 0 °C and 
lithium diisopropylamide (2.0 M solution in heptane-tetrahydrofuran-ethylbenzene) 
(1.43 mL, 2.86 mmol) was added dropwise over 15 minutes. After stirring for an 
additional 45 minutes at 0 °C, 2 M HCl (4.7 mL) was carefully added and stirred at 0 °C 
for 5 minutes. The resulting organic layer was separated and the aqueous layer was 
extracted using EtOAc twice. The combined organic layers were dried using Na2SO4, 
filtered and concentrated to dryness in vacuo to provide 3.14 (572 mg, 98%) which was 








Compound 3.15. A biphasic suspension of 3.14 (572 mg, 1.86 mmol), 2-bromo-5- 
fluoropyridine (298 mg, 1.69 mmol), tetrakis(triphenylphosphine)palladium(0) (137 mg, 
0.12 mmol) and Na2CO3 (493 mg, 4.65 mmol) in 1,2-dimethoxyethane (17 mL) and 
water (2.0 mL) was purged with nitrogen and refluxed overnight. The resulting reaction 
mixture was cooled to room temperature, diluted with water and extracted with EtOAc 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (8:1) as 
the eluting solvent. The combined product eluents were isolated as a mixture of 
Boc-protected pyridylindole and 3.15. The resulting solid was dissolved into DCM and 
adsorbed onto silica gel (8 g) using rotary evaporati n. The white powder was heated to 
80 °C overnight under high vacuum. The silica gel was cooled to room temperature, 
filtered through celite with EtOAc and the filtrate was dried in vacuo to provide 3.15 
(380 mg, 87% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.44 (s, 
1H), 8.43 (d, J = 2.8 Hz, 1H), 7.77 (dd, J = 8.8, 4.3 Hz, 1H), 7.63 (br, 1H), 7.45 (td, J = 
8.5, 2.8 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.24 (dd, J = 8.5, 1.7 Hz, 1H), 6.88 (d, J = 
1.7 Hz, 1H), 2.53 (s, 3H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 160.4, 157.1, 146.74, 
146.69, 137.5, 137.2, 136.6, 135.4, 130.0, 128.7, 125.3, 124.1, 123.9, 121.6, 120.93, 
120.87, 112.0, 99.90, 99.89, 18.7. IR (film): ν (cm-1) 3427, 1730, 1547, 1469, 1451, 
1422, 1311, 1266, 1230, 837, 796, 735, 535. HRMS calculated for C14H12FN2S (M + 













Compound 3.16. A solution of 3.15 (380 mg, 1.47 mmol) in anhydrous THF (4.0 mL) 
was prepared after drying 3.15 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (4.4 mL, 4.40 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (571 
mg, 1.55 mmol) in THF (4.0 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried in vacuo to provide 3.16 as a solid which was 










Compound 3.17. A solution of 3.16 in toluene (220 mL) was irradiated with a medium 
pressure Hg lamp (150 W) using a pyrex filter for 2.5 hours with constant nitrogen flow 
through the solution. The resulting red solution was concentrated to dryness in vacuo. 
The crude material was adsorbed onto silica gel andsubjected to silica gel 
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chromatography with hexane : EtOAc (3:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.17 (123 mg, 18% over two steps) as a 
yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.85 (s, 1H), 9.07-9.03 (m, 2H), 
8.88 (d, J = 2.8 Hz, 1H), 7.57 (m, 2H), 2.67 (s, 3H), 1.06 (s, 9H), 0.63 (s, 6H). 13C NMR 
(125.8 MHz, CDCl3): δ (ppm) 175.3, 173.7, 159.2, 157.1, 141.9, 141.7, 140.4, 137.8, 
135.4, 131.7, 131.3, 128.5, 124.8, 123.1, 122.6, 122.5, 120.55, 120.52, 117.9, 117.8, 
114.2, 112.0, 26.6, 19.3, 18.2, -3.9. IR (film): ν (cm-1) 2930, 2859, 1750, 1692, 1561, 
1461, 1414, 1336, 1304, 1282, 1257, 1057, 846, 826, 768. HRMS calculated for 
C24H24FN3O2SSiNa (M + Na)













Complex FL1288. A suspension of the ligand 3.17 (7 mg, 0.015 mmol), K2CO3 (2.3 mg, 
0.017 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (11.6 mg, 0.017 mmol) in DMF 
(0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (2 mg, 0.031 mmol), then the mixture was stirred at 85 °C for an 
additional 40 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as the eluting solvent. The metal complex FL1288 
was isolated as a solid (4.5 mg, 45%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.17 (s, 
1H), 9.11 (t, J = 2.5 Hz, 1H), 8.77 (dd, J = 9.4, 2.3 Hz, 1H), 8.71 (d, J = 1.9 Hz, 1H), 
7.70 (d, J = 8.6 Hz, 1H), 7.54 (dd, J = 8.7, 1.9 Hz, 1H), 3.02-2.26 (m, 12H), 2.57 (s, 3H). 
13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 170.7, 170.5, 158.4, 155.9, 154.0, 150.6, 
140.9, 140.5, 131.0, 127.1, 126.7, 124.3, 123.9, 120.9, 120.8, 116.3, 116.1, 115.6, 113.9, 
111.62, 111.57, 33.9, 33.5, 33.3, 33.0, 32.6, 30.0, 17.9. IR (film): ν (cm-1) 2033, 1736, 
 159 






Compound 3.19. A biphasic suspension of 3.14 (572 mg, 1.86 mmol), 2-bromo 
pyridine (268 mg, 1.70 mmol), tetrakis(triphenylphosphine)palladium(0) (137 mg, 0.12 
mmol) and Na2CO3 (493 mg, 4.65 mmol) in 1,2-dimethoxyethane (17 mL) and water 
(2.0 mL) was purged with nitrogen and refluxed overnight. The resulting reaction 
mixture was cooled to room temperature, diluted with water and extracted with EtOAc 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (first 8:1, 
then 6:1) as the eluting solvent. The combined product eluents were isolated as a 
mixture of Boc-protected pyridylindole and 3.19. The resulting solid was dissolved into 
DCM and adsorbed onto silica gel (6 g) using rotary evaporation. The white powder 
was heated to 80 °C overnight under high vacuum. The silica gel was cooled to room 
temperature, filtered through celite with EtOAc and the filtrate was dried in vacuo to 
provide 3.19 (310 mg, 76% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ 
(ppm) 9.57 (s, 1H), 8.57 (d, J = 4.7 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.72 (td, J = 8.0, 
1.7 Hz, 1H), 7.64 (br, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.24 (dd, J = 8.5, 1.7 Hz, 1H), 7.18 
(m, 1H), 6.95 (br, 1H), 2.53 (s, 3H). 13C NMR (100.6 MHz, CDCl3): δ (ppm) 150.2, 
149.3, 137.5, 136.8, 135.3, 130.1, 128.5, 125.3, 122.3, 121.7, 120.0, 112.0, 100.1, 18.8. 
IR (film): ν (cm-1) 3138, 2916, 1592, 1563, 1542, 1440, 1408, 1310, 185, 1152, 775, 
743, 5973, 527. HRMS calculated for C14H13N2S (M + H)













Compound 3.20. A solution of 3.19 (310 mg, 1.29 mmol) in anhydrous THF (3.9 mL) 
was prepared after drying 3.19 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (3.9 mL, 3.90 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (500 
mg, 1.35 mmol) in THF (3.9 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (3:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.20 as a solid which was carried 









Compound 3.21. A solution of 3.20 in toluene (950 mL) was irradiated with a medium 
pressure Hg lamp (700 W) for 30 minutes with constat nitrogen flow through the 
solution. The resulting red solution was concentrated to dryness in vacuo. The crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
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hexane : EtOAc (6:1) as the eluting solvent. The combined product eluents were dried 
in vacuo to provide 3.21 (242 mg, 42% over two steps) as a yellow solid. 1H NMR (300 
MHz, CDCl3): δ (ppm) 10.57 (s, 1H), 9.42 (dd, J = 8.5, 1.6 Hz, 1H), 9.05 (br, 1H), 9.0 
(dd, J = 4.3, 1.7 Hz, 1H), 7.65 (dd, J = 8.5, 4.3 Hz, 1H), 7.55-7.47 (m, 2H), 2.66 (s, 3H), 
1.07 (s, 9H), 0.64 (s, 6H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 175.5, 174.0, 150.7, 
140.3, 138.5, 138.0, 134.5, 130.9, 130.8, 128.5, 124.9, 123.2, 123.1, 122.1, 114.6, 112.0, 
26.7, 19.3, 18.3, -3.8. IR (film): ν (cm-1) 2927, 2854, 1685, 1594, 1332, 1303, 1276, 
1258, 1056, 1039, 823, 793, 736, 694, 524, 478. HRMS calculated for 
C24H25N3O2SSiNa (M + Na)












Complex FL1343. A suspension of the ligand 3.21 (7 mg, 0.016 mmol), K2CO3 (2.4 mg, 
0.017 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (12.1 mg, 0.017 mmol) in DMF 
(0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (2 mg, 0.031 mmol), then the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (10:1) as the eluting solvent. The metal complex FL1343 
was isolated as a solid (5 mg, 48%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) 11.05 (s, 
1H), 9.11-9.08 (m, 2H), 8.74 (d, J = 1.8 Hz, 1H), 7.79 (dd, J = 8.3, 5.1 Hz, 1H), 7.73 (d, 
J = 8.6 Hz, 1H), 7.53 (dd, J = 8.6, 2.0 Hz, 1H), 3.07-2.21 (m, 12H), 2.58 (s, 3H). 13C 
NMR (125.8 MHz, DMSO-d6): δ (ppm) 170.9, 170.8, 154.0, 150.7, 150.6, 143.5, 132.2, 
130.3, 126.9, 126.1, 124.4, 124.1, 123.4, 121.2, 115.6, 113.9, 112.2, 34.5, 33.8, 33.4, 
32.7, 31.7, 29.5, 18.0. IR (film): ν (cm-1) 2032, 1738, 1701, 1595, 1527, 1486, 1418, 
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1339, 1225, 1131, 1093, 820, 792, 671, 638. HRMS calculated for C24H22N6O2S4RuNa 







Compound 3.24. A biphasic suspension of 3.14 (675 mg, 2.20 mmol), 3.23 (504 mg, 
2.0 mmol), tetrakis(triphenylphosphine)palladium(0) 162 mg, 0.14 mmol) and Na2CO3 
(583 mg, 5.50 mmol) in 1,2-dimethoxyethane (20 mL) and water (2.4 mL) was purged 
with nitrogen and refluxed overnight. The resulting reaction mixture was cooled to 
room temperature, diluted with water and extracted with EtOAc for three times. The 
combined organic layers were washed with brine, dried using Na2SO4, filtered and 
concentrated to dryness in vacuo. The crude material was adsorbed onto silica gel and 
subjected to silica gel chromatography with hexane : EtOAc (first 8:1, then 6:1) as the 
eluting solvent. The combined product eluents were isolated as a mixture of 
Boc-protected pyridylindole and 3.24. The resulting solid was dissolved into DCM and 
adsorbed onto silica gel (10 g) using rotary evaporti n. The white powder was heated 
to 80 °C overnight under high vacuum. The silica gel was cooled to room temperature, 
filtered through celite with EtOAc and the filtrate was dried in vacuo to provide 3.24 
(490 mg, 73% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.49 (s, 
1H), 8.06 (d, J = 2.9 Hz, 1H), 7.61 (d, J = 8.9 Hz, 1H), 7.60 (br, 1H), 7.28 (d, J = 8.5 Hz, 
1H), 7.17 (dd, J = 8.4, 1.7 Hz, 1H), 7.01 (dd, J = 8.9, 3.0 Hz, 1H), 6.72 (m, 1H), 
5.92-5.80 (m, 2H), 5.23-5.17 (m, 4H), 3.98 (m, 4H), 2.52 (s, 3H). 13C NMR (100.6 
MHz, CDCl3): δ (ppm) 143.7, 138.7, 138.5, 135.1, 133.7, 133.0, 13.5, 127.9, 124.2, 
121.4, 120.5, 119.6, 116.9, 111.6, 97.1, 52.9, 19.0. IR (film): ν (cm-1) 3080, 2915, 1590, 
1554, 1485, 1458, 1439, 1418, 1393, 1304, 1234, 1176, 917, 823, 791, 734, 546. HRMS 
calculated for C20H22N3S (M + H)













Compound 3.25. A solution of 3.24 (480 mg, 1.43 mmol) in anhydrous THF (4.3 mL) 
was prepared after drying 3.24 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (4.3 mL, 4.30 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (555 
mg, 1.50 mmol) in THF (4.3 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to flush silica gel 
chromatography with CH2Cl2 : MeOH (10:1) as the eluting solvent. The combined 
product eluents were dried in vacuo to provide 3.25 as a solid which was carried 










Compound 3.26. A solution of 3.25 in toluene (950 mL) was irradiated with a medium 
pressure Hg lamp (700 W) for 1 hour with constant nitrogen flow through the solution. 
The resulting red solution was concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with hexane : 
EtOAc (first 2:1, then 1:2) as the eluting solvent. The combined product eluents were 
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dried in vacuo to provide 3.26 (300 mg, 39% over two steps) as a yellow solid and
mono allyl protected product (83 mg, 11%). 1H NMR (300 MHz, CDCl3): δ (ppm) 
10.08 (s, 1H), 9.03 (br, 1H), 8.63 (d, J = 3.0 Hz, 1H), 8.47 (d, J = 3.0 Hz, 1H), 7.51-7.44 
(m, 2H), 6.0-5.88 (m, 2H), 5.31-5.25 (m, 4H), 4.15 (d, J = 3.0 Hz, 4H), 2.64 (s, 3H), 
1.06 (s, 9H), 0.61 (s, 6H). 13C NMR (100.6 MHz, CDCl3): δ (ppm) 175.8, 174.5, 143.9, 
141.2, 140.5, 138.0, 132.5, 131.1, 130.7, 130.2, 127.7, 124.9, 123.9, 123.7, 119.4, 117.5, 
112.0, 111.7, 110.6, 52.9, 26.7, 19.3, 18.6, -3.7. IR (film): ν (cm-1) 2953, 2927, 2856, 
1743, 1686, 1589, 1562, 1447, 1408, 1311, 1277, 1250, 1053, 929, 846, 824, 677. 
HRMS calculated for C30H34N4O2SSiNa (M + Na)











Compound 3.27. A mixture solution of 3.26 (56 mg, 0.103 mmol), 1,3- 
dimethylbarbituric acid (96.8 mg, 0.620 mmol), and tetrakis(triphenylphosphine)- 
palladium(0) (23.9 mg, 0.021 mmol) in dichloromethane (5 mL) was purged with 
nitrogen and refluxed for 7 hours. The resulting reaction mixture was cooled to room 
temperature, diluted with dichloromethane and washed with saturated NaHCO3. The 
organic layer was separated, and the aqueous phase was xtracted with dichloromethane 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (1:1) as 
the eluting solvent. The combined product eluents were dried in vacuo to provide 3.27 
(33 mg, 69%) as a yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 10.47 (s, 1H), 
8.93 (d, J = 1.4 Hz, 1H), 8.45-8.39 (m, 2H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 7.33 (d, J = 
8.5 Hz, 1H), 4.19 (s, 2H), 2.62 (s, 3H), 1.06 (s, 9H), 0.63 (s, 6H). 13C NMR (75.5 MHz, 
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CDCl3): δ (ppm) 176.0, 174.1, 142.3, 142.2, 141.1, 137.9, 132.0, 131.0, 130.3, 127.7, 
124.7, 123.43, 123.37, 119.1, 113.2, 112.4, 111.7, 26.7, 19.3, 18.4, -3.8. IR (film): ν
(cm-1) 3368, 2952, 2927, 1743, 1683, 1619, 1563, 1432, 1415, 1346, 1311, 1291, 1277, 
1057, 846, 824, 695, 678. HRMS calculated for C24H27N4O2SSi (M + H)
+ 463.1618, 













Complex FL1358. A suspension of the ligand 3.27 (6 mg, 0.013 mmol), K2CO3 (2 mg, 
0.014 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (10 mg, 0.014 mmol) in DMF (0.5 
mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (1.7 mg, 0.026 mmol), then the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (10:1) as the eluting solvent. The metal complex FL1358 
was isolated as a solid (4.3 mg, 49%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.83 
(s, 1H), 8.62-8.60 (m, 2H), 8.12 (d, J = 1.9 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.42 (dd, J 
= 8.5, 1.7 Hz, 1H), 6.21 (br, 2H), 3.11-2.04 (m, 12H), 2.54 (s, 3H). 13C NMR (100.6 
MHz, DMSO-d6): δ (ppm) 171.7, 171.5, 156.0, 151.2, 145.9, 142.1, 136.5, 130.8, 126.9, 
125.5, 125.4, 124.6, 123.6, 122.8, 119.6, 115.4, 112.0, 110.8, 110.4, 35.7, 35.3, 34.6, 
32.3, 31.3, 29.1, 18.9. IR (film): ν (cm-1) 2030, 1742, 1703, 1621, 1566, 1487, 1415, 
1349, 1269, 12304, 1168, 1034, 821, 762, 639. HRMS calculated for 
C24H23N7O2S4RuNa (M + Na)







Compound 3.34. To a solution of Boc-protected 5-methoxyindole (948 mg, 3.83 mmol) 
in anhydrous THF (5 mL) was added triisopropyl borate (1.36 mL, 5.75 mmol), the 
reaction mixture was cooled to 0 °C and lithium diisopropylamide (2.0 M solution in 
heptane-tetrahydrofuran-ethylbenzene) (2.87 mL, 5.74 mmol) was added dropwise over 
15 minutes. After stirring for an additional 45 minutes at 0 °C, 2 M HCl (10.5 mL) was 
carefully added and stirred at 0 °C for 5 minutes. The resulting organic layer was 
separated and the aqueous layer was extracted usingEtOAc twice. The combined 
organic layers were dried using Na2SO4, filtered and concentrated to dryness in vacuo to 







Compound 3.35. A biphasic suspension of 3.34 (1.08 g, 3.71 mmol), 2-bromo-5- 
fluoropyridine (594 mg, 3.37 mmol), tetrakis(triphenylphosphine)palladium(0) (390 mg, 
0.34 mmol) and Na2CO3 (984 mg, 9.28 mmol) in 1,2-dimethoxyethane (34 mL) and 
water (4.0 mL) was purged with nitrogen and refluxed overnight. The resulting reaction 
mixture was cooled to room temperature, diluted with water and extracted with EtOAc 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (8:1) as 
the eluting solvent. The combined product eluents were isolated as a mixture of 
Boc-protected pyridylindole and 3.35. The resulting solid was dissolved into DCM and 
adsorbed onto silica gel (12 g) using rotary evaporti n. The white powder was heated 
to 80 °C overnight under high vacuum. The silica gel was cooled to room temperature, 
filtered through celite with EtOAc and the filtrate was dried in vacuo to provide 3.35 
(760 mg, 84% over two steps) as a solid. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 
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11.51 (s, 1H), 8.61 (d, J = 2.9 Hz, 1H), 8.02 (dd, J = 8.8, 4.3 Hz, 1H), 7.81 (td, J = 8.8, 
2.8 Hz, 1H), 7.34 (d, J = 8.8 Hz, 1H), 7.05 (d, J = 2.3 Hz, 1H), 7.03 (d, J = 1.5 Hz, 1H), 
6.78 (dd, J = 8.8, 2.3 Hz, 1H), 3.76 (s, 3H). 13C NMR (75.5 MHz, DMSO-d6): δ (ppm) 
159.7, 156.3, 153.7, 147.3, 147.2, 137.1, 136.8, 136.6, 132.4, 128.7, 124.3, 124.1, 121.1, 
121.0, 113.0, 112.7, 101.7, 100.4, 55.2. IR (film): ν (cm-1) 3449, 1547, 1461, 1445, 1214, 
1149, 1113, 1029, 828, 785, 748, 732, 517, 443. HRMS calculated for C14H12FN2O (M 












Compound 3.36. A solution of 3.35 (526 mg, 2.17 mmol) in anhydrous THF (6.0 mL) 
was prepared after drying 3.35 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (6.5 mL, 6.50 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (841 
mg, 2.28 mmol) in THF (6.0 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried n vacuo to provide 3.36 (600 mg, 52%) as a solid 











Compound 3.37. A solution of 3.36 (585 mg, 1.10 mmol) in toluene (220 mL) was 
irradiated with a medium pressure Hg lamp (150 W) using a pyrex filter for 3.5 hours 
with constant nitrogen flow through the solution. The resulting red solution was 
concentrated to dryness in vacuo. The crude material was adsorbed onto silica gel and 
subjected to silica gel chromatography with hexane : EtOAc (first 6:1, then 3:1) as the 
eluting solvent. The combined product eluents were dri d in vacuo to provide 3.37 (430 
mg, 86%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6): δ (ppm) 12.95 (s, 1H), 
9.06 (d, J = 2.9 Hz, 1H), 8.80 (dd, J = 9.7, 2.9 Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 7.59 (d, 
J = 8.9 Hz, 1H), 7.21 (dd, J = 8.9, 2.5 Hz, 1H), 3.89 (s, 3H), 0.98 (s, 9H), 0.57 (s, 6H). 
13C NMR (75.5 MHz, DMSO-d6): δ (ppm) 174.3, 173.7, 158.9, 155.5, 154.4, 141.4, 
141.0, 140.4, 135.0, 130.9, 121.4, 121.3, 121.2, 117.9, 117.8, 116.4, 116.1, 113.3, 113.1, 
106.3, 55.6, 26.2, 18.7, -4.3. IR (film): ν (cm-1) 3445, 2953, 2928, 1745, 1688, 1472, 
1445, 1308, 1288, 1254, 1214, 1040, 847, 828, 804, 762 473. HRMS calculated for 
C24H25FN3O3Si (M + H)













Complex FL1055. A suspension of the ligand 3.37 (10 mg, 0.022 mmol), K2CO3 (3.4 
mg, 0.025 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (17.2 mg, 0.024 mmol) in 
DMF (0.7 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
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followed by adding sodium azide (2.9 mg, 0.045 mmol), then the mixture was stirred at 
85 °C for an additional 30 minutes. The resulting suspen ion was dried in vacuo and the 
crude material was adsorbed onto silica gel and subjected to silica gel chromatography 
with dichloromethane : methanol (10:1) as the eluting solvent. The metal complex 
FL1055 was isolated as a solid (10 mg, 68%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 
11.09 (s, 1H), 9.06 (t, J = 2.4 Hz, 1H), 8.74 (dd, J = 9.5, 2.4 Hz, 1H), 8.28 (d, J = 2.6 Hz, 
1H), 7.65 (d, J = 8.9 Hz, 1H), 7.21 (dd, J = 8.9, 2.7 Hz, 1H), 3.90 (s, 3H), 3.03-2.26 (m, 
12H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 170.8, 170.7, 158.3, 155.8, 153.9, 
153.5, 147.1, 141.1, 140.2, 139.9, 131.1, 124.0, 12.9, 120.8, 116.2, 116.0, 115.7, 114.6, 
110.34, 110.29, 106.3, 55.7, 34.1, 33.5, 33.4, 33.1, 32.5, 30.0. IR (film): ν (cm-1) 2021, 







Compound 3.39. A biphasic suspension of 3.34 (409 mg, 1.41 mmol), 2-bromo-5- 
methoxypyridine (240 mg, 1.28 mmol), tetrakis(triphenylphosphine)palladium(0) (147 
mg, 0.13 mmol) and Na2CO3 (372 mg, 3.51 mmol) in 1,2-dimethoxyethane (13.5 mL) 
and water (2.0 mL) was purged with nitrogen and reflux d overnight. The resulting 
reaction mixture was cooled to room temperature, diluted with water and extracted with 
EtOAc for three times. The combined organic layers were washed with brine, dried 
using Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with hexane : 
EtOAc (first 6:1, then 3:1) as the eluting solvent. The combined product eluents were 
isolated as a mixture of Boc-protected pyridylindole and 3.39. The resulting solid was 
dissolved into DCM and adsorbed onto silica gel (5 g) using rotary evaporation. The 
white powder was heated to 80 °C overnight under high vacuum. The silica gel was 
cooled to room temperature, filtered through celite with EtOAc and the filtrate was 
dried in vacuo to provide 3.39 (260 mg, 80% over two steps) as a solid. 1H NMR (300 
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MHz, CDCl3): δ (ppm) 9.43 (s, 1H), 8.26 (d, J = 2.8 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 
7.28-7.23 (m, 2H), 7.08 (d, J = 2.3 Hz, 1H), 6.86 (dd, J = 8.8, 2.4 Hz, 1H), 6.81 (m, 1H), 
3.89 (s, 3H), 3.86 (s, 3H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 155.6, 137.1, 132.3, 












Compound 3.40. A solution of 3.39 (260 mg, 1.02 mmol) in anhydrous THF (5.0 mL) 
was prepared after drying 3.39 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (3.1 mL, 3.10 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (397 
mg, 1.07 mmol) in THF (3.5 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (first 6:1, then 3:1) as the eluting solvent. The 
combined product eluents were dried n vacuo to provide 3.40 (320 mg, 58%) as a solid 










Compound 3.41. A solution of 3.40 (320 mg, 0.59 mmol) in toluene (220 mL) was 
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irradiated with a medium pressure Hg lamp (150 W) using a pyrex filter for 3 hours 
with constant nitrogen flow through the solution. The resulting solution was 
concentrated to dryness in vacuo. The crude material was adsorbed onto silica gel and 
subjected to silica gel chromatography with hexane : EtOAc (first 6:1, then 3:1) as the 
eluting solvent. The combined product eluents were dri d in vacuo to provide 3.41 (240 
mg, 88%) as a yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 9.81 (s, 1H), 8.70 (d, 
J = 2.9 Hz, 1H), 8.64 (d, J = 2.9 Hz, 1H), 8.57 (d, J = 2.5 Hz, 1H), 7.48 (d, J = 8.8 Hz, 
1H), 7.18 (dd, J = 8.8, 2.6 Hz, 1H), 4.03 (s, 3H), 4.02 (s, 3H), 1.07 (s, 9H), 0.63 (s, 6H). 
IR (film): ν (cm-1) 3462, 2929, 1744, 1689, 1600, 1565, 1470, 1446, 1310, 1291, 1218, 
1026, 830, 799, 761, 470. HRMS calculated for C25H28N3O4Si (M + H)
+ 462.1844, 













Complex FL1229. A suspension of the ligand 3.41 (8 mg, 0.017 mmol), K2CO3 (2.6 mg, 
0.019 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (13.4 mg, 0.019 mmol) in DMF 
(0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (2.3 mg, 0.035 mmol), then the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (10:1) as the eluting solvent. The metal complex FL1229 
was isolated as a solid (6.6 mg, 57%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.98 
(s, 1H), 8.70 (d, J = 2.4 Hz, 1H), 8.47 (d, J = 2.4 Hz, 1H), 8.25 (d, J = 2.6 Hz, 1H), 7.58 
(d, J = 8.9 Hz, 1H), 7.15 (dd, J = 8.9, 2.7 Hz, 1H), 4.05 (s, 3H), 3.89 (s, 3H), 3.01-2.26 
(m, 12H). IR (film): ν (cm-1) 2029, 1740, 1712, 1564, 1468, 1427, 1399, 1345, 1235, 
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Complex FL123. A suspension of the ligand 3.69 (15 mg, 0.027 mmol), K2CO3 (4.2 mg, 
0.030 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (21.6 mg, 0.030 mmol) in DMF 
(0.8 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (3.5 mg, 0.054 mmol), then the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as the eluting solvent. The main fraction was 
isolated as a solid which was carried forward without characterization. To a solution of 
the solid product in acetone (5 mL) at 0 °C was added TBAF (1 M in THF, 81 µL, 0.081 
mmol) under nitrogen, the resulting purple solution was stirred at 0 °C for 5 minutes, 
followed by adding glacial acetic acid (3.7 µL, 0.081 mmol). The resulting solution was 
dried in vacuo and the crude material was adsorbed onto silica gel and subjected to 
silica gel chromatography with dichloromethane : methanol (first 20:1, then 10:1) as the 
eluting solvent. The metal complex FL123 was isolated as a green solid (7.4 mg, 42%). 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.01 (s, 1H), 9.18 (s, 1H), 9.02 (t, J = 2.4 Hz, 
1H), 8.72 (dd, J = 9.5, 2.3 Hz, 1H), 8.16 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 
7.05 (dd, J = 8.8, 2.5 Hz, 1H), 3.03-2.56 (m, 12H). 13C NMR (100.6 MHz, DMSO-d6): 
δ (ppm) 170.8, 170.6, 158.2, 155.7, 153.7, 151.3, 146.3, 141.0, 139.8, 139.5, 131.1, 
124.4, 120.9, 120.8, 116.1, 115.9, 115.4, 114.5, 109.54, 109.50, 108.6, 34.1, 33.5, 33.3, 
33.1, 32.4, 29.9. IR (film): ν (cm-1) 2029, 1744, 1708, 1557, 1493, 1468, 1411, 1332, 
1223, 1196, 1021, 996, 818, 765, 698, 635. HRMS calculated for C23H19FN6O3S3RuNa 
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Compound 3.54. A biphasic suspension of 3.34 (692 mg, 2.38 mmol), 2-bromo- 
pyridine (341 mg, 2.16 mmol), tetrakis(triphenylphosphine)palladium(0) (174 mg, 0.15 
mmol) and Na2CO3 (629 mg, 5.93 mmol) in 1,2-dimethoxyethane (22 mL) and water 
(2.5 mL) was purged with nitrogen and refluxed overnight. The resulting reaction 
mixture was cooled to room temperature, diluted with water and extracted with EtOAc 
for three times. The combined organic layers were washed with brine, dried using 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with hexane : EtOAc (first 6:1, 
then 3:1) as the eluting solvent. The combined product eluents were isolated as a 
mixture of Boc-protected pyridylindole and 3.54. The resulting solid was dissolved into 
DCM and adsorbed onto silica gel (10 g) using rotary evaporation. The white powder 
was heated to 80 °C overnight under high vacuum. The silica gel was cooled to room 
temperature, filtered through celite with EtOAc and the filtrate was dried in vacuo to 
provide 3.54 (420 mg, 87% over two steps) as a solid. 1H NMR (300 MHz, CDCl3): δ 
(ppm) 9.55 (s, 1H), 8.56 (d, J = 4.8 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.71 (td, J = 8.0, 
1.7 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.16 (ddd, J = 7.1, 4.9, 1.3 Hz, 1H), 7.09 (d, J = 
2.3 Hz, 1H), 6.94 (d, J = 1.9 Hz, 1H), 6.89 (dd, J = 8.8, 2.4 Hz, 1H), 3.87 (s, 3H). 13C 
NMR (75.5 MHz, CDCl3): δ (ppm) 154.6, 150.5, 149.3, 137.4, 136.7, 132.0, 129.7, 
122.0, 119.9, 114.0, 112.3, 102.5, 100.4, 56.0. IR (film): ν (cm-1) 3434, 2993, 2941, 
1622, 1591, 1543, 1444, 1300, 1219, 1149, 1118, 1030, 8 9, 775, 740. HRMS 
calculated for C14H13N2O (M + H)












Compound 3.55. A solution of 3.54 (420 mg, 1.87 mmol) in anhydrous THF (5.6 mL) 
was prepared after drying 3.54 under high vacuum overnight. After cooling the soluti n 
to -15 °C, lithium bis(trimethylsilyl)amide (1 M solution in hexanes) (5.6 mL, 5.60 
mmol) was added dropwise over 15 minutes and the resulting suspension was stirred at 
-15 °C for an additional 1 hour. A solution of TBS-protect d dibromomaleimide (726 
mg, 1.97 mmol) in THF (5.6 mL) cooled to 0 °C was added and the reaction mixture 
was stirred at -15 °C for 20 minutes and 10 °C overnight. The resulting dark purple 
reaction mixture was carefully poured into stirring ice cold 10% HCl (50 mL) and 
extracted with EtOAc twice. The combined organic layers were washed with saturated 
NaHCO3 followed by brine, dried using Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with hexane : EtOAc (first 3:1, then 1:1) as the eluting solvent. The 
combined product eluents were dried in vacuo to provide 3.55 as a solid which was 









Compound 3.56. A solution of 3.55 in toluene (900 mL) was irradiated with a medium 
pressure Hg lamp (700 W) for 1 hour with constant nitrogen flow through the solution. 
The resulting solution was concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (first 75:1, then 50:1) as the eluting solvent. The combined 
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product eluents were dried in vacuo to provide 3.56 (455 mg, 56% over two steps) as a 
yellow solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 10.50 (s, 1H), 9.42 (dd, J = 8.5, 1.6 
Hz, 1H), 8.99 (dd, J = 4.3, 1.6 Hz, 1H), 8.60 (d, J = 2.3 Hz, 1H), 7.63 (dd, J = 8.5, 4.3 
Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.19 (dd, J = 8.8, 2.3 Hz, 1H), 4.03 (s, 3H), 1.07 (s, 
9H), 0.64 (s, 6H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 175.7, 174.3, 155.4, 150.5, 
140.6, 138.6, 134.5, 134.4, 130.9, 123.0, 122.9, 121.9, 120.4, 117.6, 115.2, 112.3, 107.2, 
101.5, 56.3, 26.7, 19.3, -3.8. IR (film): ν (cm-1) 2926, 2855, 1749, 1689, 1475, 1436, 
1333, 1316, 1282, 1216, 1044, 845, 826, 799, 696. HRMS calculated for C24H26N3O3Si 












Complex FL1381. A suspension of the ligand 3.56 (6 mg, 0.014 mmol), K2CO3 (2.1 mg, 
0.015 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (10.8 mg, 0.015 mmol) in DMF 
(0.5 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, followed by 
adding sodium azide (1.8 mg, 0.028 mmol), the mixture was stirred at 85 °C for an 
additional 30 minutes. The resulting suspension wasdried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as the eluting solvent. The metal complex FL1381 
was isolated as a solid (5.5 mg, 62%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.0 (s, 
1H), 9.07-9.03 (m, 2H), 8.29 (d, J = 2.6 Hz, 1H), 7.75 (dd, J = 8.3, 5.1 Hz, 1H), 7.67 (d, 
J = 8.9 Hz, 1H), 7.19 (dd, J = 8.9, 2.7 Hz, 1H), 3.90 (s, 3H), 3.05-2.19 (m, 12H). 13C 
NMR (125.8 MHz, DMSO-d6): δ (ppm) 171.01, 170.99, 153.8, 153.2, 150.2, 147.1, 
143.7, 132.0, 130.5, 124.0, 123.1, 121.1, 115.6, 115.5, 114.6, 110.9, 106.1, 55.6, 34.6, 
34.0, 33.5, 32.6, 31.6, 29.4. IR (film): ν (cm-1) 2025, 1738, 1698, 1587, 1492, 1418, 
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1339, 1235, 1212, 1028, 817, 794, 695, 637, 493. HRMS calculated for 
C24H22N6O3S3RuNa (M + Na)













Complex FL475. To a solution of precursor 2.3 (7 mg, 0.012 mmol) in DMF (2 mL) 
was added [9]aneS3 (2.2 mg, 0.012 mmol) under nitrogen, the mixture was stirred at 85 
°C for 1 hour, followed by adding sodium cyanate (0.8 mg, 0.012 mmol), then the 
mixture was kept at 85 °C for an additional 1.5 hours. The resulting solutin was dried 
in vacuo and the crude material was adsorbed onto silica gel nd subjected to silica gel 
chromatography with dichloromethane : methanol (first 20:1, then 10:1) as the eluting 
solvent. The metal complex FL475 was isolated as a green solid (2.1 mg, 27%). 1H 
NMR (300 MHz, DMSO-d6): δ (ppm) 11.0 (s, 1H), 9.18 (s, 1H), 9.02 (t, J = 2.4 Hz, 1H), 
8.72 (dd, J = 9.5, 2.4 Hz, 1H), 8.17 (d, J = 2.5 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.05 
(dd, J = 8.8, 2.5 Hz, 1H), 3.01-2.27 (m, 12H). IR (film): ν (cm-1) 2237, 1738, 1707, 






Compound 3.60. To a solution of [9]aneS3 (150 mg, 0.83 mmol) in DCM (10 mL) at 0 
°C was added the DCM solution (10 mL) of mCPBA dropwise in 10 minutes. The 
resulting mixture solution was stirred at 0 °C for additional 1 hour, followed by adding 
10 mL saturated NaHCO3 solution, then the organic layer was separated, an the 
aqueous layer was extracted with DCM twice. The combined organic layers were dried 
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using Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with DCM : MeOH 
(15:1) as the eluting solvent. The combined product eluents were dried in vacuo to 
provide 3.60 (105 mg, 64%) as white solid. 1H NMR (300 MHz, CDCl3): δ (ppm) 
4.05-3.97 (m, 2H), 3.47-3.39 (m, 2H), 3.35-3.26 (m,2H), 3.07-2.89 (m, 4H), 2.84-2.75 
(m, 2H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 52.9, 35.5, 26.1. IR (film): ν (cm
-1) 
3419, 2905, 1645, 1408, 1272, 1206, 1141, 1020, 925, 833, 625. HRMS calculated for 
C6H12OS3Na (M + Na)











Compound 3.61. A solution of 3.60 (97 mg, 0.49 mmol) and RuCl2(dmso)4 (240 mg, 
0.49 mmol) in chloroform (6 mL) was refluxed under nitrogen for 4 hours, the resulting 
yellow solid was collected and washed with chlorofom for three times and dried in 
vacuo to provide the ruthenium intermediate which was carried forward without 
characterization. To the solution of ruthenium interm diate (210 mg, 0.47 mmol) in 
MeCN (10 mL) was added AgOTf (242 mg, 0.94 mmol) under nitrogen, the mixture 
was refluxed for 8 hours. The resulting suspension was cooled to room temperature and 
filtered through celite. The yellow filtrate was reduced in volume to 2 mL and 
precipitated by the addition of Et2O to provide 3.61 (284 mg, 80% over two steps). 
1H 
NMR (300 MHz, CD3CN): δ (ppm) 3.89-3.82 (m, 2H), 3.62-3.55 (m, 2H), 3.28-3.19 (m, 
2H), 2.82-2.61 (m, 6H). IR (film): ν (cm-1) 3554, 2995, 2936, 2296, 1636, 1417, 1253, 
1149, 1104, 1026, 946, 913, 843, 634, 572, 516. HRMS calculated for 
C13H21F3N3O4S4Ru (M)















Complex FL1528-1. A suspension of the ligand 3.6 (10 mg, 0.022 mmol), K2CO3 (3.3 
mg, 0.024 mmol), and 3.61 (17.2 mg, 0.024 mmol) in DMF (0.7 mL) was stirred at 85 
°C under microwave irradiation for 30 minutes, followed by adding sodium azide (2.8 
mg, 0.043 mmol), then the mixture was stirred at 85 °C for an additional 30 minutes. 
The resulting suspension was dried n vacuo and the crude material was adsorbed onto 
silica gel and subjected to silica gel chromatography with dichloromethane : methanol 
(10:1) as the eluting solvent. The metal complex FL1528-1 was isolated as a solid (1.8 
mg, 12%), and the mixture of other two diastereoisomers (5.0 mg, 34%). 1H NMR (300 
MHz, DMSO-d6): δ (ppm) 11.06 (s, 1H), 9.26 (dd, J = 5.2, 1.2 Hz, 1H), 9.12 (dd, J = 
8.4, 1.2 Hz, 1H), 8.32 (d, J = 2.5 Hz, 1H), 7.85 (dd, J = 8.4, 5.1 Hz, 1H), 7.57 (d, J = 
8.9 Hz, 1H), 7.17 (dd, J = 8.9, 2.6 Hz, 1H), 4.66 (septet, J = 6.0 Hz, 1H), 4.07-3.95 (m, 
2H), 3.57-3.41 (m, 2H), 3.27-3.02 (m, 3H), 2.80-2.54 (m, 4H), 2.18 (m, 1H), 1.36 (d, J 
= 6.0 Hz, 6H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 171.0, 170.8, 153.3, 151.2, 
151.0, 146.6, 143.0, 132.8, 130.7, 124.3, 123.2, 121.1, 117.5, 115.3, 114.9, 111.7, 109.7, 
70.4, 60.5, 56.4, 35.3, 32.4, 31.7, 30.2, 22.12, 22.09. IR (film): ν (cm-1) 2033, 1744, 
1705, 1490, 1461, 1416, 1336, 1271, 1159, 1118, 1035, 952, 699, 636, 519, 494. HRMS 
calculated for C26H26N6O4S3RuNa (M + Na)







Compound 3.62. To a solution of MeNH2
.HCl (58.4 mg, 0.87 mmol) in methanol (1 
mL) at 0 °C was added potassium carbonate (119.4 mg, 0.87 mmol) under nitrogen. The 
resulting mixture was stirred at 0 °C for an additional 1 hour, followed by adding 
1,4,7-trithiacyclodecan-9-one (150 mg, 0.72 mmol) in 10 mL methanol, then the 
suspension was stirred at room temperature for 3 hours. Water was added and extracted 
with DCM twice, the combined organic layers were drie  using Na2SO4, filtered and 
concentrated to dryness in vacuo. The residue was dissolved in methanol (6 mL) and 
NaBH4 (54.8 mg, 1.44 mmol) was added. The resulting solution was stirred at room 
temperature for 1 hour, followed by adding 5 mL satur ted NaHCO3 solution, the 
aqueous layer was extracted with DCM twice. The combined organic layers were dried 
using Na2SO4, filtered and concentrated to dryness in vacuo. The crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with DCM : 
methanol (first 35:1, then 20:1) as the eluting solvent. The combined product eluents 
were dried in vacuo to provide 3.62 (120 mg, 75%). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 3.24-2.79 (m, 13H), 2.38 (s, 3H), 1.40 (br, 1H). 13C NMR (75.5 MHz, CDCl3): δ 
(ppm) 59.4, 34.3, 34.1, 34.0, 33.8. IR (film): ν (cm-1) 2904, 2848, 2787, 1476, 1411, 
1268, 1103, 820, 742. HRMS calculated for C8H18NS3 (M + H)








Compound 3.63. To a solution of 3.62 (90 mg, 0.40 mmol) in DCM (3 mL) at 0 °C was 
added allyl chloroformate (72.8 mg, 0.60 mmol), pyridine (31.8 mg, 0.40 mmol), and 
DMAP (2 mg, 0.016 mmol) under nitrogen, then the resulting mixture solution was 
allowed to warm to room temperature slowly and stirred overnight. The solution was 
diluted with DCM and washed with brine and water twice. The organic layer was 
separated and dried using Na2SO4, filtered and concentrated to dryness in vacuo. The 
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crude material 3.63 (90 mg, 76%) was used in the next step without any purification. 1H 
NMR (300 MHz, CDCl3): δ (ppm) 5.93 (m, 1H), 5.32-5.18 (m, 2H), 4.59 (d, J = 5.5 Hz, 
2H), 3.33-2.90 (m, 13H), 2.86 (s, 3H). IR (film): ν (cm-1) 2910, 1692, 1448, 1399, 1321, 
1266, 1231, 1198, 1145, 992, 928, 768. HRMS calculated for C12H21NO2S3Na (M + 












Compound 3.65. A solution of 3.63 (54 mg, 0.17 mmol) and RuCl2(dmso)4 (85 mg, 
0.17 mmol) in chloroform (5 mL) was refluxed under nitrogen for 5 hours, then the 
resulting solution was concentrated and precipitated with diethyl ether. The solid was 
collected and washed with diethyl ether for three times and dried in vacuo to provide 
3.64 which was carried forward without characterization. To the solution of 3.64 (89 mg, 
0.16 mmol) in MeCN (5 mL) was added AgOTf (82 mg, 0.32 mmol) under nitrogen, the 
mixture was refluxed for 6 hours. The resulting suspension was cooled to room 
temperature and filtered through celite. The yellow filtrate was reduced in volume to 1 
mL and precipitated by the addition of Et2O to provide 3.65 (106 mg, 72% over two 
steps). 1H NMR (300 MHz, CD3CN): δ (ppm) 5.95 (m, 1H), 5.30 (m, 1H), 5.21 (m, 1H), 
4.57-4.55 (m, 2H), 3.31-2.61 (m, 16H), 2.53 (s, 3H), 2.41 (s, 6H). IR (film): ν (cm-1) 
3509, 2993, 2936, 2293, 1691, 1404, 1369, 1327, 1250, 1148, 1024, 954, 833, 761, 632, 
571, 514. HRMS calculated for C19H30F3N4O5S4Ru (M)















Complex FL1392. A suspension of the ligand 3.6 (15 mg, 0.033 mmol), K2CO3 (5 mg, 
0.036 mmol), and ruthenium precursor 3.65 (30 mg, 0.036 mmol) in DMF (0.9 mL) was 
stirred at 85 °C under microwave irradiation for 40 minutes, followed by adding sodium 
azide (4.2 mg, 0.065 mmol), then the mixture was stirred at 85 °C for an additional 40 
minutes. The resulting suspension was dried in vacuo and the crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (35:1) as the eluting solvent. The first main fraction was 
isolated as a solid (10 mg, 38%) which was carried forward without characterization. To 
a solution of the solid product (6 mg, 0.0075 mmol) in DCM (2.5 mL) was added 
1,3-dimethylbarbituric acid (9.4 mg, 0.06 mmol) and P (PPh3)4 (1.3 mg, 0.0011 mmol) 
under nitrogen. The resulting mixture was stirred at room temperature for 5 minutes, 
followed by adding 0.5 mL saturated NaHCO3 solution to quench the reaction. The 
resulting suspension was dried in vacuo and the crude material was adsorbed onto silica 
gel and subjected to silica gel chromatography with d chloromethane : methanol (first 
10:1, then 5:1) as the eluting solvent to get the metal complex FL1392 (3.2 mg, 59%). 
FL1392: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.99 (s, 1H), 9.07 (d, J = 8.3 Hz, 
1H), 9.01 (d, J = 5.3 Hz, 1H), 8.29 (d, J = 2.5 Hz, 1H), 7.99 (d, J = 8.9 Hz, 1H), 7.80 
(dd, J = 8.3, 5.2 Hz, 1H), 4.65 (septet, J = 6.1 Hz, 1H), 3.71-2.16 (m, 17H), 1.35 (d, J = 
6.1 Hz, 6H). 13C NMR (125.8 MHz, DMSO-d6): δ (ppm) 171.01, 170.99, 153.8, 150.9, 
148.0, 147.2, 143.9, 132.1, 130.3, 124.5, 122.5, 121.1, 117.1, 115.9, 114.7, 110.9, 109.3, 
70.3, 55.9, 35.8, 33.3, 31.5, 30.7, 29.6, 28.2, 26.2, 22.14, 22.08. IR (film): ν (cm-1) 2033, 
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1747, 1701, 1596, 1460, 1424, 1338, 1234, 1209, 1112, 020, 823, 793, 698, 638, 500. 
HRMS calculated for C28H31N7O3S3RuNa (M + Na)












Compound 3.68. A suspension of 3.66 (78 mg, 0.44 mmol) and [RuCl2(η
6-C6H6)]2 (104 
mg, 0.21 mmol) in acetonitrile/ethanol (2.6 mL/5.2 mL) was refluxed under nitrogen for 
24 hours. The resulting solution was concentrated and precipitated with diethyl ether, 
then the solid was collected and washed with diethyl ether for three times and dried in 
vacuo to provide 3.67 which was carried forward without characterization. To the 
solution of 3.67 (70 mg, 0.18 mmol) in MeCN (6 mL) was added AgOTf (92 mg, 0.36 
mmol) under nitrogen, the mixture was refluxed for 7 hours. The resulting suspension 
was cooled to room temperature and filtered through celite. The yellow filtrate was 
reduced in volume to 1 mL and precipitated by the addition of Et2O to provide 3.68 (83 
mg, 60% over two steps). 1H NMR (300 MHz, CD3CN): δ (ppm) 3.04-2.95 (m, 2H), 
2.81 (s, 3H), 2.78-2.59 (m, 10H), 2.48 (s, 6H), 2.33 (s, 3H). IR (film): ν (cm-1) 2994, 
2941, 2290, 1469, 1422, 1258, 1221, 1147, 1024, 821752, 631, 572, 515. HRMS 
calculated for C14H24F3N4O3S3Ru (M)












Complex FL1473. A suspension of the ligand 3.6 (12 mg, 0.026 mmol), K2CO3 (3.9 mg, 
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0.028 mmol), and ruthenium precursor 3.68 (20 mg, 0.028 mmol) in DMF (0.7 mL) was 
stirred at 85 °C under microwave irradiation for 40 minutes, followed by adding sodium 
azide (3.4 mg, 0.052 mmol), then the mixture was stirred at 85 °C for an additional 30 
minutes. The resulting suspension was dried in vacuo and the crude material was 
adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1 with 0.5% concentrated ammonium hydroxide) as the 
eluting solvent. The metal complex FL1473 was isolated as a mixture with the other 
two diastereoisomers (1.7 mg, 10%) which were separated by crystallization in acetone. 
1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.94 (s, 1H), 9.33 (dd, J = 5.1, 1.1 Hz, 1H), 
9.05 (dd, J = 8.4, 1.1 Hz, 1H), 8.34 (d, J = 2.5 Hz, 1H), 7.87 (d, J = 8.9 Hz, 1H), 7.81 
(dd, J = 8.3, 5.1 Hz, 1H), 7.23 (dd, J = 8.9, 2.6 Hz, 1H), 4.69 (septet, J = 6.0 Hz, 1H), 
3.21-2.03 (m, 12H), 1.38 (d, J = 6.0 Hz, 6H), 1.35 (s, 3H). IR (film): ν (cm-1) 2972, 
2926, 2023, 1742, 1709, 1591, 1490, 1460, 1420, 1341, 1280, 1235, 1213, 1023, 952, 
700, 639, 498.  













Complex FL823-1. A suspension of the ligand 2.1 (32 mg, 0.058 mmol), K2CO3 (8.8 
mg, 0.064 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (45.1 mg, 0.064 mmol) in 
DMF (2 mL) was stirred at 85 °C under microwave irradiation for 40 minutes, followed 
by adding sodium thiocyanate (9.4 mg, 0.116 mmol), then the mixture was stirred at 85 
°C for an additional 30 minutes. The resulting suspen ion was dried in vacuo and the 
crude material was adsorbed onto silica gel and subjected to silica gel chromatography 
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with dichloromethane : methanol (10:1) as the eluting solvent. These two linkage 
isomers were collected together (28 mg, 62%), which was carried forward without 
characterization. To a solution of the product (28 mg, 0.036 mmol) in acetone (20 mL) 
at 0 °C was added TBAF (1 M in THF, 72.7 µL, 0.073 mmol) under nitrogen, the 
resulting mixture was stirred at 0 °C for 2 minutes, followed by adding glacial acetic 
acid (4.3 µL, 0.072 mmol). The reaction mixture was dried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (first 20:1, then 15:1) as the eluting solvent. The metal 
complex FL823-1 was isolated as a solid (10 mg, 42%) and the other linkage isomer 
FL823-2 was also obtained (8 mg, 34%). FL823-1: 1H NMR (300 MHz, DMSO-d6): δ 
(ppm) 11.0 (s, 1H), 9.23 (s, 1H), 9.06 (t, J = 2.4 Hz, 1H), 8.76 (dd, J = 9.4, 2.3 Hz, 1H), 
8.18 (d, J = 2.5 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.07 (dd, J = 8.8, 2.5 Hz, 1H), 
3.06-2.27 (m, 12H). IR (film): ν (cm-1) 2105, 1739, 1706, 1556, 1494, 1468, 1410, 1332, 
1229, 1196, 1167, 1022, 998, 819, 699, 636. FL823-2: 1H NMR (300 MHz, DMSO-d6): 
δ (ppm) 11.0 (s, 1H), 9.20 (s, 1H), 8.94 (t, J = 2.5 Hz, 1H), 8.72 (dd, J = 9.5, 2.4 Hz, 
1H), 8.15 (d, J = 2.5 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.03 (dd, J = 8.8, 2.5 Hz, 1H), 
3.07-2.37 (m, 12H). IR (film): ν (cm-1) 2111, 1738, 1704, 1555, 1493, 1468, 1409, 1330, 













Complex FL253. A solution of precursor complex 2.3 (7 mg, 0.012 mmol) and 
1,4,7-trithiacyclononane (2.2 mg, 0.012 mmol) in DMF (1.5 mL) was stirred at 85 °C 
under nitrogen for 1 hour. To the resulting solution was added sodium cyanide (0.6 mg, 
0.012 mmol), then the solution was stirred at 85 °C for an additional 30 minuts, after 
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which the solution was dried under high vacuum. Thecrude material was adsorbed onto 
silica gel and subjected to silica gel chromatography with dichloromethane : methanol 
(first 20:1, then 10:1) as the eluting solvent. The m tal complex FL253 was isolated as 
a solid (1.4 mg, 17%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.03 (s, 1H), 9.20 (s, 
1H), 8.91 (t, J = 2.4 Hz, 1H), 8.71 (dd, J = 9.5, 2.3 Hz, 1H), 8.15 (d, J = 2.5 Hz, 1H), 
7.49 (d, J = 8.8 Hz, 1H), 7.05 (dd, J = 8.8, 2.5 Hz, 1H), 3.05-2.27 (m, 12H). IR (film): ν













Complex FL528. A solution of precursor complex 2.3 (7 mg, 0.012 mmol) and 
1,4,7-trithiacyclononane (2.2 mg, 0.012 mmol) in DMF (1.5 mL) was stirred at 85 °C 
under nitrogen for 1 hour. To the resulting solution was added potassium selenocyanate 
(1.7 mg, 0.012 mmol), then the solution was stirred at 85 °C for an additional 40 minuts, 
after which the solution was dried under high vacuum. The crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
methanol (first 20:1, then 15:1) as the eluting solvent. The metal complex FL528 was 
isolated as a solid (3.8 mg, 45%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.02 (s, 
1H), 9.20 (s, 1H), 8.94 (t, J = 2.5 Hz, 1H), 8.71 (dd, J = 9.5, 2.3 Hz, 1H), 8.15 (d, J = 
2.5 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.03 (dd, J = 8.8, 2.5 Hz, 1H), 3.07-2.34 (m, 12H). 
IR (film): ν (cm-1) 3143, 3150, 2101, 1742, 1701, 1582, 1490, 1413, 1342, 1289, 1263, 


















Complex FL576. A solution of precursor complex 2.3 (27 mg, 0.047 mmol) in DMF (3 
mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere of 
CO for 1.5 hours. To the resulting solution was added 1,4,7-trithiacyclononane (8.5 mg, 
0.047 mmol), then the solution was stirred at 95 °C under an atmosphere of nitrogen for 
2.5 hours, after which the purple solution was dried under high vacuum. The crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
MeCN : H2O : KNO3 (100:3:1) to obtain purple solid. The resulting materi l was 
dissolved in minimal acetonitrile/water. The product was precipitated by the addition of 
excess solid NH4PF6. The precipitate was centrifuged and washed twice ith water. The 
material was then dried under high vacuum to yield FL576 (18 mg, 50%). 1H NMR 
(500 MHz, DMSO-d6): δ (ppm) 11.1 (s, 1H), 9.36 (s, 1H), 9.05 (t, J = 2.3 Hz, 1H), 8.92 
(dd, J = 9.1, 2.3 Hz, 1H), 8.21 (d, J = 2.5 Hz, 1H), 7.45 (d, J = 8.7 Hz, 1H), 7.13 (dd, J 
= 8.8, 2.5 Hz, 1H), 3.50-2.57 (m, 12H). 13C NMR (125.8 MHz, DMSO-d6): δ (ppm) 
191.8, 170.5, 170.0, 158.2, 156.2, 152.7, 151.9, 144.6, 143.1, 142.9, 140.1, 131.8, 124.5, 
121.04, 120.97, 118.9, 118.7, 117.1, 114.8, 114.3, 112.09, 112.06, 108.9, 37.9, 37.2, 
35.6, 32.5, 31.5, 31.1. IR (film): ν (cm-1) 2011, 1750, 1713, 1564, 1495, 1413, 1335, 
1228, 1203, 1026, 1000, 840, 760, 700, 638, 557, 488. HRMS calculated for 
C24H19FN3O4S3Ru (M)













Complex FL1352-1. A suspension of the ligand 3.21 (7 mg, 0.016 mmol), K2CO3 (2.4 
mg, 0.017 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (12.1 mg, 0.017 mmol) in 
DMF (0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (2.5 mg, 0.031 mmol), then the mixture was 
stirred at 85 °C for an additional 30 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 20:1, then 15:1) as the eluting 
solvent. The metal complex FL1352-1 was isolated as a solid (2.4 mg, 23%) and the 
other linkage isomer was also obtained (2 mg, 19%). FL1352-1: 1H NMR (300 MHz, 
DMSO-d6): δ (ppm) 11.1 (s, 1H), 9.14 (d, J = 8.5 Hz, 1H), 9.11 (d, J = 5.1 Hz, 1H), 8.75 
(d, J = 1.8 Hz, 1H), 7.81 (dd, J = 8.4, 5.2 Hz, 1H), 7.70 (d, J = 8.7 Hz, 1H), 7.55 (dd, J 
= 8.6, 1.8 Hz, 1H), 3.10-2.63 (m, 12H), 2.58 (s, 3H). IR (film): ν (cm-1) 2098, 1741, 













Complex FL1289-1. A suspension of the ligand 3.17 (7 mg, 0.015 mmol), K2CO3 (2.3 
mg, 0.017 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (11.6 mg, 0.017 mmol) in 
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DMF (0.6 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (2.5 mg, 0.031 mmol), then the mixture was 
stirred at 85 °C for an additional 40 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 20:1, then 15:1) as the eluting 
solvent. The metal complex FL1289-1 was isolated as a solid (1.8 mg, 17%) and the 
other linkage isomer FL1289-2 was also obtained (0.8 mg, 8%). FL1289-1: 1H NMR 
(300 MHz, DMSO-d6): δ (ppm) 11.2 (s, 1H), 9.15 (t, J = 2.3 Hz, 1H), 8.81 (dd, J = 9.3, 
2.3 Hz, 1H), 8.73 (d, J = 1.9 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.56 (dd, J = 8.5, 1.8 Hz, 
1H), 3.04-2.33 (m, 12H), 2.58 (s, 3H). IR (film): ν (cm-1) 2105, 1735, 1698, 1556, 1490, 
1404, 1334, 1253, 1223, 1199, 1024, 1000, 803, 635,521  475. FL1289-2: 1H NMR 
(300 MHz, DMSO-d6): δ (ppm) 11.2 (s, 1H), 9.03 (t, J = 2.5 Hz, 1H), 8.77 (dd, J = 9.4, 
2.3 Hz, 1H), 8.70 (d, J = 1.9 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 8.7, 1.9 Hz, 
1H), 3.10-2.40 (m, 12H), 2.57 (s, 3H). IR (film): ν (cm-1) 2103, 1739, 1704, 1611, 1558, 













Complex FL1334. A suspension of the ligand 3.27 (10 mg, 0.022 mmol), K2CO3 (3.3 
mg, 0.024 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (16.7 mg, 0.024 mmol) in 
DMF (0.7 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (3.5 mg, 0.043 mmol), then the mixture was 
stirred at 85 °C for an additional 30 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 10:1, then 5:1) as the eluting 
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solvent. The metal complex FL1334 was isolated as a mixture of two linkage isomers. 
(6.4 mg, 43%). IR (film): ν (cm-1) 3344, 3213, 2102, 1741, 1702, 620, 1565, 1414, 138, 
1293, 1268, 1228, 1048, 1023, 1003, 816, 679, 638, 472. HRMS calculated for 
C25H23N5O2S5RuNa (M + Na)













Complex FL812-1. A suspension of the ligand 3.37 (20 mg, 0.045 mmol), K2CO3 (6.8 
mg, 0.049 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (34.4 mg, 0.049 mmol) in 
DMF (1.4 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (7.2 mg, 0.089 mmol), then the mixture was 
stirred at 85 °C for an additional 30 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 35:1, then 10:1) as the eluting 
solvent. The metal complex FL812-1 was isolated as a solid (9.8 mg, 33%) and the 
other linkage isomer FL812-2 was also obtained (7 mg, 23%). FL812-1: 1H NMR (400 
MHz, DMSO-d6): δ (ppm) 11.1 (s, 1H), 9.09 (t, J = 2.4 Hz, 1H), 8.79 (dd, J = 9.4, 2.3 
Hz, 1H), 8.30 (d, J = 2.6 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.23 (dd, J = 8.9, 2.7 Hz, 
1H), 3.91 (s, 3H), 3.06-2.30 (m, 12H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 
170.7, 170.5, 158.2, 155.7, 153.6, 153.5, 146.8, 140.9, 140.89, 140.7, 140.4, 132.8, 
131.3, 124.0, 120.8, 120.7, 116.8, 116.6, 115.9, 115.4, 114.5, 110.69, 110.64, 106.4, 
55.6, 33.8, 33.3, 33.2, 33.0, 30.3. IR (film): ν (cm-1) 2103, 1739, 1702, 1558, 1496, 
1421, 1405, 13326, 1281, 1256, 1231, 1196, 1028, 996, 816, 634. FL812-2: 1H NMR 
(300 MHz, DMSO-d6): δ (ppm) 11.1 (s, 1H), 8.98 (t, J = 2.5 Hz, 1H), 8.75 (dd, J = 9.5, 
2.4 Hz, 1H), 8.27 (d, J = 2.6 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.19 (dd, J = 8.9, 2.7 Hz, 
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Complex FL1353-1. A suspension of the ligand 3.10 (10 mg, 0.021 mmol), K2CO3 (3.2 
mg, 0.023 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (16.2 mg, 0.023 mmol) in 
DMF (0.7 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (3.4 mg, 0.042 mmol), then the mixture was 
stirred at 85 °C for an additional 40 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (15:1) as the eluting solvent. The 
metal complex FL1353-1 was isolated as a green solid (5.5 mg, 37%)and  the o er 
linkage isomer FL1353-2 was also obtained (3.6 mg, 24%). FL1353-1: 1H NMR (300 
MHz, DMSO-d6): δ (ppm) 11.1 (s, 1H), 9.11 (t, J = 2.0 Hz, 1H), 8.79 (dd, J = 9.3, 2.0 
Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.21 (dd, J = 9.0, 2.4 Hz, 
1H), 4.67 (septet, J = 6.1 Hz, 1H), 3.06-2.32 (m, 12H), 1.37 (d, J = 6.1 Hz, 6H). 13C 
NMR (100.6 MHz, DMSO-d6): δ (ppm) 170.7, 170.5, 162.3, 158.2, 155.7, 153.7, 151.4, 
146.9, 140.9, 140.7, 140.4, 132.8, 131.3, 124.1, 120.8, 120.7, 117.6, 116.8, 116.6, 115.3, 
114.5, 110.65, 110.61, 109.8, 70.5, 35.8, 33.7, 33.4, 33.2, 33.1, 30.8, 30.4, 22.11, 22.08. 
IR (film): ν (cm-1) 3369, 2969, 2106, 1747, 1713, 1593, 1457, 1410, 1337, 1223, 1196, 
1109, 965, 939, 801. HRMS calculated for C27H25FN4O3RuS4 (M) 701.9836, found (M) 
701.9834. FL1353-2: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.09 (s, 1H), 8.98 (t, J 
= 1.9 Hz, 1H), 8.74 (dd, J = 9.4, 1.9 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 7.55 (d, J = 8.9 
Hz, 1H), 7.17 (dd, J = 9.0, 2.3 Hz, 1H), 4.65 (septet, J = 6.0 Hz, 1H), 3.09-2.40 (m, 
12H), 1.36 (d, J = 6.0 Hz, 6H). IR (film): ν (cm-1) 3154, 2972, 2100, 1749, 1717, 1560, 
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1491, 1458, 1410, 1333, 1223, 1200, 1112, 810, 698, 37. HRMS calculated for 












Complex FL1370-1. A suspension of the ligand 3.6 (10 mg, 0.022 mmol), K2CO3 (3.3 
mg, 0.024 mmol), and [Ru(MeCN)3([9]aneS3)](CF3SO3)2
 (16.8 mg, 0.024 mmol) in 
DMF (0.7 mL) was stirred at 85 °C under microwave irradiation for 30 minutes, 
followed by adding sodium thiocyanate (3.5 mg, 0.043 mmol), then the mixture was 
stirred at 85 °C for an additional 40 minutes. The resulting suspen ion was dried in 
vacuo and the crude material was adsorbed onto silica gel and subjected to silica gel 
chromatography with dichloromethane : methanol (first 20:1, then 15:1) as the eluting 
solvent. The metal complex FL1370-1 was isolated as a solid (6 mg, 40%) and the other 
linkage isomer FL1370-2 was also obtained (4.4 mg, 29%). FL1370-1: 1H NMR (300 
MHz, DMSO-d6): δ (ppm) 11.0 (s, 1H), 9.10 (dd, J = 8.4, 1.0 Hz, 1H), 9.05 (dd, J = 5.1, 
1.0 Hz, 1H), 8.30 (d, J = 2.5 Hz, 1H), 7.77 (dd, J = 8.9, 5.1 Hz, 1H), 7.63 (d, J = 8.9 Hz, 
1H), 7.19 (dd, J = 8.9, 2.6 Hz, 1H), 4.66 (septet, J = 6.1 Hz, 1H), 3.10-2.20 (m, 12H), 
1.37 (d, J = 6.1 Hz, 6H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 170.9, 170.8, 
153.7, 151.1, 150.6, 146.9, 143.5, 132.6, 132.5, 130.7, 124.1, 123.3, 121.1, 117.5, 115.3, 
114.6, 111.2, 109.7, 70.5, 34.3, 33.6, 32.6, 32.2, 9.7, 22.11, 22.08. IR (film): ν (cm-1) 
2099, 1745, 1698, 1597, 1490, 1461, 1413, 1337, 1232, 1214, 1181, 1118, 1003, 982, 
823, 799, 698, 635, 497. HRMS calculated for C27H26N4O3S4RuNa (M + Na)
+ 706.9828, 
found (M + Na)+ 706.9838. FL1370-2: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.0 (s, 
1H), 9.05 (dd, J = 8.4, 1.1 Hz, 1H), 8.97 (dd, J = 5.1, 1.1 Hz, 1H), 8.27 (d, J = 2.5 Hz, 
1H), 7.76 (dd, J = 8.4, 5.1 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.16 (dd, J = 8.9, 2.6 Hz, 
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1H), 4.65 (septet, J = 6.1 Hz, 1H), 3.06-2.27 (m, 12H), 1.36 (d, J = 6.1 Hz, 6H). IR 
(film): ν (cm-1) 2974, 2100, 1745, 1703, 1596, 1493, 1460, 1418, 1338, 1278, 1232, 
1208, 1116, 1023, 819, 799, 495. HRMS calculated for C27H26N4O3S4RuNa (M + Na)
+ 
706.9828, found (M + Na)+ 706.9832. 











Complex 3.70. A suspension of the pyridocarbazole ligand 3.69 (160 mg, 0.24 mmol), 
K2CO3 (36 mg, 0.26 mmol), and [RuCl2(η
6-C6H6)]2 (89 mg, 0.18 mmol) in CH3CN (30 
mL) was purged with nitrogen for 5 minutes and stirred at 50 °C under nitrogen 
overnight. The resulting dark red suspension was dried in vacuo and the crude material 
was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (35:1) as the eluting solvent. The half-sandwich complex 
3.70 was isolated as a dark red solid (200 mg, 95%). 1H NMR (300 MHz, CDCl3): δ 
(ppm) 9.26 (d, J = 1.3 Hz, 1H), 9.05 (d, J = 1.3 Hz, 1H), 8.35 (d, J = 2.5 Hz, 1H), 7.64 
(d, J = 8.7 Hz, 1H), 7.14 (dd, J = 8.7, 2.5 Hz, 1H), 5.82 (s, 6H), 5.05 (d, J = 13.6 Hz, 
1H), 4.98 (d, J = 13.6 Hz, 1H), 1.07 (s, 9H), 1.04 (s, 9H), 1.03 (s, 9H), 0.60 (s, 6H), 
0.31 (s, 3H), 0.30 (s, 3H), 0.22 (s, 3H), 0.20 (s, 3H). 13C NMR (75.5 MHz, CDCl3): δ 
(ppm) 175.5, 174.4, 153.3, 150.0, 149.9, 146.6, 142.3, 136.4, 133.4, 132.1, 125.1, 121.3, 
120.5, 114.9, 114.8, 114.6, 114.3, 83.3, 63.2, 26.6, 26.1, 19.2, 18.5, -3.8, -4.09, -4.12, 
-4.99, -5.05. IR (film): ν (cm-1) 2928, 2856, 1744, 1691, 1608, 1555, 1461, 1430, 15, 
1255, 1209, 1148, 1096, 1048, 907, 836, 778. HRMS calculated for C42H58N3O4Si3Ru 













Complex 3.71. A red solution of 3.70 (200 mg, 0.22 mmol) in CH3CN (220 mL) was 
purged with nitrogen for 10 min, then irradiated with a mercury medium pressure lamp 
(150 W, pyrex filter) for 3 hours while nitrogen was bubbled through the solution. The 
resulting dark green solution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 
methanol (first 35:1, then 15:1). The combined product eluents were isolated as a 
mixture of two diastereoisomers (170 mg, 80%). To the stirred green solution of the 
mixture (170 mg, 0.18 mmol) in CH3CN (25 mL) was added tetrabutylammonium 
fluoride (820 µL, 1 M in THF, 0.82 mmol) at 0 °C, then the solution was stirred at 0 °C 
for 10 min. To the resulting green solution was added glacial acetic acid (47.7 µL, 0.82 
mmol) and stirred for 1 min at 0 °C. The solution was dried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (first 10:1, then 5:1) to yield the precursor complex 3.71 
(44 mg, 41%) and a second diastereoisomer in lower amounts (31 mg, 29%). Analytical 
data for the main diastereomer 3.71: 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.83 (s, 
1H), 9.42 (br, 1H), 9.06 (s, 1H), 8.87 (br, 1H), 8.07 (br, 1H), 7.65 (d, J = 8.7 Hz, 1H), 
7.03 (d, J = 8.7 Hz, 1H), 5.69 (t, J = 5.4 Hz, 1H), 4.83 (d, J = 5.4 Hz, 2H), 2.94 (s, 3H), 
2.21 (s, 6H). IR (film): ν (cm-1) 3231, 2926, 2274, 1745, 1686, 1556, 1490, 1422, 1337, 
1285, 1229, 1192, 1138, 1028, 858, 700, 671, 638, 506 478. HRMS calculated for 

















Complex FL1360. A solution of precursor complex 3.71 (15 mg, 0.025 mmol) in DMF 
(2.5 mL) was purged with CO gas for 5 min, then stirred at 75 °C under an atmosphere 
of CO for 1 hour. To the resulting solution was adde  [9]aneS3, then the solution was 
stirred at 95 °C under an atmosphere of nitrogen for 3 hours, after which the purple 
solution was dried under high vacuum. The crude material was adsorbed onto silica gel 
and subjected to silica gel chromatography with MeCN : H2O : KNO3 (50:3:1) to obtain 
purple solid. The resulting material was dissolved in a minimal acetonitrile/water. The 
product was precipitated by the addition of excess solid NH4PF6. The precipitate was 
centrifuged and washed twice with water. The materil was then dried under high 
vacuum to yield FL1360 (8.4 mg, 42%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 
11.18 (s, 1H), 9.35 (s, 1H), 9.21 (s, 1H), 8.81 (s, 1H), 8.20 (d, J = 2.4 Hz, 1H), 7.45 (d, J
= 8.8 Hz, 1H), 7.11 (dd, J = 8.8, 2.4 Hz, 1H), 5.79 (br, 1H), 4.89 (br, 2H), 3.52-2.53 (m, 
12H). 13C NMR (100.6 MHz, DMSO-d6): δ (ppm) 192.3, 170.7, 170.3, 152.8, 151.6, 
151.0, 144.6, 141.7, 139.0, 131.7, 131.3, 124.6, 121.1, 117.0, 114.7, 114.2, 112.4, 108.8, 
60.5, 38.2, 36.6, 36.0, 32.0, 31.6, 31.0. IR (film): ν (cm-1) 3210, 2008, 1751, 1714, 1492, 
1470, 1418, 1337, 1026, 999, 842, 704. HRMS calculated for C25H22N3O5S3Ru (M)
+ 
641.9760, found (M)+ 641.9750. 
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Chapter 6.1.5: Synthesis of TrkA inhibitors 
General procedure for the synthesis of ruthenium coplexes with tridentate ligands: To 
a soulution of ruthenium precursor in DMF (8 mM, 2 mL) was added tridentate ligand 
(1 equiv), then the mixture was stirred at 70 °C under an atmosphere of nitrogen for 1 
hour. The resulting solution was dried in vacuo and the crude material was adsorbed 
onto silica gel and subjected to silica gel chromatography with dichloromethane : 











Complex FL792-1. Using dichloromethane : methanol (75:1) as the eluting solvent. (5 
mg, 26%). 1H NMR (300 MHz, CDCl3): δ (ppm) 10.02 (dd, J = 5.1, 1.2 Hz, 1H), 9.32 
(dd, J = 8.4, 1.2 Hz, 1H), 8.71 (d, J = 7.5 Hz, 1H), 8.27 (s, 1H), 8.26 (s, 1H), 7.92 (dd, J 
= 8.4, 5.1 Hz, 1H), 7.88-7.85 (m, 2H), 7.73 (m, 1H), 7.43 (s, 1H), 7.15 (m, 1H), 7.01 (m, 











Complex FL792-2. Using dichloromethane : methanol (75:1) as the eluting solvent. 
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(4.6 mg, 24%). 1H NMR (300 MHz, CDCl3): δ (ppm) 9.05 (d, J = 8.0 Hz, 1H), 8.87 (d, 
J = 8.0 Hz, 1H), 8.32 (s, 1H), 8.31 (s, 1H), 7.85-7.83 (m, 2H), 7.73-7.62 (m, 3H), 7.53 













Complex FL1138-1. Using dichloromethane : methanol (75:1) as the eluting solvent. 
(2.5 mg, 24%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.90-9.88 (m, 2H), 8.87 (dd, J 
= 9.5, 2.5 Hz, 1H), 8.58 (s, 1H), 8.57 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 8.17-8.15 (m, 
2H), 7.80 (dd, J = 8.2, 7.7 Hz, 1H), 6.66 (dd, J = 8.9, 2.6 Hz, 1H), 5.60 (d, J = 8.9 Hz, 













Complex FL1138-2. Using dichloromethane : methanol (75:1) as the eluting solvent. 
(2.5 mg, 24%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.01 (s, 1H), 8.71 (d, J = 9.0 
Hz, 1H), 8.60 (s, 1H), 8.59 (s, 1H), 8.39-8.34 (m, 2H), 8.11-8.08 (m, 2H), 7.83 (t, J = 
8.1 Hz, 1H), 7.23 (dd, J = 9.0, 2.7 Hz, 1H), 6.87 (t, J = 2.5 Hz, 1H), 3.95 (s, 3H), 2.93 (s, 












Complex FL1124-1. Using dichloromethane : methanol (75:1) as the eluting solvent. 
(2.7 mg, 25%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 11.28 (s, 1H), 10.67 (d, J = 8.4 
Hz, 1H), 10.48 (s, 1H), 8.70 (d, J = 7.4 Hz, 1H), 8.63 (s, 1H), 8.62 (s, 1H), 8.56 (d, J = 
7.8 Hz, 1H), 8.18-8.12 (m, 3H), 8.01 (t, J = 7.4 Hz, 1H), 7.90 (t, J = 8.0 Hz, 1H), 











Complex FL1124-2. Using dichloromethane : methanol (75:1) as the eluting solvent. 
(2.4 mg, 22%). 1H NMR (300 MHz, CDCl3): δ (ppm) 10.49 (d, J = 8.5 Hz, 1H), 9.24 (d, 
J = 7.9 Hz, 1H), 8.97 (br, 1H), 8.34 (s, 2H), 7.91-7.83 (m, 3H), 7.76-7.57 (m, 4H), 7.45 














Complex FL609-1. Using dichloromethane : methanol (50:1) as the eluting solvent. 
(1.5 mg, 21%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 9.87 (dd, J = 3.4, 2.5 Hz, 1H), 
9.79 (br, 1H), 8.84 (dd, J = 9.5, 2.5 Hz, 1H), 8.57 (s, 1H), 8.56 (s, 1H), 8.17-8.14 (m, 
2H), 8.07 (d, J = 2.5 Hz, 1H), 7.98 (m, 1H), 7.89 (dd, J = 8.2, 7.6 Hz, 1H), 6.60 (dd, J = 












Complex FL1190-1. Using dichloromethane : methanol (first 35:1, then 20:1) as the 
eluting solvent. (1.8 mg, 24%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 10.81 (d, J = 
8.6 Hz, 1H), 10.57 (s, 1H), 9.97 (s, 1H), 8.67-8.58 (m, 2H), 8.50 (m, 1H), 8.16-7.95 (m, 














Complex FL1190-2. Using dichloromethane : methanol (first 35:1, then 20:1) as the 
eluting solvent. (1.5 mg, 21%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 10.58 (d, J = 
8.6 Hz, 1H), 9.93 (br, 1H), 8.92 (d, J = 8.9 Hz, 1H), 8.65 (d, J = 2.4 Hz, 1H), 8.63 (s, 
1H), 8.62 (s, 1H), 8.14-8.11 (m, 2H), 7.96 (s, 1H), 7.85-7.79 (m, 2H), 7.69-7.59 (m, 2H), 












Complex FL1260-1. Using dichloromethane : methanol (35:1) as the eluting solvent. 
(1.8 mg, 16%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 10.70 (d, J = 8.5 Hz, 1H), 
10.23 (s, 1H), 9.97 (br, 1H), 8.49 (d, J = 2.5 Hz, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.0 (m, 
1H), 7.92-7.75 (m, 5H), 6.82 (dd, J = 8.7, 2.6 Hz, 1H), 5.96 (d, J = 8.7 Hz, 1H), 














Complex FL1260-2. Using dichloromethane : methanol (first 35:1) as the eluting 
solvent. (2.5 mg, 22%). 1H NMR (300 MHz, acetone-d6): δ (ppm) 10.68 (d, J = 8.6 Hz, 
1H), 9.97 (br, 1H), 8.96 (d, J = 8.9 Hz, 1H), 8.57 (d, J = 2.4 Hz, 1H), 8.17-8.14 (m, 2H), 
7.92 (s, 1H), 7.82-7.76 (m, 2H), 7.74-7.64 (m, 2H), 7.48 (s, 1H), 7.16 (dd, J = 8.8, 2.6 
Hz, 1H), 5.01-4.86 (m, 2H), 4.35-4.21 (m, 2H), and the methyl group was overlapped 
by the solvent peak. HRMS calculated for C30H24ClN4O3S2Ru (M + H)
+ 689.0027, 












Complex FL1220. A mixture solution of compound 4.3 (15 mg, 0.030 mmol), precursor 
4.2 (13.6 mg, 0.036 mmol), and K2CO3 (5 mg, 0.036 mmol) in ethanol (3 mL) was 
refluxed under an atmosphere of nitrogen for 6 hours. The resulting solution was dried 
in vacuo and the crude material was filtered by flash silica gel chromatography with 
dichloromethane : methanol (20:1) as eluting solvent. The resulting solid was dissolved 
in acetonitrile, followed by adding TBAF (1 M in THF, 60 µL, 0.06 mmol) at 0 °C. 
After stirring for 3 minutes at 0 °C, the reaction was quenched with saturated 
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ammonium chloride solution. The resulting solution was dried in vacuo and the crude 
material was adsorbed onto silica gel and subjected to silica gel chromatography with 
dichloromethane : methanol (15:1) as eluting solvent to yield complex FL1220 (3.4 mg, 
18% over two steps). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 10.42 (s, 1H), 8.99 (s, 
1H), 8.63-8.56 (m, 4H), 8.22 (d, J = 2.4 Hz, 1H), 8.15-8.09 (m, 3H), 8.94 (m, 1H), 7.84 





Compound 4.6. A mixture solution of 2,6-bis(chloromethyl)pyridine (50 mg, 0.286 
mmol), sodium methanethiolate (20 mg, 0.286 mmol), and 12-crown-4 (50 mg, 0.284 
mmol) in ethanol (1 mL) was stirred at room temperature under an atmosphere of 
nitrogen overnight. The resulting mixture was diluted with water and extracted with 
DCM twice. The combined organic layers were concentrated, then dissolved in DMF (1 
mL), followed by adding sodium azide (17 mg, 0.254 mmol). After stirring at 50 °C 
overnight, the resulting mixture was dried in vacuo and filtered by flash silica gel 
chromatography with hexane : EtOAc (3:1) as eluting solvent. The resulting product 
was dissolved in THF (1 mL), followed by adding triphenylphosphine (150 mg, 0.572 
mmol), and water (20.6 mg, 1.14 mmol). After refluxing under nitrogen for 2 hours, the 
resulting solution was dried in vacuo and the crude material was adsorbed onto silica 
gel and subjected to silica gel chromatography with d chloromethane : methanol (first 
35:1, then 20:1 with 0.5% concentrated ammonium) as eluting solvent to yield 
compound 4.6 (10 mg, 20% over three steps). 1H NMR (300 MHz, CDCl3): δ (ppm) 
7.59 (t, J = 7.7 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 7.13 (d, J = 7.7 Hz, 1H), 3.94 (s, 2H), 
3.76 (s, 2H), 2.23 (s, 2H), 2.04 (s, 3H). 13C NMR (75.5 MHz, CDCl3): δ (ppm) 159.0, 
158.3, 137.5, 121.5, 119.8, 46.6, 40.1, 15.5. HRMS calculated for C8H13N2S (M + H)
+ 
169.0794, found (M + H)+ 169.0794. 
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Chapter 6.2: Resolution of racemic mixtures and determination 
of absolute configurations 
Complex FL172. The enantiomers were seperated using a CHIRALPAK IB analytical 
HPLC column (Daicel/Chiral Technologies, 250 x 4.6 mm) using the solvent of ethanol : 
hexane (1 : 1) in 15 minutes with a flow rate of 0.75 ml/minute. The enantiomers were 
baseline separated under these conditions with retention times of 12.9 (E1) and 15.3 min 
(E2). The enantiomers did not show any racemization in an ethanol solution over a time 
period of 12 hours. The CD spectra of the separated enantiomers were were recorded on 
a Model J-810 Spectropolarimeter and shown in Figure 2.8. The slower eluting 
enantiomer E2 showed more potent PAK-1 inhibition and was cocrystallized with PAK1 
and based on this cocrystal structure assigned with the Λ-configuration. 
Complex FL411: For the resolution of the racemic mixture of FL411, the amino group 
at the 4-position of the pyridine was BOC-protected an  removed after the separation 
with a CHIRALPAK IB analytical HPLC column (Daicel/Chiral Technologies, 250 x 
4.6 mm) with the solvent of ethanol : hexane (2 : 3) in 15 minutes with a flow rate of 
0.75 ml/minute. The enantiomers were baseline-separated under these conditions with 
retention times of ca. 10.5 (E1) and 15.7 min (E2). The enantiomers did not show any 
significant racemization in an ethanol solution over a time period of 12 hours. The CD 
spectra of the separated enantiomers after BOC-deprotection were shown in Figure 2.14. 
Absolute configurations were assigned by correlation with the CD spectra of FL172. 
Complex FL1422: For the resolution of the racemic mixture of FL1422, the amino 
group at the 4-position of the pyridine was BOC-protected and removed after the 
separation with a CHIRALPAK IB analytical HPLC column (Daicel/Chiral 
Technologies, 250 x 4.6 mm) with the solvent of ethanol : hexane (45 : 55) in 16 
minutes with a flow rate of 0.75 ml/minute. The enantiomers were baseline-separated 
under these conditions with retention times of ca. 8.7 (E1) and 15.5 min (E2). The 
enantiomers did not show any significant racemization in an ethanol solution over a 
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time period of 12 hours. The CD spectra of the separated enantiomers after 
BOC-deprotection were shown in Figure 2.16. Absolute configurations were assigned 
by correlation with the CD spectra of FL172. 
Chapter 6.3: Kinase assays 
Protein kinase (human) and substrate were purchased from Upstate Biotechnology 
USA, Millipore or MoBiTec GmbH, and PAK1 was purified by Jasna Maksimoska 
(University of Pennsylvania and The Wistar Institute, Philadelphia, USA). [γ-33P]ATP 
was purchased from PerkinElmer. 
Protein Kinase PAK1 Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.8 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate (12.5 µg MBP peptide), and kinase PAK1 (0.2 nM). After 15 min, 
the reaction was initiated by adding ATP to a final concentration of 100 µM, including 
approximately 0.06 µCi/µL [γ-33P]ATP. Reactions were performed in a total volume of 
25 µL. After 45 minutes, the reaction was terminated by spotting 15 µL on a circular 
P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by washing three 
times (5 minutes each wash) with 0.75% phosphoric acid nd once with acetone. The 
dried P81 papers were transferred to a scintillation vial, 5mL of scintillation cocktail 
was added and the counts per minute (CPM) were determin d with a Beckmann 6500 
scintillation counter. IC50 values were defined to be the concentration of inhib tor at 
which the CPM was 50% of the control sample, corrected by the background. 
Protein Kinase Pim1 Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 10 mM MOPS, 10 mM Mg(OAc)2, 
0.1 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate S6 peptide (50 µM, AKRRRLSSLRA), and kinase Pim1 (1.6 nM). 
After 15 min, the reaction was initiated by adding ATP to a final concentration of 100 
µM, including approximately 0.04 µCi/µL [γ-33P]ATP. Reactions were performed in a 
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total volume of 25 µL. After 30 minutes, the reaction was terminated by spotting 15 µL 
on a circular P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by 
washing three times (5 minutes each wash) with 0.75% phosphoric acid and once with 
acetone. The dried P81 papers were transferred to ascintillation vial, 5mL of 
scintillation cocktail was added and the counts per minute (CPM) were determined with 
a Beckmann 6500 scintillation counter. IC50 values were defined to be the concentration 
of inhibitor at which the CPM was 50% of the control sample, corrected by the 
background. 
Protein Kinase GSK3β Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.8 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate phosphoglycogen synthase peptide-2 (20 µM, 
YRRAAVPPSPSLSRHSSPHQ-pS-EDEEE), and kinase GSK3β (1.8 nM). After 15 min, 
the reaction was initiated by adding ATP to a final concentration of 100 µM, including 
approximately 0.05 µCi/µL [γ-33P]ATP. Reactions were performed in a total volume of 
25 µL. After 45 minutes, the reaction was terminated by spotting 15 µL on a circular 
P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by washing three 
times (5 minutes each wash) with 0.75% phosphoric acid nd once with acetone. The 
dried P81 papers were transferred to a scintillation vial, 5mL of scintillation cocktail 
was added and the counts per minute (CPM) were determin d with a Beckmann 6500 
scintillation counter. IC50 values were defined to be the concentration of inhib tor at 
which the CPM was 50% of the control sample, corrected by the background. 
Protein Kinase MLCK Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 10 mM MOPS, 10 mM Mg(OAc)2, 
0.1 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate ZIP peptide (62.5 µM, KKLNRTLSFAEPG), calmodulin (1 µM), 
CaCl2 (0.5 mM) and kinase MLCK (4.6 nM). After 15 min, the reaction was initiated by 
adding ATP to a final concentration of 100 µM, including approximately 0.1 µCi/µL 
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[γ-33P]ATP. Reactions were performed in a total volume of 25 µL. After 30 minutes, the 
reaction was terminated by spotting 15 µL on a circular P81 phosphocellulose paper 
(2.1 cm diameter, Whatman), followed by washing three times (5 minutes each wash) 
with 0.75% phosphoric acid and once with acetone. The dried P81 papers were 
transferred to a scintillation vial, 5mL of scintillation cocktail was added and the counts 
per minute (CPM) were determined with a Beckmann 6500 scintillation counter. IC50 
values were defined to be the concentration of inhibitor at which the CPM was 50% of 
the control sample, corrected by the background. 
Protein Kinase GSK3α Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.8 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate phosphoglycogen synthase peptide-2 (20 µM, 
YRRAAVPPSPSLSRHSSPHQ-pS-EDEEE), and kinase GSK3α (1.8 nM). After 15 min, 
the reaction was initiated by adding ATP to a final concentration of 100 µM, including 
approximately 0.05 µCi/µL [γ-33P]ATP. Reactions were performed in a total volume of 
25 µL. After 45 minutes, the reaction was terminated by spotting 15 µL on a circular 
P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by washing three 
times (5 minutes each wash) with 0.75% phosphoric acid nd once with acetone. The 
dried P81 papers were transferred to a scintillation vial, 5mL of scintillation cocktail 
was added and the counts per minute (CPM) were determin d with a Beckmann 6500 
scintillation counter. IC50 values were defined to be the concentration of inhib tor at 
which the CPM was 50% of the control sample, corrected by the background. 
Protein Kinase Flt4 Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.8 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate Jak3tide (100 µM, GGEEEEYFELVKKKK), and kinase Flt4 (8.8 
nM). After 30 min, the reaction was initiated by adding ATP to a final concentration of 
100 µM, including approximately 0.1 µCi/µL [γ-33P]ATP. Reactions were performed in 
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a total volume of 25 µL. After 120 minutes, the reaction was terminated by spotting 15 
µL on a circular P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by 
washing three times (5 minutes each wash) with 0.75% phosphoric acid and once with 
acetone. The dried P81 papers were transferred to ascintillation vial, 5mL of 
scintillation cocktail was added and the counts per minute (CPM) were determined with 
a Beckmann 6500 scintillation counter. IC50 values were defined to be the concentration 
of inhibitor at which the CPM was 50% of the control sample, corrected by the 
background. 
Protein Kinase DAPK1 Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.1 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate (62.5 µM ZIP peptide KKLNRTLSFAEPG) and kinase DAPK1 (1 
nM). After 15 min, the reaction was initiated by adding ATP to a final concentration of 
100 µM, including approximately 0.08 µCi/µL [γ-33P]ATP. Reactions were performed in 
a total volume of 25 µL. After 30 minutes, the reaction was terminated by spotting 15 
µL on a circular P81 phosphocellulose paper (2.1 cm dia eter, Whatman), followed by 
washing three times (5 minutes each wash) with 0.75% phosphoric acid and once with 
acetone. The dried P81 papers were transferred to ascintillation vial, 5mL of 
scintillation cocktail was added and the counts per minute (CPM) were determined with 
a Beckmann 6500 scintillation counter. IC50 values were defined to be the concentration 
of inhibitor at which the CPM was 50% of the control sample, corrected by the 
background. 
Protein Kinase ZIPK Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 10 mM Mg(OAc)2, 
0.1 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate (62.5 µM ZIP peptide KKLNRTLSFAEPG) and kinase ZIPK (10 
nM). After 15 min, the reaction was initiated by adding ATP to a final concentration of 
100 µM, including approximately 0.1 µCi/µL [γ-33P]ATP. Reactions were performed in 
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a total volume of 25 µL. After 30 minutes, the reaction was terminated by spotting 15 
µL on a circular P81 phosphocellulose paper (2.1 cm dia eter, Whatman), followed by 
washing three times (5 minutes each wash) with 0.75% phosphoric acid and once with 
acetone. The dried P81 papers were transferred to ascintillation vial, 5mL of 
scintillation cocktail was added and the counts per minute (CPM) were determined with 
a Beckmann 6500 scintillation counter. IC50 values were defined to be the concentration 
of inhibitor at which the CPM was 50% of the control sample, corrected by the 
background. 
Protein Kinase TrkA Assay Using [γ-33P]ATP. Various concentrations of ruthenium 
complexes were incubated at room temperature in 20 mM MOPS, 30 mM Mg(OAc)2, 
0.8 µg/µL BSA, 5% DMSO (resulting from the inhibitor stock solution), pH 7.0, in the 
presence of substrate IGF-IR peptide (150 µM, KKKSPGEYVNIEFG) and kinase TrkA 
(9.8 nM). After 15 min, the reaction was initiated by adding ATP to a final concentration 
of 100 µM, including approximately 0.1 µCi/µL [γ-33P]ATP. Reactions were performed 
in a total volume of 25 µL. After 2 hours, the reaction was terminated by spotting 15 µL 
on a circular P81 phosphocellulose paper (2.1 cm diameter, Whatman), followed by 
washing three times (5 minutes each wash) with 0.75% phosphoric acid and once with 
acetone. The dried P81 papers were transferred to ascintillation vial, 5mL of 
scintillation cocktail was added and the counts per minute (CPM) were determined with 
a Beckmann 6500 scintillation counter. IC50 values were defined to be the concentration 
of inhibitor at which the CPM was 50% of the control sample, corrected by the 
background. 
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Appendix 
A. Crystallographic Data 
Crystal structure of FL151-1. 
       
Table 6.1. Crystal data and structure refinement for FL151-1. 
 
Identification code  fl151-1 
Habitus, colour  plate,  red 
Crystal size 0.30 x 0.26 x 0.06 mm3 
Crystal system  Triclinic 
Space group  P 1 Z = 2 
Unit cell dimensions a = 10.6778(4) Å α= 88.265(3)°. 
 b = 13.2390(4) Å β= 70.059(2)°. 
 c = 13.9507(4) Å γ = 68.259(3)°. 
Volume 1711.56(10) Å3 
Cell determination  21187 peaks with Theta 1.5 to 28°.
Empirical formula  C37.50 H30 Cl F N5 O6.50 Ru 
Formula weight  810.18 
Density (calculated) 1.572 Mg/m3 
Absorption coefficient 0.599 mm-1 
F(000) 824 
 
Data collection:  
 
Diffractometer type  IPDS2  
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.56 to 27.91°. 
Index ranges -14<=h<=13, -17<=k<=17, -18<=l<=18 
 Data collection software  STOE WinXpose (X-Area)  
Cell refinement software  STOE WinCell (X-Area)   
Data reduction software  STOE WinIntegrate (X-Area)  
 
Solution and refinement: 
 
Reflections collected 19070 
Independent reflections 8134 [R(int) = 0.0334] 
Completeness to theta = 25.00° 100.0 %  
Observed reflections  6933[I>2sigma(I)]  
Reflections used for refinement  8134 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9838 and 0.8168 
Largest diff. peak and hole 0.506 and -0.901 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  C-H geometrical, O-H located, “mixed” refinement 
Programs used  SIR2004 (Giacovazzo et al, 2004) 
 SHELXL-97 (Sheldrick, 1997) 
 Diamond 3.1, STOE IPDS2 software  
Data / restraints / parameters 8134 / 6 / 501 
Goodness-of-fit on F2 0.977 
R index (all data) wR2 = 0.0717 
R index conventional  [I>2sigma(I)] R1 = 0.0285 
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Table 6.2. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL151-1.  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
N1 0.21583(17) 0.24244(12) 0.15534(11) 0.0219(3) 1 
O1 0.26653(17) -0.16933(11) -0.11508(11) 0.0322(3) 1 
Cl1 -0.19529(5) 0.32146(4) 0.42267(3) 0.02774(10) 1 
Ru1 0.03256(2) 0.28269(1) 0.28516(1) 0.02062(5) 1 
F1 -0.13800(14) -0.05047(10) 0.24125(10) 0.0399(3) 1 
C2 0.2323(2) 0.15579(14) 0.09788(13) 0.0218(3) 1 
O2 0.56811(16) 0.01599(11) -0.21740(10) 0.0307(3) 1 
C3 0.1398(2) 0.09878(14) 0.13185(13) 0.0217(3) 1 
O3 0.67426(18) 0.33568(14) -0.10060(12) 0.0354(3) 1 
N4 0.03425(17) 0.13695(12) 0.22581(12) 0.0226(3) 1 
O4 0.1742(2) 0.17242(13) 0.43272(12) 0.0411(4) 1 
C5 -0.0572(2) 0.08645(15) 0.26063(15) 0.0261(4) 1 
C6 -0.0411(2) -0.00376(15) 0.20093(16) 0.0285(4) 1 
C7 0.0628(2) -0.04434(15) 0.10669(15) 0.0284(4) 1 
C8 0.1590(2) 0.00918(14) 0.06793(14) 0.0239(4) 1 
C9 0.2734(2) -0.01631(14) -0.02849(14) 0.0236(4) 1 
C10 0.3191(2) -0.10314(15) -0.11091(14) 0.0255(4) 1 
N11 0.43754(19) -0.09498(13) -0.18836(13) 0.0277(3) 1 
C12 0.4722(2) -0.01067(15) -0.16406(14) 0.0250(4) 1 
C13 0.3643(2) 0.04054(14) -0.05924(14) 0.0221(3) 1 
C14 0.3480(2) 0.12883(14) 0.00333(13) 0.0223(3) 1 
C15 0.4106(2) 0.20816(14) 0.00366(13) 0.0222(3) 1 
C16 0.5291(2) 0.22623(15) -0.06456(14) 0.0253(4) 1 
C17 0.5599(2) 0.31183(16) -0.03877(14) 0.0273(4) 1 
C18 0.4743(2) 0.37982(16) 0.05411(14) 0.0269(4) 1 
C19 0.3583(2) 0.36262(15) 0.12310(14) 0.0249(4) 1 
C20 0.3248(2) 0.27636(14) 0.09890(14) 0.0223(3) 1 
C21 0.1255(2) 0.21323(15) 0.37382(15) 0.0290(4) 1 
N21 -0.07938(17) 0.37301(12) 0.19026(11) 0.0218(3) 1 
C22 -0.0936(2) 0.47950(14) 0.19380(14) 0.0232(3) 1 
C23 -0.0364(2) 0.51312(14) 0.26057(14) 0.0232(3) 1 
N24 0.02789(17) 0.43583(12) 0.31450(11) 0.0228(3) 1 
C25 0.0838(2) 0.46629(16) 0.37513(14) 0.0275(4) 1 
C26 0.0780(2) 0.57306(17) 0.38579(15) 0.0321(4) 1 
C27 0.0117(2) 0.65088(17) 0.33294(16) 0.0330(4) 1 
C28 -0.0468(2) 0.62169(15) 0.26704(16) 0.0293(4) 1 
C29 -0.1155(3) 0.69626(16) 0.20695(18) 0.0360(5) 1 
C30 -0.1685(3) 0.66454(17) 0.14400(18) 0.0362(5) 1 
C31 -0.1589(2) 0.55405(16) 0.13514(15) 0.0281(4) 1 
C32 -0.2097(2) 0.51493(17) 0.06948(16) 0.0318(4) 1 
C33 -0.1945(2) 0.40772(17) 0.06594(15) 0.0296(4) 1 
C34 -0.1294(2) 0.33907(15) 0.12793(14) 0.0252(4) 1 
O100 0.5753(3) -0.25325(18) -0.36931(15) 0.0760(8) 1 
C100 0.5575(2) -0.33285(18) -0.39152(17) 0.0371(5) 1 
C101 0.4835(3) -0.3892(2) -0.31250(18) 0.0426(5) 1 
C102 0.6133(3) -0.3798(2) -0.50087(18) 0.0478(6) 1 
O200 0.81068(18) 0.19712(14) -0.27848(12) 0.0425(4) 1 
C200 0.7503(3) 0.18318(18) -0.33333(16) 0.0377(5) 1 
C201 0.6022(3) 0.2583(2) -0.3237(2) 0.0517(6) 1 
C202 0.8230(4) 0.0873(2) -0.4128(2) 0.0642(9) 1 
O300 0.3741(5) -0.0971(4) -0.4630(3) 0.0603(10) 0.50 
C300 0.4541(5) -0.0484(4) -0.4866(4) 0.0421(10) 0.50 
C301 0.4259(19) 0.0530(11) -0.4247(14) 0.068(4) 0.50 
C302 0.5896(14) -0.0877(11) -0.5788(12) 0.053(2) 0.50 
___________________________________________________________________________
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Table 6.3. Bond lengths [Å] and angles [°] for FL151-1. 
___________________________________________________ 
N1-C2  1.342(2) 
N1-C20  1.384(2) 
N1-Ru1  2.0645(15) 
O1-C10  1.215(2) 
Cl1-Ru1  2.4112(5) 
Ru1-C21  1.858(2) 
Ru1-N24  2.0596(15) 
Ru1-N4  2.1141(15) 
Ru1-N21  2.1299(15) 
F1-C6  1.351(2) 
C2-C3  1.407(2) 
C2-C14  1.409(2) 
O2-C12  1.208(2) 
C3-N4  1.362(2) 
C3-C8  1.416(2) 
O3-C17  1.373(2) 
O3-H3  0.77(3) 
N4-C5  1.333(2) 
O4-C21  1.137(3) 
C5-C6  1.400(3) 
C5-H5  0.9500 
C6-C7  1.362(3) 
C7-C8  1.410(3) 
C7-H7  0.9500 
C8-C9  1.420(3) 
C9-C13  1.389(2) 
C9-C10  1.471(2) 
C10-N11  1.393(3) 
N11-C12  1.383(2) 
N11-H11  0.78(3) 
C12-C13  1.503(2) 
C13-C14  1.402(2) 
C14-C15  1.439(2) 
C15-C16  1.398(2) 
C15-C20  1.431(2) 
C16-C17  1.380(3) 
C16-H16  0.9500 
C17-C18  1.406(3) 
C18-C19  1.377(3) 
C18-H18  0.9500 
C19-C20  1.398(2) 
C19-H19  0.9500 
N21-C34  1.327(2) 
N21-C22  1.361(2) 
C22-C31  1.400(3) 
C22-C23  1.433(3) 
C23-N24  1.367(2) 
C23-C28  1.403(2) 
N24-C25  1.333(2) 
C25-C26  1.402(3) 
C25-H25  0.9500 
C26-C27  1.369(3) 
C26-H26  0.9500 
C27-C28  1.406(3) 
C27-H27  0.9500 
C28-C29  1.431(3) 
C29-C30  1.344(3) 
C29-H29  0.9500 
C30-C31  1.434(3) 
C30-H30  0.9500 
C31-C32  1.406(3) 
C32-C33  1.368(3) 
C32-H32  0.9500 
C33-C34  1.397(3) 
C33-H33  0.9500 
C34-H34  0.9500 
O100-C100  1.204(3) 
C100-C101  1.480(3) 
C100-C102  1.494(3) 
C101-H10A  0.9800 
C101-H10B  0.9800 
C101-H10C  0.9800 
C102-H10D  0.9800 
C102-H10E  0.9800 
C102-H10F  0.9800 
O200-C200  1.212(3) 
C200-C201  1.485(4) 
C200-C202  1.487(3) 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C202-H20D  0.9800 
C202-H20E  0.9800 
C202-H20F  0.9800 
O300-C300  1.207(6) 
C300-C301  1.493(12) 
C300-C302  1.494(13) 
C301-H30A  0.9800 
C301-H30B  0.9800 
C301-H30C  0.9800 
C302-H30D  0.9800 
C302-H30E  0.9800 





























































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.4. Anisotropic displacement parameters (Å2) for FL151-1.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
N1 0.0244(7)  0.0202(7) 0.0237(7)  0.0020(6) -0.0094(6)  -0.0105(6) 
O1 0.0386(8)  0.0255(7) 0.0360(7)  -0.0021(6) -0.0126(6)  -0.0162(6) 
Cl1 0.0303(2)  0.0275(2) 0.0249(2)  -0.00025(16) -0.00613(17)  -0.01371(18) 
Ru1 0.02495(8)  0.01817(7) 0.02108(7)  0.00172(5) -0.00902(5)  -0.01000(5) 
F1 0.0426(7)  0.0320(6) 0.0450(7)  -0.0029(5) -0.008(6)  -0.0270(6) 
C2 0.0251(9)  0.0184(8) 0.0238(8)  0.0028(6) -0.0100(7)  -0.0091(7) 
O2 0.0314(7)  0.0316(7) 0.0284(7)  0.0004(5) -0.0071(6)  -0.0145(6) 
C3 0.0245(9)  0.0181(8) 0.0226(8)  0.0013(6) -0.0081(7)  -0.0085(7) 
O3 0.0358(8)  0.0425(9) 0.0323(8)  -0.0020(7) -0.0046(7)  -0.0262(7) 
N4 0.0271(8)  0.0175(7) 0.0259(7)  0.0026(6) -0.0103(6)  -0.0107(6) 
O4 0.0549(10)  0.0363(8) 0.0412(8)  0.0113(7) -0.0296(8)  -0.0166(7) 
C5 0.0291(9)  0.0213(8) 0.0286(9)  0.0035(7) -0.0077(8)  -0.0127(7) 
C6 0.0315(10)  0.0213(8) 0.0358(10)  0.0033(7) -0.0090(8)  -0.0162(8) 
C7 0.0323(10)  0.0206(8) 0.0337(10)  0.0015(7) -0.01 1(8)  -0.0129(8) 
C8 0.0276(9)  0.0177(8) 0.0287(9)  0.0033(7) -0.0109(7)  -0.0105(7) 
C9 0.0273(9)  0.0170(8) 0.0273(9)  0.0008(6) -0.0106(7)  -0.0083(7) 
C10 0.0289(9)  0.0202(8) 0.0282(9)  0.0009(7) -0.0122(8)  -0.0081(7) 
N11 0.0322(9)  0.0240(8) 0.0262(8)  -0.0032(6) -0.0087(7)  -0.0110(7) 
C12 0.0278(9)  0.0214(8) 0.0261(9)  0.0014(7) -0.0124(7)  -0.0069(7) 
C13 0.0235(8)  0.0187(8) 0.0241(8)  0.0016(6) -0.0097(7)  -0.0070(7) 
C14 0.0247(9)  0.0192(8) 0.0247(8)  0.0026(6) -0.0110(7)  -0.0084(7) 
C15 0.0244(9)  0.0213(8) 0.0243(8)  0.0038(6) -0.0117(7)  -0.0098(7) 
C16 0.0265(9)  0.0263(9) 0.0257(9)  0.0019(7) -0.015(7)  -0.0119(7) 
C17 0.0276(9)  0.0324(10) 0.0272(9)  0.0046(7) -0.01 4(8)  -0.0166(8) 
C18 0.0316(10)  0.0278(9) 0.0295(9)  0.0031(7) -0.0139(8)  -0.0175(8) 
C19 0.0292(9)  0.0235(8) 0.0264(8)  0.0020(7) -0.0130(7)  -0.0121(7) 
C20 0.0255(9)  0.0206(8) 0.0251(8)  0.0037(6) -0.0129(7)  -0.0099(7) 
C21 0.0353(10)  0.0234(9) 0.0297(9)  0.0007(7) -0.0097(8)  -0.0142(8) 
N21 0.0233(7)  0.0200(7) 0.0230(7)  0.0012(5) -0.0080(6)  -0.0094(6) 
C22 0.0241(9)  0.0200(8) 0.0256(8)  0.0020(6) -0.0073(7)  -0.0097(7) 
C23 0.0244(9)  0.0193(8) 0.0253(8)  -0.0003(6) -0.0063(7)  -0.0099(7) 
N24 0.0258(8)  0.0219(7) 0.0234(7)  -0.0005(6) -0.0088(6)  -0.0115(6) 
C25 0.0303(10)  0.0297(9) 0.0252(9)  -0.0015(7) -0.0090(8)  -0.0148(8) 
C26 0.0342(11)  0.0360(11) 0.0311(10)  -0.0056(8) -0.0094(8)  -0.0203(9) 
C27 0.0373(11)  0.0267(9) 0.0360(10)  -0.0048(8) -0.0080(9)  -0.0173(9) 
C28 0.0309(10)  0.0226(9) 0.0346(10)  -0.0007(7) -0.0081(8)  -0.0133(8) 
C29 0.0430(12)  0.0203(9) 0.0468(12)  0.0058(8) -0.0162(10)  -0.0143(9) 
C30 0.0403(12)  0.0240(9) 0.0469(12)  0.0105(9) -0.02 3(10)  -0.0112(9) 
C31 0.0292(10)  0.0242(9) 0.0327(10)  0.0052(7) -0.0125(8)  -0.0109(8) 
C32 0.0322(10)  0.0335(10) 0.0325(10)  0.0086(8) -0.0160(8)  -0.0121(9) 
C33 0.0285(10)  0.0350(10) 0.0304(9)  0.0027(8) -0.0134(8)  -0.0148(8) 
C34 0.0264(9)  0.0253(9) 0.0268(9)  0.0008(7) -0.012(7)  -0.0122(7) 
O100 0.1058(19)  0.0649(13) 0.0474(11)  -0.0209(9) 0.0158(11)  -0.0590(14) 
C100 0.0354(11)  0.0332(11) 0.0369(11)  -0.0058(9) -0.0091(9)  -0.0096(9) 
C101 0.0423(13)  0.0505(13) 0.0423(12)  0.0031(10) -0.0175(10)  -0.0233(11) 
C102 0.0542(15)  0.0399(12) 0.0387(12)  -0.0060(10) -0.0126(11)  -0.0093(11) 
O200 0.0386(9)  0.0468(9) 0.0388(8)  0.0002(7) -0.0039(7)  -0.0215(8) 
C200 0.0480(13)  0.0345(11) 0.0297(10)  0.0072(8) -0.0061(9)  -0.0220(10) 
C201 0.0531(15)  0.0646(17) 0.0369(12)  0.0182(11) -0.0152(11)  -0.0236(13) 
C202 0.100(3)  0.0424(14) 0.0381(13)  -0.0011(11) -0.0171(15)  -0.0207(16) 
O300 0.059(2)  0.067(3) 0.060(2)  -0.0007(19) -0.0099(19)  -0.039(2) 
C300 0.045(3)  0.051(3) 0.040(2)  0.008(2) -0.017(2)  -0.028(2) 
C301 0.086(8)  0.075(9) 0.046(4)  -0.001(5) -0.006(5)  -0.052(7) 
C302 0.043(4)  0.074(8) 0.044(4)  0.009(5) -0.013(3)  -0.028(5) 
_________________________________________________________________________
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Table 6.5. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL151-1. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H5 -0.1327 0.1115 0.3255 0.031 1 
H7 0.0701 -0.1060 0.0688 0.034 1 
H16 0.5872 0.1805 -0.1274 0.030 1 
H18 0.4971 0.4388 0.0696 0.032 1 
H19 0.3021 0.4085 0.1860 0.030 1 
H25 0.1295 0.4134 0.4127 0.033 1 
H26 0.1197 0.5913 0.4294 0.038 1 
H27 0.0054 0.7239 0.3407 0.040 1 
H29 -0.1238 0.7701 0.2117 0.043 1 
H30 -0.2129 0.7160 0.1048 0.043 1 
H32 -0.2543 0.5625 0.0280 0.038 1 
H33 -0.2279 0.3801 0.0217 0.036 1 
H34 -0.1205 0.2650 0.1254 0.030 1 
H10A 0.4436 -0.3465 -0.2454 0.064 1 
H10B 0.5526 -0.4620 -0.3104 0.064 1 
H10C 0.4052 -0.3966 -0.3294 0.064 1 
H10D 0.6593 -0.3351 -0.5452 0.072 1 
H10E 0.5331 -0.3805 -0.5197 0.072 1 
H10F 0.6841 -0.4548 -0.5095 0.072 1 
H20A 0.5688 0.3203 -0.2722 0.078 1 
H20B 0.5371 0.2189 -0.3024 0.078 1 
H20C 0.6028 0.2852 -0.3900 0.078 1 
H20D 0.9213 0.0467 -0.4140 0.096 1 
H20E 0.8267 0.1125 -0.4801 0.096 1 
H20F 0.7689 0.0394 -0.3965 0.096 1 
H30A 0.4333 0.1103 -0.4698 0.101 0.50 
H30B 0.4971 0.0373 -0.3911 0.101 0.50 
H30C 0.3288 0.0778 -0.3725 0.101 0.50 
H30D 0.6731 -0.1088 -0.5571 0.079 0.50 
H30E 0.5900 -0.0290 -0.6233 0.079 0.50 
H30F 0.5944 -0.1511 -0.6165 0.079 0.50 
H3 0.717(3) 0.294(2) -0.149(2) 0.046(8) 1 
H11 0.480(3) -0.134(2) -0.240(2) 0.043(7) 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.7. Hydrogen bonds for FL151-1 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 O3-H3...O200 0.77(3) 1.97(3) 2.734(2) 173(3) 
 N11-H11...O100 0.78(3) 2.13(3) 2.904(2) 172(3) 
_______________________________________________________________________ 





Crystal structure of FL327. 
       
Table 6.8. Crystal data and structure refinement for FL327. 
 
Identification code  fl327 
Habitus, colour  plate,  dark red 
Crystal size 0.14 x 0.09 x 0.03 mm3 
Crystal system  Monoclinic 
Space group  P 21/n Z = 4 
Unit cell dimensions a = 9.7730(5) Å α= 90°. 
 b = 11.8601(6) Å β= 98.014(4)°. 
 c = 29.6398(16) Å γ = 90°. 
Volume 3402.0(3) Å3 
Cell determination  9578 peaks with Theta 1.4 to 25°.
Empirical formula  C37 H31 Cl F N5 O6 Ru 
Formula weight  797.19 
Density (calculated) 1.556 Mg/m3 
Absorption coefficient 0.601 mm-1 
F(000) 1624 
 
Data collection:  
 
Diffractometer type  IPDS2  
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.39 to 25.00°. 
Index ranges -11<=h<=11, -14<=k<=13, -35<=l<=34 
 Data collection software  STOE WinXpose (X-Area)  
Cell refinement software  STOE WinCell (X-Area)   
Data reduction software  STOE WinIntegrate (X-Area)  
 
Solution and refinement: 
 
Reflections collected 19119 
Independent reflections 5988 [R(int) = 0.0771] 
Completeness to theta = 25.00° 100.0 %  
Observed reflections  3554[I>2sigma(I)]  
Reflections used for refinement  5988 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.1054 and 0.8848 
Largest diff. peak and hole 0.480 and -0.610 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  geom, constr 
Programs used  SIR92 (Giacovazzo et al, 1993) 
 SHELXL-97 (Sheldrick, 1997) 
 Diamond 3.1, STOE IPDS2 software  
Data / restraints / parameters 5988 / 0 / 473 
Goodness-of-fit on F2 0.797 
R index (all data) wR2 = 0.0776 
R index conventional  [I>2sigma(I)] R1 = 0.0396 
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Table 6.9. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL327.   
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C1 1.1167(4) 0.1500(4) 0.62114(12) 0.0329(9) 1 
C2 1.0168(4) 0.0666(3) 0.60773(13) 0.0328(9) 1 
C3 0.8313(4) -0.0355(3) 0.60474(14) 0.0348(10) 1 
C4 0.7042(4) -0.0811(4) 0.61063(15) 0.0422(11) 1 
C5 0.6572(4) -0.1741(4) 0.58538(14) 0.0450(11) 1 
C6 0.7332(4) -0.2224(4) 0.55398(15) 0.0428(11) 1 
C7 0.8585(4) -0.1773(4) 0.54653(13) 0.0389(10) 1 
C8 0.9080(4) -0.0830(4) 0.57184(13) 0.0350(10) 1 
C9 1.0313(4) -0.0151(3) 0.57378(13) 0.0335(10) 1 
C10 1.1535(4) -0.0085(3) 0.55410(13) 0.0328(9) 1 
C11 1.2083(4) -0.0818(4) 0.51959(13) 0.0356(10) 1 
C12 1.3683(4) 0.0573(4) 0.54115(13) 0.0372(10) 1 
C13 1.2528(4) 0.0750(4) 0.56642(12) 0.0336(10) 1 
C14 1.2375(4) 0.1584(4) 0.60010(12) 0.0334(9) 1 
C15 1.3305(4) 0.2464(4) 0.61533(13) 0.0363(10) 1 
C16 1.2943(4) 0.3169(4) 0.64794(13) 0.0357(10) 1 
C17 1.1756(4) 0.3036(3) 0.66843(13) 0.0368(10) 1 
C18 0.8517(4) 0.3863(4) 0.71603(15) 0.0462(11) 1 
C19 0.7792(4) 0.3886(4) 0.66985(15) 0.0434(11) 1 
C20 0.7079(5) 0.4825(4) 0.65078(17) 0.0526(13) 1 
C21 0.6493(5) 0.4773(4) 0.60564(18) 0.0555(13) 1 
C22 0.6596(4) 0.3813(4) 0.58026(18) 0.0519(13) 1 
C23 0.7321(4) 0.2896(4) 0.60173(15) 0.0436(11) 1 
C24 0.6016(5) 0.3732(4) 0.53062(17) 0.0664(16) 1 
C25 1.0037(5) 0.2980(4) 0.77380(14) 0.0427(11) 1 
C26 1.0833(5) 0.3915(4) 0.78754(15) 0.0449(11) 1 
C27 1.1655(5) 0.3917(4) 0.82991(15) 0.0515(13) 1 
C28 1.1678(6) 0.2978(4) 0.85746(17) 0.0589(14) 1 
C29 1.0890(5) 0.2043(4) 0.84330(15) 0.0585(14) 1 
C30 1.0069(5) 0.2048(4) 0.80158(15) 0.0515(12) 1 
C100 1.0105(4) 0.0582(4) 0.71679(14) 0.0396(11) 1 
C200 1.0455(4) 0.6514(4) 0.69833(14) 0.0448(11) 1 
C201 0.9470(5) 0.7353(4) 0.67357(18) 0.0625(15) 1 
C202 1.1251(4) 0.6921(4) 0.74181(15) 0.0488(12) 1 
N1 1.0873(3) 0.2198(3) 0.65577(10) 0.0327(8) 1 
N2 0.9002(3) 0.0566(3) 0.62655(11) 0.0356(8) 1 
N3 0.7924(3) 0.2928(3) 0.64566(12) 0.0395(9) 1 
N4 0.9219(4) 0.2957(3) 0.72925(11) 0.0416(9) 1 
N5 1.3347(4) -0.0372(3) 0.51418(12) 0.0384(9) 1 
O1 1.1549(3) -0.1652(3) 0.50046(9) 0.0439(7) 1 
O2 1.4755(3) 0.1113(2) 0.54306(9) 0.0372(7) 1 
O3 0.6772(3) -0.3169(3) 0.53172(11) 0.0540(9) 1 
O100 1.0741(3) -0.0140(3) 0.73698(10) 0.0523(8) 1 
O200 1.0566(3) 0.5558(3) 0.68485(11) 0.0559(9) 1 
F1 1.3779(2) 0.4047(2) 0.66251(8) 0.0492(7) 1 
Cl1 0.69881(11) 0.10741(10) 0.70823(4) 0.0473(3) 1 
Ru1 0.91023(4) 0.16574(3) 0.68281(1) 0.03517(10) 1 
C300 0.8842(5) -0.4731(4) 0.44780(16) 0.0521(13) 1 
C302 1.0090(6) -0.4223(7) 0.4366(2) 0.117(3) 1 
C301 0.8489(8) -0.5867(5) 0.4303(2) 0.105(2) 1 
O300 0.8129(5) -0.4261(4) 0.47119(13) 0.0929(14) 1 
___________________________________________________________________________
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Table 6.10. Bond lengths [Å] and angles [°] for FL327. 
___________________________________________________ 
C1-N1  1.380(5) 
C1-C2  1.408(5) 
C1-C14  1.413(5) 
C2-N2  1.342(5) 
C2-C9  1.418(5) 
C3-C4  1.388(6) 
C3-N2  1.394(5) 
C3-C8  1.426(6) 
C4-C5  1.376(6) 
C4-H4  0.9500 
C5-C6  1.393(6) 
C5-H5A  0.9500 
C6-O3  1.375(5) 
C6-C7  1.382(6) 
C7-C8  1.395(6) 
C7-H7  0.9500 
C8-C9  1.443(5) 
C9-C10  1.403(6) 
C10-C13  1.399(5) 
C10-C11  1.497(6) 
C11-O1  1.221(5) 
C11-N5  1.374(5) 
C12-O2  1.222(5) 
C12-N5  1.389(5) 
C12-C13  1.454(6) 
C13-C14  1.428(5) 
C14-C15  1.416(6) 
C15-C16  1.361(5) 
C15-H15  0.9500 
C16-F1  1.357(4) 
C16-C17  1.392(5) 
C17-N1  1.334(5) 
C17-H17  0.9500 
C18-N4  1.305(5) 
C18-C19  1.451(6) 
C18-H18  0.9500 
C19-N3  1.360(5) 
C19-C20  1.391(6) 
C20-C21  1.382(7) 
C20-H20  0.9500 
C21-C22  1.377(7) 
C21-H21  0.9500 
C22-C23  1.401(6) 
C22-C24  1.504(7) 
C23-N3  1.353(5) 
C23-H23  0.9500 
C24-H24A  0.9800 
C24-H24B  0.9800 
C24-H24C  0.9800 
C25-C30  1.376(6) 
C25-C26  1.383(6) 
C25-N4  1.445(5) 
C26-C27  1.394(6) 
C26-H26  0.9500 
C27-C28  1.380(6) 
C27-H27  0.9500 
C28-C29  1.382(7) 
C28-H28  0.9500 
C29-C30  1.377(6) 
C29-H29  0.9500 
C30-H30  0.9500 
C100-O100  1.173(5) 
C100-Ru1  1.823(5) 
C200-O200  1.211(5) 
C200-C202  1.490(6) 
C200-C201  1.503(6) 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C202-H20D  0.9800 
C202-H20E  0.9800 
C202-H20F  0.9800 
N1-Ru1  2.106(3) 
N2-Ru1  2.103(3) 
N3-Ru1  2.111(3) 
N4-Ru1  2.059(4) 
N5-H5  0.82(4) 
O3-H3  0.97(5) 
Cl1-Ru1  2.3979(11) 
C300-O300  1.189(6) 
C300-C302  1.439(7) 
C300-C301  1.467(7) 
C302-H30A  0.9800 
C302-H30B  0.9800 
C302-H30C  0.9800 
C301-H30D  0.9800 
C301-H30E  0.9800 
































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.11. Anisotropic displacement parameters (Å2) for FL327.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C1 0.038(2)  0.033(3) 0.029(2)  -0.0002(19) 0.0094(17)  0.002(2) 
C2 0.033(2)  0.034(2) 0.031(2)  0.0047(19) 0.0032(18)  -0.0005(19) 
C3 0.035(2)  0.028(2) 0.041(2)  0.0039(19) 0.0028(19)  0.0011(19) 
C4 0.036(2)  0.040(3) 0.049(3)  0.006(2) 0.002(2)  0.003(2) 
C5 0.035(2)  0.045(3) 0.054(3)  0.004(3) 0.003(2)  -0.007(2) 
C6 0.047(3)  0.035(3) 0.042(3)  0.007(2) -0.012(2)  -0.010(2) 
C7 0.041(2)  0.037(3) 0.037(2)  0.003(2) -0.0012(18)  0.001(2) 
C8 0.032(2)  0.034(3) 0.037(2)  0.0046(19) -0.0008(18)  -0.0021(19) 
C9 0.038(2)  0.034(2) 0.027(2)  0.0030(18) -0.0009(18)  -0.0001(19) 
C10 0.038(2)  0.033(2) 0.028(2)  -0.0006(18) 0.0051(18)  0.004(2) 
C11 0.041(2)  0.036(3) 0.030(2)  0.005(2) 0.0040(19)  0.000(2) 
C12 0.045(3)  0.039(3) 0.027(2)  0.001(2) 0.0026(19)  0.005(2) 
C13 0.038(2)  0.039(3) 0.024(2)  0.0029(18) 0.0053(17)  0.000(2) 
C14 0.035(2)  0.034(2) 0.032(2)  0.001(2) 0.0059(16)  -0.001(2) 
C15 0.037(2)  0.041(3) 0.033(2)  -0.001(2) 0.0123(18)  -0.001(2) 
C16 0.043(2)  0.032(3) 0.034(2)  -0.0051(19) 0.0092(18)  -0.014(2) 
C17 0.043(2)  0.036(3) 0.032(2)  -0.0032(18) 0.0082(1 )  -0.002(2) 
C18 0.047(3)  0.048(3) 0.048(3)  -0.005(2) 0.021(2)  0.001(2) 
C19 0.041(2)  0.045(3) 0.048(3)  0.005(2) 0.020(2)  0.006(2) 
C20 0.049(3)  0.041(3) 0.072(3)  0.004(3) 0.023(3)  0.007(2) 
C21 0.041(3)  0.046(3) 0.078(4)  0.016(3) 0.003(3)  0.005(2) 
C22 0.035(2)  0.046(3) 0.074(3)  0.014(3) 0.003(2)  -0.003(2) 
C23 0.036(2)  0.044(3) 0.051(3)  0.009(2) 0.006(2)  -0.005(2) 
C24 0.066(3)  0.056(4) 0.068(3)  0.019(3) -0.023(3)  -0.008(3) 
C25 0.050(3)  0.042(3) 0.039(3)  -0.002(2) 0.016(2)  0.000(2) 
C26 0.058(3)  0.038(3) 0.042(3)  -0.004(2) 0.018(2)  -0.003(2) 
C27 0.064(3)  0.046(3) 0.046(3)  -0.006(2) 0.013(2)  -0.007(3) 
C28 0.082(4)  0.053(4) 0.041(3)  -0.004(2) 0.007(3)  -0.005(3) 
C29 0.087(4)  0.052(3) 0.038(3)  0.001(2) 0.017(3)  -0.006(3) 
C30 0.068(3)  0.050(3) 0.040(3)  -0.001(2) 0.018(2)  -0.010(2) 
C100 0.048(3)  0.034(3) 0.039(2)  -0.012(2) 0.013(2)  -0.002(2) 
C200 0.049(2)  0.043(3) 0.043(2)  0.003(2) 0.009(2)  -0.001(3) 
C201 0.069(3)  0.045(3) 0.066(3)  0.005(3) -0.016(3)  0.005(3) 
C202 0.045(2)  0.043(3) 0.057(3)  0.007(2) 0.001(2)  -0.003(2) 
N1 0.0401(19)  0.0295(19) 0.0290(18)  0.0018(15) 0.0061(15)  0.0012(16) 
N2 0.0353(19)  0.036(2) 0.0372(19)  0.0067(16) 0.010( 5)  -0.0002(16) 
N3 0.0332(19)  0.041(2) 0.047(2)  -0.0002(18) 0.0146( 7)  -0.0017(16) 
N4 0.045(2)  0.045(2) 0.038(2)  0.0006(17) 0.0169(17)  0.0007(19) 
N5 0.043(2)  0.040(2) 0.034(2)  -0.0076(18) 0.0094(18)  -0.0018(19) 
O1 0.0525(16)  0.0404(17) 0.0393(15)  -0.0103(16) 0.0083(13)  -0.0066(17) 
O2 0.0392(16)  0.0398(17) 0.0335(15)  -0.0023(13) 0.0080(13)  -0.0030(14) 
O3 0.0555(19)  0.043(2) 0.060(2)  -0.0042(17) -0.0024(17)  -0.0159(17) 
O100 0.060(2)  0.048(2) 0.0481(19)  0.0037(17) 0.0037(16)  0.0083(17) 
O200 0.067(2)  0.046(2) 0.054(2)  -0.0023(17) 0.0047(17)  0.0023(18) 
F1 0.0526(15)  0.0502(17) 0.0486(14)  -0.0154(13) 0.0199(12)  -0.0180(13) 
Cl1 0.0446(6)  0.0479(7) 0.0531(7)  0.0074(6) 0.0201(5)  -0.0033(5) 
Ru1 0.03740(17)  0.03490(19) 0.03504(17)  0.0019(2) 0.01151(13)  0.0004(2) 
C300 0.064(3)  0.054(3) 0.038(3)  0.013(2) 0.005(2)  -0.003(3) 
C302 0.084(4)  0.193(9) 0.070(4)  0.059(5) -0.009(3)  -0.050(5) 
C301 0.186(7)  0.066(5) 0.060(4)  -0.005(3) 0.005(4)  -0.021(5) 
O300 0.142(4)  0.085(3) 0.056(2)  -0.003(2) 0.027(3)  0.029(3) 
_________________________________________________________________________
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Table 6.12. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL327. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H4 0.6507 -0.0486 0.6317 0.051 1 
H5A 0.5707 -0.2062 0.5895 0.054 1 
H7 0.9095 -0.2097 0.5248 0.047 1 
H15 1.4148 0.2559 0.6033 0.044 1 
H17 1.1572 0.3545 0.6916 0.044 1 
H18 0.8482 0.4486 0.7360 0.055 1 
H20 0.6998 0.5485 0.6684 0.063 1 
H21 0.6011 0.5410 0.5919 0.067 1 
H23 0.7391 0.2224 0.5847 0.052 1 
H24A 0.5032 0.3541 0.5277 0.100 1 
H24B 0.6509 0.3144 0.5161 0.100 1 
H24C 0.6130 0.4457 0.5157 0.100 1 
H26 1.0819 0.4554 0.7682 0.054 1 
H27 1.2196 0.4560 0.8397 0.062 1 
H28 1.2239 0.2974 0.8863 0.071 1 
H29 1.0915 0.1396 0.8623 0.070 1 
H30 0.9523 0.1406 0.7919 0.062 1 
H20A 0.8964 0.6999 0.6464 0.094 1 
H20B 0.9989 0.8003 0.6646 0.094 1 
H20C 0.8815 0.7605 0.6937 0.094 1 
H20D 1.0639 0.6964 0.7653 0.073 1 
H20E 1.1630 0.7670 0.7371 0.073 1 
H20F 1.2009 0.6396 0.7516 0.073 1 
H30A 1.0198 -0.3470 0.4503 0.176 1 
H30B 1.0036 -0.4161 0.4035 0.176 1 
H30C 1.0884 -0.4692 0.4486 0.176 1 
H30D 0.7590 -0.6088 0.4385 0.158 1 
H30E 0.9197 -0.6401 0.4436 0.158 1 
H30F 0.8443 -0.5869 0.3971 0.158 1 
H3 0.734(4) -0.339(5) 0.5086(15) 0.062(15) 1 
H5 1.386(4) -0.070(3) 0.4990(13) 0.026(12) 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms: 
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Table 6.14. Hydrogen bonds for FL327 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 O3-H3...O300 0.97(5) 1.77(5) 2.705(6) 159(5) 
 N5-H5...O2#1 0.82(4) 2.03(4) 2.823(5) 165(4) 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  






Crystal structure of FL389. 
       
Table 6.15. Crystal data and structure refinement for FL389. 
 
Identification code  fl389 
Habitus, colour  prism,  red 
Crystal size 0.27 x 0.09 x 0.02 mm3 
Crystal system  Triclinic 
Space group  P 1  Z = 2 
Unit cell dimensions a = 7.6625(3) Å α= 101.764(3)° 
 b = 15.8593(6) Å β= 92.604(3)° 
 c = 15.9895(5) Å γ = 96.270(3)° 
Volume 1886.30(12) Å3 
Cell determination  18229 peaks with Theta 4.5 to 25°.
Empirical formula  C39 H36 Cl F N6 O7 Ru 
Formula weight  856.26 
Density (calculated) 1.508 Mg/m3 
Absorption coefficient 0.550 mm-1 
F(000) 876 
 
Data collection:  
 
Diffractometer type  IPDS 2T  
Wavelength  0.71073 Å 
Temperature  193(2) K 
Theta range for data collection 4.64 to 25.00°. 
Index ranges -8<=h<=9, -18<=k<=18, -18<=l<=18 
 Data collection software  STOE WinXpose (X-Area)  
Cell refinement software  STOE WinCell (X-Area)   
Data reduction software  STOE WinIntegrate (X-Area)  
 
Solution and refinement: 
 
Reflections collected 16388 
Independent reflections 6276 [R(int) = 0.0611] 
Completeness to theta = 25.00° 94.7 %  
Observed reflections  5215[I>2sigma(I)]  
Reflections used for refinement  6276 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9761 and 0.9054 
Largest diff. peak and hole 0.615 and -0.595 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, riding model 
Programs used  SIR92 (Giacovazzo et al, 1993) 
 SHELXL-97 (Sheldrick, 1997) 
 Diamond 3.1, STOE IPDS2 software  
Data / restraints / parameters 6276 / 0 / 503 
Goodness-of-fit on F2 1.066 
R index (all data) wR2 = 0.1015 
R index conventional  [I>2sigma(I)] R1 = 0.0454 
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Table 6.16. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL389.   
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C2 0.9858(5) 0.8349(2) 0.1618(2) 0.0266(7) 1 
C3 0.8261(5) 0.8562(2) 0.1302(2) 0.0261(7) 1 
C5 0.6536(5) 0.9653(3) 0.1209(2) 0.0302(8) 1 
C6 0.5258(5) 0.9026(3) 0.0738(2) 0.0306(8) 1 
C7 0.5400(5) 0.8171(3) 0.0544(2) 0.0299(8) 1 
C8 0.6975(5) 0.7907(2) 0.0842(2) 0.0269(8) 1 
C9 0.7386(5) 0.7042(2) 0.0738(2) 0.0284(8) 1 
C10 0.6278(5) 0.6231(3) 0.0361(2) 0.0331(8) 1 
C12 0.8913(5) 0.5878(2) 0.0853(2) 0.0301(8) 1 
C13 0.8974(5) 0.6840(2) 0.1047(2) 0.0274(8) 1 
C14 1.0284(5) 0.7487(2) 0.1489(2) 0.0251(7) 1 
C15 1.2021(5) 0.7575(2) 0.1900(2) 0.0250(7) 1 
C16 1.3197(5) 0.6976(2) 0.1999(2) 0.0291(8) 1 
C17 1.4780(5) 0.7285(3) 0.2461(2) 0.0318(8) 1 
C18 1.5214(5) 0.8175(3) 0.2817(2) 0.0336(9) 1 
C19 1.4090(5) 0.8778(3) 0.2718(2) 0.0293(8) 1 
C20 1.2472(5) 0.8476(2) 0.2250(2) 0.0258(7) 1 
C22 0.9090(5) 0.9434(2) 0.3781(2) 0.0273(8) 1 
C23 0.8225(5) 0.9435(3) 0.4540(2) 0.0307(8) 1 
C24 0.7244(5) 1.0111(3) 0.4832(2) 0.0338(9) 1 
C25 0.7137(5) 1.0742(3) 0.4364(2) 0.0335(8) 1 
C26 0.8023(5) 1.0716(3) 0.3624(2) 0.0297(8) 1 
C27 0.8084(5) 1.1375(2) 0.3121(2) 0.0299(8) 1 
C29 0.9124(5) 1.1998(2) 0.2009(2) 0.0299(8) 1 
C30 0.9526(6) 1.2837(3) 0.2455(3) 0.0444(10) 1 
C31 0.9619(8) 1.3500(3) 0.2001(4) 0.0580(13) 1 
C32 0.9351(7) 1.3328(3) 0.1132(4) 0.0544(13) 1 
C33 0.8963(6) 1.2492(3) 0.0691(3) 0.0423(10) 1 
C34 0.8854(5) 1.1816(3) 0.1125(3) 0.0344(9) 1 
C35 1.1277(5) 1.0440(3) 0.1246(3) 0.0364(9) 1 
C100 1.0162(5) 0.6820(3) 0.3567(3) 0.0391(9) 1 
C101 1.1883(7) 0.7120(5) 0.4063(3) 0.0656(15) 1 
C102 0.9732(8) 0.5880(3) 0.3180(4) 0.0597(13) 1 
C200 0.7674(8) 0.6397(5) 0.5249(4) 0.0740(18) 1 
C201 0.6022(9) 0.6670(6) 0.4963(6) 0.107(3) 1 
C202 0.7641(13) 0.5499(7) 0.5341(7) 0.131(4) 1 
C300 0.4902(10) 0.3734(6) 0.2514(5) 0.093(2) 1 
C301 0.4610(14) 0.4464(6) 0.2101(6) 0.117(3) 1 
C302 0.4465(10) 0.2855(5) 0.1952(6) 0.097(2) 1 
N1 1.1115(4) 0.89448(19) 0.20618(18) 0.0250(6) 1 
N4 0.8050(4) 0.9425(2) 0.14865(19) 0.0268(6) 1 
N11 0.7273(4) 0.5566(2) 0.0439(2) 0.0354(7) 1 
N21 0.8985(4) 1.0059(2) 0.33386(18) 0.0260(6) 1 
N23 0.8349(5) 0.8776(2) 0.4957(2) 0.0382(8) 1 
N28 0.8996(4) 1.1292(2) 0.24563(19) 0.0280(7) 1 
O10 0.4769(4) 0.61258(18) 0.0048(2) 0.0412(7) 1 
O12 1.0021(4) 0.54371(18) 0.10187(19) 0.0402(7) 1 
O17 1.5908(4) 0.66924(19) 0.2565(2) 0.0425(7) 1 
O35 1.1887(5) 1.0651(2) 0.0663(2) 0.0584(10) 1 
O100 0.9119(4) 0.7331(2) 0.3491(2) 0.0466(7) 1 
O200 0.9018(6) 0.6908(4) 0.5387(3) 0.0906(15) 1 
O300 0.5472(12) 0.3858(7) 0.3235(4) 0.175(4) 1 
F6 0.3789(3) 0.93192(16) 0.04606(16) 0.0457(6) 1 
Cl1 1.28290(12) 1.09337(6) 0.30739(6) 0.0342(2) 1 
Ru1 1.02562(4) 1.01860(2) 0.21998(2) 0.02367(10) 1 
___________________________________________________________________________
 231 
Table 6.17. Bond lengths [Å] and angles [°] for FL389. 
___________________________________________________ 
C2-N1  1.339(5) 
C2-C3  1.403(5) 
C2-C14  1.417(5) 
C3-N4  1.370(5) 
C3-C8  1.412(5) 
C5-N4  1.336(5) 
C5-C6  1.388(5) 
C5-H5  0.9500 
C6-C7  1.346(6) 
C6-F6  1.354(4) 
C7-C8  1.413(5) 
C7-H7  0.9500 
C8-C9  1.420(5) 
C9-C13  1.386(5) 
C9-C10  1.462(5) 
C10-O10  1.219(5) 
C10-N11  1.389(5) 
C12-O12  1.211(5) 
C12-N11  1.384(5) 
C12-C13  1.489(5) 
C13-C14  1.405(5) 
C14-C15  1.437(5) 
C15-C16  1.406(5) 
C15-C20  1.422(5) 
C16-C17  1.378(5) 
C16-H16  0.9500 
C17-O17  1.374(5) 
C17-C18  1.407(6) 
C18-C19  1.382(6) 
C18-H18  0.9500 
C19-C20  1.402(5) 
C19-H19  0.9500 
C20-N1  1.399(5) 
C22-N21  1.337(4) 
C22-C23  1.408(5) 
C22-H22  0.9500 
C23-N23  1.358(5) 
C23-C24  1.391(6) 
C24-C25  1.375(5) 
C24-H24  0.9500 
C25-C26  1.386(5) 
C25-H25  0.9500 
C26-N21  1.357(5) 
C26-C27  1.442(5) 
C27-N28  1.291(5) 
C27-H27  0.9500 
C29-C30  1.371(6) 
C29-C34  1.385(5) 
C29-N28  1.443(4) 
C30-C31  1.391(6) 
C30-H30  0.9500 
C31-C32  1.362(8) 
C31-H31  0.9500 
C32-C33  1.362(7) 
C32-H32  0.9500 
C33-C34  1.388(5) 
C33-H33  0.9500 
C34-H34  0.9500 
C35-O35  1.155(5) 
C35-Ru1  1.841(4) 
C100-O100  1.218(5) 
C100-C101  1.486(7) 
C100-C102  1.487(7) 
C101-H10A  0.9800 
C101-H10B  0.9800 
C101-H10C  0.9800 
C102-H10D  0.9800 
C102-H10E  0.9800 
C102-H10F  0.9800 
C200-O200  1.220(8) 
C200-C202  1.459(11) 
C200-C201  1.465(9) 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C202-H20D  0.9800 
C202-H20E  0.9800 
C202-H20F  0.9800 
C300-O300  1.184(9) 
C300-C301  1.476(12) 
C300-C302  1.492(11) 
C301-H30A  0.9800 
C301-H30B  0.9800 
C301-H30C  0.9800 
C302-H30D  0.9800 
C302-H30E  0.9800 
C302-H30F  0.9800 
N1-Ru1  2.116(3) 
N4-Ru1  2.105(3) 
N11-H11  0.8800 
N21-Ru1  2.138(3) 
N23-H23A  0.8020 
N23-H23B  0.8879 
N28-Ru1  2.071(3) 
O17-H17  0.8400 












































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.18. Anisotropic displacement parameters (Å2) for FL389.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C2 0.0272(19)  0.0242(19) 0.0271(18)  0.0050(15) -0.00 7(14)  -0.0006(15) 
C3 0.0296(19)  0.0217(18) 0.0271(18)  0.0071(15) 0.0013(14)  0.0007(15) 
C5 0.031(2)  0.030(2) 0.0314(19)  0.0076(16) 0.0012(15)  0.0068(16) 
C6 0.0236(18)  0.034(2) 0.035(2)  0.0059(17) -0.0018(15)  0.0076(15) 
C7 0.0251(18)  0.031(2) 0.0309(19)  0.0040(16) -0.0038(14)  0.0005(15) 
C8 0.0250(18)  0.0262(19) 0.0276(18)  0.0033(15) -0.00 1(14)  0.0003(15) 
C9 0.0270(19)  0.0263(19) 0.0300(19)  0.0037(15) -0.0025(14)  0.0011(15) 
C10 0.034(2)  0.026(2) 0.036(2)  0.0023(16) -0.0050(16)  -0.0017(16) 
C12 0.033(2)  0.0245(19) 0.0311(19)  0.0045(16) -0.0026(15)  0.0012(16) 
C13 0.0283(19)  0.0226(19) 0.0297(18)  0.0032(15) 0.00 1(14)  0.0013(15) 
C14 0.0250(18)  0.0226(18) 0.0261(17)  0.0025(14) -0.0010(14)  0.0021(14) 
C15 0.0238(18)  0.0236(18) 0.0270(18)  0.0060(15) -0.0013(14)  -0.0002(14) 
C16 0.0250(18)  0.0250(19) 0.036(2)  0.0049(16) -0.0020(15)  0.0005(15) 
C17 0.0264(19)  0.031(2) 0.038(2)  0.0085(17) -0.0019(15)  0.0021(16) 
C18 0.0244(19)  0.036(2) 0.037(2)  0.0056(17) -0.0060(15)  -0.0046(16) 
C19 0.0255(18)  0.027(2) 0.0322(19)  0.0026(16) -0.0034(14)  -0.0022(15) 
C20 0.0275(18)  0.0236(18) 0.0254(17)  0.0043(15) 0.00 7(14)  0.0011(15) 
C22 0.0304(19)  0.0266(19) 0.0244(18)  0.0080(15) -0.0019(14)  -0.0023(15) 
C23 0.0290(19)  0.030(2) 0.0297(19)  0.0064(16) -0.0042(15)  -0.0079(16) 
C24 0.028(2)  0.042(2) 0.0281(19)  0.0048(17) 0.0034(15)  -0.0027(17) 
C25 0.0283(19)  0.039(2) 0.0313(19)  0.0038(17) 0.0012(15)  0.0034(17) 
C26 0.0273(19)  0.029(2) 0.0312(19)  0.0036(16) -0.0025(15)  0.0024(15) 
C27 0.0310(19)  0.0260(19) 0.0314(19)  0.0042(16) -0.0009(15)  0.0032(15) 
C29 0.034(2)  0.0237(19) 0.0326(19)  0.0075(16) 0.0033(15)  0.0035(15) 
C30 0.055(3)  0.027(2) 0.050(3)  0.0053(19) 0.006(2)  0.0029(19) 
C31 0.079(4)  0.022(2) 0.074(4)  0.010(2) 0.016(3)  0.006(2) 
C32 0.065(3)  0.036(3) 0.072(3)  0.029(3) 0.013(3)  0.012(2) 
C33 0.044(2)  0.046(3) 0.045(2)  0.024(2) 0.0071(19)  0.013(2) 
C34 0.032(2)  0.030(2) 0.041(2)  0.0100(18) 0.0012(16)  0.0035(16) 
C35 0.041(2)  0.025(2) 0.043(2)  0.0027(18) 0.0045(18)  0.0093(17) 
C100 0.037(2)  0.045(3) 0.036(2)  0.0077(19) 0.0042(17)  0.007(2) 
C101 0.042(3)  0.098(5) 0.054(3)  0.011(3) -0.002(2)  0.009(3) 
C102 0.076(4)  0.039(3) 0.065(3)  0.007(2) 0.006(3)  0.016(3) 
C200 0.060(4)  0.112(5) 0.057(3)  0.034(4) 0.010(3)  0.009(4) 
C201 0.059(4)  0.126(7) 0.156(8)  0.085(6) 0.003(4)  0.004(4) 
C202 0.129(8)  0.141(9) 0.163(9)  0.094(8) 0.060(7)  0.056(7) 
C300 0.089(5)  0.123(7) 0.068(4)  0.026(4) 0.030(4)  -0.007(4) 
C301 0.153(8)  0.084(6) 0.101(6)  0.007(5) 0.022(6)  -0.023(5) 
C302 0.087(5)  0.080(5) 0.130(7)  0.033(5) 0.028(5)  0.014(4) 
N1 0.0248(15)  0.0224(16) 0.0260(15)  0.0034(12) 0.00 7(11)  -0.0010(12) 
N4 0.0295(16)  0.0249(16) 0.0271(15)  0.0066(13) 0.0030(12)  0.0057(13) 
N11 0.0328(18)  0.0197(16) 0.0480(19)  -0.0005(14) -0.0072(14)  -0.0034(13) 
N21 0.0224(15)  0.0246(16) 0.0276(15)  0.0017(13) -0.0014(12)  -0.0035(12) 
N23 0.047(2)  0.0354(19) 0.0321(17)  0.0107(15) 0.0040(14)  -0.0031(15) 
N28 0.0310(16)  0.0229(16) 0.0278(16)  0.0032(13) -0.0020(13)  -0.0006(13) 
O10 0.0329(16)  0.0285(15) 0.0564(18)  0.0018(13) -0.0125(13)  -0.0027(12) 
O12 0.0411(16)  0.0235(14) 0.0526(17)  0.0039(13) -0.0132(13)  0.0034(12) 
O17 0.0307(15)  0.0361(16) 0.0591(19)  0.0086(14) -0.0123(13)  0.0066(12) 
O35 0.079(2)  0.059(2) 0.056(2)  0.0341(18) 0.0395(18)  0.0349(19) 
O100 0.0412(17)  0.0410(18) 0.0551(19)  0.0056(15) -0.0040(14)  0.0063(14) 
O200 0.062(3)  0.142(5) 0.071(3)  0.035(3) 0.004(2)  0.004(3) 
O300 0.185(8)  0.263(11) 0.072(4)  0.034(5) 0.015(4)  -0.003(7) 
F6 0.0336(13)  0.0417(14) 0.0595(15)  0.0037(12) -0.0123(11)  0.0142(11) 
Cl1 0.0325(5)  0.0293(5) 0.0362(5)  0.0018(4) -0.0014(4)  -0.0062(4) 
Ru1 0.02657(16)  0.01878(15) 0.02449(15)  0.00348(11) 0.00129(10)  -0.00018(10) 
_________________________________________________________________________
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Table 6.19. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL389. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H5 0.6332 1.0245 0.1333 0.036 1 
H7 0.4486 0.7765 0.0224 0.036 1 
H16 1.2909 0.6376 0.1754 0.035 1 
H18 1.6313 0.8368 0.3134 0.040 1 
H19 1.4403 0.9377 0.2960 0.035 1 
H22 0.9767 0.8977 0.3578 0.033 1 
H24 0.6659 1.0135 0.5346 0.041 1 
H25 0.6450 1.1201 0.4548 0.040 1 
H27 0.7462 1.1864 0.3276 0.036 1 
H30 0.9737 1.2964 0.3060 0.053 1 
H31 0.9875 1.4085 0.2304 0.070 1 
H32 0.9435 1.3790 0.0834 0.065 1 
H33 0.8766 1.2372 0.0086 0.051 1 
H34 0.8595 1.1233 0.0818 0.041 1 
H10A 1.2143 0.7750 0.4131 0.098 1 
H10B 1.2810 0.6835 0.3756 0.098 1 
H10C 1.1830 0.6973 0.4628 0.098 1 
H10D 0.9957 0.5540 0.3612 0.090 1 
H10E 1.0467 0.5721 0.2700 0.090 1 
H10F 0.8488 0.5759 0.2973 0.090 1 
H20A 0.6276 0.7202 0.4745 0.160 1 
H20B 0.5276 0.6780 0.5446 0.160 1 
H20C 0.5410 0.6211 0.4507 0.160 1 
H20D 0.7276 0.5109 0.4788 0.196 1 
H20E 0.6806 0.5387 0.5763 0.196 1 
H20F 0.8818 0.5399 0.5534 0.196 1 
H30A 0.4923 0.5013 0.2516 0.175 1 
H30B 0.3368 0.4412 0.1900 0.175 1 
H30C 0.5345 0.4451 0.1614 0.175 1 
H30D 0.4396 0.2416 0.2304 0.145 1 
H30E 0.5382 0.2747 0.1549 0.145 1 
H30F 0.3330 0.2824 0.1632 0.145 1 
H11 0.6904 0.5012 0.0249 0.042 1 
H23A 0.8804 0.8364 0.4734 0.046 1 
H23B 0.7923 0.8846 0.5470 0.046 1 
H17 1.6827 0.6951 0.2852 0.064 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.21. Hydrogen bonds for FL389 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N11-H11...O10#1 0.88 2.05 2.894(4) 159.6 
 O17-H17...O100#2 0.84 1.96 2.790(4) 169.0 
 N23-H23A...O100 0.80 2.34 3.054(5) 148.1 
 N23-H23B...Cl1#3 0.89 2.39 3.271(3) 172.5 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  




Crystal structure of FL1359. 
   
Table 6.22. Crystal data and structure refinement for FL1359. 
 
Identification code  fl1359 
Habitus, colour  prism,  red 
Crystal size 0.22 x 0.10 x 0.04 mm3 
Crystal system  Triclinic 
Space group  P -1 Z = 2 
Unit cell dimensions a = 7.8921(6) Å α= 103.536(5)°. 
 b = 12.7358(8) Å β= 91.381(6)°. 
 c = 17.8734(12) Å γ = 98.699(6)°. 
Volume 1723.2(2) Å3 
Cell determination  7424 peaks with Theta 25 to 1.7°. 
Empirical formula  C32 H38 N6 O5 Ru S3 
Formula weight  783.93 
Density (calculated) 1.511 Mg/m3 
Absorption coefficient 0.686 mm-1 
F(000) 808 
 
Data collection:  
 
Diffractometer type  STOE IPDS2 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.67 to 25.00°. 
Index ranges -9<=h<=9, -15<=k<=14, -17<=l<=21 
 Data collection software  STOE X-AREA 
Cell refinement software  STOE X-AREA 
Data reduction software  STOE X-AREA 
 
Solution and refinement: 
 
Reflections collected 12554 
Independent reflections 6038 [R(int) = 0.0656] 
Completeness to theta = 25.00° 99.5 %  
Observed reflections  3295[I>2(I)]  
Reflections used for refinement  6038 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9645 and 0.9005 
Largest diff. peak and hole 0.511 and -0.328 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  C-H geom, N-H located, C-H riding, N-H isotr. ref. 
Programs used  SUPERFLIP (Palatinus & Chapuis, 2007) 
 SHELXL-97 (Sheldrick, 2008) 
 Daimond 3.2 (Crystal Impact) 
 STOE IPDS2 software  
Data / restraints / parameters 6038 / 0 / 472 
Goodness-of-fit on F2 0.731 
R index (all data) wR2 = 0.0781 
R index conventional  [I>2sigma(I)] R1 = 0.0406 
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Table 6.23. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL1359.  
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C2 0.8809(6) 0.5071(4) 0.1440(3) 0.0372(12) 1 
C3 0.8670(6) 0.5930(4) 0.2063(3) 0.0349(12) 1 
C5 0.8868(6) 0.6919(4) 0.3234(3) 0.0388(13) 1 
C6 0.9170(6) 0.7352(4) 0.4019(3) 0.0455(14) 1 
C7 0.8664(7) 0.8327(4) 0.4353(3) 0.0475(14) 1 
C8 0.7810(7) 0.8905(4) 0.3916(3) 0.0458(13) 1 
C9 0.7443(6) 0.8478(4) 0.3131(3) 0.0418(13) 1 
C10 0.7958(6) 0.7496(4) 0.2783(3) 0.0385(12) 1 
C11 0.7813(6) 0.6832(4) 0.2015(3) 0.0367(12) 1 
C12 0.7156(6) 0.6797(4) 0.1275(3) 0.0387(13) 1 
C13 0.6236(6) 0.7610(4) 0.1013(3) 0.0428(13) 1 
C15 0.6447(6) 0.6175(5) -0.0032(3) 0.0446(13) 1 
C16 0.7260(6) 0.5949(4) 0.0653(3) 0.0379(13) 1 
C17 0.8077(6) 0.5037(4) 0.0698(3) 0.0373(12) 1 
C18 0.8264(6) 0.4128(4) 0.0096(3) 0.0451(13) 1 
C19 0.9085(6) 0.3328(4) 0.0247(3) 0.0468(14) 1 
C20 0.9768(6) 0.3429(4) 0.0989(3) 0.0427(13) 1 
C21 0.6814(8) 1.0626(5) 0.3952(3) 0.0614(17) 1 
C22 0.8379(9) 1.1187(5) 0.3646(4) 0.083(2) 1 
C23 0.6017(10) 1.1406(5) 0.4552(4) 0.089(2) 1 
C24 1.3840(6) 0.6440(4) 0.3475(3) 0.0410(12) 1 
C25 1.3600(6) 0.5848(4) 0.4117(3) 0.0383(12) 1 
C26 1.1761(6) 0.3827(4) 0.4257(3) 0.0402(12) 1 
C27 1.2681(7) 0.3143(4) 0.3643(3) 0.0423(14) 1 
C28 1.3840(6) 0.3428(4) 0.2188(3) 0.0429(13) 1 
C29 1.4668(6) 0.4609(4) 0.2427(3) 0.0413(13) 1 
N1 0.9659(5) 0.4270(3) 0.1582(2) 0.0366(11) 1 
N4 0.9307(5) 0.5969(3) 0.2781(2) 0.0369(10) 1 
N5 0.8212(5) 0.3685(3) 0.2963(3) 0.0442(11) 1 
N6 0.7558(5) 0.3957(3) 0.3550(3) 0.0365(10) 1 
N7 0.6834(5) 0.4192(4) 0.4119(3) 0.0510(12) 1 
N14 0.5883(6) 0.7180(4) 0.0231(3) 0.0493(13) 1 
O8 0.7314(5) 0.9845(3) 0.4342(2) 0.0571(10) 1 
O13 0.5843(4) 0.8455(3) 0.1383(2) 0.0522(10) 1 
O15 0.6266(4) 0.5626(3) -0.0695(2) 0.0527(10) 1 
S1 1.14083(16) 0.51131(11) 0.40486(7) 0.0375(3) 1 
S2 1.18563(16) 0.31027(11) 0.26573(7) 0.0394(3) 1 
S3 1.31211(16) 0.55703(10) 0.25260(7) 0.0383(3) 1 
Ru1 1.05772(6) 0.46219(4) 0.27637(3) 0.03495(13) 1 
O100 0.4320(6) 0.8271(4) -0.0805(3) 0.0845(14) 1 
C101 0.3299(8) 0.8855(5) -0.0891(4) 0.0683(18) 1 
C102 0.2635(12) 0.8890(6) -0.1657(4) 0.118(3) 1 
C103 0.2580(12) 0.9563(7) -0.0232(5) 0.135(3) 1 
O200 0.9429(13) 0.1063(7) 0.8658(6) 0.085(4) 0.545(12) 
C200 0.855(3) 0.0961(16) 0.8171(10) 0.071(5) 0.545(12) 
C20A 0.806(4) 0.068(5) 0.807(3) 0.32(4) 0.455(12) 
C201 0.8016(17) 0.1900(11) 0.7935(11) 0.082(5) 0.545(12) 
C202 0.770(3) -0.0162(18) 0.7759(15) 0.160(12) 0.545(12) 
O201 0.685(2) -0.0580(14) 0.7232(10) 0.125(6) 0.455(12) 
C203 0.751(2) 0.0339(19) 0.7409(13) 0.089(7) 0.455(12) 
C204 0.749(2) 0.099(2) 0.693(2) 0.20(2) 0.455(12) 
___________________________________________________________________________
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Table 6.24. Bond lengths [Å] and angles [°] for FL1359. 
___________________________________________________ 
C2-N1  1.370(6) 
C2-C3  1.386(6) 
C2-C17  1.422(6) 
C3-N4  1.352(6) 
C3-C11  1.437(6) 
C5-C6  1.382(7) 
C5-N4  1.387(6) 
C5-C10  1.454(6) 
C6-C7  1.367(6) 
C6-H6  0.9500 
C7-C8  1.414(6) 
C7-H7  0.9500 
C8-O8  1.376(6) 
C8-C9  1.386(7) 
C9-C10  1.384(6) 
C9-H9  0.9500 
C10-C11  1.426(6) 
C11-C12  1.397(6) 
C12-C16  1.370(6) 
C12-C13  1.503(7) 
C13-O13  1.213(6) 
C13-N14  1.381(6) 
C15-O15  1.219(6) 
C15-N14  1.399(7) 
C15-C16  1.475(7) 
C16-C17  1.428(6) 
C17-C18  1.413(6) 
C18-C19  1.360(6) 
C18-H18  0.9500 
C19-C20  1.391(7) 
C19-H19  0.9500 
C20-N1  1.334(6) 
C20-H20  0.9500 
C21-O8  1.435(6) 
C21-C23  1.502(8) 
C21-C22  1.511(8) 
C21-H21  1.0000 
C22-H22A  0.9800 
C22-H22B  0.9800 
C22-H22C  0.9800 
C23-H23A  0.9800 
C23-H23B  0.9800 
C23-H23C  0.9800 
C24-C25  1.514(6) 
C24-S3  1.820(5) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-S1  1.825(5) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-C27  1.508(6) 
C26-S1  1.822(5) 
C26-H26A  0.9900 
C26-H26B  0.9900 
C27-S2  1.849(5) 
C27-H27A  0.9900 
C27-H27B  0.9900 
C28-C29  1.504(6) 
C28-S2  1.832(5) 
C28-H28A  0.9900 
C28-H28B  0.9900 
C29-S3  1.839(4) 
C29-H29A  0.9900 
C29-H29B  0.9900 
N1-Ru1  2.137(4) 
N4-Ru1  2.109(4) 
N5-N6  1.183(6) 
N5-Ru1  2.143(5) 
N6-N7  1.177(6) 
N14-H14  0.79(5) 
S1-Ru1  2.2863(14) 
S2-Ru1  2.2861(13) 
S3-Ru1  2.2843(15) 
O100-C101  1.206(6) 
C101-C102  1.467(9) 
C101-C103  1.488(9) 
C102-H10A  0.9800 
C102-H10B  0.9800 
C102-H10C  0.9800 
C103-H10D  0.9800 
C103-H10E  0.9800 
C103-H10F  0.9800 
O200-C200  1.072(16) 
C200-C201  1.47(2) 
C200-C202  1.49(3) 
C20A-C203  1.21(4) 
C20A-H201  0.9800 
C20A-H202  0.9800 
C20A-H202  0.9800 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C202-H20D  0.9800 
C202-H20E  0.9800 
C202-H20F  0.9800 
O201-C203  1.17(2) 
C203-C204  1.32(3) 
C204-H20G  0.9800 
C204-H20H  0.9800 



















































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.25. Anisotropic displacement parameters (Å2) for FL1359.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C2 0.039(3)  0.039(3) 0.037(3)  0.014(3) 0.003(2)  0.008(2) 
C3 0.034(3)  0.039(3) 0.036(3)  0.016(3) 0.009(2)  0.008(2) 
C5 0.047(3)  0.030(3) 0.039(3)  0.006(2) 0.009(2)  0.006(2) 
C6 0.053(3)  0.045(3) 0.043(3)  0.015(3) 0.005(3)  0.015(3) 
C7 0.070(4)  0.041(3) 0.036(3)  0.015(3) 0.010(3)  0.014(3) 
C8 0.059(3)  0.035(3) 0.046(4)  0.013(3) 0.006(3)  0.012(3) 
C9 0.052(3)  0.034(3) 0.044(3)  0.020(3) 0.002(3)  0.007(2) 
C10 0.039(3)  0.035(3) 0.046(3)  0.019(3) 0.008(2)  0.008(2) 
C11 0.040(3)  0.028(3) 0.044(3)  0.011(3) 0.002(2)  0.008(2) 
C12 0.038(3)  0.041(3) 0.042(3)  0.017(3) 0.005(2)  0.006(2) 
C13 0.044(3)  0.040(3) 0.046(4)  0.015(3) -0.002(3)  0.004(3) 
C15 0.039(3)  0.052(4) 0.045(4)  0.017(3) 0.000(3)  0.007(3) 
C16 0.039(3)  0.044(3) 0.032(3)  0.012(3) -0.002(2)  0.003(2) 
C17 0.032(3)  0.039(3) 0.041(3)  0.012(3) 0.002(2)  0.004(2) 
C18 0.040(3)  0.048(3) 0.046(3)  0.011(3) 0.001(2)  0.004(3) 
C19 0.051(3)  0.044(3) 0.041(3)  0.002(3) 0.002(3)  0.006(3) 
C20 0.039(3)  0.049(3) 0.039(3)  0.006(3) 0.002(2)  0.008(3) 
C21 0.084(5)  0.040(3) 0.062(4)  0.009(3) -0.015(3)  0.025(3) 
C22 0.119(6)  0.053(4) 0.076(5)  0.027(4) -0.015(4)  -0.001(4) 
C23 0.134(6)  0.061(4) 0.074(5)  -0.002(4) -0.014(4)  0.054(4) 
C24 0.044(3)  0.038(3) 0.039(3)  0.009(2) 0.001(2)  0.001(2) 
C25 0.044(3)  0.037(3) 0.035(3)  0.007(2) -0.005(2)  0.009(2) 
C26 0.045(3)  0.043(3) 0.034(3)  0.012(2) -0.001(2)  0.006(2) 
C27 0.048(3)  0.038(3) 0.043(3)  0.013(3) -0.009(3)  0.009(3) 
C28 0.045(3)  0.047(3) 0.042(3)  0.010(3) 0.004(2)  0.022(3) 
C29 0.041(3)  0.045(3) 0.040(3)  0.010(3) 0.003(2)  0.012(3) 
N1 0.036(2)  0.035(3) 0.041(3)  0.010(2) 0.005(2)  0.010(2) 
N4 0.038(2)  0.035(3) 0.037(3)  0.007(2) 0.005(2)  0.005(2) 
N5 0.049(3)  0.035(3) 0.047(3)  0.007(2) -0.006(2)  0.009(2) 
N6 0.036(2)  0.039(3) 0.035(3)  0.012(2) -0.007(2)  0.0065(19) 
N7 0.050(3)  0.065(3) 0.039(3)  0.013(2) 0.002(2)  0.009(2) 
N14 0.059(3)  0.052(3) 0.044(3)  0.023(3) -0.007(2)  0.015(2) 
O8 0.089(3)  0.043(2) 0.046(2)  0.0119(19) 0.006(2)  0.030(2) 
O13 0.060(2)  0.044(2) 0.056(2)  0.015(2) -0.0051(19)  0.0153(19) 
O15 0.061(2)  0.064(3) 0.034(2)  0.014(2) -0.0073(18)  0.0095(19) 
S1 0.0415(8)  0.0375(8) 0.0356(8)  0.0120(7) 0.0018(6)  0.0080(6) 
S2 0.0418(8)  0.0388(8) 0.0384(8)  0.0083(7) -0.0008(6)  0.0112(6) 
S3 0.0419(8)  0.0386(8) 0.0363(8)  0.0112(6) 0.0024(6)  0.0087(6) 
Ru1 0.0381(3)  0.0352(3) 0.0333(3)  0.0097(2) 0.00177( 9)  0.0090(2) 
O100 0.087(3)  0.092(3) 0.087(3)  0.038(3) -0.011(3)  0.030(3) 
C101 0.069(4)  0.056(4) 0.079(5)  0.020(4) -0.011(4)  0.005(3) 
C102 0.191(9)  0.074(5) 0.090(6)  0.029(5) -0.053(6)  0.021(5) 
C103 0.169(9)  0.093(6) 0.121(8)  -0.013(6) 0.060(6)  0.002(6) 
O200 0.093(8)  0.090(7) 0.073(7)  0.025(5) 0.024(6)  0.011(5) 
C200 0.053(11)  0.112(14) 0.033(8)  -0.001(9) -0.017(7)  -0.006(9) 
C20A 0.057(18)  0.40(7) 0.30(6)  -0.26(5) -0.07(2)  -0.01(3) 
C201 0.053(8)  0.057(8) 0.158(15)  0.054(9) 0.049(9)  0.028(7) 
C202 0.21(2)  0.064(12) 0.18(2)  -0.007(14) -0.13(2)  0.038(13) 
O201 0.150(15)  0.109(13) 0.147(16)  0.059(11) 0.022(11)  0.071(11) 
C203 0.075(12)  0.084(16) 0.087(15)  -0.025(14) -0.028(10)  0.026(12) 
C204 0.032(9)  0.20(3) 0.46(6)  0.28(4) 0.004(18)  -0.001(12) 
_________________________________________________________________________
 245 
Table 6.26. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL1359. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H6 0.9727 0.6974 0.4325 0.055 1 
H7 0.8892 0.8622 0.4891 0.057 1 
H9 0.6846 0.8853 0.2837 0.050 1 
H18 0.7818 0.4076 -0.0412 0.054 1 
H19 0.9190 0.2706 -0.0153 0.056 1 
H20 1.0348 0.2864 0.1079 0.051 1 
H21 0.5947 1.0250 0.3518 0.074 1 
H22A 0.9226 1.1546 0.4074 0.124 1 
H22B 0.8044 1.1734 0.3392 0.124 1 
H22C 0.8881 1.0643 0.3273 0.124 1 
H23A 0.5011 1.1007 0.4733 0.133 1 
H23B 0.5664 1.1977 0.4328 0.133 1 
H23C 0.6856 1.1742 0.4987 0.133 1 
H24A 1.5072 0.6740 0.3473 0.049 1 
H24B 1.3198 0.7064 0.3581 0.049 1 
H25A 1.3834 0.6383 0.4622 0.046 1 
H25B 1.4422 0.5326 0.4079 0.046 1 
H26A 1.2441 0.3987 0.4755 0.048 1 
H26B 1.0636 0.3398 0.4315 0.048 1 
H27A 1.2549 0.2387 0.3713 0.051 1 
H27B 1.3922 0.3445 0.3703 0.051 1 
H28A 1.4672 0.2970 0.2305 0.051 1 
H28B 1.3584 0.3229 0.1623 0.051 1 
H29A 1.5487 0.4762 0.2041 0.050 1 
H29B 1.5331 0.4736 0.2927 0.050 1 
H10A 0.3553 0.8822 -0.2016 0.177 1 
H10B 0.2225 0.9587 -0.1626 0.177 1 
H10C 0.1684 0.8285 -0.1840 0.177 1 
H10D 0.2982 0.9420 0.0252 0.203 1 
H10E 0.1323 0.9403 -0.0286 0.203 1 
H10F 0.2961 1.0334 -0.0227 0.203 1 
H201 0.7233 0.0406 0.8410 0.474 0.455(12) 
H202 0.8232 0.1482 0.8203 0.474 0.455(12) 
H202 0.9154 0.0431 0.8139 0.474 0.455(12) 
H20A 0.8524 0.2579 0.8304 0.123 0.545(12) 
H20B 0.6762 0.1830 0.7921 0.123 0.545(12) 
H20C 0.8408 0.1916 0.7421 0.123 0.545(12) 
H20D 0.8318 -0.0423 0.7300 0.241 0.545(12) 
H20E 0.6509 -0.0143 0.7604 0.241 0.545(12) 
H20F 0.7720 -0.0658 0.8103 0.241 0.545(12) 
H20G 0.6669 0.0627 0.6490 0.304 0.455(12) 
H20H 0.8638 0.1132 0.6743 0.304 0.455(12) 
H20I 0.7143 0.1677 0.7197 0.304 0.455(12) 
H14 0.549(6) 0.748(4) -0.006(3) 0.039(16) 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.28. Hydrogen bonds for FL1359 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N14-H14...O100 0.79(5) 2.12(5) 2.915(6) 177(5) 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  
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Crystal structure of FL626-1. 
   
Table 6.29. Crystal data and structure refinement for FL626-1. 
 
Identification code  fl626-1 
Habitus, colour  prism,  red 
Crystal size 0.09 x 0.06 x 0.06 mm3 
Crystal system  Monoclinic 
Space group  P 21/n Z = 4 
Unit cell dimensions a = 9.2402(8) Å α= 90°. 
 b = 26.2854(16) Å β= 106.154(7)°. 
 c = 15.8451(17) Å γ = 90°. 
Volume 3696.5(6) Å3 
Cell determination  2729 peaks with Theta 1.6 to 22°.
Empirical formula  C33 H35 Cl3 F N5 O6 Ru S3 
Formula weight  920.26 
Density (calculated) 1.654 Mg/m3 
Absorption coefficient 0.867 mm-1 
F(000) 1872 
 
Data collection:  
 
Diffractometer type  IPDS2  
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.55 to 25.00°. 
Index ranges -8<=h<=10, -31<=k<=30, -18<=l<=18 
 Data collection software  STOE WinXpose (X-Area)  
Cell refinement software  STOE WinCell (X-Area)   
Data reduction software  STOE WinIntegrate (X-Area)  
 
Solution and refinement: 
 
Reflections collected 18101 
Independent reflections 6489 [R(int) = 0.2282] 
Completeness to theta = 25.00° 99.8 %  
Observed reflections  1531[I>2(I)]  
Reflections used for refinement  6489 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9544 and 0.9263 
Largest diff. peak and hole 0.389 and -0.315 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, riding model 
Programs used  SIR92 (Giacovazzo et al, 1993) 
 SHELXL-97 (Sheldrick, 2008) 
 Diamond 3.1, STOE IPDS2 software  
Data / restraints / parameters 6489 / 0 / 474 
Goodness-of-fit on F2 0.581 
R index (all data) wR2 = 0.1197 
R index conventional  [I>2sigma(I)] R1 = 0.0539 
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Table 6.30. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL626-1. 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C1 0.2177(16) -0.0392(5) 0.7611(9) 0.046(4) 1 
C2 0.3246(13) -0.0039(5) 0.8082(8) 0.039(3) 1 
C3 0.4348(16) 0.0680(6) 0.8507(8) 0.052(4) 1 
C4 0.4756(16) 0.1181(5) 0.8632(8) 0.054(4) 1 
C5 0.6204(15) 0.1296(5) 0.9242(7) 0.041(3) 1 
C6 0.7119(13) 0.0921(5) 0.9675(8) 0.041(4) 1 
C7 0.6730(16) 0.0420(5) 0.9508(8) 0.046(4) 1 
C8 0.5384(15) 0.0292(5) 0.8976(8) 0.045(4) 1 
C9 0.4613(16) -0.0167(5) 0.8668(9) 0.050(4) 1 
C10 0.4862(15) -0.0698(5) 0.8828(8) 0.049(4) 1 
C11 0.6144(19) -0.0964(6) 0.9390(10) 0.057(4) 1 
C12 0.439(2) -0.1554(5) 0.8711(9) 0.061(4) 1 
C13 0.3799(17) -0.1044(5) 0.8398(9) 0.046(4) 1 
C14 0.2445(16) -0.0919(5) 0.7766(10) 0.048(4) 1 
C15 0.1362(16) -0.1247(5) 0.7282(8) 0.049(4) 1 
C16 0.0096(15) -0.1031(5) 0.6663(9) 0.053(4) 1 
C17 -0.0105(17) -0.0534(5) 0.6523(9) 0.054(4) 1 
C18 0.9515(14) 0.0687(5) 1.0647(8) 0.059(4) 1 
C19 -0.2306(15) 0.0619(6) 0.7456(9) 0.074(4) 1 
C20 -0.2729(14) 0.0787(5) 0.6592(9) 0.064(4) 1 
C21 -0.1486(14) 0.1190(5) 0.5267(8) 0.050(4) 1 
C22 -0.1127(14) 0.1707(4) 0.5707(8) 0.046(4) 1 
C23 0.0472(15) 0.1819(5) 0.6224(8) 0.057(4) 1 
C24 0.0018(15) 0.1684(4) 0.7868(7) 0.047(4) 1 
C25 -0.0086(14) 0.1259(4) 0.8526(8) 0.045(3) 1 
C26 -0.0967(15) 0.2284(4) 0.4483(8) 0.050(4) 1 
C27 -0.2967(16) 0.2402(5) 0.5187(8) 0.045(3) 1 
C28 -0.4940(17) 0.2473(5) 0.5918(9) 0.055(4) 1 
C29 -0.6266(17) 0.2484(5) 0.5156(11) 0.084(5) 1 
C30 -0.5238(19) 0.2112(5) 0.6622(11) 0.085(5) 1 
C31 -0.437(2) 0.2964(6) 0.6362(10) 0.096(6) 1 
C100 0.5864(15) -0.0961(6) 0.6544(9) 0.081(5) 1 
C201 0.273(2) 0.0686(9) 0.5714(11) 0.058(6) 1 
N1 0.0933(15) -0.0195(4) 0.7002(8) 0.053(3) 1 
N2 0.3044(13) 0.0475(4) 0.7974(7) 0.055(3) 1 
N3 0.5809(14) -0.1477(4) 0.9273(7) 0.053(3) 1 
N4 -0.1753(13) 0.2129(4) 0.5125(7) 0.048(3) 1 
N200 0.2154(18) 0.0626(7) 0.6084(9) 0.067(5) 1 
O1 -0.3353(11) 0.2794(3) 0.4748(6) 0.060(3) 1 
O2 -0.3661(11) 0.2201(3) 0.5740(6) 0.060(3) 1 
O4 0.8450(10) 0.1099(3) 1.0234(6) 0.066(3) 1 
O5 0.7303(12) -0.0792(3) 0.9881(6) 0.060(3) 1 
O6 0.3821(11) -0.1984(4) 0.8484(6) 0.069(3) 1 
O200 0.3721(14) 0.0776(6) 0.5206(8) 0.142(6) 1 
F1 -0.0965(8) -0.1341(2) 0.6178(5) 0.063(2) 1 
S1 -0.0322(4) 0.06281(15) 0.8073(2) 0.0497(9) 1 
S2 -0.1294(4) 0.06492(14) 0.5979(2) 0.0549(9) 1 
S3 0.1259(4) 0.14796(12) 0.7220(2) 0.0503(10) 1 
Ru1 0.09698(13) 0.06189(4) 0.70318(7) 0.0426(3) 1 
Cl1 0.4499(5) -0.04729(13) 0.6293(3) 0.0745(12) 1 
Cl2 0.4928(5) -0.15697(14) 0.6581(3) 0.0756(11) 1 
Cl3 0.7187(4) -0.08713(15) 0.7524(2) 0.0720(12) 1 
___________________________________________________________________________
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Table 6.31. Bond lengths [Å] and angles [°] for FL626-1. 
___________________________________________________ 
C1-N1  1.380(15) 
C1-C2  1.410(16) 
C1-C14  1.416(15) 
C2-N2  1.368(14) 
C2-C9  1.386(16) 
C3-C4  1.369(17) 
C3-N2  1.374(15) 
C3-C8  1.453(17) 
C4-C5  1.447(16) 
C4-H4  0.9500 
C5-C6  1.354(16) 
C5-H5  0.9500 
C6-C7  1.373(15) 
C6-O4  1.382(13) 
C7-C8  1.337(17) 
C7-H7  0.9500 
C8-C9  1.416(17) 
C9-C10  1.426(17) 
C10-C13  1.373(18) 
C10-C11  1.448(19) 
C11-O5  1.222(14) 
C11-N3  1.383(17) 
C12-O6  1.257(15) 
C12-N3  1.378(17) 
C12-C13  1.480(18) 
C13-C14  1.406(18) 
C14-C15  1.380(17) 
C15-C16  1.419(16) 
C15-H15  0.9500 
C16-C17  1.329(16) 
C16-F1  1.339(13) 
C17-N1  1.374(16) 
C17-H17  0.9500 
C18-O4  1.486(13) 
C18-H18A  0.9800 
C18-H18B  0.9800 
C18-H18C  0.9800 
C19-C20  1.388(15) 
C19-S1  1.822(13) 
C19-H19A  0.9900 
C19-H19B  0.9900 
C20-S2  1.884(13) 
C20-H20A  0.9900 
C20-H20B  0.9900 
C21-C22  1.521(15) 
C21-S2  1.793(12) 
C21-H21A  0.9900 
C21-H21B  0.9900 
C22-N4  1.456(13) 
C22-C23  1.505(15) 
C22-H22  1.0000 
C23-S3  1.782(12) 
C23-H23A  0.9900 
C23-H23B  0.9900 
C24-C25  1.549(14) 
C24-S3  1.820(13) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-S1  1.797(11) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-N4  1.463(15) 
C26-H26A  0.9800 
C26-H26B  0.9800 
C26-H26C  0.9800 
C27-O1  1.239(14) 
C27-O2  1.332(14) 
C27-N4  1.358(16) 
C28-C29  1.462(18) 
C28-O2  1.475(16) 
C28-C31  1.494(18) 
C28-C30  1.547(18) 
C29-H29A  0.9800 
C29-H29B  0.9800 
C29-H29C  0.9800 
C30-H30A  0.9800 
C30-H30B  0.9800 
C30-H30C  0.9800 
C31-H31A  0.9800 
C31-H31B  0.9800 
C31-H31C  0.9800 
C100-Cl3  1.704(14) 
C100-Cl1  1.766(14) 
C100-Cl2  1.827(16) 
C100-H100  1.0000 
C201-N200  0.910(18) 
C201-O200  1.395(19) 
N1-Ru1  2.140(10) 
N2-Ru1  2.110(11) 
N3-H3  0.8800 
N200-Ru1  2.090(15) 
S1-Ru1  2.290(4) 
S2-Ru1  2.285(3) 























































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.32. Anisotropic displacement parameters (Å2) for FL626-1.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C1 0.037(9)  0.036(8) 0.059(9)  0.016(7) 0.001(7)  0.000(7) 
C2 0.017(8)  0.051(8) 0.049(8)  0.015(7) 0.011(6)  0.018(7) 
C3 0.042(9)  0.061(10) 0.052(8)  -0.007(9) 0.013(7)  -0.004(9) 
C4 0.042(10)  0.059(10) 0.056(9)  0.013(8) 0.005(7)  -0.002(8) 
C5 0.054(10)  0.037(7) 0.044(8)  -0.001(6) 0.035(7)  0.009(7) 
C6 0.010(7)  0.064(10) 0.045(8)  -0.014(7) 0.002(6)  -0.018(7) 
C7 0.040(9)  0.044(8) 0.046(8)  -0.009(7) -0.001(7)  -0.004(7) 
C8 0.028(8)  0.073(10) 0.034(8)  0.006(7) 0.007(6)  0.010(8) 
C9 0.049(10)  0.037(8) 0.068(10)  0.001(7) 0.024(8)  0.013(7) 
C10 0.035(8)  0.055(10) 0.055(8)  0.011(8) 0.012(7)  0.009(8) 
C11 0.065(12)  0.061(11) 0.054(10)  -0.016(8) 0.033(9)  -0.002(9) 
C12 0.105(15)  0.043(9) 0.052(10)  0.001(8) 0.049(10)  -0.003(10) 
C13 0.047(10)  0.041(8) 0.062(9)  0.004(8) 0.032(8)  0.011(8) 
C14 0.028(9)  0.031(8) 0.091(11)  0.000(8) 0.025(8)  -0.002(7) 
C15 0.050(10)  0.046(8) 0.062(10)  0.011(7) 0.036(8)  0.012(8) 
C16 0.034(9)  0.047(8) 0.070(10)  -0.020(8) 0.004(7)  -0.003(8) 
C17 0.069(10)  0.034(8) 0.070(9)  0.001(8) 0.037(8)  0.006(8) 
C18 0.050(9)  0.048(8) 0.062(8)  0.005(8) -0.014(7)  0.019(8) 
C19 0.056(10)  0.066(9) 0.099(12)  -0.021(11) 0.022(9)  -0.017(10) 
C20 0.036(9)  0.065(10) 0.089(11)  0.044(8) 0.015(8)  0.013(7) 
C21 0.033(9)  0.081(11) 0.037(7)  -0.005(7) 0.009(6)  0.002(7) 
C22 0.027(8)  0.040(7) 0.061(9)  0.013(7) -0.009(7)  0.007(6) 
C23 0.049(10)  0.050(8) 0.075(10)  -0.005(7) 0.022(8)  0.004(8) 
C24 0.055(10)  0.037(7) 0.046(8)  0.013(6) 0.009(7)  0.003(7) 
C25 0.031(8)  0.063(8) 0.043(8)  -0.015(7) 0.014(6)  0.012(7) 
C26 0.066(11)  0.035(7) 0.053(9)  0.011(6) 0.022(8)  0.007(7) 
C27 0.032(9)  0.048(9) 0.046(9)  0.001(7) -0.003(7)  -0.008(8) 
C28 0.050(11)  0.052(9) 0.065(10)  0.003(8) 0.020(8)  -0.002(8) 
C29 0.056(12)  0.064(10) 0.128(14)  0.015(10) 0.021(10)  0.014(9) 
C30 0.058(11)  0.077(11) 0.135(15)  0.019(11) 0.048(11)  0.002(10) 
C31 0.105(16)  0.096(14) 0.102(14)  -0.003(11) 0.055(12)  0.007(12) 
C100 0.039(10)  0.123(14) 0.083(11)  0.006(10) 0.022(9)  0.020(10) 
C201 0.070(15)  0.062(12) 0.037(11)  0.008(10) 0.007(8)  0.024(12) 
N1 0.043(8)  0.050(7) 0.065(8)  0.000(7) 0.010(6)  0.003(7) 
N2 0.048(8)  0.027(6) 0.089(9)  0.004(6) 0.016(7)  0.007(5) 
N3 0.056(9)  0.043(7) 0.059(8)  0.021(6) 0.012(6)  0.023(7) 
N4 0.043(8)  0.036(7) 0.053(8)  0.005(5) -0.006(6)  0.004(6) 
N200 0.066(12)  0.037(7) 0.080(12)  0.002(10) -0.009(8)  0.007(9) 
O1 0.051(7)  0.025(5) 0.088(7)  -0.001(5) -0.010(5)  0.011(5) 
O2 0.041(6)  0.044(6) 0.097(8)  -0.004(5) 0.024(6)  0.001(5) 
O4 0.040(7)  0.058(6) 0.092(7)  0.007(6) 0.004(5)  -0.011(6) 
O5 0.069(7)  0.062(7) 0.055(6)  0.019(5) 0.026(5)  0.029(6) 
O6 0.071(8)  0.051(6) 0.089(7)  0.014(6) 0.029(6)  0.004(6) 
O200 0.076(10)  0.225(18) 0.118(10)  0.051(11) 0.017(8)  0.052(11) 
F1 0.053(5)  0.040(4) 0.082(5)  -0.009(4) -0.005(4)  -0.006(4) 
S1 0.038(2)  0.0402(19) 0.073(2)  -0.008(2) 0.0179(8)  0.0028(19) 
S2 0.046(2)  0.0364(18) 0.073(2)  0.003(2) 0.0006(18)  -0.001(2) 
S3 0.037(2)  0.0347(18) 0.068(3)  0.0039(18) -0.0037(19)  -0.0014(17) 
Ru1 0.0347(7)  0.0330(6) 0.0573(7)  0.0057(7) 0.0082(5)  0.0034(7) 
Cl1 0.061(3)  0.056(2) 0.098(3)  -0.005(2) 0.008(2)  0.0010(19) 
Cl2 0.061(3)  0.068(2) 0.095(3)  -0.007(2) 0.017(2)  -0.004(2) 
Cl3 0.053(3)  0.092(3) 0.071(3)  -0.009(2) 0.016(2)  -0.007(2) 
_________________________________________________________________________
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Table 6.33. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL626-1. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H4 0.4112 0.1444 0.8330 0.065 1 
H5 0.6517 0.1640 0.9339 0.049 1 
H7 0.7426 0.0161 0.9773 0.055 1 
H15 0.1460 -0.1605 0.7361 0.058 1 
H17 -0.0968 -0.0414 0.6090 0.065 1 
H18A 0.9132 0.0509 1.1084 0.089 1 
H18B 1.0503 0.0834 1.0934 0.089 1 
H18C 0.9611 0.0446 1.0194 0.089 1 
H19A -0.2666 0.0264 0.7458 0.089 1 
H19B -0.2860 0.0826 0.7786 0.089 1 
H20A -0.2903 0.1159 0.6588 0.077 1 
H20B -0.3693 0.0623 0.6279 0.077 1 
H21A -0.0820 0.1139 0.4881 0.060 1 
H21B -0.2535 0.1199 0.4885 0.060 1 
H22 -0.1702 0.1712 0.6156 0.056 1 
H23A 0.0538 0.2186 0.6366 0.069 1 
H23B 0.1123 0.1757 0.5833 0.069 1 
H24A 0.0416 0.1999 0.8192 0.056 1 
H24B -0.0997 0.1758 0.7475 0.056 1 
H25A -0.0944 0.1336 0.8765 0.054 1 
H25B 0.0843 0.1267 0.9022 0.054 1 
H26A -0.1689 0.2436 0.3971 0.075 1 
H26B -0.0495 0.1986 0.4298 0.075 1 
H26C -0.0189 0.2535 0.4750 0.075 1 
H29A -0.6064 0.2703 0.4700 0.125 1 
H29B -0.7128 0.2619 0.5331 0.125 1 
H29C -0.6494 0.2139 0.4925 0.125 1 
H30A -0.5362 0.1763 0.6394 0.128 1 
H30B -0.6157 0.2218 0.6767 0.128 1 
H30C -0.4384 0.2125 0.7152 0.128 1 
H31A -0.3320 0.2923 0.6711 0.143 1 
H31B -0.4987 0.3063 0.6748 0.143 1 
H31C -0.4431 0.3229 0.5917 0.143 1 
H100 0.6382 -0.0976 0.6068 0.097 1 
H3 0.6424 -0.1723 0.9526 0.064 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.35. Hydrogen bonds for FL626-1 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N3-H3...O1#1 0.88 2.23 3.094(14) 167.2 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  
#1 -x+1/2,y-1/2,-z+3/2      
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Crystal structure of FL1473. 
      
Table 6.36. Crystal data and structure refinement for FL1473. 
 
Identification code  fl1473 
Habitus, colour  plate,  red 
Crystal size 0.30 x 0.12 x 0.03 mm3 
Crystal system  Triclinic 
Space group  P1 Z = 2 
Unit cell dimensions a = 7.8245(5) Å α= 103.037(6)°. 
 b = 12.9163(9) Å β= 92.371(6)°. 
 c = 18.1901(13) Å γ = 98.690(5)°. 
Volume 1765.0(2) Å3 
Cell determination  11100 peaks with Theta 1.6 to 25°.
Empirical formula  C31.50 H39 N7 O5 Ru S2 
Formula weight  760.89 
Density (calculated) 1.432 Mg/m3 
Absorption coefficient 0.611 mm-1 
F(000) 786 
 
Data collection:  
 
Diffractometer type  STOE IPDS2 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.64 to 25.00°. 
Index ranges -9<=h<=9, -15<=k<=15, -21<=l<=21 
Data collection software  STOE X-AREA 
Cell refinement software  STOE X-AREA 
Data reduction software  STOE X-AREA 
 
Solution and refinement: 
 
Reflections collected 13673 
Independent reflections 6203 [R(int) = 0.0638] 
Completeness to theta = 25.00° 99.7 %  
Observed reflections  4022[I>2(I)]  
Reflections used for refinement  6203 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9876 and 0.8903 
Largest diff. peak and hole 0.775 and -0.731 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH calc., riding, NH located, isotr. ref. 
Programs used  SIR92 (Giacovazzo et al, 1993) 
 SHELXL-97 (Sheldrick, 2008) 
 DIAMOND 3.2 (Crystal Impcat) 
STOE IPDS2 software  
Data / restraints / parameters 6203 / 25 / 461 
Goodness-of-fit on F2 0.862 
R index (all data) wR2 = 0.1043 
R index conventional  [I>2sigma(I)] R1 = 0.0459 
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Table 6.37. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL1473.   
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C2 0.3795(6) 0.5145(4) 0.6495(3) 0.0323(11) 1 
C3 0.3665(6) 0.6007(4) 0.7122(3) 0.0301(11) 1 
C5 0.3845(6) 0.6971(4) 0.8274(3) 0.0334(11) 1 
C6 0.4143(6) 0.7372(4) 0.9052(3) 0.0377(12) 1 
C7 0.3598(7) 0.8333(4) 0.9371(3) 0.0452(13) 1 
C8 0.2765(7) 0.8902(4) 0.8933(3) 0.0431(13) 1 
C9 0.2441(6) 0.8515(4) 0.8155(3) 0.0378(12) 1 
C10 0.2971(6) 0.7542(4) 0.7825(3) 0.0308(11) 1 
C11 0.2847(6) 0.6900(4) 0.7059(3) 0.0307(11) 1 
C12 0.2176(6) 0.6888(4) 0.6333(3) 0.0324(11) 1 
C13 0.1245(6) 0.7664(4) 0.6067(3) 0.0387(12) 1 
C15 0.1430(6) 0.6263(4) 0.5041(3) 0.0413(12) 1 
C16 0.2277(6) 0.6046(4) 0.5719(3) 0.0344(11) 1 
C17 0.3077(6) 0.5147(4) 0.5773(3) 0.0341(11) 1 
C18 0.3232(6) 0.4239(4) 0.5176(3) 0.0418(13) 1 
C19 0.4063(6) 0.3457(4) 0.5341(3) 0.0414(13) 1 
C20 0.4733(6) 0.3535(4) 0.6077(3) 0.0376(12) 1 
C21 0.1805(9) 1.0612(5) 0.8950(4) 0.0636(17) 1 
C22 0.3421(10) 1.1186(5) 0.8640(5) 0.086(2) 1 
C23 0.1045(10) 1.1396(5) 0.9535(4) 0.077(2) 1 
C24 0.7650(6) 0.3189(4) 0.8657(3) 0.0395(13) 1 
C25 0.6717(6) 0.3821(4) 0.9272(3) 0.0372(12) 1 
C26 0.8433(6) 0.5885(4) 0.9152(3) 0.0344(11) 1 
C27 0.8580(6) 0.6374(4) 0.8471(3) 0.0364(11) 1 
C29 0.9446(6) 0.4813(4) 0.7621(3) 0.0375(12) 1 
C30 0.8694(6) 0.3635(4) 0.7269(3) 0.0395(12) 1 
C31 0.8058(6) 0.6099(4) 0.7127(3) 0.0411(12) 1 
N1 0.4653(5) 0.4366(3) 0.6660(2) 0.0329(10) 1 
N4 0.4284(5) 0.6029(3) 0.7825(2) 0.0311(10) 1 
N5 0.3067(5) 0.3786(3) 0.7955(2) 0.0369(10) 1 
N6 0.2456(5) 0.3991(3) 0.8555(3) 0.0359(10) 1 
N7 0.1798(5) 0.4168(4) 0.9126(2) 0.0455(11) 1 
N14 0.0846(6) 0.7259(4) 0.5293(3) 0.0441(11) 1 
N28 0.8061(5) 0.5544(3) 0.7721(2) 0.0330(9) 1 
O1 0.0851(5) 0.8504(3) 0.6433(2) 0.0498(9) 1 
O2 0.1227(5) 0.5746(3) 0.4395(2) 0.0484(9) 1 
O3 0.2304(5) 0.9846(3) 0.9342(2) 0.0525(10) 1 
S1 0.67704(16) 0.31788(11) 0.77051(8) 0.0381(3) 1 
S2 0.62603(15) 0.50928(10) 0.90970(7) 0.0329(3) 1 
Ru1 0.55005(5) 0.46766(4) 0.78292(3) 0.02997(13) 1 
O100 -0.0548(15) 0.8326(7) 0.4251(6) 0.147(5) 0.75 
C100 -0.124(2) 0.8779(7) 0.3974(6) 0.109(5) 0.75 
C101 -0.236(3) 0.9267(14) 0.4492(13) 0.266(16) 0.75 
C102 -0.1464(18) 0.8802(7) 0.3226(6) 0.102(4) 0.75 
O200 -0.2305(17) 1.0662(8) 0.7744(7) 0.166(5) 0.75 
C201 -0.3400(13) 0.8967(9) 0.6837(8) 0.102(4) 0.75 
C200 -0.2741(15) 0.9682(10) 0.7630(9) 0.104(4) 0.75 
C202 -0.2544(14) 0.9216(9) 0.8272(9) 0.112(5) 0.75 
O300 -0.525(4) 0.895(2) 0.574(2) 0.176(16) 0.25 
O400 -0.660(4) 0.888(3) 0.3957(17) 0.149(11) 0.25 
___________________________________________________________________________
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Table 6.38. Bond lengths [Å] and angles [°] for FL1473. 
___________________________________________________ 
C2-N1  1.369(6) 
C2-C17  1.409(7) 
C2-C3  1.422(7) 
C3-N4  1.341(6) 
C3-C11  1.425(6) 
C5-C6  1.390(7) 
C5-N4  1.402(6) 
C5-C10  1.433(7) 
C6-C7  1.384(7) 
C6-H6  0.9500 
C7-C8  1.401(7) 
C7-H7  0.9500 
C8-O3  1.385(6) 
C8-C9  1.389(7) 
C9-C10  1.396(6) 
C9-H9  0.9500 
C10-C11  1.443(7) 
C11-C12  1.395(7) 
C12-C16  1.386(7) 
C12-C13  1.477(7) 
C13-O1  1.228(6) 
C13-N14  1.392(7) 
C15-O2  1.204(6) 
C15-N14  1.416(7) 
C15-C16  1.478(7) 
C16-C17  1.420(7) 
C17-C18  1.430(7) 
C18-C19  1.362(7) 
C18-H18  0.9500 
C19-C20  1.395(7) 
C19-H19  0.9500 
C20-N1  1.338(6) 
C20-H20  0.9500 
C21-O3  1.432(7) 
C21-C23  1.504(8) 
C21-C22  1.558(10) 
C21-H21  1.0000 
C22-H22A  0.9800 
C22-H22B  0.9800 
C22-H22C  0.9800 
C23-H23A  0.9800 
C23-H23B  0.9800 
C23-H23C  0.9800 
C24-C25  1.513(7) 
C24-S1  1.833(5) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-S2  1.825(5) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-C27  1.513(7) 
C26-S2  1.834(5) 
C26-H26A  0.9900 
C26-H26B  0.9900 
C27-N28  1.529(6) 
C27-H27A  0.9900 
C27-H27B  0.9900 
C29-C30  1.526(7) 
C29-N28  1.533(6) 
C29-H29A  0.9900 
C29-H29B  0.9900 
C30-S1  1.812(5) 
C30-H30A  0.9900 
C30-H30B  0.9900 
C31-N28  1.424(6) 
C31-H31A  0.9800 
C31-H31B  0.9800 
C31-H31C  0.9800 
N1-Ru1  2.132(4) 
N4-Ru1  2.113(4) 
N5-N6  1.200(6) 
N5-Ru1  2.120(4) 
N6-N7  1.170(6) 
N14-H14  1.07(7) 
N28-Ru1  2.183(4) 
S1-Ru1  2.2767(14) 
S2-Ru1  2.2785(14) 
O100-C100  1.048(13) 
C100-C102  1.371(12) 
C100-C101  1.423(17) 
C101-H10A  0.9800 
C101-H10B  0.9800 
C101-H10C  0.9800 
C102-H10D  0.9800 
C102-H10E  0.9800 
C102-H10F  0.9800 
O200-C200  1.228(14) 
C201-C200  1.548(18) 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C200-C202  1.441(17) 
C202-H20D  0.9800 
C202-H20E  0.9800 







































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.39. Anisotropic displacement parameters (Å2) for FL1473.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C2 0.026(3)  0.040(3) 0.034(3)  0.012(2) 0.008(2)  0.008(2) 
C3 0.025(2)  0.038(3) 0.030(3)  0.013(2) 0.004(2)  0.007(2) 
C5 0.030(3)  0.031(3) 0.038(3)  0.006(2) 0.005(2)  0.003(2) 
C6 0.041(3)  0.048(3) 0.026(3)  0.008(2) 0.002(2)  0.017(2) 
C7 0.057(3)  0.047(3) 0.036(3)  0.010(3) 0.002(3)  0.020(3) 
C8 0.056(3)  0.036(3) 0.038(3)  0.004(2) 0.006(3)  0.016(2) 
C9 0.035(3)  0.040(3) 0.042(3)  0.015(2) 0.004(2)  0.011(2) 
C10 0.027(2)  0.036(3) 0.034(3)  0.013(2) 0.007(2)  0.008(2) 
C11 0.027(2)  0.034(3) 0.036(3)  0.013(2) 0.005(2)  0.010(2) 
C12 0.031(3)  0.039(3) 0.030(3)  0.011(2) 0.004(2)  0.009(2) 
C13 0.038(3)  0.040(3) 0.039(3)  0.013(3) -0.001(2)  0.005(2) 
C15 0.036(3)  0.049(3) 0.040(3)  0.010(3) 0.006(2)  0.008(2) 
C16 0.029(2)  0.046(3) 0.030(3)  0.012(2) 0.003(2)  0.008(2) 
C17 0.029(2)  0.039(3) 0.035(3)  0.008(2) 0.006(2)  0.007(2) 
C18 0.037(3)  0.056(3) 0.031(3)  0.008(3) 0.002(2)  0.006(2) 
C19 0.037(3)  0.043(3) 0.042(3)  0.001(3) 0.005(2)  0.010(2) 
C20 0.033(3)  0.042(3) 0.038(3)  0.004(2) 0.004(2)  0.013(2) 
C21 0.088(5)  0.051(3) 0.056(4)  0.008(3) -0.011(3)  0.033(3) 
C22 0.105(6)  0.054(4) 0.094(6)  0.027(4) -0.028(5)  -0.007(4) 
C23 0.112(6)  0.056(4) 0.059(4)  -0.015(3) -0.022(4)  0.050(4) 
C24 0.030(3)  0.044(3) 0.043(3)  0.007(3) -0.004(2)  0.009(2) 
C25 0.036(3)  0.039(3) 0.038(3)  0.012(2) 0.003(2)  0.007(2) 
C26 0.036(3)  0.033(2) 0.035(3)  0.008(2) 0.002(2)  0.009(2) 
C27 0.031(3)  0.043(3) 0.036(3)  0.008(2) 0.006(2)  0.010(2) 
C29 0.028(2)  0.048(3) 0.041(3)  0.013(2) 0.004(2)  0.015(2) 
C30 0.037(3)  0.050(3) 0.038(3)  0.013(2) 0.011(2)  0.020(2) 
C31 0.038(3)  0.049(3) 0.038(3)  0.009(3) 0.007(2)  0.014(2) 
N1 0.028(2)  0.041(2) 0.032(2)  0.009(2) 0.0031(18)  0.0110(19) 
N4 0.032(2)  0.034(2) 0.029(2)  0.0078(19) 0.0053(18)  0.0082(18) 
N5 0.033(2)  0.040(2) 0.038(3)  0.007(2) 0.0021(19)  0.0069(18) 
N6 0.026(2)  0.037(2) 0.046(3)  0.015(2) -0.006(2)  0.0031(17) 
N7 0.035(2)  0.071(3) 0.031(2)  0.016(2) 0.002(2)  0.006(2) 
N14 0.051(3)  0.050(3) 0.035(3)  0.015(2) -0.006(2)  0.014(2) 
N28 0.027(2)  0.033(2) 0.037(2)  0.0001(19) 0.0007(17)  0.0110(17) 
O1 0.064(3)  0.045(2) 0.043(2)  0.0122(19) -0.0056(19)  0.0175(19) 
O2 0.050(2)  0.061(2) 0.031(2)  0.0033(18) 0.0000(17)  0.0124(18) 
O3 0.078(3)  0.042(2) 0.041(2)  0.0038(17) 0.0015(19)  0.034(2) 
S1 0.0344(7)  0.0410(7) 0.0402(8)  0.0082(6) 0.0014(6)  0.0126(6) 
S2 0.0297(6)  0.0378(7) 0.0332(7)  0.0098(6) 0.0035(5)  0.0095(5) 
Ru1 0.0256(2)  0.0347(2) 0.0305(2)  0.00634(17) 0.00306(15)  0.00935(15) 
O100 0.229(11)  0.085(5) 0.130(8)  0.059(6) -0.111(8)  0.017(6) 
C100 0.226(15)  0.027(5) 0.053(6)  0.013(5) -0.058(8)  -0.031(7) 
C101 0.35(3)  0.137(16) 0.23(2)  -0.025(16) 0.14(2)  -0.15(2) 
C102 0.195(13)  0.039(5) 0.071(7)  0.016(5) -0.008(8)  0.019(6) 
O200 0.255(13)  0.091(6) 0.181(11)  0.050(7) 0.075(10)  0.071(7) 
C201 0.062(6)  0.090(8) 0.140(11)  0.006(8) 0.035(7)  -0.003(6) 
C200 0.089(8)  0.072(7) 0.171(14)  0.047(9) 0.046(8)  0.038(6) 
C202 0.067(7)  0.073(7) 0.209(15)  0.066(9) 0.013(8)  0.007(5) 
O300 0.17(2)  0.16(2) 0.31(4)  0.19(3) 0.20(3)  0.14(2) 
O400 0.17(3)  0.17(3) 0.11(2)  0.006(19) 0.001(19)  0.10(2) 
_________________________________________________________________________
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Table 6.40. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL1473. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H6 0.4705 0.6996 0.9357 0.045 1 
H7 0.3794 0.8615 0.9902 0.054 1 
H9 0.1877 0.8899 0.7858 0.045 1 
H18 0.2764 0.4184 0.4676 0.050 1 
H19 0.4188 0.2852 0.4950 0.050 1 
H20 0.5280 0.2964 0.6172 0.045 1 
H21 0.0911 1.0245 0.8525 0.076 1 
H22A 0.4267 1.1566 0.9063 0.129 1 
H22B 0.3064 1.1703 0.8370 0.129 1 
H22C 0.3949 1.0649 0.8294 0.129 1 
H23A 0.0024 1.1017 0.9715 0.116 1 
H23B 0.0705 1.1964 0.9310 0.116 1 
H23C 0.1911 1.1719 0.9962 0.116 1 
H24A 0.7556 0.2438 0.8713 0.047 1 
H24B 0.8895 0.3508 0.8719 0.047 1 
H25A 0.7432 0.3973 0.9758 0.045 1 
H25B 0.5609 0.3370 0.9326 0.045 1 
H26A 0.8629 0.6463 0.9623 0.041 1 
H26B 0.9322 0.5416 0.9160 0.041 1 
H27A 0.9791 0.6729 0.8467 0.044 1 
H27B 0.7829 0.6934 0.8518 0.044 1 
H29A 1.0317 0.5069 0.7295 0.045 1 
H29B 1.0047 0.4866 0.8121 0.045 1 
H30A 0.9582 0.3182 0.7325 0.047 1 
H30B 0.8401 0.3545 0.6721 0.047 1 
H31A 0.7099 0.6511 0.7169 0.062 1 
H31B 0.7914 0.5575 0.6637 0.062 1 
H31C 0.9159 0.6590 0.7165 0.062 1 
H10A -0.2811 0.8766 0.4797 0.399 0.75 
H10B -0.3330 0.9443 0.4211 0.399 0.75 
H10C -0.1717 0.9927 0.4825 0.399 0.75 
H10D -0.0348 0.8800 0.3001 0.153 0.75 
H10E -0.1919 0.9455 0.3187 0.153 0.75 
H10F -0.2286 0.8166 0.2957 0.153 0.75 
H20A -0.3785 0.9415 0.6515 0.153 0.75 
H20B -0.4373 0.8417 0.6884 0.153 0.75 
H20C -0.2459 0.8615 0.6609 0.153 0.75 
H20D -0.1789 0.8670 0.8156 0.168 0.75 
H20E -0.3683 0.8881 0.8383 0.168 0.75 
H20F -0.2025 0.9782 0.8713 0.168 0.75 
H14 0.040(8) 0.771(5) 0.492(4) 0.07(2) 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.42. Hydrogen bonds for FL1473 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N14-H14...O100 1.07(7) 1.79(7) 2.852(9) 173(5) 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  
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Crystal structure of FL1528-1. 
      
Table 6.43. Crystal data and structure refinement for FL1528-1. 
 
Identification code  fl1528-1 
Habitus, colour  prism,  colourless 
Crystal size 0.33 x 0.06 x 0.04 mm3 
Crystal system  Triclinic 
Space group  P 1 Z = 2 
Unit cell dimensions a = 7.9971(19) Å α= 74.807(19)°. 
 b = 13.072(3) Å β= 89.225(19)°. 
 c = 17.991(4) Å γ = 78.37(2)°. 
Volume 1776.1(7) Å3 
Cell determination  3421 peaks with Theta 1.6 to 23°.
Empirical formula  C32 H39 N8 O6 Ru S3 
Formula weight  828.96 
Density (calculated) 1.550 Mg/m3 
Absorption coefficient 0.673 mm-1 
F(000) 854 
 
Data collection:  
 
Diffractometer type  STOE IPDS 2 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.65 to 25.00°. 
Index ranges -9<=h<=9, -15<=k<=15, -21<=l<=18 
Data collection software  STOE X-AREA 
Cell refinement software  STOE X-AREA 
Data reduction software  STOE X-AREA 
 
Solution and refinement: 
 
Reflections collected 12663 
Independent reflections 6223 [R(int) = 0.2069] 
Completeness to theta = 25.00° 99.4 %  
Observed reflections  1513[I>2(I)]  
Reflections used for refinement  6223 
Absorption correction Integration 
Max. and min. transmission 0.9855 and 0.8708 
Largest diff. peak and hole 0.635 and -0.720 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, riding model 
Programs used  SIR2008 (Giacovazzo et al, 2008) 
 SHELXL-97 (Sheldrick, 2008) 
 DIAMOND 3.2 (Crystal Impcat) 
 STOE IPDS2 software  
Data / restraints / parameters 6223 / 149 / 457 
Goodness-of-fit on F2 0.650 
R index (all data) wR2 = 0.1423 
R index conventional  [I>2sigma(I)] R1 = 0.0650 
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Table 6.44. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL1528-1.   
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C2 0.6157(16) 0.5051(13) 0.3510(8) 0.041(3) 1 
C3 0.6238(16) 0.5911(12) 0.2898(7) 0.038(3) 1 
C5 0.6005(14) 0.6910(12) 0.1707(7) 0.036(3) 1 
C6 0.5722(16) 0.7417(13) 0.0929(8) 0.052(4) 1 
C7 0.6195(16) 0.8366(12) 0.0591(8) 0.049(4) 1 
C8 0.6988(16) 0.8903(12) 0.1051(8) 0.044(4) 1 
C9 0.7345(16) 0.8449(13) 0.1839(7) 0.048(4) 1 
C10 0.6824(14) 0.7499(11) 0.2158(7) 0.036(3) 1 
C11 0.6982(15) 0.6805(12) 0.2907(8) 0.042(4) 1 
C12 0.7586(16) 0.6740(13) 0.3687(8) 0.044(4) 1 
C13 0.8479(17) 0.7523(13) 0.3930(8) 0.049(4) 1 
C15 0.8314(17) 0.6103(13) 0.4985(8) 0.049(4) 1 
C16 0.7559(17) 0.5864(13) 0.4291(8) 0.047(4) 1 
C17 0.6863(15) 0.4980(12) 0.4238(7) 0.043(4) 1 
C18 0.6682(15) 0.4069(12) 0.4865(8) 0.046(4) 1 
C19 0.5917(16) 0.3258(13) 0.4730(7) 0.047(4) 1 
C20 0.5283(16) 0.3345(12) 0.3991(7) 0.041(4) 1 
C21 0.8115(19) 1.0542(13) 0.0998(9) 0.066(4) 1 
C22 0.668(2) 1.1135(15) 0.1396(9) 0.087(6) 1 
C23 0.892(2) 1.1271(15) 0.0404(9) 0.087(6) 1 
C24 0.0344(14) 0.4702(12) 0.2628(8) 0.049(4) 1 
C25 0.1258(14) 0.3510(11) 0.2847(7) 0.042(3) 1 
C26 0.1126(15) 0.6551(12) 0.1514(7) 0.051(3) 1 
C27 0.1360(15) 0.5945(11) 0.0892(7) 0.050(3) 1 
C28 0.2433(19) 0.3275(14) 0.1364(7) 0.057(4) 1 
C29 0.3306(16) 0.3908(12) 0.0747(7) 0.044(3) 1 
C300 0.607(2) 0.0611(17) 0.6763(11) 0.099(7) 1 
C301 0.7370(18) 0.1846(14) 0.7188(11) 0.078(5) 1 
C302 0.719(2) 0.0141(17) 0.8040(10) 0.118(9) 1 
N1 0.5341(14) 0.4242(11) 0.3404(6) 0.048(3) 1 
N4 0.5606(14) 0.5969(11) 0.2153(6) 0.044(3) 1 
N14 0.8783(13) 0.7074(10) 0.4714(6) 0.052(3) 1 
N101 0.6868(14) 0.3733(10) 0.2002(7) 0.051(3) 1 
N102 0.7543(12) 0.4004(10) 0.1433(6) 0.040(3) 1 
N103 0.8321(14) 0.4263(12) 0.0872(7) 0.070(4) 1 
N300 0.6906(18) 0.0828(13) 0.7311(9) 0.090(5) 1 
O8 0.7427(11) 0.9864(8) 0.0613(5) 0.055(3) 1 
O13 0.8760(11) 0.8380(9) 0.3540(5) 0.061(3) 1 
O15 0.8471(10) 0.5492(9) 0.5659(5) 0.053(3) 1 
O19 0.3998(11) 0.2117(8) 0.2715(5) 0.057(3) 1 
O300 0.5657(19) 0.1217(13) 0.6094(7) 0.123(5) 1 
S1 0.1852(5) 0.5617(3) 0.2480(2) 0.0503(11) 1 
S2 0.3200(5) 0.3248(4) 0.2347(2) 0.0471(11) 1 
S3 0.3622(5) 0.5169(3) 0.0919(2) 0.0452(11) 1 
Ru1 0.44363(17) 0.46305(13) 0.22152(8) 0.0433(4) 1 
C200 1.0962(18) 0.8679(12) 0.5434(9) 0.064(5) 1 
C201 1.146(3) 0.8947(18) 0.6691(9) 0.118(8) 1 
C202 1.3234(18) 0.9670(13) 0.5539(10) 0.077(5) 1 
N200 1.1827(14) 0.9127(11) 0.5870(7) 0.062(4) 1 
O200 0.9807(12) 0.8228(9) 0.5656(5) 0.064(3) 1 
___________________________________________________________________________
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Table 6.45. Bond lengths [Å] and angles [°] for FL1528-1. 
___________________________________________________ 
C2-C3  1.363(18) 
C2-N1  1.403(16) 
C2-C17  1.406(15) 
C3-N4  1.417(15) 
C3-C11  1.418(17) 
C5-N4  1.375(16) 
C5-C6  1.383(16) 
C5-C10  1.492(16) 
C6-C7  1.356(18) 
C6-H6  0.9500 
C7-C8  1.442(17) 
C7-H7  0.9500 
C8-C9  1.395(17) 
C8-O8  1.404(15) 
C9-C10  1.370(18) 
C10-C11  1.404(17) 
C11-C12  1.467(16) 
C12-C16  1.360(19) 
C12-C13  1.512(18) 
C13-O13  1.217(15) 
C13-N14  1.383(16) 
C15-O15  1.256(15) 
C15-N14  1.361(18) 
C15-C16  1.525(17) 
C16-C17  1.405(18) 
C17-C18  1.439(18) 
C18-C19  1.399(18) 
C18-H18  0.9500 
C19-C20  1.397(15) 
C19-H19  0.9500 
C20-N1  1.365(16) 
C20-H20  0.9500 
C21-O8  1.448(15) 
C21-C23  1.47(2) 
C21-C22  1.53(2) 
C21-H21  1.0000 
C22-H22A  0.9800 
C22-H22B  0.9800 
C22-H22C  0.9800 
C23-H23A  0.9800 
C23-H23B  0.9800 
C23-H23C  0.9800 
C24-C25  1.531(18) 
C24-S1  1.833(12) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-S2  1.801(13) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-C27  1.521(18) 
C26-S1  1.866(13) 
C26-H26A  0.9900 
C26-H26B  0.9900 
C27-S3  1.882(13) 
C27-H27A  0.9900 
C27-H27B  0.9900 
C28-C29  1.461(17) 
C28-S2  1.869(12) 
C28-H28A  0.9900 
C28-H28B  0.9900 
C29-S3  1.821(14) 
C29-H29A  0.9900 
C29-H29B  0.9900 
C300-O300  1.262(19) 
C300-N300  1.32(2) 
C300-H300  0.9500 
C301-N300  1.41(2) 
C301-H30A  0.9800 
C301-H30B  0.9800 
C301-H30C  0.9800 
C302-N300  1.374(19) 
C302-H30D  0.9800 
C302-H30E  0.9800 
C302-H30F  0.9800 
N1-Ru1  2.163(11) 
N4-Ru1  2.122(13) 
N14-H14  0.8800 
N101-N102  1.156(14) 
N101-Ru1  2.145(13) 
N102-N103  1.188(14) 
O19-S2  1.467(10) 
S1-Ru1  2.320(5) 
S2-Ru1  2.188(4) 
S3-Ru1  2.313(4) 
C200-O200  1.203(15) 
C200-N200  1.362(16) 
C200-H200  0.9500 
C201-N200  1.469(19) 
C201-H20A  0.9800 
C201-H20B  0.9800 
C201-H20C  0.9800 
C202-N200  1.485(18) 
C202-H20D  0.9800 
C202-H20E  0.9800 























































































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.46. Anisotropic displacement parameters (Å2) for FL1528-1.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C2 0.042(8)  0.051(9) 0.034(6)  -0.007(5) -0.007(6)  -0.026(7) 
C3 0.038(7)  0.050(9) 0.029(6)  -0.012(5) 0.005(6)  -0.016(7) 
C5 0.022(7)  0.049(9) 0.033(6)  -0.006(5) -0.001(6)  -0.007(6) 
C6 0.050(8)  0.067(10) 0.039(6)  0.002(7) -0.005(7)  -0.037(8) 
C7 0.057(9)  0.058(10) 0.035(7)  -0.008(6) -0.007(7)  -0.027(8) 
C8 0.043(8)  0.050(9) 0.045(7)  -0.010(6) 0.006(7)  -0.025(7) 
C9 0.042(8)  0.069(10) 0.033(6)  -0.005(6) -0.002(6)  -0.023(8) 
C10 0.021(7)  0.042(8) 0.046(6)  -0.014(5) 0.002(6)  -0.007(6) 
C11 0.038(7)  0.063(9) 0.040(6)  -0.018(6) 0.002(6)  -0.034(8) 
C12 0.038(8)  0.064(9) 0.040(6)  -0.018(6) -0.003(7)  -0.028(8) 
C13 0.053(9)  0.057(10) 0.041(7)  -0.010(6) -0.017(7)  -0.024(8) 
C15 0.053(9)  0.057(10) 0.041(6)  -0.015(6) -0.010(7)  -0.019(8) 
C16 0.048(8)  0.059(9) 0.039(6)  -0.014(6) -0.013(7)  -0.020(8) 
C17 0.033(7)  0.063(9) 0.036(6)  -0.010(6) -0.018(6)  -0.022(7) 
C18 0.036(8)  0.068(10) 0.036(7)  -0.011(6) -0.007(6)  -0.020(8) 
C19 0.046(8)  0.066(10) 0.029(6)  -0.009(7) -0.009(6)  -0.016(7) 
C20 0.052(8)  0.042(9) 0.027(6)  0.000(6) -0.009(6)  -0.017(7) 
C21 0.070(10)  0.061(11) 0.070(11)  -0.002(8) -0.03(7)  -0.040(8) 
C22 0.114(13)  0.114(17) 0.059(11)  -0.047(10) -0.025(8)  -0.048(12) 
C23 0.113(13)  0.098(15) 0.063(11)  -0.007(10) -0.02 (8)  -0.069(11) 
C24 0.024(6)  0.064(8) 0.057(9)  -0.001(7) -0.010(6)  -0.020(5) 
C25 0.049(6)  0.053(7) 0.028(7)  -0.005(7) -0.017(5)  -0.030(5) 
C26 0.035(7)  0.063(10) 0.045(7)  -0.002(6) 0.019(6)  -0.007(5) 
C27 0.059(7)  0.044(9) 0.039(7)  0.006(7) -0.012(6)  -0.015(6) 
C28 0.074(10)  0.073(11) 0.035(6)  -0.017(7) -0.009(6)  -0.040(9) 
C29 0.036(7)  0.055(8) 0.044(6)  -0.014(7) -0.005(6)  -0.019(6) 
C300 0.123(15)  0.114(18) 0.064(10)  0.013(11) -0.01 (11)  -0.078(14) 
C301 0.057(10)  0.067(11) 0.120(15)  -0.036(10) 0.032(10)  -0.020(9) 
C302 0.116(15)  0.121(18) 0.096(12)  0.034(12) -0.053(13)  -0.055(14) 
N1 0.057(7)  0.059(8) 0.031(5)  -0.006(5) -0.019(5)  -0.031(6) 
N4 0.050(6)  0.064(7) 0.026(5)  -0.010(5) 0.004(5)  -0.030(6) 
N14 0.056(7)  0.069(8) 0.044(6)  -0.028(5) -0.005(6)  -0.030(7) 
N101 0.058(5)  0.062(8) 0.053(6)  -0.024(7) -0.003(4)  -0.045(5) 
N102 0.028(6)  0.062(9) 0.030(6)  -0.006(6) -0.010(4)  -0.020(6) 
N103 0.040(7)  0.121(13) 0.050(7)  -0.015(9) -0.011(5)  -0.030(8) 
N300 0.098(11)  0.085(12) 0.085(9)  0.011(9) -0.015(8)  -0.057(10) 
O8 0.067(6)  0.047(7) 0.053(6)  -0.010(5) -0.006(5)  -0.024(5) 
O13 0.062(6)  0.079(8) 0.048(6)  -0.006(5) -0.016(5)  -0.041(6) 
O15 0.043(5)  0.086(8) 0.035(5)  -0.017(5) -0.007(4)  -0.021(5) 
O19 0.059(6)  0.052(6) 0.060(6)  -0.023(5) -0.025(5)  0.001(5) 
O300 0.186(14)  0.124(14) 0.069(8)  -0.009(9) 0.005(8)  -0.077(11) 
S1 0.058(2)  0.059(3) 0.040(2)  -0.009(2) -0.0074(18)  -0.033(2) 
S2 0.047(2)  0.060(3) 0.038(2)  -0.007(2) -0.0133(18)  -0.025(2) 
S3 0.046(2)  0.054(3) 0.039(2)  -0.013(2) -0.0100(18)  -0.016(2) 
Ru1 0.0440(7)  0.0594(10) 0.0302(7)  -0.0065(7) -0.0115(6)  -0.0251(7) 
C200 0.060(10)  0.046(11) 0.083(11)  -0.006(9) -0.036(8)  -0.019(8) 
C201 0.18(2)  0.12(2) 0.038(8)  0.023(11) -0.034(9)  -0.062(16) 
C202 0.078(11)  0.067(13) 0.100(12)  -0.028(11) -0.011(9)  -0.037(9) 
N200 0.060(8)  0.069(10) 0.060(7)  -0.019(8) -0.022(6)  -0.018(6) 
O200 0.071(7)  0.089(9) 0.047(6)  -0.022(6) -0.001(5)  -0.045(6) 
_________________________________________________________________________
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Table 6.47. Hydrogen coordinates and isotropic displacement parameters (Å2)for FL1528-1. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H6 0.5174 0.7086 0.0617 0.062 1 
H7 0.6005 0.8676 0.0051 0.058 1 
H18 0.7083 0.4018 0.5371 0.055 1 
H19 0.5828 0.2647 0.5142 0.056 1 
H20 0.4809 0.2778 0.3897 0.049 1 
H21 0.9008 1.0076 0.1394 0.079 1 
H22A 0.7091 1.1693 0.1573 0.130 1 
H22B 0.6332 1.0616 0.1840 0.130 1 
H22C 0.5703 1.1475 0.1032 0.130 1 
H23A 0.8123 1.1603 -0.0043 0.130 1 
H23B 0.9961 1.0857 0.0247 0.130 1 
H23C 0.9204 1.1838 0.0613 0.130 1 
H24A -0.0427 0.4840 0.3042 0.059 1 
H24B -0.0364 0.4856 0.2149 0.059 1 
H25A 0.0472 0.3069 0.2734 0.050 1 
H25B 0.1531 0.3275 0.3409 0.050 1 
H26A -0.0095 0.6892 0.1523 0.061 1 
H26B 0.1789 0.7133 0.1392 0.061 1 
H27A 0.1077 0.6468 0.0380 0.060 1 
H27B 0.0568 0.5438 0.0970 0.060 1 
H28A 0.2610 0.2523 0.1318 0.068 1 
H28B 0.1191 0.3585 0.1302 0.068 1 
H29A 0.2630 0.4076 0.0257 0.052 1 
H29B 0.4433 0.3464 0.0687 0.052 1 
H300 0.5744 -0.0072 0.6885 0.119 1 
H30A 0.6742 0.2352 0.6730 0.118 1 
H30B 0.8600 0.1763 0.7111 0.118 1 
H30C 0.7089 0.2128 0.7638 0.118 1 
H30D 0.6214 -0.0213 0.8175 0.178 1 
H30E 0.7319 0.0556 0.8410 0.178 1 
H30F 0.8229 -0.0409 0.8057 0.178 1 
H14 0.9240 0.7389 0.5013 0.062 1 
H200 1.1294 0.8727 0.4919 0.076 1 
H20A 1.0317 0.8778 0.6771 0.177 1 
H20B 1.1494 0.9602 0.6853 0.177 1 
H20C 1.2311 0.8340 0.6995 0.177 1 
H20D 1.3339 0.9664 0.4996 0.116 1 
H20E 1.4308 0.9284 0.5826 0.116 1 
H20F 1.2982 1.0420 0.5575 0.116 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.49. Hydrogen bonds for FL1528-1 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 N14-H14...O200 0.88 1.90 2.773(14) 169.2 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  
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Crystal structure of FL1370-1. 
      
Table 6.50. Crystal data and structure refinement for FL1370-1. 
 
Identification code  fl1370-1 
Habitus, colour  plate,  dark red 
Crystal size 0.18 x 0.12 x 0.08 mm3 
Crystal system  Orthorhombic 
Space group  P b c n Z = 8 
Unit cell dimensions a = 17.5344(12) Å α= 90°. 
 b = 14.0596(7) Å β= 90°. 
 c = 23.5300(11) Å γ = 90°. 
Volume 5800.8(6) Å3 
Cell determination  7607 peaks with Theta 1.7 to 25°.
Empirical formula  C28 H30 N4 O4 Ru S4 
Formula weight  715.87 
Density (calculated) 1.639 Mg/m3 
Absorption coefficient 0.871 mm-1 
F(000) 2928 
 
Data collection:  
 
Diffractometer type  STOE IPDS2 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 1.86 to 25.00°. 
Index ranges -20<=h<=18, -16<=k<=16, -27<=l<=27 
 Data collection software  STOE X-AREA 
Cell refinement software  STOE X-AREA 
Data reduction software  STOE X-AREA 
 
Solution and refinement: 
 
Reflections collected 21516 
Independent reflections 5117 [R(int) = 0.1483] 
Completeness to theta = 25.00° 100.0 %  
Observed reflections  2225[I>2(I)]  
Reflections used for refinement  5117 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0016 and 0.8295 
Largest diff. peak and hole 0.570 and -0.458 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  CH, OH calc.,  riding model, NH located, isotr. ref. 
Programs used  SIR92 (Giacovazzo et al, 1993) 
 SHELXL-97 (Sheldrick, 2008) 
 DIAMOND 3.2 (Crystal Impact) 
 STOE X-AREA  
Data / restraints / parameters 5117 / 0 / 377 
Goodness-of-fit on F2 0.774 
R index (all data) wR2 = 0.0827 
R index conventional  [I>2sigma(I)] R1 = 0.0495 
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Table 6.51. Atomic coordinates and equivalent isotropic displacement parameters (Å2) for FL1370-1.   
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________ 
 x y z U(eq) Occupancy 
___________________________________________________________________________ 
C2 0.3706(4) -0.2370(5) 0.4276(2) 0.041(2) 1 
C3 0.3618(4) -0.1422(5) 0.4092(2) 0.0402(19) 1 
C5 0.3375(5) 0.0095(5) 0.4109(2) 0.0385(18) 1 
C6 0.3151(4) 0.1002(5) 0.4254(2) 0.047(2) 1 
C7 0.3117(4) 0.1710(5) 0.3847(2) 0.047(2) 1 
C8 0.3289(5) 0.1485(5) 0.3270(2) 0.0424(18) 1 
C9 0.3493(4) 0.0583(5) 0.3115(2) 0.045(2) 1 
C10 0.3534(4) -0.0127(5) 0.3520(2) 0.041(2) 1 
C11 0.3696(4) -0.1128(5) 0.3513(2) 0.0419(19) 1 
C12 0.3856(4) -0.1871(5) 0.3130(2) 0.0394(19) 1 
C13 0.4002(5) -0.1845(6) 0.2498(2) 0.047(2) 1 
C15 0.4031(5) -0.3408(6) 0.2792(3) 0.052(2) 1 
C16 0.3918(4) -0.2797(5) 0.3298(2) 0.042(2) 1 
C17 0.3839(4) -0.3094(5) 0.3880(2) 0.043(2) 1 
C18 0.3864(4) -0.4033(5) 0.4098(3) 0.054(2) 1 
C19 0.3778(5) -0.4176(5) 0.4668(3) 0.053(2) 1 
C20 0.3665(4) -0.3417(5) 0.5025(3) 0.048(2) 1 
C21 0.4519(5) 0.0310(5) 0.5886(2) 0.055(2) 1 
C22 0.3815(5) 0.0885(5) 0.5740(3) 0.054(2) 1 
C23 0.2810(5) -0.0115(6) 0.6461(2) 0.058(2) 1 
C24 0.2621(4) -0.1149(7) 0.6554(2) 0.055(2) 1 
C25 0.4166(4) -0.1736(6) 0.6506(2) 0.054(2) 1 
C26 0.4794(4) -0.1625(5) 0.6077(2) 0.050(2) 1 
C27 0.3273(5) 0.3140(5) 0.2981(2) 0.054(2) 1 
C28 0.3060(4) 0.3679(5) 0.2449(2) 0.057(2) 1 
C29 0.4054(5) 0.3406(6) 0.3179(3) 0.071(3) 1 
C100 0.4311(5) -0.4823(6) 0.1284(3) 0.077(3) 1 
C101 0.1621(6) -0.1670(6) 0.5048(3) 0.047(3) 1 
N1 0.3613(3) -0.2507(4) 0.48491(16) 0.0427(16) 1 
N4 0.3431(4) -0.0692(4) 0.44479(17) 0.0378(15) 1 
N14 0.4079(4) -0.2765(5) 0.2334(2) 0.053(2) 1 
N100 0.2178(4) -0.1575(4) 0.5093(2) 0.0353(18) 1 
O8 0.3235(3) 0.2151(3) 0.28375(14) 0.0545(15) 1 
O13 0.4025(3) -0.1152(4) 0.21900(15) 0.0512(14) 1 
O15 0.4079(4) -0.4274(4) 0.27535(18) 0.0637(17) 1 
O100 0.4320(4) -0.3740(5) 0.12939(18) 0.0808(19) 1 
S1 0.45607(13) -0.08303(14) 0.54961(6) 0.0490(6) 1 
S2 0.29446(12) 0.01553(14) 0.57040(6) 0.0493(5) 1 
S3 0.32405(13) -0.19578(15) 0.61571(6) 0.0531(6) 1 
S4 0.06211(15) -0.18106(16) 0.49794(8) 0.0674(7) 1 
Ru01 0.33227(4) -0.12346(4) 0.52848(2) 0.04400(17) 1 
___________________________________________________________________________
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Table 6.52. Bond lengths [Å] and angles [°] for FL1370-1. 
___________________________________________________ 
C2-N1  1.372(7) 
C2-C17  1.399(9) 
C2-C3  1.410(9) 
C3-N4  1.364(7) 
C3-C11  1.430(7) 
C5-N4  1.368(7) 
C5-C6  1.378(8) 
C5-C10  1.446(7) 
C6-C7  1.381(8) 
C6-H6  0.9500 
C7-C8  1.427(8) 
C7-H7  0.9500 
C8-C9  1.367(8) 
C8-O8  1.386(6) 
C9-C10  1.382(8) 
C9-H9  0.9500 
C10-C11  1.435(9) 
C11-C12  1.408(8) 
C12-C16  1.367(9) 
C12-C13  1.509(7) 
C13-O13  1.215(8) 
C13-N14  1.357(8) 
C15-O15  1.224(8) 
C15-N14  1.410(9) 
C15-C16  1.482(9) 
C16-C17  1.437(8) 
C17-C18  1.417(9) 
C18-C19  1.363(8) 
C18-H18  0.9500 
C19-C20  1.373(8) 
C19-H19  0.9500 
C20-N1  1.349(7) 
C20-H20  0.9500 
C21-C22  1.514(10) 
C21-S1  1.848(7) 
C21-H21A  0.9900 
C21-H21B  0.9900 
C22-S2  1.841(8) 
C22-H22A  0.9900 
C22-H22B  0.9900 
C23-C24  1.506(11) 
C23-S2  1.837(6) 
C23-H23A  0.9900 
C23-H23B  0.9900 
C24-S3  1.829(8) 
C24-H24A  0.9900 
C24-H24B  0.9900 
C25-C26  1.503(8) 
C25-S3  1.845(7) 
C25-H25A  0.9900 
C25-H25B  0.9900 
C26-S1  1.811(6) 
C26-H26A  0.9900 
C26-H26B  0.9900 
C27-O8  1.433(8) 
C27-C29  1.494(11) 
C27-C28  1.509(8) 
C27-H27  1.0000 
C28-H28A  0.9800 
C28-H28B  0.9800 
C28-H28C  0.9800 
C29-H29A  0.9800 
C29-H29B  0.9800 
C29-H29C  0.9800 
C100-O100  1.523(9) 
C100-H10A  0.9800 
C100-H10B  0.9800 
C100-H10C  0.9800 
C101-N100  0.991(9) 
C101-S4  1.772(10) 
N1-Ru01  2.123(6) 
N4-Ru01  2.120(4) 
N14-H14  0.89(6) 
N100-Ru01  2.112(7) 
O100-H100  0.8400 
S1-Ru01  2.298(2) 
S2-Ru01  2.287(2) 
























































































































































Symmetry transformations used to generate equivalent toms:  
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Table 6.53. Anisotropic displacement parameters (Å2) for FL1370-1.   
The anisotropicdisplacement factor exponent takes th  form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
_________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_________________________________________________________________________ 
C2 0.054(5)  0.046(5) 0.025(3)  -0.010(3) 0.001(3)  0.000(4) 
C3 0.046(5)  0.041(5) 0.033(3)  0.004(3) -0.002(3)  -0.002(4) 
C5 0.052(5)  0.035(4) 0.028(3)  0.002(3) -0.006(3)  0.007(5) 
C6 0.053(6)  0.058(5) 0.029(3)  0.002(3) -0.004(3)  -0.002(5) 
C7 0.062(6)  0.045(5) 0.034(3)  -0.003(3) -0.006(3)  0.008(4) 
C8 0.061(5)  0.035(5) 0.031(3)  0.003(3) -0.010(4)  -0.002(5) 
C9 0.060(6)  0.054(5) 0.020(3)  -0.002(3) -0.002(3)  -0.006(5) 
C10 0.052(6)  0.048(5) 0.025(3)  -0.005(3) -0.005(3)  -0.002(4) 
C11 0.062(5)  0.044(5) 0.020(3)  0.003(3) 0.000(3)  -0.006(5) 
C12 0.063(6)  0.039(5) 0.016(3)  -0.002(3) 0.002(3)  0.001(4) 
C13 0.062(6)  0.056(6) 0.025(3)  -0.002(4) -0.002(3)  -0.002(5) 
C15 0.059(6)  0.053(6) 0.045(4)  -0.003(4) 0.005(4)  -0.009(5) 
C16 0.055(5)  0.041(5) 0.032(3)  -0.005(3) 0.003(3)  -0.002(4) 
C17 0.053(6)  0.041(5) 0.036(3)  0.005(3) -0.001(3)  -0.004(4) 
C18 0.053(6)  0.049(6) 0.058(4)  0.008(4) 0.001(4)  -0.002(4) 
C19 0.081(7)  0.031(4) 0.046(4)  0.006(4) 0.003(4)  -0.001(4) 
C20 0.052(5)  0.051(6) 0.041(3)  0.011(4) -0.008(4)  0.003(4) 
C21 0.068(6)  0.071(6) 0.026(3)  -0.013(3) -0.006(4)  -0.007(5) 
C22 0.071(6)  0.056(6) 0.035(3)  -0.008(3) -0.002(4)  -0.003(5) 
C23 0.056(6)  0.094(7) 0.025(3)  -0.013(4) 0.005(4)  0.000(6) 
C24 0.054(5)  0.085(7) 0.028(3)  0.018(4) 0.008(3)  0.005(6) 
C25 0.054(6)  0.077(6) 0.032(3)  0.013(4) -0.010(4)  0.012(5) 
C26 0.056(6)  0.063(6) 0.031(3)  0.003(3) 0.004(3)  -0.005(5) 
C27 0.073(6)  0.052(5) 0.037(3)  0.005(3) -0.006(4)  0.010(6) 
C28 0.072(6)  0.045(5) 0.056(4)  0.015(4) -0.016(4)  0.002(5) 
C29 0.103(8)  0.062(7) 0.049(4)  0.011(4) -0.026(5)  -0.014(6) 
C100 0.097(8)  0.065(7) 0.067(5)  -0.016(5) 0.007(5)  0.003(7) 
C101 0.091(8)  0.038(5) 0.012(3)  -0.004(3) -0.009(5)  0.020(6) 
N1 0.055(4)  0.050(4) 0.023(3)  0.017(2) 0.000(2)  -0.009(3) 
N4 0.052(4)  0.033(3) 0.028(2)  0.001(2) 0.001(3)  0.005(3) 
N14 0.070(5)  0.059(5) 0.032(3)  -0.016(3) 0.005(3)  -0.003(4) 
N100 0.046(5)  0.037(4) 0.023(3)  0.000(2) 0.004(3)  0.003(4) 
O8 0.094(4)  0.037(3) 0.032(2)  0.0059(19) -0.012(3)  -0.004(4) 
O13 0.075(4)  0.058(3) 0.021(2)  -0.002(2) 0.001(2)  0.000(3) 
O15 0.096(5)  0.047(4) 0.048(3)  -0.009(3) 0.008(3)  -0.002(4) 
O100 0.098(5)  0.099(5) 0.046(3)  -0.014(3) 0.003(3)  -0.007(5) 
S1 0.0600(15)  0.0613(14) 0.0256(7)  0.0015(8) -0.0014(9)  0.0003(12) 
S2 0.0619(14)  0.0617(14) 0.0242(7)  -0.0034(8) 0.00 3(9)  -0.0002(13) 
S3 0.0605(15)  0.0698(14) 0.0289(8)  0.0115(8) 0.0014(10)  0.0012(14) 
S4 0.0771(18)  0.0746(16) 0.0504(10)  -0.0036(10) -0.0041(12)  -0.0053(15) 
Ru01 0.0571(4)  0.0540(4) 0.02093(19)  0.0028(3) -0.00 3(3)  -0.0018(4) 
_________________________________________________________________________
 284 
Table 6.54. Hydrogen coordinates and isotropic displacement parameters (Å2) for FL1370-1. 
___________________________________________________________________________ 
 x  y  z  U(eq)  Occupancy  
___________________________________________________________________________ 
  
H6 0.3018 0.1142 0.4636 0.056 1 
H7 0.2980 0.2340 0.3951 0.057 1 
H9 0.3606 0.0444 0.2729 0.053 1 
H18 0.3940 -0.4558 0.3850 0.064 1 
H19 0.3797 -0.4803 0.4818 0.063 1 
H20 0.3621 -0.3541 0.5421 0.058 1 
H21A 0.4523 0.0180 0.6299 0.066 1 
H21B 0.4978 0.0689 0.5794 0.066 1 
H22A 0.3894 0.1202 0.5369 0.065 1 
H22B 0.3745 0.1386 0.6031 0.065 1 
H23A 0.3282 0.0045 0.6672 0.070 1 
H23B 0.2393 0.0283 0.6614 0.070 1 
H24A 0.2086 -0.1262 0.6440 0.067 1 
H24B 0.2665 -0.1295 0.6965 0.067 1 
H25A 0.4131 -0.1152 0.6739 0.065 1 
H25B 0.4287 -0.2273 0.6763 0.065 1 
H26A 0.4920 -0.2259 0.5918 0.060 1 
H26B 0.5255 -0.1382 0.6272 0.060 1 
H27 0.2895 0.3283 0.3287 0.065 1 
H28A 0.2545 0.3493 0.2329 0.086 1 
H28B 0.3424 0.3528 0.2146 0.086 1 
H28C 0.3071 0.4363 0.2526 0.086 1 
H29A 0.4173 0.3059 0.3529 0.107 1 
H29B 0.4073 0.4092 0.3253 0.107 1 
H29C 0.4427 0.3242 0.2884 0.107 1 
H10A 0.4771 -0.5057 0.1093 0.115 1 
H10B 0.3859 -0.5044 0.1078 0.115 1 
H10C 0.4297 -0.5065 0.1674 0.115 1 
H100 0.4165 -0.3531 0.0980 0.121 1 
H14 0.415(4) -0.305(5) 0.200(2) 0.05(2) 1 
___________________________________________________________________________  
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Symmetry transformations used to generate equivalent toms:  
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Table 6.56. Hydrogen bonds for FL1370-1 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________ 
 O100-H100...S4#1 0.84 2.43 3.190(5) 150.5 
 N14-H14...O100 0.89(6) 1.94(6) 2.836(7) 176(6) 
_______________________________________________________________________ 
Symmetry transformations used to generate equivalent toms:  






B. 1H NMR, 13C NMR Spectra 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.1.2. 13C NMR of complex 2.2 (CDCl3). 
 289 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   180.0    170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.2.2. 13C NMR of complex 2.3 (DMF-d7). 
 290 
  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   180.0    160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    0.0    
Figure 6.3.2. 13C NMR of complex FL172 (DMSO-d6). 
 291 
PPM   9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    





PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.4.2. 13C NMR of complex FL411 (DMSO-d6). 
 292 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.6.1. 1H NMR of complex FL115-2 (Acetone-d6). 
 293 
PPM   9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.8.1. 1H NMR of complex FL114-2 (Acetone-d6). 
 294 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.10.1. 1H NMR of complex FL111-2 (Acetone-d6). 
 295 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.12.1. 1H NMR of complex FL161-2 (Acetone-d6). 
 296 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.14.1. 1H NMR of complex FL178 (Acetone-d6). 
 297 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.16.1. 1H NMR of complex FL151-1 (Acetone-d6). 
 298 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.18.1. 1H NMR of complex FL182-1 (Acetone-d6). 
 299 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.20.1. 1H NMR of complex FL162-1 (Acetone-d6). 
 300 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.22.1. 1H NMR of complex FL227 (Acetone-d6). 
 301 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.24.1. 1H NMR of complex FL224 (Acetone-d6). 
 302 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.26.1. 1H NMR of complex FL252 (Acetone-d6). 
 303 
  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.28.1. 1H NMR of complex FL256 (Acetone-d6). 
 304 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.30.1. 1H NMR of complex FL262-3 (Acetone-d6). 
 305 
  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.32.1. 1H NMR of complex FL262-9 (Acetone-d6). 
 306 
  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.34.1. 1H NMR of complex FL389 (Acetone-d6). 
 307 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.36.1. 1H NMR of complex FL637 (Acetone-d6). 
 308 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0   
 
Figure 6.38.1. 1H NMR of complex FL922 (Acetone-d6). 
 309 
  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.40.1. 1H NMR of complex FL864 (Acetone-d6). 
 310 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.42.1. 1H NMR of complex FL1088 (Acetone-d6). 
 311 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.44.1. 1H NMR of complex FL1109 (Acetone-d6). 
 312 
  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.46.1. 1H NMR of compound 2.5 (CDCl3). 
 313 
PPM   160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    -10.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.47.1. 1H NMR of compound 2.7 (CDCl3). 
 314 
PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    0.0    





PPM   8.8     8.4     8.0     7.6     7.2     6.8     6.4     6.0     5.6     5.2     4.8     4.4     4.0     3.6     3.2     2.8     2.4     2.0     1.6     1.2    0.8    0.4   -0.0    
Figure 6.48.1. 1H NMR of complex 2.8 (CDCl3). 
 315 
PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    





PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.49.1. 1H NMR of complex 2.9 (DMSO-d6). 
 316 
PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   180.0    160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    
Figure 6.50.2. 13C NMR of complex FL1422 (DMSO-d6). 
 317 
  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    




  170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.51.2. 13C NMR of complex 3.82 (DMSO-d6). 
 318 
PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.52.2. 13C NMR of complex 3.83 (DMSO-d6). 
 319 
  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.53.2. 13C NMR of complex 3.84 (DMSO-d6). 
 320 
  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
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Figure 6.54.2. 13C NMR of complex 3.86 (DMSO-d6). 
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Figure 6.55.2. 13C NMR of compound 3.2 (CDCl3). 
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Figure 6.56.2. 13C NMR of compound 3.4 (CDCl3). 
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Figure 6.57.2. 13C NMR of compound 3.6 (CDCl3). 
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Figure 6.58.2. 13C NMR of complex FL1359 (DMSO-d6). 
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Figure 6.59.2. 13C NMR of compound 3.8 (CDCl3). 
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PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    0.0    
Figure 6.60.2. 13C NMR of compound 3.10 (CDCl3). 
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Figure 6.61.2. 13C NMR of complex FL1335 (DMSO-d6). 
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Figure 6.62.2. 13C NMR of compound 3.13 (CDCl3). 
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Figure 6.63.2. 13C NMR of compound 3.15 (CDCl3). 
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Figure 6.64.2. 13C NMR of compound 3.17 (CDCl3). 
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Figure 6.65.2. 13C NMR of complex FL1288 (DMSO-d6). 
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Figure 6.66.2. 13C NMR of compound 3.19 (CDCl3). 
 333 
PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





  170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    0.0    
Figure 6.67.2. 13C NMR of compound 3.21 (CDCl3). 
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Figure 6.68.2. 13C NMR of complex FL1343 (DMSO-d6). 
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Figure 6.69.2. 13C NMR of compound FL3.24 (CDCl3). 
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Figure 6.70.2. 13C NMR of compound FL3.26 (CDCl3). 
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Figure 6.71.2. 13C NMR of compound FL3.27 (CDCl3). 
 338 
PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   170.0    160.0    150.0    140.0    130.0    120.0    110.0    100.0    90.0     80.0     70.0     60.0     50.0     40.0     30.0     20.0     10.0    
Figure 6.72.2. 13C NMR of complex FL1358 (DMSO-d6). 
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Figure 6.73.2. 13C NMR of compound 3.62 (CDCl3). 
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Figure 6.75.1. 1H NMR of compound 3.65 (CD3CN). 
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Figure 6.77.1. 1H NMR of compound 3.68 (CD3CN). 
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Figure 6.79.1. 1H NMR of compound 3.35 (DMSO-d6). 
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  12.0     11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.80.1. 1H NMR of compound 3.37 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.81.1. 1H NMR of complex FL1055 (DMSO-d6). 
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  9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.82.1. 1H NMR of compound 3.39 (CDCl3). 
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PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.83.1. 1H NMR of compound 3.41 (CDCl3). 
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  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.85.1. 1H NMR of complex FL1125 (DMSO-d6). 
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Figure 6.86.2. 13C NMR of complex FL123 (DMSO-d6). 
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PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.88.1. 1H NMR of compound 3.54 (CDCl3). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.89.1. 1H NMR of compound 3.56 (CDCl3). 
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  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.90.1. 1H NMR of complex FL1381 (DMSO-d6). 
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  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.91.1. 1H NMR of complex FL1041 (DMSO-d6). 
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Figure 6.93.1. 1H NMR of compound 3.60 (CDCl3). 
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Figure 6.94.1. 1H NMR of compound 3.61 (CD3CN). 
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Figure 6.95.2. 13C NMR of complex FL1528-1 (DMSO-d6). 
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Figure 6.96.2. 13C NMR of complex FL1353-1 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.98.1. 1H NMR of complex FL1370-1 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.99.1. 1H NMR of complex FL1370-2 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.101.1. 1H NMR of complex FL1289-1 (DMSO-d6). 
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  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.103.1. 1H NMR of complex FL1399-1 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.105.1. 1H NMR of complex FL848-1 (DMSO-d6). 
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Figure 6.106.2. 13C NMR of complex FL812-1 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.108.1. 1H NMR of complex FL253 (DMSO-d6). 
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  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.110.1. 1H NMR of complex FL823-1 (DMSO-d6). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.111.1. 1H NMR of complex FL823-2 (DMSO-d6). 
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  180.0    160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    
Figure 6.112.2. 13C NMR of complex FL829 (DMSO-d6). 
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PPM   10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    
Figure 6.114.1. 1H NMR of complex FL534-2 (DMSO-d6). 
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PPM   160.0    140.0    120.0    100.0    80.0     60.0     40.0     20.0    0.0   
 
Figure 6.115.2. 13C NMR of complex 3.70 (CDCl3). 
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PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    
Figure 6.117.1. 1H NMR of complex FL1360 (DMSO-d6). 
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  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.118.1. 1H NMR of complex FL792-1 (CDCl3). 
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  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.120.1. 1H NMR of complex FL1138-1 (Acetone-d6). 
 372 
  11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    





PPM   11.0     10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.122.1. 1H NMR of complex FL1124-1 (DMSO-d6). 
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  10.0     9.0     8.0     7.0     6.0     5.0     4.0     3.0     2.0     1.0    0.0    
Figure 6.124.1. 1H NMR of complex FL609-1 (Acetone-d6). 
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Figure 6.126.1. 1H NMR of compound 4.6 (CDCl3). 
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C. Kinase Screening Data 








Abl(h) 94 FGFR2(h) 108 PDGF(842)(h) 60 
Abl(m) 77 FGFR(N549H)(h) 84 PDGF(561)(h) 51 
Abl(H396P)(h) 83 FGFR3(h) 97 PDGFRβ(h) 104 
Abl(M351T)(h) 92 FGFR4(h) 89 PDK1(h) 92 
Abl(Q252H)(h) 80 Fgr(h) 63 PhKγ2(h) 93 
Abl(T315I)(h) 88 Flt1(h) 75 Pim-1(h) 1 
Abl(Y253F)(h) 88 Flt3(D835Y)(h) 26 Pim-2(h) 1 
ACK1(h) 91 Flt3(h) 33 Pim-3(h) 24 
ALK(h) 117 Flt4(h) 30 PKA(h) 69 
ALK4(h) 0 Fms(h) 28 PKBα(h) 20 
Arg(h) 68 Fyn(h) 83 PKBβ(h) 54 
AMPK(r) 74 GCK(h) 99 PKBγ(h) 27 
Arg(m) 88 GRK5(h) 81 PKCα(h) 63 
ARK5(h) 0 GRK6(h) 75 PKCβI(h) 38 
ASK1(h) 0 GRK7(h) 25 PKCβII(h) 25 
Aurora-A(h) 77 GSK3α(h) 2 PKCγ(h) 33 
Axl(h) 50 GSK3β(h) 25 PKCδ(h) 71 
Blk(m) 54 Haspin(h) 66 PKCε(h) 65 
Bmx(h) 147 Hck(h) 30 PKCη(h) 97 
BRK(h) 115 HIPK1(h) 83 PKCι(h) 77 
BrSK1(h) 95 HIPK2(h) 64 PKCµ(h) 102 
BrSK2(h) 101 HIPK3(h) 87 PKCθ(h) 15 
BTK(h) 71 IGF-1R(h) 78 PKCζ(h) 73 
CaMKI(h) 107 IGF (h),activated 78 PKD2(h) 98 
CaMKIIβ(h) 66 IKKα(h) 123 PKG1α(h) 40 
CaMKIIγ(h) 50 IKKβ(h) 93 PKG1β(h) 36 
CaMKIδ(h) 80 IR(h) 103 Plk1(h) 101 
CaMKIIδ(h) 45 IR(h),activated 105 Plk3(h) 108 
CaMKIV(h) 81 IRR(h) 59 PRAK(h) 48 
CDK1/cyclinB(h) 72 IRAK1(h) 86 PRK2(h) 32 
CDK2/cyclinA(h) 78 IRAK4(h) 97 PrKX(h) 76 
CDK2/cyclinE(h) 54 Itk(h) 73 PTK5(h) 68 
CDK3/cyclinE(h) 108 JAK2(h) 117 Pyk2(h) 76 
CDK5/p25(h) 81 JAK3(h) 92 Ret(h) 87 
CDK5/p35(h) 56 JNK1α1(h) 107 Ret(I804L)(h) 89 
CDK7/MAT1(h) 114 JNK2α2(h) 100 Ret(I804M)(h) 79 
CDK9/T1(h) 96 JNK3(h) 68 RIPK2(h) 95 
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CHK1(h) 74 KDR(h) 39 ROCK-I(h) 108 
CHK2(h) 52 Lck(h) 61 ROCK-II(h) 83 
CHK1(I157T)(h) 67 LIMK1(h) 95 ROCK-II(r) 85 
CHK2(I145W)(h) 55 LKB1(h) 100 Ron(h) 98 
CK1γ1(h) 89 LOK(h) 90 Ros(h) 90 
CK1γ2(h) 85 Lyn(h) 14 Rse(h) 21 
CK1γ3(h) 50 Lyn(m) 12 Rsk1(h) 13 
CK1δ(h) 88 MAPK1(h) 86 Rsk1(r) 22 
CK1(y) 59 MAPK2(h) 103 Rsk2(h) 33 
CK2(h) 109 MAPK2(m) 99 Rsk3(h) 33 
CK2α2(h) 109 MAPKAP-K2(h) 100 Rsk4(h) 20 
CLK2(h) 20 MAPKAP-K3(h) 112 SAPK2a(h) 103 
CLK3(h) 80 MEK1(h) 106 SAPK(TM)(h) 106 
cKit(h) 88 MARK1(h) 86 SAPK2b(h) 96 
cKit(D816V)(h) 105 MELK(h) 23 SAPK3(h) 112 
cKit(D816H)(h) 66 Mer(h) 33 SAPK4(h) 107 
cKit(V560G)(h) 19 Met(h) 57 SGK(h) 84 
cKit(V654A)(h) 94 MINK(h) 95 SGK2(h) 104 
CSK(h) 110 MKK4(m) 117 SGK3(h) 98 
c-RAF(h) 44 MKK6(h) 109 SIK(h) 59 
cSRC(h) 59 MKK7β(h) 65 Snk(h) 99 
DAPK1(h) 104 MLCK(h) 14 Src(1-530)h 60 
DAPK2(h) 90 MLK1(h) 33 Src(T341M)h 73 
DCAMKL2(h) 80 Mnk2(h) 99 SRPK1(h) 93 
DDR2(h) 84 MRCKα(h) 111 SRPK2(h) 85 
DMPK(h) 107 MRCKβ(h) 96 STK33(h) 50 
DRAK1(h) 52 MSK1(h) 48 Syk(h) 83 
DYRK2(h) 113 MSK2(h) 61 TAK1(h) 108 
eEF-2K(h) 112 MSSK1(h) 100 TAO1(h) 60 
EGFR(h) 94 MST1(h) 95 TAO2(h) 37 
EGFR(L858R)(h) 80 MST2(h) 65 TAO3(h) 65 
EGFR(L861Q)(h) 94 MST3(h) 39 TBK1(h) 81 
EGFR(T790M)(h) 90 mTOR(h) 87 Tec(h) 94 
EGFR(V858R)(h) 62 mTOR/FKBP (h) 100 Tie2(h) 67 
EphA1(h) 97 MuSK(h) 81 Tie(I849W)(h) 61 
EphA2(h) 96 NEK2(h) 86 Tie(I897S)(h) 82 
EphA3(h) 109 NEK3(h) 85 TLK2(h) 100 
EphA4(h) 111 NEK6(h) 112 TrkA(h) 30 
EphA5(h) 119 NEK7(h) 102 TrkB(h) 7 
EphA7(h) 106 NEK11(h) 49 TSSK1(h) 74 
EphA8(h) 118 NLK(h) 98 TSSK2(h) 104 
EphB2(h) 135 p70S6K(h) 76 Txk(h) 96 
EphB1(h) 112 PAK1(h) 17 ULK2(h) 97 
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EphB3(h) 94 PAK2(h) 26 ULK3(h) 111 
EphB4(h) 124 PAK3(h) 8 WNK2(h) 77 
ErbB4(h) 93 PAK4(h) 82 WNK3(h) 81 
FAK(h) 83 PAK5(h) 71 VRK2(h) 93 
Fer(h) 80 PAK6(h) 92 Yes(h) 54 
Fes(h) 127 PAR-1Bα(h) 42 ZAP-70(h) 126 
FGFR1(h) 96 PASK(h) 109 ZIPK(h) 18 
Measured by Millipore UK Ltd (Millipore Kinase ProfilerTM). PAK1 was purified 
and the PAK1 assay was measured separately by JasnaMaksimoska because it was not 
available in the Kinase Profiler panel. Conditions: 3 µM FL172 at an ATP 
concentration of 10 µM. Measurements were performed in uplicate and the average 
taken. Kinases displaying less than 20% activity under these conditions were 
highlighted. 








Abl(h) 101 Flt4(h) 55 PDK1(h) 24 
ACK1(h) 96 Fms(h) 68 PhKγ2(h) 95 
ALK(h) 60 Fyn(h) 77 Pim-1(h) 31 
ALK4(h) 123 GCK(h) 109 Pim-2(h) 24 
Arg(h) 93 GRK5(h) 65 Pim-3(h) 30 
AMPK(r) 93 GRK6(h) 53 PKA(h) 72 
Arg(m) 113 GRK7(h) 46 PKBα(h) 76 
ARK5(h) 88 GSK3α(h) 58 PKBβ(h) 90 
ASK1(h) 104 GSK3β(h) 90 PKBγ(h) 49 
Aurora-A(h) 117 Haspin(h) 79 PKCα(h) 113 
Axl(h) 100 Hck(h) 50 PKCβI(h) 99 
Blk(m) 113 HIPK1(h) 85 PKCβII(h) 82 
Bmx(h) 124 HIPK2(h) 70 PKCγ(h) 99 
BRK(h) 114 HIPK3(h) 91 PKCδ(h) 88 
BrSK1(h) 92 IGF-1R(h) 92 PKCε(h) 90 
BrSK2(h) 80 IKKα(h) 119 PKCη(h) 106 
BTK(h) 99 IKKβ(h) 97 PKCι(h) 88 
CaMKI(h) 108 IR(h) 104 PKCµ(h) 100 
CaMKIIβ(h) 63 IRR(h) 54 PKCθ(h) 42 
CaMKIIγ(h) 29 IRAK1(h) 97 PKCζ(h) 96 
CaMKIδ(h) 49 IRAK4(h) 108 PKD2(h) 103 
CaMKIIδ(h) 23 Itk(h) 96 PKG1α(h) 25 
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CaMKIV(h) 59 JAK2(h) 108 PKG1β(h) 24 
CDK1/cyclinB(h) 120 JAK3(h) 103 Plk1(h) 103 
CDK2/cyclinA(h) 115 JNK1α1(h) 106 Plk3(h) 113 
CDK2/cyclinE(h) 103 JNK2α2(h) 98 PRAK(h) 86 
CDK3/cyclinE(h) 119 JNK3(h) 86 PRK2(h) 76 
CDK5/p25(h) 106 KDR(h) 78 PrKX(h) 66 
CDK5/p35(h) 98 Lck(h) 105 PTK5(h) 73 
CDK7/MAT1(h) 114 LIMK1(h) 103 Pyk2(h) 62 
CDK9/cyclin T1(h) 108 LKB1(h) 106 Ret(h) 45 
CHK1(h) 97 LOK(h) 93 RIPK2(h) 87 
CHK2(h) 89 Lyn(h) 86 ROCK-I(h) 113 
CK1γ1(h) 66 Lyn(m) 72 ROCK-II(h) 99 
CK1γ2(h) 44 MAPK1(h) 47 ROCK-II(r) 107 
CK1γ3(h) 28 MAPK2(h) 89 Ron(h) 108 
CK1δ(h) 24 MAPKAP-K2(h) 115 Ros(h) 102 
CK1(y) 14 MAPKAP-K3(h) 105 Rse(h) 61 
CK2(h) 113 MEK1(h) 103 Rsk1(h) 26 
CK2α2(h) 107 MARK1(h) 78 Rsk1(r) 25 
CLK2(h) 2 MELK(h) 4 Rsk2(h) 21 
CLK3(h) 105 Mer(h) 19 Rsk3(h) 31 
cKit(h) 121 Met(h) 132 Rsk4(h) 22 
CSK(h) 102 MINK(h) 77 SAPK2a(h) 111 
c-RAF(h) 111 MKK4(m) 103 SAPK2b(h) 106 
cSRC(h) 80 MKK6(h) 115 SAPK3(h) 109 
DAPK1(h) 21 MKK7β(h) 63 SAPK4(h) 91 
DAPK2(h) 8 MLCK(h) 2 SGK(h) 82 
DCAMKL2(h) 97 MLK1(h) 86 SGK2(h) 53 
DDR2(h) 92 Mnk2(h) 95 SGK3(h) 92 
DMPK(h) 110 MRCKα(h) 108 SIK(h) 69 
DRAK1(h) 94 MRCKβ(h) 105 Snk(h) 96 
DYRK2(h) 114 MSK1(h) 15 SRPK1(h) 35 
eEF-2K(h) 107 MSK2(h) 22 SRPK2(h) 30 
EGFR(h) 121 MSSK1(h) 57 STK33(h) 100 
EphA1(h) 107 MST1(h) 78 Syk(h) 114 
EphA2(h) 97 MST2(h) 50 TAK1(h) 107 
EphA3(h) 115 MST3(h) 43 TAO1(h) 105 
EphA4(h) 107 mTOR(h) 99 TAO2(h) 103 
EphA5(h) 124 mTOR (h) 108 TAO3(h) 100 
EphA7(h) 113 MuSK(h) 108 TBK1(h) 90 
EphA8(h) 134 NEK2(h) 105 Tec(h) 102 
EphB2(h) 116 NEK3(h) 97 Tie2(h) 86 
EphB1(h) 146 NEK6(h) 94 TLK2(h) 108 
EphB3(h) 109 NEK7(h) 83 TrkA(h) 104 
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EphB4(h) 113 NEK11(h) 101 TrkB(h) 75 
ErbB4(h) 111 NLK(h) 104 TSSK1(h) 50 
FAK(h) 98 p70S6K(h) 54 TSSK2(h) 100 
Fer(h) 101 PAK2(h) 91 Txk(h) 99 
Fes(h) 97 PAK3(h) 98 ULK2(h) 106 
FGFR1(h) 132 PAK4(h) 104 ULK3(h) 109 
FGFR2(h) 118 PAK5(h) 96 WNK2(h) 90 
FGFR3(h) 100 PAK6(h) 96 WNK3(h) 99 
FGFR4(h) 98 PAR-1Bα(h) 54 VRK2(h) 77 
Fgr(h) 81 PASK(h) 102 ZIPK(h) 18 
Flt1(h) 64 PDGFRα(h) 127   
Flt3(h) 32 PDGFRβ(h) 107   
Measured by Millipore UK Ltd (Millipore Kinase ProfilerTM). Conditions: 100 nM of 
FL475 with an ATP concentration of 10 µM. Measurements were performed in 
duplicate and the average taken. 






Kinase Activity  
(%) 
Abl(h) 93 CK2α2(h) 98 MST1(h) 91 
ACK1(h) 85 CLK2(h) 53 MST2(h) 85 
ALK(h) 77 CLK3(h) 92 MST3(h) 41 
ALK4(h) 80 cKit(h) 111 mTOR(h) 99 
Arg(h) 82 CSK(h) 104 mTOR(h) 95 
AMPKα1(h) 71 c-RAF(h) 87 MuSK(h) 108 
AMPKα2(h) 67 cSRC(h) 105 NEK2(h) 87 
ARK5(h) 90 DAPK1(h) 15 NEK3(h) 95 
ASK1(h) 88 DAPK2(h) 12 NEK6(h) 90 
Aurora-A(h) 74 DCAMKL2(h) 98 NEK7(h) 88 
Aurora-B(h) 71 DDR2(h) 94 NEK11(h) 99 
Axl(h) 77 DMPK(h) 101 NLK(h) 84 
Bmx(h) 94 DRAK1(h) 80 p70S6K(h) 26 
BRK(h) 96 DYRK2(h) 99 PAK2(h) 94 
BrSK1(h) 77 eEF-2K(h) 78 PAK4(h) 101 
BrSK2(h) 70 EGFR(h) 110 PAK3(h) 99 
BTK(h) 99 EphA1(h) 99 PAK5(h) 93 
CaMKI(h) 65 EphA2(h) 94 PAK6(h) 101 
CaMKIIβ(h) 98 EphA3(h) 103 PAR-1Bα(h) 56 
CaMKIIγ(h) 66 EphA4(h) 99 PASK(h) 98 
CaMKIδ(h) 60 EphA5(h) 99 PDGFRα(h) 85 
CaMKIIδ(h) 77 MAPKAP-K2(h) 98 PDGFRβ(h) 75 
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CaMKIV(h) 61 MAPKAP-K3(h) 107 PDK1(h) 40 
CDK1/cyclinB(h) 92 MEK1(h) 105 PhKγ2(h) 94 
CDK2/cyclinA(h) 101 MARK1(h) 59 Pim-1(h) 56 
CDK2/cyclinE(h) 86 MELK(h) 34 Pim-2(h) 42 
CDK3/cyclinE(h) 93 Mer(h) 25 Pim-3(h) 82 
CDK5/p25(h) 98 Met(h) 50 PKA(h) 78 
CDK5/p35(h) 99 MINK(h) 74 PKBα(h) 86 
CDK6 (h) 94 MKK6(h) 94 PKBβ(h) 88 
CDK7 (h) 96 MKK7β(h) 95 PKBγ(h) 63 
CDK9 (h) 88 MLCK(h) 2 PKCα(h) 91 
CHK1(h) 91 MLK1(h) 59 PKCβI(h) 92 
CHK2(h) 43 Mnk2(h) 100 PKCβII(h) 93 
CK1γ1(h) 89 MRCKα(h) 98 PKCγ(h) 97 
CK1γ2(h) 83 MRCKβ(h) 102 PKCδ(h) 84 
CK1γ3(h) 93 MSK1(h) 44 PKCε(h) 100 
CK1δ(h) 85 MSK2(h) 33 PKCη(h) 89 
CK2(h) 106 MSSK1(h) 74 PKCι(h) 89 
PKCµ(h) 100 Rse(h) 86 TBK1(h) 82 
PKCθ(h) 84 Rsk1(h) 20 Tec(h) 112 
PKCζ(h) 82 Rsk2(h) 19 Tie2(h) 100 
PKD2(h) 95 Rsk3(h) 34 TLK2(h) 96 
PKG1α(h) 55 Rsk4(h) 27 TrkA(h) 94 
PKG1β(h) 49 SAPK2a(h) 100 TrkB(h) 118 
Plk1(h) 104 SAPK2b(h) 94 TSSK1(h) 78 
Plk3(h) 93 SAPK3(h) 63 TSSK2(h) 85 
PRAK(h) 79 SAPK4(h) 64 Txk(h) 83 
PRK2(h) 95 SGK(h) 45 ULK2(h) 97 
PrKX(h) 56 SGK3(h) 39 ULK3(h) 99 
PTK5(h) 99 SIK(h) 89 WNK2(h) 87 
Pyk2(h) 98 Snk(h) 85 WNK3(h) 97 
Ret(h) 13 SRPK1(h) 81 VRK2(h) 84 
RIPK2(h) 84 SRPK2(h) 81 Yes(h) 84 
ROCK-I(h) 90 STK33(h) 76 ZAP-70(h) 99 
ROCK-II(h) 101 Syk(h) 97 ZIPK(h) 5 
Ron(h) 84 TAK1(h) 98   
Ros(h) 100 TAO1(h) 94   
Measured by Millipore UK Ltd (Millipore Kinase ProfilerTM). Conditions: 30 nM of 
FL1528-1 with an ATP concentration of 10 µM. Measurements were performed in 
duplicate and the average taken. Kinases displaying less than 30% activity under these 
conditions were highlighted. 
 381 








Abl(h) 104 eEF-2K(h) 103 Mer(h) 74 
Arg(h) 102 EGFR(h) 98 PAK2(h) 103 
AMPKα1(h) 82 EphA5(h) 111 PAK3(h) 102 
AMPKα2(h) 74 Fes(h) 105 PAK5(h) 96 
Aurora-B(h) 107 FGFR2(h) 108 PAK6(h) 109 
BrSK1(h) 83 FGFR3(h) 111 PAR-1Bα(h) 64 
CaMKI(h) 76 FGFR4(h) 88 Pim-1(h) 38 
CaMKIIβ(h) 92 Fgr(h) 88 Pim-3(h) 97 
CaMKIIγ(h) 66 GCK(h) 117 PKA(h) 88 
CaMKIδ(h) 75 GSK3α(h) 94 PKBγ(h) 77 
CaMKIIδ(h) 69 GSK3β(h) 95 PKCα(h) 80 
CDK1/cyclinB(h) 99 Hck(h) 100 PKCβI(h) 98 
CDK2/cyclinA(h) 101 HIPK1(h) 104 PKCβII(h) 101 
CDK2/cyclinE(h) 104 HIPK2(h) 107 PKCγ(h) 101 
CDK3/cyclinE(h) 105 HIPK3(h) 101 PKCδ(h) 98 
CDK5/p25(h) 97 IGF-1R(h) 99 PKCε(h) 101 
CDK5/p35(h) 98 IR(h), activated 87 PKCη(h) 104 
CHK2(h) 88 IRAK1(h) 102 PKCι(h) 103 
CK1γ1(h) 102 IRAK4(h) 96 PKCµ(h) 105 
CK1γ2(h) 99 JAK2(h) 99 PKCζ(h) 98 
CK1γ3(h) 101 JAK3(h) 97 PKD2(h) 99 
CK1δ(h) 80 Lck(h) activated 80 PKG1α(h) 99 
CK2(h) 98 Lyn(h) 103 PKG1β(h) 79 
CK2α2(h) 113 MAPK1(h) 107 PRAK(h) 95 
CLK2(h) 67 MAPKAP-K2(h) 99 Ret(h) 67 
CLK3(h) 108 MAPKAP-K3(h) 100 ROCK-II(h) 105 
DAPK1(h) 12 MEK1(h) 108 Rsk1(h) 31 
DCAMKL2(h) 97 MARK1(h) 77 Rsk2(h) 27 
DYRK2(h) 108 MELK(h) 37 SGK(h) 94 
SGK3(h) 139 TAO1(h) 98 TSSK2(h) 102 
Src(1-530)(h) 92 TAO2(h) 98 Txk(h) 79 
SRPK1(h) 74 Tec(h) activated 103 ULK3(h) 111 
SRPK2(h) 104 TLK2(h) 103 Yes(h) 99 
Syk(h) 84 TSSK1(h) 86 ZIPK(h) 22 
Measured by Millipore UK Ltd (Millipore Kinase ProfilerTM). Conditions: 10 nM of 
FL1353-1 with an ATP concentration of 10 µM. Measurements were performed in 
duplicate and the average taken. Kinases displaying less than 50% activity under these 
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conditions were highlighted. 















Abl(h) 102 98 cKit(h) 83 95 
ACK1(h) 75 79 CSK(h) 105 101 
ALK(h) 86 88 c-RAF(h) 82 93 
ALK4(h) 85 91 cSRC(h) 92 88 
Arg(h) 81 82 DAPK1(h) 106 100 
ARK5(h) 95 96 DAPK2(h) 91 87 
ASK1(h) 108 113 DDR2(h) 104 96 
Aurora-A(h) 51 37 DMPK(h) 108 109 
Aurora-B(h) 80 104 DRAK1(h) 126 129 
Axl(h) 80 80 DYRK2(h) 111 112 
Bmx(h) 86 75 eEF-2K(h) 105 103 
BRK(h) 91 94 EGFR(h) 103 110 
BrSK1(h) 102 103 EphA1(h) 106 108 
BrSK2(h) 90 87 EphA2(h) 106 98 
BTK(h) 99 84 EphA3(h) 109 103 
CaMKI(h) 87 91 EphA4(h) 120 105 
CaMKIIβ(h) 53 60 EphA5(h) 97 100 
CaMKIIγ(h) 64 83 EphA7(h) 93 71 
CaMKIδ(h) 103 103 EphA8(h) 102 110 
CaMKIIδ(h) 56 86 EphB2(h) 113 97 
CaMKIV(h) 101 94 EphB1(h) 88 97 
CDK1/cyclinB(h) 87 97 EphB3(h) 86 83 
CDK2/cyclinA(h) 97 107 EphB4(h) 111 104 
CDK2/cyclinE(h) 85 95 ErbB4(h) 114 106 
CDK3/cyclinE(h) 93 98 FAK(h) 76 85 
CDK5/p25(h) 84 90 Fer(h) 63 69 
CDK5/p35(h) 96 102 Fes(h) 88 99 
CDK6/cyclinD3(h) 82 96 FGFR1(h) 40 47 
CDK7/cyclinH (h) 90 94 FGFR2(h) 68 58 
CDK9/cyclinT1(h) 62 29 FGFR3(h) 94 108 
CHK1(h) 98 106 FGFR4(h) 101 114 
CHK2(h) 89 3 Fgr(h) 91 86 
CK1γ1(h) 91 84 Flt1(h) 41 34 
CK1γ2(h) 72 78 Flt3(h) 46 41 
CK1γ3(h) 98 113 Flt4(h) 26 28 
CK1δ(h) 96 84 Fms(h) 19 17 
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CK2(h) 104 94 Fyn(h) 66 76 
CK2α2(h) 109 108 GCK(h) 98 98 
CLK2(h) 89 107 GRK5(h) 109 123 
CLK3(h) 19 98 MKK6(h) 103 96 
GRK7(h) 92 86 MKK7β(h) 94 44 
GSK3α(h) 9 28 MLCK(h) 61 84 
GSK3β(h) 22 50 MLK1(h) 63 64 
Haspin(h) 122 119 Mnk2(h) 95 99 
Hck(h) 65 74 MRCKα(h) 104 89 
Hck(h) activated 88 87 MRCKβ(h) 102 84 
HIPK1(h) 67 87 MSK1(h) 88 71 
HIPK2(h) 69 95 MSK2(h) 89 70 
HIPK3(h) 95 101 MSSK1(h) 112 110 
IGF-1R(h) 91 77 MST1(h) 79 90 
IGF-1R(h), activated 84 79 MST2(h) 73 81 
IKKα(h) 107 94 MST3(h) 69 49 
IKKβ(h) 103 102 mTOR(h) 103 112 
IR(h) 98 86 mTOR/FKBP12(h) 94 89 
IR(h), activated 89 90 MuSK(h) 72 87 
IRR(h) 101 97 NEK2(h) 99 97 
IRAK1(h) 109 107 NEK3(h) 89 92 
IRAK4(h) 99 108 NEK6(h) 104 99 
Itk(h) 101 92 NEK7(h) 97 95 
JAK2(h) 110 108 NEK11(h) 92 100 
JAK3(h) 106 115 NLK(h) 76 77 
JNK1α1(h) 118 107 p70S6K(h) 88 80 
JNK2α2(h) 94 97 PAK2(h) 91 91 
JNK3(h) 78 51 PAK4(h) 82 89 
KDR(h) 68 73 PAK3(h) 230 145 
Lck(h) 84 91 PAK5(h) 85 90 
Lck(h) activated 103 106 PAK6(h) 99 97 
LIMK1(h) 97 98 PAR-1Bα(h) 96 86 
LKB1(h) 100 98 PASK(h) 107 114 
LOK(h) 71 93 PDGFRα(h) 119 89 
Lyn(h) 68 69 PDGFRβ(h) 94 103 
MAPK1(h) 101 105 PDK1(h) 91 91 
MAPK2(h) 96 103 PhKγ2(h) 104 99 
MAPKAP-K2(h) 105 105 Pim-1(h) 6 8 
MAPKAP-K3(h) 102 108 Pim-2(h) 51 98 
MEK1(h) 78 101 Pim-3(h) 77 100 
MARK1(h) 79 81 PKA(h) 102 104 
MELK(h) 66 88 PKBα(h) 101 106 
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Mer(h) 63 95 PKBβ(h) 100 111 
Met(h) 93 99 PKBγ(h) 82 85 
MINK(h) 87 81 SRPK1(h) 98 104 
PKCα(h) 95 87 SAPK2b(h) 109 104 
PKCβI(h) 106 100 SAPK3(h) 100 101 
PKCβII(h) 97 94 SAPK4(h) 91 95 
PKCγ(h) 95 100 SGK(h) 108 101 
PKCδ(h) 93 76 SGK2(h) 105 99 
PKCε(h) 97 82 SGK3(h) 102 105 
PKCη(h) 104 94 SIK(h) 111 109 
PKCι(h) 86 120 Snk(h) 114 103 
PKCµ(h) 96 84 SRPK2(h) 88 99 
PKCθ(h) 80 59 STK33(h) 105 107 
PKCζ(h) 96 100 Syk(h) 86 86 
PKD2(h) 102 104 TAK1(h) 100 108 
PKG1α(h) 43 94 TAO1(h) 86 94 
PKG1β(h) 43 91 TAO2(h) 89 91 
Plk1(h) 90 96 TAO3(h) 75 76 
Plk3(h) 104 106 TBK1(h) 102 96 
PRAK(h) 67 69 Tec(h) activated 89 99 
PRK2(h) 47 52 Tie2(h) 105 88 
PrKX(h) 108 95 TLK2(h) 99 100 
PTK5(h) 86 89 TrkA(h) 4 22 
Pyk2(h) 66 89 TrkB(h) 17 93 
Ret(h) 83 73 TSSK1(h) 102 108 
RIPK2(h) 102 104 TSSK2(h) 101 104 
ROCK-I(h) 109 100 Txk(h) 103 108 
ROCK-II(h) 98 97 ULK2(h) 99 103 
Ron(h) 97 106 ULK3(h) 92 87 
Ros(h) 79 110 WNK2(h) 92 95 
Rse(h) 133 132 WNK3(h) 90 95 
Rsk1(h) 89 82 VRK2(h) 105 95 
Rsk2(h) 94 95 Yes(h) 86 89 
Rsk3(h) 104 83 ZAP-70(h) 96 106 
Rsk4(h) 95 89 ZIPK(h) 113 122 
SAPK2a(h) 118 109    
Measured by Millipore UK Ltd (Millipore Kinase ProfilerTM) Conditions: 1 µM of 
FL792-1 and FL792-2 with an ATP concentration of 10 µM. Measurements were 
performed in duplicate and the average taken. Kinases displaying less than 10% activity 
under these conditions were highlighted. 
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Initial screening of an organometallic library for PAK1 inhibition 
A library of 48 organometallic complexes was tested for PAK1 inhibition at the 
concentration of 10 µM with an ATP concentration of 1 µM. The results are shown in 
the bar diagram below (Figure 5.127) with the corresponding molecular structures of the 
library members displayed in Figure 5.128. These complexes were synthesized by 








































































































































































































































Figure 5.127. Initial screening of a 48-member organometallic library for PAK1 inhibition at a 
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Figure 5.128. Molecular structures of the 48-member organometallic library. Complexes were 
racemic, except for E5E2 for which the absolute stereochemistry is indicated. 
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